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Background: The use of aspirin is well established for secondary prevention of cardiovascular disease.
However, a proportion of patients suffer repeat cardiovascular events despite being prescribed aspirin
treatment. It is uncertain whether or not this is due to an inherent inability of aspirin to sufficiently modify
platelet activity. This report aims to investigate whether or not insufficient platelet function inhibition by
aspirin (‘aspirin resistance‘), as defined using platelet function tests (PFTs), is linked to the occurrence of
adverse clinical outcomes, and further, whether or not patients at risk of future adverse clinical events can
be identified through PFTs.
Objectives: To review systematically the clinical effectiveness and cost-effectiveness evidence regarding
the association between PFT designation of ‘aspirin resistance’ and the risk of adverse clinical outcome(s) in
patients prescribed aspirin therapy. To undertake exploratory model-based cost-effectiveness analysis on
the use of PFTs.
Data sources: Bibliographic databases (e.g. MEDLINE from inception and EMBASE from 1980), conference
proceedings and ongoing trial registries up to April 2012.
Methods: Standard systematic review methods were used for identifying clinical and cost studies.
A risk-of-bias assessment tool was adapted from checklists for prognostic and diagnostic studies.
(Un)adjusted odds and hazard ratios for the association between ‘aspirin resistance’, for different PFTs,
and clinical outcomes are presented; however, heterogeneity between studies precluded pooling of results.
A speculative economic model of a PFT and change of therapy strategy was developed.
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Results: One hundred and eight relevant studies using a variety of PFTs, 58 in patients on aspirin
monotherapy, were analysed in detail. Results indicated that some PFTs may have some prognostic
utility, i.e. a trend for more clinical events to be associated with groups classified as ‘aspirin resistant’.
Methodological and clinical heterogeneity prevented a quantitative summary of prognostic effect.
Study-level effect sizes were generally small and absolute outcome risk was not substantially different
between ‘aspirin resistant’ and ‘aspirin sensitive’ designations.
No studies on the cost-effectiveness of PFTs for ‘aspirin resistance’ were identified. Based on assumptions
of PFTs being able to accurately identify patients at high risk of clinical events and such patients benefiting
from treatment modification, the economic model found that a test–treat strategy was likely to be
cost-effective. However, neither assumption is currently evidence based.
Limitations: Poor or incomplete reporting of studies suggests a potentially large volume of inaccessible
data. Analyses were confined to studies on patients prescribed aspirin as sole antiplatelet therapy at the
time of PFT. Clinical and methodological heterogeneity across studies precluded meta-analysis. Given the
lack of robust data the economic modelling was speculative.
Conclusions: Although evidence indicates that some PFTs may have some prognostic value,
methodological and clinical heterogeneity between studies and different approaches to analyses create
confusion and inconsistency in prognostic results, and prevented a quantitative summary of their
prognostic effect. Protocol-driven and adequately powered primary studies are needed, using standardised
methods of measurements to evaluate the prognostic ability of each test in the same population(s),
and ideally presenting individual patient data. For any PFT to inform individual risk prediction, it will likely
need to be considered in combination with other prognostic factors, within a prognostic model.
Study registration: This study is registered as PROSPERO 2012:CRD42012002151.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
‘Aspirin resistant’ Those individuals prescribed aspirin therapy classified as having insufficient inhibition
of platelet reactivity (i.e. elevated platelet reactivity) based on the platelet function test and threshold
specified by the authors of the relevant studies.
‘Aspirin sensitive’ Those individuals prescribed aspirin therapy classified as having sufficient inhibition of
platelet reactivity (i.e. low platelet reactivity) based on the platelet function test and threshold specified by
the authors of the relevant studies.
Major adverse cardiac event (MACE) Individual definitions vary between studies, but for the purposes
of this report, this is any composite measure including death and cardiovascular events with or without
ischaemic events.
Predictive utility Whether or not a platelet function test with good prognostic utility is able for individual
patients to distinguish between those who will and those who will not have an adverse outcome, in order
to determine if treatment modification should be considered based on the test result.
Prognostic utility Whether or not a platelet function test is able to distinguish between groups of
patients with different average outcome risks even if it does not accurately predict individual outcome risk.
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Plain English summary
Aspirin is prescribed for people who have had diseases of the heart or circulation, such as a heartattack, angina (chest pain) or stroke. Aspirin is thought to lower the risk of further disease by
preventing platelets (a type of blood cell) from sticking together and forming blood clots. In some people
aspirin does not seem to work as well as expected, and further heart attacks, strokes or other events
are more common. Platelet function tests (PFTs) are a type of test that can assess how platelets are
aggregating (‘sticking’ together) and whether or not taking aspirin reduces the aggregation. Depending on
the amount of platelet aggregation, a person may be classified as ‘aspirin resistant’, meaning that their
platelet aggregation might not be reduced sufficiently by aspirin.
The aim of this report was to gather all the studies that have looked at the relationship between platelet
aggregation (assessed using a PFT) and the risk of having a cardiovascular event, and to see if ‘aspirin
resistance’ is associated with an increased chance of future heart attacks or strokes. If patients at higher
risk could be identified, then a change in their treatment might be considered to prevent future problems.
Fifty-eight studies were reviewed in detail and these indicate that, on average, some tests may have some
value, but differences between the studies create a confused and inconsistent picture. As such, no firm
conclusions about the value of specific PFTs for individual patients could be made. Therefore, this report
makes recommendations for future research.
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Scientific summary
Background
Aspirin is recommended in cardiovascular disease to prevent future thrombotic complications. However,
not all patients benefit from being prescribed aspirin to the same extent, and the question is therefore
whether or not patients who suffer events do so because of insufficient antiplatelet effect of aspirin. This
systematic review assesses whether or not insufficient platelet function inhibition by aspirin, as measured
by platelet function tests (PFTs), is linked to the occurrence of adverse clinical outcomes. This process was
undertaken in order to ascertain the prognostic utility of the available PFTs. For the purposes of this report,
those individuals prescribed aspirin and classified as having insufficient inhibition of platelet reactivity
(i.e. elevated platelet reactivity), based on a PFT and threshold specified by the authors of the studies,
are deemed to be ‘aspirin resistant’.
Objectives
1. To review systematically the clinical evidence relating platelet function test results to the risk of adverse
clinical outcome(s) in patients on aspirin therapy with established cardiovascular disease, cerebrovascular
disease (CVD) or diabetes. More specifically, to determine whether or not PFT results have any utility as
a prognostic factor and, should that be demonstrated, whether or not they also have any utility in
identifying (diagnosing) individuals at higher risk of cardiovascular events.
2. To review systematically the evidence relating to the economic utility of PFTs in patients on aspirin
therapy with established cardiovascular disease, CVD, or diabetes.
3. To undertake exploratory model-based cost-effectiveness analysis of the use of PFTs in patients on
long-term aspirin therapy with investigation of the potential for populating the model with data based
on the results of the systematic review outlined in objective 1.
Methods
For the systematic reviews standard methods were employed.
For the review of prognostic utility, studies were eligible for inclusion if they were prospective primary
studies or systematic reviews of studies assessing PFTs in relation to clinical outcomes; were in patients
aged ≥ 18 years on aspirin, with established cardiovascular disease, CVD, or diabetes; and included either
a cyclo-oxygenase-1 enzyme-specific PFT (which measures aspirin response specifically) or a global PFT in
patients receiving aspirin as the only antiplatelet therapy. Relevant clinical outcomes were vascular events,
haemorrhagic events, all-cause mortality, mortality due to vascular events and composite outcomes
containing the above [e.g. major adverse cardiac events (MACEs)]. Reported outcomes had to occur after
the undertaking of a PFT and the post-test follow-up period had to be 7 days or longer.
Bibliographic databases (e.g. MEDLINE from inception and EMBASE from 1980, and ongoing studies and
conference proceedings databases) were searched up to April 2012, and citation searching was undertaken.
Study selection was performed in duplicate using predefined criteria, with recourse to full texts where
necessary, and disagreements were resolved by discussion or by referral to a third reviewer. No language or
publication restrictions were placed on searches or study selection.
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Risk of bias was assessed by one reviewer and independently checked by a second. Disagreements were
resolved by discussion. Assessment criteria were based on criteria for checking the quality of prognostic
studies and the quality assessment of diagnostic accuracy studies (revised tool) (QUADAS-2). Criteria
related to the domains of patient selection, PFT, outcomes, study attrition and confounding.
Data extraction was conducted by one reviewer using a standardised, piloted data extraction form,
and independently checked by a second. Disagreements were resolved through discussion or referral
to a third reviewer. Data were extracted on study design and characteristics, patient characteristics,
antiplatelet regimens, PFT utilised, outcome measures and length of follow-up, data required for analyses,
statistical methods employed and their appropriateness.
Studies were grouped according to whether patients were prescribed monotherapy (aspirin only) or dual
therapy (with a second antiplatelet agent added to aspirin) at the time of PFTs in order to distinguish
between patients with different therapeutic needs. It was decided to undertake a stepwise approach to
reporting and analysing studies, starting with monotherapy studies and then moving on to dual-therapy
studies owing to the added complexity engendered in the latter. As prognostic utility of PFTs in patients
treated with aspirin as monotherapy was not convincingly demonstrated, it was decided not to undertake
analyses of the dual-therapy studies. However, all data extracted in relation to dual-therapy studies have
been made available to readers via a web portal.
Where possible, results were presented for different PFTs, different outcome measures (e.g. death, MACE)
and different outcome statistics (e.g. odds ratios, hazard ratios). Adjusted and unadjusted results were also
presented separately. Where more than one threshold was used (for classification of ‘aspirin resistance’),
results were presented for all thresholds. Methodological and clinical heterogeneity precluded pooling of
results, but forest plots were used to visualise data and indicate heterogeneity between studies.
Similar review methods were employed for the review of cost-effectiveness studies. Any of the following
study designs was eligible: cost–consequence analysis, cost-effectiveness analysis, cost–benefit analysis,
cost–utility analysis and cost studies. Outcomes of interest were cost-effectiveness, cost estimates,
utilisation estimates and quality-of-life estimates.
A speculative economic model developed as a decision tree combined with a Markov model was built to
estimate the cost-effectiveness of PFTs, with the option of change in treatment based on a designation of
‘aspirin resistant’ compared with no testing and no change in treatment (current treatment), from a NHS
and Personal Social Services perspective.
Results and discussion
Systematic review of the primary studies linking platelet function testing
and future thrombotic risk
Searches identified 120 articles reporting the result(s) of one or more PFTs in relation to clinical outcome
data, and these articles represented 108 separate studies. Fifty-eight studies reported on a patient group
solely or predominantly receiving aspirin as monotherapy at the time of testing. The PFTs used in
these studies were (i) light transmission aggregometry (LTA), (ii) VerifyNow® Aspirin (Accumetrics, Inc.,
San Diego, CA, USA), (iii) measurement of urinary or serum/plasma thromboxane B2 metabolites,
(iv) platelet function analyser-100 (PFA-100®; Siemens, Malvern, PA, USA), (v) whole-blood aggregometry
(WBA), (vi) thromboelastography (TEG) and (vii) other miscellaneous tests.
The studies were highly heterogeneous with regard to patient groups studied, designation of ‘aspirin
resistance’, range and definition of clinical outcomes and types of statistics reported.
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Nineteen studies used LTA, mainly in stable coronary artery disease populations. The most frequently
reported test threshold to define ‘aspirin resistance’ was 20% platelet aggregation induced by arachidonic
acid, although other agonists (particularly adenosine diphosphate and collagen) were also used with
different threshold levels. For the point-of-care VerifyNow® Aspirin assay, seven studies were identified.
The most common threshold used to define poor response to aspirin was 550 aspirin response units, as
recommended by the manufacturer. Eleven studies were identified using thromboxane metabolites to
define ‘aspirin resistance’. Thromboxane metabolites were measured in urine, serum or plasma, usually by
enzyme immunoassay, although radioactive labelling was also reported. Methods for deriving thresholds
and thresholds to define ‘aspirin resistance’ themselves were variable. For the PFA-100® assay, 21 studies
were identified, for the most part in stable populations, although studies in acute populations contributed
substantially to results. The collagen/epinephrine cartridge was used to assess platelet responses to aspirin.
For WBA, eight studies were identified, all in stable disease patients except in one study. The most
commonly reported agonist was arachidonic acid, although collagen was also sometimes used. The
threshold to define ‘aspirin resistance’ was not always reported or consistent across studies. The TEG
system was reported in three studies (two with a stable, one with an acute disease population), and a
threshold for ‘aspirin resistance’ of 50% was consistently used across studies.
In general, study reporting lacked detail to assess quality criteria, regardless of the PFT used, thus
hampering an overall risk-of-bias assessment. Lack of detail related in particular to blinding (to patient
characteristics or of outcome assessors), loss-to-follow-up information and level of compliance with aspirin
treatment. There was no consistent reporting of adjusted analyses.
Overall, there is a possible trend suggestive of more clinical events occurring in those groups of patients
designated ‘aspirin resistant’, with some results in some studies showing statistical significance; this is
the case across the majority of tests (LTA, VerifyNow® Aspirin, PFA-100®, thromboxane metabolite
measurement), though to a lesser extent for TEG, and with data for WBA not allowing many conclusions
to be drawn. This trend is also fairly consistent across some outcomes (i.e. death, MACEs and ischaemic/
thrombotic events) irrespective of test, though the direction of effect is not always consistent for different
thresholds applied to the data from the same study. There are very limited data on bleeding events and
thus no inference could be drawn.
The results suggest that PFTs (specifically LTA, VerifyNow® Aspirin, PFA-100®, thromboxane metabolite
measurement and TEG) may have some prognostic value as they are fairly consistently associated with
elevated risk of cardiovascular events (MACE or death). However, as meta-analysis was not possible, no
firm quantitative conclusions can be drawn as to the prognostic value. Given that the effect sizes for an
association with clinical events are relatively small and highly uncertain, a determination of the diagnostic
utility of PFTs (for determining if an individual is at higher risk of a clinical event) was not possible in
this report.
Review of the existing systematic reviews
Fifteen systematic reviews relevant to prognostic utility were identified, and of these, four were considered
methodologically more robust than the others. All four reviews found a positive association between
aspirin non-responder status (‘resistance’) and likelihood of adverse cardiovascular outcomes, despite their
differences in precise research question, range of included studies and primary outcome measures.
However, these reviews had important deficiencies, variously:
l a lack of a rigorous and transparent approach to quality assessment
l insufficient comprehensiveness and a failure to account for the complexity of the field by not
considering the effect of different PFTs, thresholds, etc.
l not distinguishing between adjusted and non-adjusted statistical data
l uncertainty regarding whether or not patients receiving aspirin as monotherapy and participants who
received additional antiplatelet agents (most commonly dual antiplatelet therapy with aspirin and
clopidogrel) were combined in the analysis
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l uncertainty over whether included studies were prospective or retrospective in design
l failure to account for the effect of non-compliance.
In this context, caution must be exercised in interpretation of the findings from these previous reviews.
Systematic review of economic evaluations and economic model
Currently, there is no existing economic evidence on the cost or cost-effectiveness of platelet function
testing for ‘aspirin resistance’. This report presents the first model to attempt to estimate the
cost-effectiveness of a ‘test and change treatment’ strategy using platelet function testing to define an
at-risk population. The model (based on a decision tree coupled with a Markov model) is highly speculative
owing to the large degree of heterogeneity and uncertainty around the prognostic utility of PFTs,
and it contains numerous assumptions. This has been addressed, where possible, by deterministic
sensitivity analysis and also by taking into account the uncertainty around many of the model parameter
values. In addition, further analyses have been presented to show scenarios where platelet function testing
for ‘aspirin resistance’ and a change in treatment would not be cost-effective.
Assuming a PFT can accurately identify patients at higher risk of adverse clinical outcomes while receiving
aspirin therapy as the sole antiplatelet agent and patients changed to an effective treatment, a ‘test and
change treatment’ option is very likely to be cost-effective. Conversely, if a PFT cannot identify these
patients, and a treatment change is not effective in reducing adverse clinical outcome (MACE) risk, then a
‘test and change treatment’ strategy is not cost-effective. The parameters with the greatest impact on
model results are the proportion that are correctly identified as having a high risk of clinical outcome,
the effectiveness of a change in treatment if designated ‘aspirin resistant’, the cost of a test and the cost
of a change in treatment. The accuracy of testing, the additional risk of an adverse outcome associated
with a designation of ‘aspirin resistant’ and the effectiveness of a change in therapy are the most
uncertain. The model requires more robust data on all of these aspects.
Conclusions
The current report has demonstrated a lack of a consistent association between a laboratory designation
of ‘aspirin resistance’ and clinical outcome, on any test and in any outcome, despite the existence of a vast
number of studies which have sought to clarify this association. Although evidence indicates that some
tests may have some prognostic value, methodological and clinical heterogeneity between studies and
different approaches to analyses create confusion and inconsistency in prognostic results, and prevented a
quantitative summary of their prognostic effect. As no large/consistent effect for prognostic utility could be
shown, consideration of diagnostic utility was not meaningful.
Recommendations for future research
There is a need for large, protocol-driven and adequately powered primary studies using standardised and
agreed methods of measurement to evaluate the prognostic ability of each test in the same population(s).
For the tests to inform individual risk prediction, it is likely that they need to be considered in combination
and alongside other prognostic factors, within a prognostic model. Once these issues have been addressed
it may be possible to undertake a ‘test–treat trial’ using a prognostic model to tailor antiplatelet therapy
to individuals.
SCIENTIFIC SUMMARY
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Study registration
This study is registered as PROSPERO 2012:CRD42012002151.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Cardiovascular disease is the leading cause of death in the developed world, with coronary artery disease(CAD) and stroke accounting for one-quarter of all deaths in the UK.1 Important progress has been
made in the management of heart disease over the last century, driving the incidence of disease down in
both men and women. Among the many beneficial medical therapies which have been shown to decrease
the risk of recurrent vascular events, antiplatelet agents have become the cornerstone of therapy in patients
suffering from atherosclerotic vascular disease. It is thus not surprising that over 40,000 tons of aspirin
are produced every year worldwide, and 35,000 kg of aspirin are consumed every day in the USA alone
(the figure for the UK is 6000 kg per day).2 In the UK, aspirin was the second most prescribed drug in 2011,
with 32.4 million prescriptions dispensed in the community, 95% of which were for cardioprotection.3
Indications for antiplatelet therapy
The use of antiplatelet agents covers a large spectrum of vascular diseases.4 In primary prevention,
antiplatelet agents can be given to patients at high risk of thrombotic events, such as patients with multiple
risk factors for CAD or diabetes.5 In secondary prevention, antiplatelet agents can be given either acutely
in patients with acute coronary syndromes (ACSs), following percutaneous coronary intervention (PCI) or
coronary artery bypass graft (CABG), or chronically in patients with stable CAD, in patients with a history of
transient ischaemic attacks (TIAs) or strokes and patients with peripheral arterial disease (PAD).5 The benefit
of aspirin therapy in each of these pathologies is related to the underlying thrombotic risk, and is usually
greatest in high-risk individuals and lowest in individuals with no overt atherosclerotic disease (Figure 1).
Antiplatelet therapy in primary prevention of cardiovascular disease
There is little clinical evidence to support the use of antiplatelets for the primary prevention of
cardiovascular events in patients with a cardiovascular disease risk less than 20%.4 In patient groups
carrying the highest cardiovascular disease risk, the benefit (i.e. the expected number of individuals
avoiding a serious vascular event by using aspirin) exceeds the risk associated with aspirin treatment
(i.e. experiencing a major bleed).5 The latest meta-analysis by the Antithrombotic Trialists’ Collaboration
found that aspirin therapy in primary prevention of cardiovascular events resulted in a 12% proportional
reduction in the incidence of serious vascular events [rate ratio (RR) 0.88, 95% confidence interval (CI)
0.82 to 0.94] and an 18% proportional reduction in the incidence of major coronary events (RR 0.82,
95% CI 0.75 to 0.90).4 On the other hand, aspirin was associated with an increase in major gastrointestinal
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FIGURE 1 The benefit of aspirin in terms of risk prevention in different patient groups. From Eikelboom JW,
Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis,
9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl.):
e89–119.5 Reproduced with permission from the American College of Chest Physicians. MI, myocardial infarction.
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1
(GI) and other extracranial bleeds (RR 1.54, 95% CI 1.30 to 1.82). In absolute numbers, however, the
decrease in major coronary events from 0.34% to 0.28% per year is only slightly superior to the increase in
bleeding events from 0.07% to 0.10% per year.4 As a consequence, most guidelines advise against daily
aspirin therapy in men and women without evidence of manifest vascular disease. However, daily aspirin
therapy (75–160mg) can be considered in apparently healthy individuals in whom the vascular risk is
considered high and the bleeding risk low.5,6
Within the primary prevention populations, patients suffering from diabetes mellitus have specific
guidelines when it comes to antiplatelet therapy in prevention of vascular events.7 This stems from
epidemiological studies which have shown that diabetic patients have a two- to three-fold increase in risk
of major ischaemic events. Despite the higher risk of cardiovascular disease, the benefit of giving aspirin in
patients suffering from diabetes alone is, however, less certain.8 Recent guidelines reflect this by moving
away from a universal recommendation for aspirin in all diabetic patients, and advising daily aspirin therapy
only in diabetic patients with concomitant risk factors for CAD where the most benefit can be gained.7,8
As a consequence, daily administration of aspirin is usually initiated in primary prevention in diabetic
patients at increased cardiovascular risk (10-year risk > 10%). This includes most men aged > 50 years or
women aged > 60 years who have at least one additional major risk factor (family history of cardiovascular
disease, hypertension, smoking, dyslipidaemia or albuminuria).7
Antiplatelet therapy in secondary prevention of cardiovascular disease
Daily low-dose aspirin therapy (75–325mg) is strongly recommended for all patients with established
cardiovascular disease. In patients with a prior cardiovascular event, evidence that daily aspirin therapy
reduces the risk of major adverse cardiovascular events is arguably strong.4 Although the proportional
reduction in risk of any serious vascular event does not differ significantly between primary and secondary
prevention trials, the absolute risk reduction is much greater in secondary prevention, thus rendering the
benefit-to-risk ratio unquestionably in favour of aspirin therapy.4 It is therefore not surprising that all US,
European and UK guidelines recommend life-long aspirin therapy in all patients with established
cardiovascular disease.5
Although aspirin is recommended in all patients indefinitely, in patients who have suffered an ACS, which
may or may not have required revascularisation, additional antiplatelet therapy on top of daily aspirin
treatment is recommended. Thus, in patients who have had a ST-elevation myocardial infarction (MI) or
non-ST-elevation ACS (including unstable angina), and in patients who have undergone PCI, addition of an
adenosine diphosphate (ADP) receptor blocker such as clopidogrel, prasugrel (Efient®, Eli Lilly) or ticagrelor
(Brilique®, AstraZeneca) is recommended for up to 1 year.9 Although the ADP receptor blocker is usually
discontinued at the end of the year, thus covering the acute phase of thrombotic disease, aspirin is
continued indefinitely, thus maintaining antiplatelet coverage into stable CAD.
Antiplatelet therapy in stroke
Stroke is a leading cause of functional impairments, with 20% of survivors requiring institutional care
after 3 months and 15–30% being permanently disabled.10 Although the role of anticoagulation is well
established in stroke prevention, the role of aspirin therapy is less clear in this patient group.11 As such,
most recent guidelines do not recommend the use of aspirin in primary prevention, but warrant the
use of aspirin cardiovascular prophylaxis (including but not specific to stroke) in individuals whose risk is
sufficiently high for the benefits to outweigh the risks associated with treatment (a 10-year risk of
cardiovascular events of 6–10%).11
In patients suffering from atrial fibrillation, aspirin is recommended either on top of or in replacement of
anticoagulation in low-risk and some moderate-risk patients. The decision is based on patient preference,
estimated bleeding risk if anticoagulated and access to anticoagulation monitoring.11 For high-risk patients
with atrial fibrillation deemed unsuitable for anticoagulation, dual antiplatelet therapy with aspirin and
clopidogrel might be reasonable; the combination offers more protection against stroke than aspirin alone
but with increased risk of major bleeding.
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Antiplatelet therapy in peripheral arterial disease
Lower-extremity artery disease (LEAD) is a relatively common pathology. The disease is often asymptomatic,
with approximately one-third of all LEAD patients in the community presenting with symptoms. A recent
study has reported a LEAD prevalence of 18%, with 7% of patients reporting symptoms of intermittent
claudication.12 In the latest meta-analysis by the Antithrombotic Trialists’ Collaboration, the incidence of
vascular death, non-fatal MI and non-fatal stroke at follow-up was significantly decreased by 23% by
antiplatelet drugs in patients with intermittent claudication.4 It follows that antiplatelet therapy is
recommended in patients with symptomatic PAD, with low-dose aspirin (75–150mg daily) at least as
effective as higher daily doses.13 Moreover, antiplatelet therapy with aspirin is recommended in all patients
with angioplasty for LEAD to reduce the risk of systemic vascular events, and dual antiplatelet therapy with
aspirin and clopidogrel is recommended for a minimum of 1 month in cases of peripheral revascularisation,
after which time clopidogrel may be discontinued but with aspirin prescribed indefinitely.
Defining aspirin response
The efficacy of aspirin to prevent thrombotic events in cardiovascular patients is well established, with
> 100 randomised trials having been conducted in high-risk patients and demonstrating a reduction in
vascular death of approximately 15% and a further reduction in non-fatal vascular events of approximately
30%.4 Few drugs have demonstrated similar efficacy, with up to 50 major vascular events avoided per
1000 patients treated for 1 year, at a cost of one to two patients experiencing a major GI bleeding event.5
Both the benefit and the risk associated with aspirin are attributed to its ability to prevent thrombus
formation via inhibition of platelet function.14
The best-characterised mechanism of aspirin is acetylation of a key enzyme in platelet function, the
cyclo-oxygenase (COX)-1 enzyme. This enzyme transforms arachidonic acid into thromboxane A2 (TxA2),
a platelet agonist and vasoconstrictor.15–17 Aspirin is effective in inhibiting platelet activity at doses as low
as 20–40mg per day,18 and is clinically effective in preventing thrombotic events in daily doses as low as
75mg with little benefit of higher doses.5 This is particularly important in view of the fact that though
low doses of aspirin appear effective in preventing thrombotic events in patients at risk, the effect on
bleeding (especially GI bleeding) has been shown to be aspirin dose dependent.19 In recent years, it has
been shown that even acutely well-managed major bleeding events are associated with worse outcomes
in cardiovascular patients, in terms of both major adverse cardiovascular events and mortality.20,21 It follows
that most treatment guidelines advocate the use of the lowest aspirin dose effective in preventing
thrombotic complications so as to minimise the risk of major bleeding.22–25 From this, a need for
monitoring of aspirin therapy has emerged and prompted the development and investigation of numerous
assays of platelet function.
Platelet function testing in routine clinical practice
Current clinical guidelines do not recommend routine platelet function testing for aspirin in cardiovascular
patients.26–28 Although platelet function testing may be considered in certain contexts, for example
‘in patients at high risk for poor clinical outcomes’27 or if ‘a diagnosis of non-compliance is likely to aid
management’,26 the general message from both European and US guidelines, as well as from the
Working Group on Aspirin Resistance of the International Society on Thrombosis and Haemostasis, is that
monitoring of antiplatelet response by platelet function assays should remain restricted to clinical research,
and not be introduced in daily clinical practice.
A number of reasons may explain the lack of enthusiasm for platelet function testing in recently published
guidelines. These include the lack of consensus on the platelet function assay to be used; on the definition
of inadequate platelet response to aspirin; and on the clinical management of patients with insufficient
platelet inhibition by aspirin.14 Although there are a number of platelet function tests (PFTs) available, it
remains to be established how best to use these assays, and whether or not adjusting antiplatelet therapy
based on these results will improve clinical outcome.
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Platelet function assays
A vast array of platelet function assays is available to test the response of platelets to the inhibitory
effect of aspirin (Table 1). Some assays are laboratory based and require extensive expertise to operate,
whereas others have been specifically developed to be point of care. Although some assays study global
haemostasis, most platelet function assays target a specific phase of platelet function, from platelet
adhesion to platelet activation, secretion and aggregation. Important methodological disparities make
the assays unique in the way that they assess platelet responses. For example, some of these assays are
carried out in whole blood [including whole-blood aggregometry (WBA), platelet counting, platelet
function analyser-100 (PFA-100®; Siemens, Malvern, PA, USA), VerifyNow® Aspirin (Accumetrics Inc.,
San Diego, CA, USA), Impact-R® (DiaMed, Cresier, Switzerland) and flow cytometry], whereas others
require sample preparation [such as light transmission aggregometry (LTA), plasma or serum thromboxane
B2 (TxB2) measurement], and others can be performed on urine (levels of the TxB2 metabolite 11-dehydro-
TxB2). There is no official guideline recommending one assay over another, and platelet function testing is
not recommended for routine clinical testing in patients requiring aspirin therapy. As a result, many of the
available platelet function assays have been used in a research capacity, and part of the uncertainty
surrounding the definition and clinical relevance of aspirin resistance is due to the non-interchangeable
nature of these assays.
From a pharmacological perspective, the monitoring of aspirin efficacy requires assessment of the ability
of aspirin to inhibit its pharmacological target (platelet COX-1), and thus inhibit the conversion from
arachidonic acid to TxA2.29 This is the accepted measurement of the European Agency for the Evaluation
of Medicinal Products to assess the efficacy of aspirin.30 Assays measuring TxA2 formation in clotting blood
or in aggregating platelet-rich plasma thus appear ideal. However, TxA2 cannot be easily measured in
biological samples as it has a very short half-life in plasma (30–60 seconds).31 As a consequence, assays
measuring stable metabolites of TxA2, most commonly TxB2 (in serum/plasma) or 11-dehydro-TxB2
(in urine), are the most widely used.
From a functional perspective, a multitude of platelet function assays are available to assess platelet
responsiveness to aspirin.32 Some assays require extensive technical expertise and are limited to specialised
laboratories, whereas others are point of care and are meant as bedside tools. The assays that use
arachidonic acid as the agonist require a functioning COX-1 to convert it to the active TxA2 molecules
which then elicit a platelet response; these are referred to as COX-1-specific (Table 2). TxA2 is a secondary
mediator of platelet activation and synergises with other platelet pathways33 to elicit full platelet responses.
Therefore, aspirin therapy can also partly inhibit platelet activation induced by other agonists, such as
collagen and epinephrine.34,35 Platelet function assays based on these agonists have been used to quantify
the platelet reactivity of platelets in patients taking aspirin, although these do not specifically assess the
pharmacological efficacy of aspirin.36 These are referred to as COX-1-non-specific assays (see Table 2).
Arguably, COX-1-specific assays may capture more faithfully the effect of aspirin on platelets and may
therefore be preferable when looking at the pharmacological efficacy of aspirin. Moreover, COX-1-specific
assays are directly targeted by aspirin and are not affected by concomitant antiplatelet therapy, whereas
COX-1-non-specific and global assays will be influenced by other antiplatelet therapy used (e.g. in cases of
dual antiplatelet therapy with aspirin and an ADP receptor blocker, such as clopidogrel).
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Prevalence and natural history of ‘aspirin resistance’
When response to aspirin is assessed by COX-1-specific assays, little variability in platelet responses is seen,
with almost complete inhibition of TxA2-dependent platelet aggregation in almost all patients.36
–40 Far
greater biological variability in aspirin-induced platelet inhibition has been reported36,37,39,41,42 when
COX-1-non-specific assays have been used to assess platelet inhibition by aspirin. The definition of normal
response to aspirin has also lacked standardisation, and insufficient platelet response to aspirin, or ‘aspirin
resistance’, has been reported in various fashions, including tertiles/quartiles of response as well as
dichotomisation based on arbitrary cut-off values. Strikingly, the correlation between the results obtained
with the various platelet function assays is disappointingly low,36,37,39,41,42 thus making the studies using
different platelet function assays difficult to compare.
Despite the uncertainties surrounding the best way to test for aspirin effects, platelet function assays have
provided a number of potential mechanisms to explain some of the variability seen in platelet reactivity in
patients taking aspirin.43,44 As none of these factors fully explain the variability seen in patients, the
phenomenon of aspirin resistance is likely to be multifactorial.
In order to assess the efficacy of aspirin, it must be ascertained that the person being assessed has
indeed ingested aspirin. However, non-compliance with prescribed aspirin therapy is common and thus
compliance needs to be verified.45,46 Although crucial to the determination of platelet response to aspirin,
assessment of compliance is often lacking in studies of aspirin resistance. In a recent report on the use of
TABLE 2 Categorisation of platelet function assays
Platelet function assays (aspirin):
eligible in any population
COX-1-non-specific and global
assays of platelet function:
eligible in patients on aspirin alone
Platelet function assays (clopidogrel):
not eligible to assess platelet
responses to aspirin
COX-1-specific assays: TxA2
l Serum TxB2
l Plasma TxB2
l Urinary 11-dehydro-TxB2
l AspirinWorks® (Corgenix,
Broomfield, Co; commercial
urinary 11-dehydro-TxB2 assay)
COX-1-specific assays: AA
l LTA
l WBA
l Multiplate®
l VerifyNow® Aspirin
l Platelet count drop
(or single-platelet counting)
l Plateletworks® (Helena
Laboratories, Beaumont, TX;
commercial platelet count
drop assay)
l Thromboelastograph with
platelet mapping technology
(AA-induced, not ADP-induced)
l Impact-R®/CPA (with AA)
l AA-induced P-selectin expression
(CD62) or GPIIb/IIIa receptor
activation (PAC-1) by flow
cytometry
COX-1-non-specific assays
l Collagen- or epinephrine-induced
aggregation (either LTA, WBA,
Plateletworks® or Multiplate®)
l PFA-100® (platelet function
analyser with CEPI cartridge)
Global platelet function assays
l Bleeding time
l ROTEM® or thromboelastograph
(without platelet mapping
technology)
Activation downstream of the
P2Y12-ADP receptor
l VASP phosphorylation assay
[Biocytex® (Marseille, France)
commercially available assay]
ADP-based
l LTA
l WBA
l Multiplate®
l VerifyNow® P2Y12
l PFA-100® [collagen/ADP or
INNOVANCE® (Siemens, Malvern, PA,
USA) P2Y cartridges]
l Platelet count drop (or single-
platelet counting)
l Plateletworks® (commercial platelet
count drop assay)
l Thromboelastograph with platelet
mapping technology (ADP-induced,
not AA-induced)
l Impact-R®/CPA (with ADP)
l ADP-induced P-selectin expression
(CD62) or GPIIb/IIIa receptor
activation (PAC-1) by flow cytometry
AA, arachidonic acid; CEPI, collagen/epinephrine; CPA, cone and plate(let) analyser; GPIIb/IIIa, glycoprotein IIb/IIIa;
PAC-1, procaspase-activating compound-1; ROTEM®, rotational thromboelastometry; VASP, vasodilator-stimulated
phosphoprotein.
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secondary prevention drugs in patients with established cardiovascular disease, Prospective Urban Rural
Epidemiology (PURE) study investigators found that approximately one-quarter of patients with an
indication for aspirin therapy were actually taking it,47 making assessment of compliance a necessity prior
to platelet function testing. In studies where aspirin administration was actively monitored, the majority of
patients who were aspirin resistant on initial testing became responsive to aspirin upon retesting following
observed ingestion.46,48 Thus, in fully compliant patients, aspirin resistance may be a rare but important
biological phenomenon.45,49,50 Another important variable to control for in studies of aspirin resistance
is the presence of interacting drugs. A well-described interaction between aspirin and NSAIDs such as
ibuprofen and naproxen [but not rofecoxib (Vioxx®, Merck Sharpe & Dohme), celecoxib (Celebrex®, Pfizer),
meloxicam, acetaminophen or diclofenac] has been shown to have an impact on platelet aggregation
responses.51–54 These drugs prevent aspirin from binding to its target, platelet COX-1. Therefore, current
guidelines recommend that concomitant use of NSAIDs with aspirin should be carefully avoided.23
Other factors have been consistently associated with altered platelet responses to aspirin. Genetic factors
are known to be associated with variability in platelet responses to aspirin.40 In a large study of over
1800 participants treated with aspirin, heritable factors contributed to 27–77% of variability in platelet
function assay results, most importantly in COX-1-non-specific assays, whereas COX-1-specific assays were
influenced by less than 2% by heritable factors.40 Among considerable environmental factors, obesity
plays an important role. Indeed, increased waist circumference and higher body mass index have been
associated with reduced efficacy of aspirin to inhibit platelets.48 This is especially important when
enteric-coated aspirin tablets are used, as these also further reduce aspirin bioavailability.48,55 In diabetic
patients, aspirin resistance is more common, and platelets have an enhanced sensitivity to platelet agonists,
which has been associated with metabolic alterations, oxidative stress and endothelial dysfunction.56–62
Finally, recent evidence suggests that accelerated platelet function recovery may be a potential source of
variability in platelet responsiveness to aspirin. The most striking example of platelet turnover involvement
in platelet responsiveness to aspirin is in patients suffering from essential thrombocythemia (ET), a natural
disease model of enhanced platelet generation. In ET, recovery of platelet function occurs within 24 hours
despite daily aspirin therapy and is due to the formation of a large number of new uninhibited platelets
from megakaryocytes, resulting in an increased rate of platelet turnover.63–65 The phenomenon is not,
however, limited to ET; both in healthy volunteers and in patients suffering from CAD or diabetes,
increased platelet turnover has been associated with insufficient platelet inhibition by aspirin.66–70 Increasing
the frequency of aspirin administration to twice daily has been shown to effectively improve the inhibition
of platelet function by aspirin in these settings, although the clinical benefit of this therapy modification
remains unknown.63,64,71–73
Although the characteristics associated with poor response have been explored in detail,74 it is noteworthy
that the different studies have used different platelet function methodologies to explore the determinants
of platelet responses. In parallel, a number of different studies have shown platelet function assay
results to lack correlation and agreement among themselves, thus identifying different patients as poor
responders to aspirin and having different determinants of response.37,75,76 Which platelet function assay,
if any, is the most clinically predictive of future major adverse cardiovascular events remains to be
established.77 As a consequence, the natural history of aspirin resistance remains somewhat uncertain.
There is a need to address basic questions on the prognostic and diagnostic utility and cost-effectiveness of
platelet function testing in the context of aspirin therapy before testing can be recommended in clinical
practice. A number of systematic reviews attempting to address this basic question have been published in
recent years. In general, these have failed to sufficiently capture the volume of available evidence or
consider the heterogeneous nature of the evidence reviewed. These reviews are explored in more detail as
part of the results section of this report (see Chapter 5, Systematic reviews). As detailed in Chapter 3,
the aims of this report were to address this question of prognostic and diagnostic utility of platelet
function testing in the context of aspirin therapy.
BACKGROUND
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Chapter 2 Decision problem
This project was commissioned to review the evidence currently available on the association between theresult of a PFT and the occurrence of clinically relevant cardiovascular and cerebrovascular events, in
those patients receiving long-term aspirin therapy for cardiovascular disease or cerebrovascular disease (CVD),
and to consider the cost-effectiveness of the use of such tests. Specifically, this entailed (i) determining
prognostic utility (whether or not a test is able to distinguish between groups of patients with different
average outcome risks, even if it does not accurately predict individual outcome risk); (ii) determining
diagnostic utility [if such tests exist, to determine whether or not they have high diagnostic/predictive utility
(e.g. sensitivity, specificity and positive and negative predictive values close to 1) in order to determine,
for individual patients, if treatment modification should be considered based on the test result]; and
(iii) undertaking an exploratory model-based cost-effectiveness analysis.
The commissioning brief produced in 2010 by the National Institute for Health Research (NIHR), prior to
this project being funded, was titled The Diagnostic Utility of Identifying Aspirin Resistance, and asked:
In patients being considered for long term aspirin therapy is there evidence to show which tests of
‘aspirin resistance’ predict which patients will benefit from a change in management? Should all such
patients be assessed and if not in which groups of patients is testing cost-effective?
The questions posed in the commissioning brief are much wider than those examined by the project that
was eventually commissioned and require extensive consideration of the clinical pathway of treating
patients with cardiovascular disease or CVD, in whom long-term therapy with aspirin is traditionally viewed
as the mainstay of antithrombotic therapy. To review the evidence for each step of the pathway is beyond
the scope of the commissioned project. Thus, there are a plethora of questions that cannot be answered
by the work undertaken for this project, yet answers are required in order to determine if patients correctly
identified as likely to be at higher risk of adverse clinical outcomes while receiving long-term aspirin
therapy should have their management changed, and if so, when, and to what alternative therapeutic
regimen. These questions include but are not limited to the following:
l If patients could be correctly identified by a PFT as being at greater risk of adverse clinical outcomes
than other patients, do such patients gain some benefit, no matter how small, from the
aspirin therapy?
l Does platelet function, as measured by a given test, change over time in a given individual, and if so,
to what degree, when and why?
l When, if at all, should platelet function testing be undertaken, and should testing be repeated
and when?
l At what threshold of risk of adverse outcomes should a change in therapy be considered?
l Which therapeutic regimen should patients considered at high risk be switched to and when?
Some of these questions are intrinsically linked, and there is potentially published evidence related to some
of these that could be systematically reviewed in the future.
This project therefore only reviews the available evidence on the prognostic and diagnostic utility of PFTs,
applied to patients on long-term aspirin therapy, in order to determine if patient groups or individual
patients with high risk of adverse clinical outcomes can be identified correctly. The cost-effectiveness of
using these tests is considered through a review of economic evidence and a speculative de novo model-
based economic evaluation using, where necessary, clinician-derived assumption-based inputs relating to
parts of the clinical pathway outside of the scope of this project for which definitive published evidence
was not readily available.
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In this context, ‘aspirin resistance’ is defined as elevated platelet reactivity measured using a PFT.
This definition does not specify a threshold for defining elevated reactivity but relies on that specified
by the authors of the studies concerned. As such, there is likely to be considerable variability in the
characterisation of aspirin resistance employed in individual studies. Based on this definition, the term
‘aspirin resistant’ is defined as those individuals classified as having elevated platelet reactivity based on the
PFT and threshold specified by the authors of the studies, and ‘aspirin sensitive’ is defined as those not
having elevated platelet reactivity based on the PFT and threshold specified by the authors of the studies.
An evaluation of prognostic utility of aspirin resistance requires assessment of whether or not PFTs are able
to distinguish between groups of patients with different average risks of clinically important outcomes.
Providing prognostic utility can be demonstrated, an evaluation of the diagnostic/predictive utility of
aspirin resistance requires assessment of whether or not PFTs are able to determine, for individual
patients, if they are at increased risk of clinically important outcomes and thus warrant consideration of
treatment modification.
DECISION PROBLEM
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Chapter 3 Aim of the review
The aims of the review were as follows:
1. To review systematically the evidence relating platelet function testing to the risk of adverse clinical
outcome(s) in patients on aspirin therapy with established cardiovascular disease or CVD, or diabetes.
More specifically, to determine whether or not different PFTs have prognostic utility or diagnostic/
predictive utility with regard to such clinical outcomes.
i. Prognostic utility To establish whether or not any of the available PFTs has prognostic ability,
i.e. is able to distinguish between groups of patients with different average outcome risks. For PFTs
demonstrating prognostic utility, to explore:
ii. Diagnostic/predictive utility To establish whether or not any of the available PFTs to determine
aspirin resistance has sufficiently high diagnostic/predictive utility (e.g. sensitivity, specificity and
positive and negative predictive values close to 1) in order to determine, for individual patients,
if treatment modification should be considered based on the test result.
2. To review systematically the evidence relating to the economic utility of platelet function testing in
patients on aspirin therapy with established cardiovascular disease or CVD, or diabetes.
3. To undertake exploratory, model-based cost-effectiveness analysis of the use of platelet function testing
in patients on long-term aspirin therapy with consideration of the potential for populating the model
with data based on the results of the systematic review outlined in (1).
Within this report, the methods and results for the aims outlined in (1) are reported in Chapters 4 and 5
respectively, and those for the aims outlined in (2) are reported in Chapter 6. The findings for all aims are
discussed in Chapter 7.
The protocol for this project was registered with PROSPERO (2012:CRD42012002151) and has been
published on the NIHR Health Technology Assessment (HTA) programme website (www.hta.ac.uk/2468).
A version of the protocol was also published in the journal BMC Systematic Reviews.78
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Chapter 4 Methods of prognostic and diagnostic
utility review
This section describes the methods for the systematic review of the evidence relating platelet functiontesting to the risk of adverse clinical outcome(s) in patients on aspirin therapy with established
cardiovascular disease or CVD, or diabetes.
The review will specifically target studies which relate platelet function testing to clinical outcome in
patients with established cardiovascular disease or CVD or diabetes who are being treated with aspirin.
Analysis will consider whether or not PFTs have prognostic ability in that they are able to distinguish
between groups of patients with different average outcome risks. If demonstrable, analysis will
subsequently consider diagnostic/predictive ability, i.e. whether or not given tests have sufficiently high
diagnostic/predictive utility to accurately distinguish those individual patients who will have an adverse
outcome from those who will not.
A standard systematic review approach was used and is described below.
Selection criteria
Two broad types of study were considered relevant for this review: those studies that provide information
on the prognostic or diagnostic/predictive utility of PFTs and those that report prognostic models, in which
a PFT is one of multiple prognostic factors predicting clinical outcomes in a population of interest. The
selection criteria for each are outlined below.
Prognostic utility and diagnostic utility studies
Types of study
Any prospective primary studies, or systematic reviews of such studies, assessing PFT(s) in relation to
clinical outcomes.
Types of participants
Patients aged ≥ 18 years on aspirin (as monotherapy or in combination with other antiplatelet agents),
with established cardiovascular disease or CVD, or diabetes. Studies with mixed populations were included
as long as data for relevant patients were extractable. Studies with patients on aspirin for peripheral
vascular disease were noted.
Setting
Studies in any setting were included.
Technology
Either a COX-1-specific PFT (which measures aspirin response specifically) or a global PFT in patients
receiving aspirin as the only antiplatelet therapy. The selection process was guided by the information
in Table 2.
Outcomes
Clinical outcomes, such as vascular events [non-fatal and fatal ischaemic stroke, TIA, systemic embolism
(pulmonary embolism, peripheral arterial embolism), MI, revascularisation procedures]; haemorrhagic
events; all-cause mortality; mortality due to vascular events; composite outcomes containing the above
[e.g. major adverse cardiac events (MACEs)].
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Timing
Reported outcomes had to occur after the undertaking of a PFT and the post-test follow-up period had
to be 7 days or longer. Thus, studies performing platelet function testing after clinical events, with no
further follow-up after the testing, were excluded (unless the testing was undertaken on stored samples
retrieved prior to the clinical event, as this retains the temporal relationship between testing and
subsequent outcome occurrence).
Prognostic model studies
Studies reporting prognostic models, in which a PFT was one of multiple prognostic factors predicting
clinical outcomes in a population of interest, were eligible for review, in order to examine the contribution
of the PFT to the overall performance of the prognostic model, and to establish whether or not predictive
accuracy of clinical outcomes was improved by combining test results with other prognostic factors.
The following criteria were used to select such studies:
i. Was a statistical model outlined to predict a relevant clinical outcome outlined above?
ii. Did the model include a factor for PFT result or aspirin resistance?
iii. Was the model developed for use in patients aged ≥ 18 years and on aspirin (alone or in combination
with another therapy) for established cardiovascular disease or CVD or diabetes?
Searches
The following bibliographic databases were searched:
l The Cochrane Library (Wiley) (issue 4 of 12) [including the Cochrane Database of Systematic Reviews,
Database of Abstracts of Reviews of Effects, HTA Database, NHS Economic Evaluation Database (NHS
EED) and Cochrane Central Register of Controlled Trials] to April 2012, MEDLINE (Ovid) from 1950 to
2012, MEDLINE In-Process & Other Non-Indexed Citations (Ovid) to
25 April 2012 and EMBASE (Ovid) from 1980 to 2012.
Search strategies combined index and text words encompassing the technologies (platelet function testing)
and the patient group (cardiovascular disease, CVD and diabetes), as well as focusing on aspirin resistance.
The Zetoc database (The British Library), Conference Proceedings Citation Index and Science Citation Index
(Web of Science) were searched for conference proceedings. ClinicalTrials.gov, the UK Clinical Research
Network Study Portfolio Database, the World Health Organization International Clinical Trials Registry
Platform and the metaRegister of Controlled Trials were also searched for ongoing studies.
Reference lists of relevant articles, particularly systematic reviews, were hand-searched to identify other
potentially relevant articles. Furthermore, a subject expert was used to identify any studies which may not
be identified using standard methods.
Restrictions on publication language and date were not applied to the searches.
Copies of the search strategies used in electronic databases can be found in Appendix 1.
In addition, abstracts from the following national and international proceedings were hand-searched from
2009 onwards:
l platelet conferences (Platelets International Symposium)
l cardiology conferences (British Cardiovascular Society, American College of Cardiology, European
Society of Cardiology, American Heart Association, American College of Chest Physicians)
l stroke conferences (International Stroke Conference, American Stroke Association)
METHODS OF PROGNOSTIC AND DIAGNOSTIC UTILITY REVIEW
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l haematology conferences (British Society for Haematology, International Society on Thrombosis and
Haemostasis, International Society for Laboratory Haematology).
Abstracts that were identified were considered for relevance in a similar way to fully published
studies/articles.
Search results were entered into reference management software [Reference Manager version 11
(Thomson ResearchSoft, San Francisco, CA, USA)]. Duplicate records were removed by built-in algorithms
and subsequent manual checking.
The searches of electronic databases were undertaken in April 2012 and were not updated after this time.
A note was made of any additional relevant studies published subsequently that came to the attention of
the authors of this report. These studies were not reviewed to avoid bias. A brief comment is made about
these studies in Chapter 5, Relevant studies identified after the search cut-off dates.
Study selection
Study selection was undertaken as a two-step process. Titles (and abstracts where available) in records
were initially screened by two reviewers, using prespecified screening criteria. These criteria were kept
necessarily broad as it was anticipated that not all relevant information would necessarily be presented in
an abstract, and thus the use of stricter criteria was likely to lead to the exclusion of relevant articles at this
screen stage. These criteria were based on whether or not the records indicated that articles were about,
or likely to be about, platelet function testing; reported, or were likely to report, clinical outcomes
measured after a PFT; and were about patients who had or were likely to have cardiovascular/
cerebrovascular or diabetic disease and were receiving aspirin therapy.
An additional criterion for conference abstracts was that these needed to be published from 2009
onwards to be retained. Letters to journals were not automatically classed as irrelevant, because often new
results relevant to this field are made available through this medium.
Full texts of any potentially relevant articles or those where a decision could not be made were sought.
In the second part of the two-step selection process, full-text articles were assessed against the full
inclusion criteria by two reviewers independently. Any discrepancies between reviewers were resolved by
discussion or by referral to a third reviewer. A copy of the selection form used for this process is available
on request.
Both stages of the selection process were piloted prior to full implementation.
At title and abstract screening and for full-text screening, appropriate portions of non-English-language
articles were translated where necessary to aid the selection process.
A record was kept of all decisions made, the reason for exclusion from the review at the full-text
screening stage, articles that were not obtainable even by The British Library and also cases where
decisions could not be made owing to missing information in a paper or abstract. In the case of this last
scenario, an e-mail was sent to an author requesting further information.
During the selection process, any study identified that was thought to be of relevance to the
cost-effectiveness review was cross-checked against the search results for that review to
ensure comprehensiveness.
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Assessment of risk of bias
Risk of bias was assessed by one reviewer and independently checked by a second reviewer.
Disagreements were resolved by discussion.
Prognostic and diagnostic/predictive utility
As the review involved assessment of both prognostic and diagnostic/predictive utility, the quality
assessment strategy involved using criteria of relevance from both the Quality Assessment of Diagnostic
Accuracy Studies (revised tool) (QUADAS-2) guidelines79 for diagnostic test studies and criteria for checking
the quality of prognostic studies suggested by Hayden et al.80
These criteria were compiled under the five domains outlined below with their corresponding
assessment questions.
l Domain 1: patient selection
¢ Was a consecutive or random sample of patients enrolled?
¢ Was patient selection independent of patient outcomes?
¢ Were reasons for any posteligibility exclusions provided?
l Domain 2: PFT
¢ If a threshold was used, was it prespecified?
¢ How was the threshold derived (e.g. literature cut-off, based on study data)?
¢ Is the undertaking and interpretation of the index test blinded to the patient characteristics
(including clinical outcomes)?
l Domain 3: outcomes
¢ Were the outcomes of interest clearly defined in advance?
¢ Were the outcome results interpreted without knowledge of the results of the PFT?
l Domain 4: study attrition
¢ What was the proportion of missing data? (State reasons for loss to follow-up or differences in
those who completed or were lost.)
l Domain 5: confounding
¢ Are confounders accounted for in the design or analysis (e.g. adjustment, stratification)?
¢ If there is an adjusted outcome measure [e.g. odds ratio (OR), hazard ratio (HR)], what were the
factors that were adjusted for?
¢ If a HR was presented, was the proportional hazards assumption met?
¢ Was compliance measured?
¢ How was compliance measured?
¢ Level of compliance.
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Prognostic models
If any prognostic models were included, the quality criteria described by Altman81 were to be used in
addition to those of Hayden et al.80 Specific elements to be considered were:
l methods of model development (selection of candidate risk variables, relative weighting, handling of
continuous variables)
l internal and external model validations
l study design (prospective/retrospective)
l sample size (considered a priori)
l missing data (quantity, and how missing data were handled in the statistical analysis)
l criteria for inclusion of prognostic factors into the model (adequately described, and whether or not
well-known prognostic factors were included regardless of significance).
Any prognostic models identified were to be summarised qualitatively (summarising, for example, included
variables, calculation of risk score, predictive accuracy and whether or not the model was validated
internally and externally) and quantitatively by extracting performance statistics for calibration (such as
observed/expected outcomes) and discrimination (such as sensitivity and specificity) of the model. Similarly,
where studies reported the incremental value of including PFTs in prognostic models, these data were to
be summarised.
Data extraction
Data extraction was conducted by one reviewer using a standardised, piloted data extraction form, and
independently checked by a second. Disagreements were resolved through discussion or referral to a
third reviewer.
The data extraction process was necessarily complex owing to the nature and variability of the included
studies. Data extraction was undertaken directly into a specially created sheet in Microsoft Excel 2010
(Microsoft Corporation, Redmond, WA, USA). Extensive data related to the following domains were
extracted: study design and characteristics; patient characteristics; antiplatelet regimens; PFT utilised;
outcome measures and length of follow-up; data required for analyses; statistical methods employed and
their appropriateness. Studies were grouped according to whether patients were on monotherapy (aspirin
only) or dual therapy (with a second antiplatelet agent such as clopidogrel added to aspirin), in order to
distinguish between patients in a stable (monotherapy) or acute phase (dual therapy) of thrombotic
disease. Patients who have experienced ACS, or who have undergone PCI, will generally have a second
agent added to their therapy for up to 1 year before reverting back to monotherapy. Note that for reasons
outlined in Presentation of results, only results pertaining to monotherapy studies have been presented in
this report.
For further details on data extracted, readers can consult a copy of the database via information presented
in Appendix 4.
With regard to the data extracted for analysis, details are given in the following section.
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Analysis
Data extraction for potential meta-analysis
A key analytical aim was to conduct meta-analysis for each test in relation to each clinical outcome
reported by the individual studies. To do this, relevant data reported by the included studies needed to be
extracted. Data extraction was conducted independently by two reviewers, and if necessary any differences
were resolved via discussion with a third reviewer. If multiple cut-off levels were considered in a study
(e.g. to define test ‘positive’ and test ‘negative’), then results were sought for each cut-off reported. Both
unadjusted and adjusted results were extracted, as both were considered to be important. Unadjusted
results help ascertain the prognostic ability of a test when it is used in isolation. Adjusted results reveal
whether or not a test has prognostic utility over and above other prognostic factors; a true causal factor of
poor outcome will retain strong prognostic value even after adjustment, and so this further informs the
clinical value of a test.
Two groups of summary results were sought during data extraction, as follows.
Prognostic ability: unadjusted and adjusted odds ratios and hazard ratios
The prognostic ability of each test reveals its association with clinical outcome and provides the relative risk
between groups defined by test values; for example, the odds of poor outcome in test-positive patients
compared with test-negative patients.
For binary outcomes, the reported unadjusted OR and its 95% CI and p-value were extracted. If these
were not available, data were sought to populate a 2 × 2 table, from which the values could be calculated
directly. Any adjusted ORs (with CIs and p-values) reported were extracted along with the reported set of
adjustment factors that were used.
When the follow-up is longer and/or there are patients lost to follow-up (censored), time-to-event analyses
are more appropriate to account for different lengths of follow-up. When time-to-event analyses were
reported (e.g. Cox regression analyses, log-rank tests), the unadjusted HR and its 95% CI and p-value were
sought and extracted. If these were not provided directly, then the methods of Parmar et al.82 to indirectly
estimate them from other available data were used. If these were not possible, and a 2 × 2 table was
available for a particular time point, the method of Perneger83 was used; this method assumes that all
patients are followed up for the same length of time. Any adjusted HRs (with CIs and p-values) reported
and the set of adjustment factors that were used were also extracted. For studies using Cox regression,
whether or not the proportional hazards assumption had been checked and was considered valid
was recorded.
If studies reported results according to the test on its continuous scale, that prognostic result was extracted
directly (and so did not force a categorisation). If results were presented for the test categorised into
three or more groups (e.g. according to tertiles or quartiles), results for each comparison presented were
extracted, but where possible the groups were collapsed down to a binary comparison (to be most
comparable with other studies, which generally used a dichotomisation). This collapsing was only possible
for calculating unadjusted ORs or unadjusted HRs when 2 × 2 tables could be derived; it was not possible
for adjusted results.
If studies provided a 2 × 2 table with one or both groups with a zero cell, then a continuity correction was
added to these in order to calculate effect sizes, using the method of Sweeting et al.84 The continuity
correction added was 1/(sample size of the opposite group).
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Diagnostic/predictive accuracy
If prognostic utility can be demonstrated, an evaluation of diagnostic/predictive utility of aspirin resistance
requires assessment of whether or not PFTs are able to determine, for individual patients, if they are at
increased risk of clinically important outcomes and thus warrant consideration of treatment modification.
Ordinarily, test accuracy is assessed on ability to distinguish between patients who are subject to a risk
factor/carry a marker for disease, etc., and those who are not. However, in the current context of platelet
function testing predicting future adverse clinical outcomes, diagnostic utility requires the test to identify
the risk factor, and then the risk factor has to be intrinsically linked to the outcome. Thus, the diagnostic
utility contains elements of the accuracy of the test in measuring platelet function and the strength of the
association between the platelet function and the outcome. Furthermore, there is no single outcome
in the current context and the risk of each possible outcome might vary over time. This means that,
prior to assessment of diagnostic utility, it is important to have demonstrable association between the
marker and outcome(s).
As will be seen in Chapter 5, no strong association was identified between any PTF and clinical outcome,
thus determination of diagnostic utility is mute. However, where data were available to consider an
assessment of diagnostic utility, the presence of these data was noted and they were extracted.
Speculative analysis of sensitivities and specificities was undertaken and this is presented in Appendix 3
along with a description of the relevant analysis methods.
Meta-analysis methods
Once the summary results were extracted for each study and for each test, the clinical experts and
researchers met to identify groups of similar patient groups and clinical outcomes across studies. For each
patient group and outcome identified, the possibility for meta-analysis was considered; that is, whether or
not suitable data were available from multiple studies for the same clinical outcome and test in relation
to prognostic ability (relative risk scale: synthesis of ORs or HRs, taking unadjusted and adjusted results
separately) and, speculatively, the diagnostic/predictive ability (absolute risk scale: sensitivity and specificity).
Where possible, a separate meta-analysis for each cut-off level was considered. The intended methods
for any meta-analyses were outlined in the protocol. As a result of the clinical and methodological
heterogeneity between studies, pooling of data was determined to be inappropriate even in subgroups of
studies employing the same PFT. However, data are presented in this report in forest plots (without the
summary estimate) along with some relevant study characteristics highlighting heterogeneity.
Amendments to protocol
Initially the protocol did not specify that studies of patients on dual/triple antiplatelet therapy [i.e. aspirin
with additional antiplatelet agent(s)] had to employ an aspirin-specific PFT, rather than any PFT. This was
changed prior to study selection and the pertinent platelet function assays are reflected in Table 2.
It was originally stated that studies which met all of the inclusion criteria except for reporting clinical
outcomes would be noted, as these might provide useful information for cost-effectiveness analysis
(e.g. uncertainty around the prevalence of those defined as aspirin resistant from specific assays in specific
populations). From very early in the study selection process, the protocol was amended to omit this owing
to the very large number of studies being identified and limited benefit of identifying these across all the
tests and populations.
These amendments were reported to the NIHR and a revised protocol was submitted.
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Presentation of results
Throughout the following sections, our aim has been to highlight the heterogeneity between studies with
regard to population, PFT, outcomes and analysis of studies.
Results have therefore been separated according to whether patients were receiving only aspirin as
antiplatelet therapy (monotherapy) or aspirin and a second antiplatelet agent (dual therapy) at the time of
the PFT. There are a number of reasons for this:
l Populations receiving monotherapy are potentially likely to differ from those receiving dual therapy
(e.g. they are less likely to have very recently had an acute cardiovascular event or to be undergoing
non-elective PCI).
l The influence of a second antiplatelet agent on an aspirin-specific PFT is unclear.
l The second antiplatelet agent is likely to influence occurrence of clinical outcomes, and occurrence of
outcome is fundamental to determination of prognostic utility.
l Resistance to other antiplatelet agents is known, and may affect event rates.
The original intention was to report and analyse studies relating to both patients receiving monotherapy
and those receiving dual therapy. It was decided to undertake a stepwise approach to the analysis, starting
with monotherapy studies and then moving on to dual-therapy studies; based on the reasons listed above,
it is possible that an association between aspirin resistance and clinical outcome may be more apparent
within those populations receiving aspirin therapy alone, as it might be more difficult to demonstrate
prognostic utility in patients receiving aspirin with additional antiplatelet therapy because of the potential
added confounding effect of the other antiplatelet agent.
Furthermore, it is debateable whether or not analysis of studies with dual therapy is warranted in the
absence of demonstrated prognostic utility of platelet function testing in patients treated with aspirin as
monotherapy. As this criterion was not met (i.e. prognostic utility could not be adequately demonstrated),
all results presented in the following sections relate to monotherapy only. However, in the interest of
transparency the authors wish for all extracted and analytical data (including those from dual-therapy
studies) to be available to readers of this report. The data have been made available through a web portal
and further details can be found in Appendix 4, including how to access the data.
Monotherapy studies were further defined as those where all, or the vast majority of, patients were on
monotherapy at the time of the PFT, given that treatment strategies may change over time depending on
disease progression. Adding a second agent may affect the rate of clinical events, and this may not be
independent of the underlying risk, as higher-risk patients are more likely to be receiving or to commence
dual therapy. Where studies have clearly specified where a proportion of patients have at some point
during the follow-up period switched therapy or received additional therapy, this information has been
extracted. It is, however, possible that not all studies have reported this information.
Populations have been broadly classified as having (i) stable CAD, (ii) stable CVD/stroke, (iii) PAD/peripheral
vascular disease (PVD) or (iv) unstable angina (UA)/ACS. Where patients are undergoing elective PCI (PCI)
or primary PCI (PPCI), this has also been indicated. Where the population comprises several patient groups,
this has been classified as miscellaneous. Note that some acute populations have been included where the
PFT was undertaken when patients were on monotherapy.
Results have been separated for different PFTs, and where several thresholds or agonists have been used,
this has been indicated. Where different PFTs have been used within the same study, results have been
presented in Chapter 5, Studies with more than one test.
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Outcomes have been classified as (i) death, (ii) MACE, (iii) ischaemic/thrombotic or (iv) haemorrhagic/
bleeding. A consistent definition for MACE is not used in the literature;85 for example, it may or may not
include stroke. For a composite outcome that includes cerebrovascular complications, the abbreviation
MACCE is sometimes used (with the additional ‘C’ indicating the cerebrovascular component), but again,
this is not consistent. Rather than devise a definition of what constitutes MACE or MACCE for this report,
studies with a composite outcome of adverse cardiovascular events have been grouped together using the
abbreviation MACE. Where stroke has been reported as a separate outcome, this has also been highlighted.
Within the categories of MACE/MACCE there are some inconsistencies between studies in how this has
been defined; this has been appropriately highlighted where necessary. The category of ‘ischaemic/
thrombotic’ events is broad and encompasses a number of different events such as revascularisation,
angina, bypass surgery, cardiovascular readmission, graft occlusion, MI, etc.
The different outcome measures used in the studies have been summarised as a first step in deciding
whether or not pooling is possible and to give an idea of the range of outcome measures used. They
have been grouped according to the following: sensitivity and specificity, unadjusted or adjusted ORs, or
unadjusted or adjusted HRs. Where HRs or ORs have not been presented but have been calculated for this
report, this has been indicated. Additionally, where groups have been collapsed in order to provide a
single threshold, this has also been indicated. Note that where outcomes have been reported for different
test characteristics (e.g. different agonist, threshold, etc.), not all results will necessarily have been
summarised using the same outcome measures.
Odds ratios and HRs provide information on the usefulness of a PFT as a prognostic risk factor. Adjusted
ORs or HRs may take into account differences in clinical characteristics, which are linked to adverse events.
At the least informative level, articles have only provided a narrative statement regarding the relationship
between PFT results and clinical events.
Quality assessment of studies is also clearly presented to aid interpretation of findings.
Owing to the extensive nature of the data extracted from included studies for this project, it was deemed
unfeasible to adequately present all the data in this report (even as appendices). The results section of
the prognostic utility review in this report contains, where necessary, details of the studies, including the
populations studied, test characteristics and quality-related features, and data for key outcomes are
presented in illustrative forest plots.
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Chapter 5 Results of prognostic utility review
Quantity of research available
The searches resulted in the identification of 16,583 records (after automatic removal of duplicate records)
and one further record from checking reference lists of relevant systematic reviews. Manual removal of
duplicate records left 13,795 article records. Screening of titles and abstracts in these records indicated
that 12,581 were not relevant. Full-text articles of the remaining 1214 were sought. Twenty of these
articles were unobtainable and these are listed in Appendix 5; 65 were reports of ongoing studies and
these are commented on later in this chapter (see Ongoing studies); and 1129 full-text articles were
obtained for assessment against the inclusion criteria. Nine hundred and thirty-three articles were excluded
and these are listed in Appendix 6, Table 85 with reasons for exclusion; 12 of these were excluded
because there was insufficient information available to make a decision despite requests by e-mail to the
authors for further details (see Appendix 6, Table 86).
One hundred and ninety-six articles met the inclusion criteria. Of these, 62 contained details of PFT results
and clinical outcome data but failed to report the outcome data in relation to the test result, and thus
provided no relevant information on prognostic utility of the PFT. These studies are listed in Appendix 7.
A further 119 included articles all reported clinical outcome data in relation to the result of one or more
PFTs.46,76,86–202 These articles report the findings of 108 studies that are detailed in the subsequent sections
of this report. The remaining 15 articles203–217 reported systematic reviews and these are described below
(see Systematic reviews).
A flow diagram presenting the process of selecting studies can be found in Figure 2.
Study mapping
As outlined in more detail below (see Monotherapy), included studies were separated into categories
based on whether enrolled patients were receiving aspirin as their only antiplatelet agent (monotherapy) or
aspirin combined with one or more other agents (dual/triple therapy) at the time of the PFT, and by the
type of PFT employed in the study. Subcategorisation was undertaken to distinguish studies in which the
therapy at the time of platelet function testing remained the same during follow-up from those in which
this changed (e.g. patients on monotherapy at the time of testing but subsequently receiving dual
therapy). Subjective decision-making was required in some cases where a proportion of patients was
receiving a different therapeutic regimen at the time of testing and/or follow-up (e.g. some on
monotherapy and some on dual therapy at the time of testing and/or follow-up). If the proportion was
considered small (≤ 5%) then these studies were categorised under the therapy of the larger proportion. If
large (≥ 11%), then these studies were put into a separate category.
The result of this mapping of studies is shown in Table 3.
Of the 108 included studies with test data linked to clinical outcome data, 57 studies reported on a patient
group solely or predominantly receiving aspirin as monotherapy at the time of testing,46,76,86,88,90,92,93,95,99,105,
108–110,112,113,115–118,121,123,125,127,128,132,133,135,137,138,142,144–155,159,162–164,166,168,169,171,174,186,187,189,193,195,196,198,201,202 51 studies
reported on a group of patients solely or predominantly receiving dual therapy87,89,91,94–98,100–102,104,106,111,114,119,
120,122,124,126,129–131,134,136,139–141,143,147,150,156–161,165,167,170–173,175–185,188,190,191,192,194,197,199,200 and one study103,107
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FIGURE 2 Flow diagram showing study selection.
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contained a mixed population of monotherapy and dual therapy. Five studies95,147,150,159,171 were able to be
mapped to both monotherapy and dual therapy categories. Turning to categories of test, LTA and the
PFA-100® were the most frequently used tests in included studies, with VerifyNow® Aspirin, thromboxane
metabolites and WBA also frequently encountered. Thromboelastography (TEG) was less well represented.
Several tests that fell outside of these categories were placed in a miscellaneous category and this included
small numbers of studies that employed, for example, tests such as flow cytometry methods and various
commercial assays not included in other categories. Proportions of tests used within the monotherapy
studies were: LTA (25%, 19 studies16,88,90,93,95,112,113,121,125,142,147,149,155,159,163,164,169,174,187,201), VerifyNow® Aspirin
(9%, 7 studies86,92,99,105,133,162,171), PFA-100® (28%, 21 studies76,99,108,109,112,115,116,118,123,127,132,135,137,138,144,145,150,162,
186,187,189,193), thromboxane metabolites measurement (14%, 11 studies46,76,99,108,110,148,151,162,164,195,202),
WBA (10%, 8 studies99,117,128,153,162,166,186,196), TEG (4%, 3 studies117,168,174) and miscellaneous tests (9%,
7 studies76,93,125,146,152,154,163,196,198). The corresponding proportions for dual-therapy studies were: LTA (25%,
14 studies95,96,98,100,101,104,111,120,122,124,126,130,136,143,147,157,159,160,172,188), VerifyNow® Aspirin (21%, 12 studies87,91,98,
101,119,157,161,170,171,178,182,190,194,200), PFA-100® (25%, 14 studies89,94,98,101,102,120,124,129,131,139–141,150,157,173,181,185),
thromboxane metabolites measurement (0%), WBA (18%, 10 studies97,100,106,114,158,165,167,175–177,179,180,183,184,191),
TEG (5%, 3 studies156,197,199) and miscellaneous tests (5%, 3 studies98,101,134,157,192). Note that several studies
utilised a range of tests concurrently in the same study population. These are also identified, along with
the tests used, in Table 3.
Prognostic utility of tests
Population characteristics and quality assessment of studies are presented in the following sections. As
outlined in more detail in Chapter 4, Presentation of results, the structuring of results has been guided by:
l population receiving monotherapy or dual therapy at the time of the PFT
l therapy received after the PFT
l PFT used
l outcome (death, MACE, ischaemic/thrombotic event, bleeding)
l outcome measures presented or calculable [(un)adjusted OR and HR, sensitivity and specificity]; note
that sensitivities and specificities are presented in Appendix 3.
This is followed by a summary for each PFT. Studies where more than one PFT were performed
concurrently are reported in Studies with more than one test.
Monotherapy
The tests identified for assessing platelet function in patients on monotherapy (aspirin only) are (i) LTA,
(ii) VerifyNow® Aspirin, (iii) measurement of urinary or serum/plasma 11-dehydro-TxB2 concentrations,
(iv) PFA-100®, (v) WBA, (vi) TEG and (vii) other miscellaneous tests.
Light transmission aggregometry
Population and test characteristics
Nineteen studies88,90,93,95,112,113,121,125,142,147,149,155,159,162,164,169,174,187,201 were identified in this category, four of
which were reported in abstract form only,162,164,169,174 and one as a letter.88 Populations had CAD
(six studies113,142,149,162,164,201), CVD/stroke (six studies88,95,121,125,155,159) or PAD/PVD (four studies90,112,147,169).
There were three studies93,174,187 in patients with UA/ACS; in one of these93 patients were all undergoing
PPCI. None of the studies reported how long patients had had their primary underlying condition for.
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In 12 studies88,90,95,112,121,142,147,155,159,162,164,174 it appeared that patients were exclusively on monotherapy both
at the time of the PFT and during follow-up. In two studies,113,125 around 4% and 5% of patients were on
dual therapy (aspirin+ clopidogrel) at the time of the PFT. Given the small proportion on dual therapy,
these studies have been included in the ‘monotherapy’ category.
In a further four studies,149,169,187,201 patients were on monotherapy at the time of the PFT, and around 4%,149
25%169,201 or 45%187 of patients respectively went on to receive an additional antiplatelet agent (clopidogrel)
at some point during follow-up. It is possible that not all studies have reported where a proportion of
patients commenced additional therapies during follow-up.
In the study where patients underwent PPCI,93 patients were on monotherapy at the time of the PFT and
all were on dual therapy (aspirin+ clopidogrel) during follow-up. This study has been listed separately,
as the addition of clopidogrel therapy in all patients may affect the rate of events, and may also be a
reflection of underlying population differences compared with the other studies.
Comedications, where reported, included statins, beta-blockers, angiotensin-converting enzyme (ACE)
inhibitors, angiotensin II receptor blockers, calcium channel blockers, nitrate esters, proton pump inhibitors
and dalteparin (Fragmin®, Pfizer). NSAIDs were not permitted (or had to be discontinued within a certain
time period) in seven studies;88,90,112,142,149,159,201 one study155 stated that drugs known to affect PFTs were
discontinued, and there were no details on NSAIDs in the remaining studies.
The number of participants in the studies ranged from 32 to 583 (see Table 4). Where reported, mean
ages of patients ranged from 60 to 75 years, with most means around the mid to late 60s or early 70s.
There were more men than women in 14 out of 15 studies that reported on this,88,90,93,95,112,121,125,147,149,155,
159,163,174,187,201 with proportions of men ranging from 53% to 81%. Only one study142 included more
women (54%). The proportion of patients with diabetes ranged from 11% to 47%, and that of smokers
from 5% to 66% (where reported, see Table 4). All studies were conducted in hospital settings.
The dose of aspirin ranged between 75mg/day and 325mg/day, with the exception of one study155
where the dose was high, at 1000mg/day. This study included patients with TIAs or reversible ischaemic
neurological deficits. There were no details on dose in one study.95 Details were variable across studies
regarding the length of time patients had been receiving aspirin therapy, with some noting a minimum
period and some whether patients were chronic or first-time users, but many giving no details (see Table 4).
No study stated whether aspirin was provided in enteric or plain form, though one study93 noted that aspirin
was in chewable form.
The main study characteristics are listed in Table 4 below. Note that in some studies baseline characteristics
have been reported only according to resistant/sensitive groups or groups with/without adverse clinical
events, rather than for the total study population.
The test performed in 18 out of 19 studies was LTA. Most tests used arachidonic acid as an agonist, with
some also using collagen and ADP, and sodium citrate as the anticoagulant (where reported). One study187
used a variant of LTA, an aggregometer that uses laser light scattering (the PA-200).
Most studies reported no details on the timing of the PFT after aspirin ingestion. One study125 noted that
there were at least 6 hours between aspirin dose and PFT, and three other studies112,147,149 stated that there
were up to 24 hours between aspirin dose and PFT. Table 5 provides details of test characteristics.
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TABLE 5 Test characteristics (LTA, monotherapy)
Study
Details of kit/
manufacturer
Anticoagulant
(concentration)
Agonist
(concentration)
Time since last
aspirin dose
Monotherapy at time of PFT and during follow-up
Abumiya 201195 MC Medical, Tokyo, Japan ‘Citrated blood’ Collagen (2 µM)
Collagen (5 µM)
ADP (1 µM)
ADP (10 µM)
No details
Cha 2008121 Model 560 VS (Chrono-log
Corporation, Havertown,
PA, USA)
Sodium citrate AA (0.5mg/ml=
1.6mM)
ADP (10 µM)
No details
De Boni 2011159 Chrono-log 700-4
lumi-aggregation systems
(Chrono-log Corporation,
Havertown, PA, USA)
Sodium citrate (3.2%) AA (0.5mM increasing
up to 1mM)
No details
Feher 201188 (letter) LTA (no further details) No details No details
(reported elsewhere)
No details
Feng 2011201 LTA (no further details) No details AA No details
Gum 2003149 PAP4 platelet aggregometer
(BioData, Horsham,
PA, USA)
Sodium citrate (3.8%) AA (0.5mg/ml=
1.6mM)
ADP 10 µM
1–24 hours before
blood sampling
Kempfert 2009113 PAP-4 (moeLab, Berlin,
Germany)
Citrate AA (1mM) No details
Linnemann 2009112 Behring Coagulation Timer®
(BCT®) (Dade Behring,
Düdingen, Switzerland)
Sodium citrate (3.2%) AA (0.5mg/ml=
1.6mM)
1–24 hours
Lordkipanidzé
2011162 (abstract)
LTA (no further details) No details AA (1.6mM)
ADP (5 µM)
ADP (10 µM)
ADP (20 µM)
No details
Miyata 2011164
(abstract)
LTA (no further details) No details AA
Collagen
No details
Modica 2009187 PA-200 Sodium citrate
(0.129M)
Epinephrine (30 µl of a
solution containing
0.1mg epinephrine)
No details
Ohmori 2006142 LTA (no further details) and
PA-20 platelet aggregation
analyser
Sodium citrate (10%) Collagen (1 µg/ml) No details
Payne 2004147 PAP4 platelet aggregometer Trisodium citrate
(3.8% wt/vol)
AA (2.5mM) < 24 hours
Schwammenthal
2008125
PACKS-4 (Helena Laboratories,
Beaumont, TX, USA)
‘Citrated blood’ AA (1.6mM) At least 6 hours
before blood
sampling
Sørensen 1983155 Turbidimetric aggregation
(Born method)
No details ADP (lowest ADP
concentration that could
produce secondary
aggregation)
No details
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Study design and quality
Results of the risk-of-bias assessment can be found in Tables 6–9.
Patient selection was independent of study outcome in all included studies, with the PFT preceding any
outcomes (as specified in the study selection criteria). Ten of 19 studies88,93,112,113,125,147,164,174,187,201 stated that
consecutive patients were enrolled into the study. Only one study159 had clear details on posteligibility
exclusion of patients; one criterion for exclusion was no or low compliance.
A predetermined threshold percentage (for platelet aggregation) was given in nine studies; in seven of
these93,121,125,147,149,159,174 the threshold was 20% (with two studies93,125 defining a further two groups:
20–39% for partial response and ≥ 40% for complete unresponsiveness). In two studies113,169 the threshold
was 30%. The remaining studies stated that quartiles were used,95,201 described the method of deriving a
threshold but not an actual percentage112,155,187 or gave no details.88,142,162,164 One study90 stated mean levels
of platelet aggregation only (for groups with and without clinical events). Most studies cited a reference
for their threshold or method of derivation; there were no details in seven studies.88,90,95,142,162,164,201 Only
one study142 gave clear details on blinding of laboratory staff to patient characteristics.
Outcome measures of interest were clearly predefined in all but five studies.88,113,155,159,169 Four studies125,142,149,187
had clear details regarding blinding to the PFT results of those assessing outcomes. There appeared to be
no loss to follow-up in three studies.90,121,187 Loss to follow-up was stated in seven studies93,112,113,125,142,149,155
and ranged from 2% to 57% (see Table 8). There were no clear details in nine studies.88,95,147,159,162,164,169,174,201
The differences in completeness of follow-up may reflect length of follow-up, study design (outcome only
followed up in those that had repeat PFTs) or quality of reporting.
Compliance was measured in seven studies.88,112,113,142,149,159,164 In three studies88,142,149 this was by a general
practitioner (GP) assessment and/or patient interview, but no details on the level of compliance were
stated; one patient was excluded on the basis of non-compliance in one of these studies.142 One study112
stated that after interview all patients confirmed that they had taken aspirin as directed over the last
14 days.
TABLE 5 Test characteristics (LTA, monotherapy) (continued )
Study
Details of kit/
manufacturer
Anticoagulant
(concentration)
Agonist
(concentration)
Time since last
aspirin dose
Tan 2010174
(abstract)
LTA (no further details) No details AA Unclear: blood
samples collected
every 2 hours up to
24 hours before
and after aspirin
administration
van der Loo 201190 APACT 4 aggregometer
(Labitec GmbH, Ahrensburg,
Germany)
Sodium citrate (3.8%) Epinephrine (0.1mM)
Collagen (5 µg/ml)
ADP (2mM)
No details
Zanow 2010169
(abstract)
LTA (no further details) No details AA
ADP
No details
Monotherapy at time of PFT, dual therapy during follow-up
Spectre 201193 PACKS-4 Sodium citrate AA (1.6mM) No details
AA, arachidonic acid.
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TABLE 6 Risk of bias, patient selection (LTA, monotherapy)
Domain 1:
patient selection
Was a consecutive or random
sample of patients enrolled?
Was patient
selection
independent of
patient outcomes?
Were reasons for any
posteligibility
exclusions provided?
Monotherapy at time of PFT and during follow-up
Abumiya 201195 No details Yes No details
Cha 2008121 Unclear; patients selected from
a larger, consecutively
enrolled group
Yes No details
De Boni 2011159 No details Yes Patients who changed therapy,
with low/no compliance,
intolerance/allergy to aspirin,
contraindications to
anticoagulants, who did not
attend follow-up
Feher 201188 (letter) Consecutive Yes No details
Feng 2011201 Consecutive Yes No details
Gum 2003149 Unclear; patients recruited from
consecutive patients presenting
to the outpatient clinic
Yes No details
Kempfert 2009113 Consecutive Yes No details
Linnemann 2009112 Consecutive Yes No details
Lordkipanidzé 2011162
(abstract)
No details Yes No details
Miyata 2011164 (abstract) Consecutive Yes No details
Modica 2009187 Consecutive Yes No details
Ohmori 2006142 No details Yes No details
Payne 2004147 Consecutive Yes Unclear; 38/138 patients
excluded before randomisation,
but unclear if any would have
met the inclusion criteria
Schwammenthal 2008125 Consecutive Yes No details
Sørensen 1983155 No details Yes No details
Tan 2010174 (abstract) Consecutive Yes No details
van der Loo 201190 Unclear (substudy of a trial) Yes No details
Zanow 2010169 (abstract) No details Yes No details
Monotherapy at time of PFT, dual therapy during follow-up
Spectre 201193 Consecutive Yes No details
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NIHR Journals Library www.journalslibrary.nihr.ac.uk
38
TABLE 7 Risk of bias, PFT (LTA, monotherapy)
Domain 2: PFT
If a threshold was used,
was it prespecified?
How was the threshold
derived? (e.g. literature
cut-off, based on study data)
Is the undertaking and
interpretation of the index
test blinded to the patient
characteristics (including
clinical outcomes)?
Monotherapy at time of PFT and during follow-up
Abumiya 201195 No Quartiles No details
Cha 2008121 Yes (> 20%) Reference cited151 No details
De Boni 2011159 Yes (> 20%) Reference cited149,218 No details
Feher 201188
(letter)
No details No details No details
Feng 2011201 No Quartiles No details
Gum 2003149 Yes (≥ 20% for AA and
≥ 70% for ADP)
No details No details
Kempfert 2009113 Yes (aspirin resistant if platelet
aggregation exceeded the
threshold of 30% despite in
vitro addition of 25 µM aspirin)
Unclear; states that platelet
aggregation was measured
according to the
manufacturers’ instructions
No details
Linnemann
2009112
Partially; method yes, actual
value no. Based on results
from group of 20 healthy
volunteers. Resistance defined
as the maximum aggregation
values within the reference
range (≥ 78%) despite
aspirin medication
In accordance with
recommendations given at the
53rd Annual Scientific and
Standardization Committee
Meeting of the ISTH in Geneva
in 2007, the 5th–95th percentile
of maximum aggregation
measured in duplicate in a group
of healthy volunteers (n= 20)
was considered as the reference
range (i.e. 78–96%)
No details
Lordkipanidzé
2011162
(abstract)
No details No details No details
Miyata 2011164
(abstract)
No details No details No details
Modica 2009187 Yes (high residual platelet
reactivity was defined as a
normal CT value even when
the subject was taking aspirin)
Reference cited77 Unclear (‘test results were
not accessible by the
attending physicians’)
Ohmori 2006142 No details No details Yes; laboratory staff were kept
unaware of patient information
Payne 2004147 Yes (> 20%) Reference cited219 Unclear; states that ‘all
personnel involved with the trial
were blinded to the nature of
the patients’ current drug
therapy.’ However, this may not
apply to PFTs
Schwammenthal
2008125
Yes (good response < 20%,
partial response 20–39%,
complete unresponsiveness
≥ 40%)
Reference cited149 Unclear; treating physicians and
the investigators evaluating the
patients were blinded to
the results of the platelet
function studies
continued
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TABLE 7 Risk of bias, PFT (LTA, monotherapy) (continued )
Domain 2: PFT
If a threshold was used,
was it prespecified?
How was the threshold
derived? (e.g. literature
cut-off, based on study data)
Is the undertaking and
interpretation of the index
test blinded to the patient
characteristics (including
clinical outcomes)?
Sørensen 1983155 Yes (platelet hyperaggregability
defined as secondary
aggregation obtained by ADP
concentration ≤ 1 µM)
Reference cited220 No details
Tan 2010174
(abstract)
Yes (> 20%) No details No details
van der Loo
201190
No (mean levels of platelet
aggregation shown for groups
with and without events)
N/A No details
Zanow 2010169
(abstract)
Yes (≥ 30%) No details No details
Monotherapy at time of PFT, dual therapy during follow-up
Spectre 201193 Yes: three groups (good
response < 20% aggregation,
intermediate 20–40%,
poor response > 40%)
No details No details
AA, arachidonic acid; CT, closure time; ISTH, International Society of Thrombosis and Haemostasis; N/A, not applicable.
TABLE 8 Risk of bias, outcomes and study attrition (LTA, monotherapy)
Domains 3 and 4:
outcomes and
study attrition
Were the
outcomes of
interest clearly
defined in
advance?
Were the outcome results
interpreted without knowledge
of the results of the PFT?
What was the proportion of
missing data? (State reasons for
loss to follow-up or differences in
those who completed or were lost)
Monotherapy at time of PFT and during follow-up
Abumiya 201195 Yes No details No details on whether or not there
were any missing data
Cha 2008121 Yes No details No loss to follow-up
De Boni 2011159 No No details Unclear; patients who did not attend
follow-up were excluded from study
Feher 201188
(letter)
Unclear No details No details
Feng 2011201 Yes No details No details
Gum 2003149 Yes Those performing follow-up
interviews were blinded to aspirin
sensitivity status
Follow-up data were available on
97% of patients
Kempfert 2009113 No No details 1/59 patients lost to follow-up.
Reason not stated
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TABLE 8 Risk of bias, outcomes and study attrition (LTA, monotherapy) (continued )
Domains 3 and 4:
outcomes and
study attrition
Were the
outcomes of
interest clearly
defined in
advance?
Were the outcome results
interpreted without knowledge
of the results of the PFT?
What was the proportion of
missing data? (State reasons for
loss to follow-up or differences in
those who completed or were lost)
Linnemann 2009112 Yes Unclear; reported events were only
considered if they were confirmed by
medical reports from GPs or
admitting hospitals
Data on clinical outcome available
only from patients whose platelet
function was assessed twice (57/98).
Of the 98, four patients died and 16
had their antithrombotic medication
changed, mainly because of an acute
cardiovascular event. Not clear what
the remaining reasons for dropouts
were. This might bias the results
though authors state that there was
no difference observed in aspirin
resistance rates between dropouts
and those remaining in the study
Lordkipanidzé
2011162 (abstract)
Yes No details No details
Miyata 2011164
(abstract)
Yes No details No details
Modica 2009187 Yes Yes (‘test results were not accessible
by the attending physicians’)
No loss to follow-up
Ohmori 2006142 Yes Yes; those performing follow-up
were unaware of the aspirin
sensitivity status
4/136 (three patients who developed
atrial fibrillation and one who did
not take aspirin were excluded
from analysis)
Payne 2004147 Yes Unclear; states that ‘all personnel
involved with the trial were blinded
to the nature of the patients’ current
drug therapy.’ However, this may
not apply to PFTs and outcomes
No details
Schwammenthal
2008125
Yes Yes; treating physicians and the
investigators evaluating the patients
were blinded to the results of the
platelet function studies
Follow-up data were available for
81/105 patients (77%)
Sørensen 1983155 No No details 48/83 patients at last follow-up, but
proportion of these in aspirin group
(n= 41) unclear
Tan 2010174
(abstract)
Yes (though
unclear if
composite or
individual
outcomes)
No details No details
van der Loo 201190 Yes No details Appears to be no loss to follow-up
for events (though repeat PFTs in
decreasing numbers of patients
over time)
Zanow 2010169
(abstract)
No details No details No details
Monotherapy at time of PFT, dual therapy during follow-up
Spectre 201193 Yes No details 7/63 lost to follow-up at 6 months
GP, general practitioner.
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A further study164 assessed compliance by interview and checking of plasma concentration of salicylic acid,
but there were no details on level of compliance. One study159 did not state the method of assessing
compliance, but stated that patients with low/no compliance were excluded. In the study by Kempfert et al.,113
the PFT was repeated after in vitro addition of aspirin where platelets were not sufficiently suppressed in order
to exclude non-compliance.
Thirteen studies did not appear to undertake any adjusted analyses.88,90,95,112,113,147,155,159,162,164,169,174,201
Six studies93,121,125,142,149,187 attempted to adjust for a number of factors. There was some overlap between
factors adjusted for (e.g. age), but no study used all the same factors as another. There may be selective
reporting in that only variables that showed significance on univariate analysis may have been included in
multivariate analyses. One study142 was unusual in that it adjusted for size of aggregates only.
Overview of outcomes
The main outcome categories reported in the LTA monotherapy studies are shown in Table 10. Note that
where a study reports MACEs, individual outcomes (e.g. death, stroke) may additionally have been
reported separately. There may also be more than one ischaemic/thrombotic outcome reported in the
same study. Follow-up periods ranged from 30 days to 3 years.
TABLE 10 Outcomes (LTA, monotherapy)
Study Death MACE
Ischaemic/
thrombotic Bleeding Length of follow-up
Monotherapy at time of PFT and during follow-up
Abumiya 201195 ✓ 1 year
Cha 2008121 ✓ ✓ ✓ 90 days
De Boni 2011159 ✓ 3 months
Feher 201188 (letter) ✓ 2 years
Feng 2011201 ✓ Up to 6 months
Gum 2003149 ✓ ✓ ✓ Mean 679 days
Kempfert 2009113 ✓ ✓ ✓ 12 months
Linnemann 2009112 ✓ ✓ Median 17 months (range 10–37 months)
Lordkipanidzé 2011162
(abstract)
✓ 3 years
Miyata 2011164 (abstract) ✓ 2 years
Modica 2009187 ✓ Median 44 months (IQR 35–55 months)
Ohmori 2006142 ✓ Mean 172 days
Payne 2004147 ✓ ✓ 30 days
Schwammenthal 2008125 ✓ Median 11.5 months (range 3.9–19.3 months)
Sørensen 1983155 ✓ Median 26 months (range 20–36 months)
Tan 2010174 (abstract) ✓ ✓ ✓ Mean 360 days (range 0–523 days)
van der Loo 201190 ✓ Mean 80 months (range 52–94 months)
Zanow 2010169 (abstract) ✓ ‘Long-term’
Monotherapy at time of PFT, dual therapy during follow-up
Spectre 201193 ✓ Up to 15 months
IQR, interquartile range.
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Death
Only 688,113,121,147,149,174 of the 19 studies reported this outcome, and 5113,121,147,174,188 reported solely the data
needed to populate 2 × 2 tables (Table 11).
Figures 3 and 4 present the unadjusted ORs and unadjusted HRs reported for death. None of these were
directly available from the publications (except for one HR149), but were calculated from other reported
data. No study reported adjusted measures. In the study by Payne et al. (2004),147 no patients (out of a
total of 54) were found to be aspirin resistant at a threshold of > 20% aggregation, therefore no summary
measures could be calculated; one stroke and no deaths occurred in this patient group (follow-up
30 days). Similarly, results could not be presented in forest plots for the study by Tan et al.;174 here the rate
of death was 26% in the resistant and 11% in the sensitive group.
In the studies by Cha et al.121 and Gum et al.,149 more deaths occurred in those patients categorised as
aspirin resistant; however, none of the unadjusted ORs or HRs were statistically significant. This is also the
case for the studies by Feher et al.88 and Kempfert et al.,113 where the extremely wide CIs are a reflection
of an adjustment factor used in cases where no events occurred in the aspirin-sensitive groups.
In terms of prognostic utility, although there was a trend towards more events in the aspirin-resistant
groups, no study was able to show a statistically significant difference (in CAD or CVD/stroke patients).
Major adverse cardiac events
Eleven90,93,112,113,121,142,149,162,164,174,187 of 19 studies reported this outcome (Table 12).
Note that one study112 reporting MACEs included death from cardiovascular causes, MI, ACS and stroke,
but also amputation or gangrene.
TABLE 11 Outcome measures for reporting death (LTA, monotherapy)
Study
Unadjusted
OR
Adjusted
OR
Unadjusted
HR
Adjusted
HR
Other measures
related to prognosis
Sensitivity/
specificity
presented
or calculable
Monotherapy at time of PFT and during follow-up
Cha 2008121 ✓a ✓a Number of events reported
for three groups: low,
intermediate, high
ADP aggregation
✓a
Feher 201188
(letter)
✓a ✓a ✓a
Gum 2003149 ✓
Kempfert
2009113
✓a ✓a ✓a
Payne
2004147
No patients found to be
aspirin resistant, therefore
not represented in
Figures 3 and 4
Tan 2010174
(abstract)
Some percentages
presented, but exact
numbers not clear
a Calculated from data given in the publication.
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The study by Miyata et al.164 reported that no ex vivo measurements for residual platelet function were
associated with cardiovascular events (no data presented). In the study by Tan et al.174 the results for
total events (MACEs) were unclear, but based on higher numbers of events for death, recurrent MI or
thrombosis, it appeared that a greater number of MACEs occurred in the aspirin-resistant group.
van der Loo et al.90 reported no significant differences in mean platelet aggregation levels in groups with
and without MACEs.
The remaining studies are presented in the forest plots in Figures 5–8.
There were 12 unadjusted ORs based on five studies,93,112,113,121,162 (different agonists, thresholds or time
points; see Figure 5), 11 of which found no statistically significant differences in event rates; there was also
no consistent trend regarding direction of effect. One study121 found a statistically significant result for one
of two thresholds, with more events in the aspirin-resistant group in a CVD/stroke population, but this
result was based on a non-aspirin-specific agonist (ADP) and the threshold was derived by collapsing
tertiles. Most ORs were not directly available from the studies (with the exception of one162).
The one statistically significant OR121 remained so after adjustment, although it moved very close to 1
(see Figure 6). There were no further adjusted ORs.
TABLE 12 Outcome measures for reporting MACEs (LTA, monotherapy)
Study
Unadjusted
OR
Adjusted
OR
Unadjusted
HR
Adjusted
HR
Other measures
related to prognosis
Sensitivity/
specificity
presented
or calculable
Monotherapy at time of PFT and during follow-up
Cha 2008121 ✓a ✓ ✓a ✓a
Gum 2003149 ✓ ✓
Kempfert
2009113
✓a ✓a ✓a
Linnemann
2009112
✓a ✓a ✓a
Lordkipanidzé
2011162
(abstract)
✓
Miyata 2011164
(abstract)
Narrative description
Modica
2009187
✓ ✓
Ohmori
2006142
✓
Tan 2010174
(abstract)
Some percentages
presented, but exact
numbers not clear
van der Loo
201190
Mean platelet aggregation
values for groups with and
without events
Monotherapy at time of PFT, dual therapy during follow-up
aSpectre
201193
✓a ✓a ✓ ✓a
a Calculated from data given in the publication.
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There were 10 unadjusted HRs (based on six studies,93,112,113,121,149,187 see Figure 7), all calculated from
other data presented in the articles. Three showed statistically significant results (more events in the
aspirin-resistant group).121,149,187 All three included different populations (CAD, CVD/stroke and UA/ACS).
Based on the three studies where an unadjusted HR was calculable, one HR149 remained statistically
significant after adjustment (see Figure 8); two previously non-significant results93 became statistically
significant and one previously significant result became non-significant.187 Of one further study included,142
one of two results was statistically significant (more events in the aspirin-resistant group).
Based on adjusted measures, there was a consistent trend towards more MACEs in the resistant groups,
with some results showing statistical significance. However, this is based on a subsample of studies only
(5 of 19 studies93,121,142,149,187), and the choice of adjustment factors and inclusion of certain factors into the
models may have affected results. Note that two93,187 of the five studies contributing to these results were
in UA/ACS patients, which may differ from the majority of stable populations, and in one study93 all
patients were on dual therapy after the PFT.
Ischaemic/thrombotic events
Thirteen studies88,90,95,112,113,121,125,147,149,155,159,169,174 reported additional ischaemic/thrombotic events (Table 13).
Seven of 13 studies90,95,112,147,159,169,174 did not provide data which would have allowed their representation
in forest plots. There was also heterogeneity across outcome measures (e.g. MI, UA, restenosis, etc.).
Many of these measures are also captured in the MACEs described above.
In the study by Abumiya and Houkin95 there appeared to be a trend for more events (recurrent cerebral
infarction) to occur in higher quartiles of platelet aggregation, but no statistical significance could be
shown. The numbers in Tan et al.174 were unclear, but it appears that a higher percentage had a recurrent
MI or thrombosis in the aspirin-resistant group. van der Loo et al.90 looked at differences in intrapatient
variability of platelet aggregation between groups with and without restenosis or occlusion; no evidence
for a difference was found (at adjusted p-value level). Zanow et al.169 found that long term there was a
poorer patency rate for aspirin-resistant patients, but this was not statistically significant.
The study by De Boni et al.159 provided no useful information, as no patients were classified as aspirin
resistant and no events occurred. Similarly, in the study by Payne et al.147 no patients were classified as
aspirin resistant; there was one stroke (in a group of 54 patients). Linnemann et al. assessed a number of
ischaemic thrombotic outcomes, but the exact numbers in the aspirin-resistant and aspirin-sensitive groups
were unclear; only 2 out of 57 patients were classified as aspirin resistant.
Twelve unadjusted ORs were presented based on four studies88,113,121,155 (different outcomes, thresholds)
(Figure 9). All were calculated for this report. CIs were generally very wide and all but one showed no
statistical significance, though there was a trend towards more events occurring in the aspirin-resistant groups.
A different study125 presented an adjusted OR for two thresholds, one of which was statistically significant
(Figure 10).
Fourteen unadjusted HRs based on five studies88,113,121,149,155 were presented (Figure 11). Again, all but one
showed no statistical significance, though there was a trend towards more events in the aspirin-resistant
groups. No adjusted HRs were presented.
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Overall, the trend towards more events in the aspirin-resistant group was consistent, but most results were
not statistically significant. These results were also consistent with those of the studies not presented in the
forest plots. Interestingly, there were three studies where no (or a very small proportion of) aspirin-resistant
patients were identified.112,147,159
Bleeding events
Only one study201 reported bleeding events (GI bleeds) (Table 14).
Of the four patients with bleeds, three were in the lowest platelet aggregation quartile (values of 2.7%,
6.75% and 9.12%). The threshold value for the lowest quartile was 9.81%. The remaining patient had a
value of 11.2% (not stated which quartile). This is consistent with the assumption that GI bleeds are more
likely to occur in aspirin-sensitive patients, but the small number of events precludes any firm conclusions.
Summary: light transmission aggregometry monotherapy
Nineteen studies were identified in this category.88,90,93,95,112,113,121,125,142,147,149,155,159,162,164,169,174,187,201 There
were differences in patient populations, though most appeared to have stable disease; note that although
there were only three studies93,174,187 with acute (UA/ACS) populations, two of these93,187 contribute
substantially to the MACE results. There was heterogeneity across studies in terms of specific patient
characteristics (e.g. smoker, diabetic, comedications, etc.).
There was a lack of detail in reporting of relevant quality criteria, making an overall judgement on risk of
bias difficult. Additionally, studies that do report relevant information may be more open to criticism. Lack
of detail related in particular to loss-to-follow-up information, blinding and details of compliance. No study
provided details on all relevant quality criteria. There were differences in threshold and method of
deriving the threshold for defining aspirin resistance, but the most consistent was a threshold of 20%
(seven studies93,121,125,147,149,159,174). Only one142 and four125,142,149,187 (of 19) studies respectively gave clear
details on blinding to patient characteristics or PFT results. Measurement of compliance was undertaken in
seven studies,88,112,113,142,149,159,164 but there was a lack of detail on the results or consequences of this; it
appears that in two studies142,159 patients were excluded on the basis of low/no compliance. Some studies
provided adjusted analyses; there was overlap but no consistency in factors adjusted for.
Six studies88,113,121,147,149,174 reported on differences in deaths between aspirin-resistant and aspirin-sensitive
groups; there was a trend towards more events in the aspirin-resistant group (based on four studies88,113,121,149),
but no significant differences were shown in any.
Eleven studies reported on MACEs.90,93,112,113,121,142,149,162,164,174,187 There was a trend towards more events in
the aspirin-resistant groups, but unadjusted measures found mostly statistically non-significant results. Five
of seven results (based on five studies93,121,142,149,187) using adjusted measures were statistically significant
and the trend was consistent with the unadjusted results; however, this was based on a subset of studies,
TABLE 14 Outcome measures for reporting bleeding (LTA, monotherapy)
Study
Unadjusted
OR
Adjusted
OR
Unadjusted
HR
Adjusted
HR
Other measures related
to prognosis
Sensitivity/
specificity
presented
or calculable
Monotherapy at time of PFT and during follow-up
Feng 2011201 Aggregation values
presented for individual
patients (according to
quartiles for some)
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different adjustment factors and two93,187 (of five93,121,142,149,187) studies in an acute population, which may
not be representative of the majority of populations receiving aspirin monotherapy.
Thirteen studies reported additional ischaemic/thrombotic events.88,90,95,112,113,121,125,147,149,155,159,169,174 Again,
there was a trend towards more events in the aspirin-resistant group, but the vast majority of results
(mainly unadjusted measures) were not statistically significant. Results of 7 of the 13 studies90,95,112,147,159,169,174
could not be presented in forest plots, but results were consistent (i.e. non-significant).
There was only one study reporting GI bleeds;201 this found a trend for more aspirin-sensitive patients to
have more bleeds, but this was based on only four events (in 136 patients).
Note that not all studies reporting the relevant outcomes could be presented in the forest plots; the results
of those studies not included in the forest plots were in the main consistent with those included or did not
add much useful information. It should also be noted that some studies contributed several results to the
forest plots as they presented results or could be analysed for different thresholds. Although no results
have been pooled, the visual impact of these forest plots might influence how the overall results are
perceived. Given the large amount of heterogeneity between the studies in terms of quality criteria, threshold,
population, test characteristics (agonists), aspirin dose, etc., it was not possible to compare results across
studies. Despite the heterogeneity and lack of many statistically significant results, the direction of prognostic
effect appears to be largely consistent with there being more events in aspirin-resistant patients (ORs and HRs
usually > 1). This suggests that LTA is a potential prognostic factor, but this is only a qualitative judgement on
the evidence available; meta-analysis was not possible owing to the heterogeneity, and therefore a firm
quantitative conclusion regarding whether or not LTA is prognostic is not currently possible.
Summary: light transmission aggregometry
l Nineteen studies were identified with mainly stable populations.
l The most frequently reported threshold was 20% platelet aggregation.
l A lack of detail in reporting of quality criteria, particularly around loss to follow-up, blinding and details
(and implications) of compliance, hampered an overall risk-of-bias assessment.
l Heterogeneity in outcomes, patient groups and types of reported statistics meant that meta-analysis
was not considered appropriate.
l Adjusted results were rarely presented, and thus the additional prognostic value of the test over other
prognostic factors is difficult to ascertain.
l Despite clinical heterogeneity between studies, there was an overall consistent trend for more events to
occur in the ‘aspirin-resistant’ group for all relevant outcomes (death, MACEs, ischaemic/thrombotic
events); however, most results were not statistically significant.
l There were more statistically significant results (more events in the resistant arm) using adjusted
measures for MACEs, but these were based on only five studies.
l One study reporting GI bleeds found a trend for more GI bleeds in ‘aspirin-sensitive’ patients, but this
was based on only four events (in 136 patients).
VerifyNow® Aspirin
Population and test characteristics
Seven studies86,92,99,105,133,162,171 were identified in this category, one162 of which was reported in abstract
form only. Populations were mainly classified as having CAD (three studies)99,133,162 or CVD/stroke
(two studies).86,171 One study105 was in patients with UA/ACS, and one92 was in patients with severe CAD
undergoing CABG. Six studies did not report for how long patients had had their underlying condition;
one study171 stated time from cerebral infarction to randomisation [≤ 90 days: 37 patients (31.1%);
91–364 days: 33 patients (27.7%); ≥ 365 days: 49 patients (41.2%)].
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In six studies86,99,105,133,162,171 it appeared that patients were exclusively on monotherapy both at the time of
the PFT and at follow-up. In the remaining study,92 patients were on monotherapy at the time of the PFT,
and on dual therapy [+ ticlopidine (Ticlid®, Sanofi Winthrop)] during follow-up.
Comedications across the studies included, where reported, ACE inhibitors, beta-blockers, angiotensin
receptor blockers, calcium channel blockers, statins, oral anticoagulants and lipid lowering agents. NSAIDs
were not permitted in four studies86,92,133,171 and were taken by 28 out of 314 (9%) patients in another,105
while one study99 stated that ‘concurrent nonsteroidal anti-inflammatory drug use did not correlate with
the presence of aspirin non-responsiveness defined by this method at either time point’. There were no
details in one study.162
The number of participants in the studies ranged from 106 to 468 (see Table 15). Mean ages were mainly
reported by group (resistant/sensitive) and ranged from 61 years to 70 years. Overall, there were more men
than women in the studies, with proportions of men ranging from 50% to 85%. All studies were
conducted in hospital settings. The proportion of smokers ranged (where reported) from 11% to 39% and
that of diabetics from 21% to 56%.
The dose of aspirin ranged from 75 to 325mg/day. Four studies86,105,133,171 noted a minimum period
(between 1 and 4 weeks) for which patients needed to have been taking aspirin; there were no details in
the remaining studies. Two studies99,133 stated that aspirin was provided in enteric form (in 65% of patients
in one study133). There were no details in the remaining studies.
The main study characteristics are listed in Table 15. Note that in some studies baseline characteristics have
been reported only according to resistant/sensitive groups, rather than for the total study population. All
studies used the commercially available VerifyNow® Aspirin test kit (Table 16), which uses arachidonic acid
as an agonist. Four studies noted the timing of the PFT after aspirin ingestion; this was between 1 and
4 hours,86 between 2 and 30 hours,133 up to 24 hours171 or on the same day.92 There were no details in the
remaining studies.
Study design and quality
Patient selection was independent of outcome in all studies, as all patients with an available PFT were
followed up. Two studies99,171 stated that consecutive patients were enrolled. Two studies92,99 provided
details on posteligibility exclusions; one of these99 reported that the study population was deemed to be
representative of the eligible population.
As this was a commercial test with a manufacturer-recommended threshold, it was assumed that all
studies used the same threshold even where not stated. No study gave clear details on whether or not the
undertaking and interpretation of the PFT was blinded to patient characteristics. Outcomes were defined in
advance in all studies, and there were details in four studies86,99,105,133 regarding the blinding of outcome
assessment (to the results of the PFT). Proportions of missing data were reported in four studies and were
less than, or around, 1%105,133 and up to 14%171 and 32%.99 Longer follow-up times did not correspond to
greater loss to follow-up.
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It was not stated whether or not the proportional hazards assumption was met in the two studies105,133
that reported HRs. Three studies86,105,133 reported adjusted measures and the factors adjusted for were
listed; there was little similarity between the adjustment factors. Four studies86,99,105,171 stated that
compliance was assessed (pill counts; ascertained by nurse, verified with patients). Only one study171 gave
details on the actual level of compliance: six patients were excluded at 4 weeks and a further six at
6 months owing to poor drug compliance (12/119 in total).
Full details are provided in Tables 17–20.
TABLE 16 Test characteristics (VerifyNow® Aspirin, monotherapy)
Study Details of kit
Anticoagulant
(concentration)
Agonist
(concentration) Time since last aspirin dose
Monotherapy at time of PFT and during follow-up
Chen 2007133 VerifyNow® Aspirin No details AA Between 2 and 30 hours
Chu 2010105 VerifyNow® Aspirin 3.2% citrate AA No details
Gluckman 201199 VerifyNow® Aspirin No details AA No details
Lee 2010171 VerifyNow® Aspirin No details AA Up to 24 hours
Lordkipanidzé
2011162 (abstract)
VerifyNow® Aspirin No details No details No details
Ozben 201186 VerifyNow® Aspirin 3.2% citrate AA Between 1 and 4 hours
Monotherapy at time of PFT, dual therapy during follow-up
Kim 201192 VerifyNow® Aspirin No details AA Aspirin administered on day of test
AA, arachidonic acid.
TABLE 17 Risk of bias, patient selection (VerifyNow® Aspirin, monotherapy)
Domain 1:
patient selection
Was a consecutive or
random sample of
patients enrolled?
Was patient selection
independent of
patient outcomes?
Were reasons for any posteligibility
exclusions provided?
Monotherapy at time of PFT and during follow-up
Chen 2007133 No details Yes No details
Chu 2010105 No details Yes No details
Gluckman 201199 No details Yes Patients where SVG patency not assessed
or those not on aspirin monotherapy.
Authors stated that the study population
was representative of patients undergoing
isolated CABG surgery based on
comparison with the Society of Thoracic
Surgeons National Database
Lee 2010171 Consecutive Yes No details
Lordkipanidzé
2011162 (abstract)
No details Yes No details
Ozben 201186 Consecutive Yes No details
Monotherapy at time of PFT, dual therapy during follow-up
Kim 201192 No details Yes 300 patients assessed for eligibility; 75 did
not meet inclusion criteria, five declined
to participate
SVG, saphenous vein graft.
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TABLE 18 Risk of bias, PFT (VerifyNow® Aspirin, monotherapy)
Domain 2: PFT
If a threshold
was used, was
it prespecified?
How was the threshold
derived (e.g. literature cut-off,
based on study data)?
Is the undertaking and interpretation
of the index test blinded to the
patient characteristics (including
clinical outcomes)?
Monotherapy at time of PFT and during follow-up
Chen 2007133 Yes (ARU≥ 550) No details No details
Chu 2010105 Yes (ARU≥ 550) No details Unclear: the clinical team managing the
patients was blinded to aspirin
resistance status
Gluckman
201199
Yes (ARU≥ 550) Manufacturer’s instructions No details
Lee 2010171 Yes (ARU≥ 550) Manufacturer’s instructions No details
Lordkipanidzé
2011162 (abstract)
No details No details No details
Ozben 201186 Yes (ARU≥ 550) Manufacturer’s instructions No details
Monotherapy at time of PFT, dual therapy during follow-up
Kim 201192 Yes (ARU≥ 550) Manufacturer’s instructions No details
ARU, aspirin reaction unit.
TABLE 19 Risk of bias, outcomes and study attrition (VerifyNow® Aspirin, monotherapy)
Domains 3 and 4:
outcomes and
study attrition
Were the
outcomes of
interest clearly
defined in
advance?
Were the outcome results
interpreted without
knowledge of the results
of the PFT?
What was the proportion of missing
data? (State reasons for loss to
follow-up or differences in those
who completed or were lost)
Monotherapy at time of PFT and during follow-up
Chen 2007133 Yes Yes. Personnel responsible for
data collection were not aware
of aspirin responsiveness results.
Hospital charts were analysed to
ascertain whether or not the
events qualified for the definition
of the end point
4/464 (0.9%) patients lost to follow-up,
one in the aspirin-resistant group, three
in the aspirin-sensitive group
Chu 2010105 Yes Yes. The clinical team managing
the patients was blinded to
aspirin resistance status
2/312 lost to follow-up (death during
index hospitalisation)
Gluckman 201199 Yes Yes. Images were analysed by
two blinded reviewers (98%
concordance) with a third
reviewer adjudicating as
necessary
65/229 not included at 6 months
Lee 2010171 Yes No details 17/119 lost to follow-up [reasons:
consent withdrawal (4), poor drug
compliance (12), miscellaneous (1)]
Lordkipanidzé
2011162 (abstract)
Yes No details No details
Ozben 201186 Yes Yes. Personnel responsible for
data collection were not aware
of aspirin responsiveness results
No details
Monotherapy at time of PFT, dual therapy during follow-up
Kim 201192 Yes No details No details
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Overview of outcomes
The most frequently reported outcome in studies using VerifyNow® Aspirin was MACEs (four studies92,105,133,162),
followed by other ischaemic/thrombotic events (three studies92,99,133), death (two studies86,92) and bleeding
events (two studies92,171). Outcomes and follow-up periods are shown in Table 21.
Death
Two studies86,92 reported this outcome (Table 22).
Only two86,92 of seven studies reported deaths and the different outcome statistics are shown in
Figures 12–14. One study (Ozben et al.86 in patients with CVD/stroke) found a statistically significant OR
and HR (greater number of deaths in the aspirin-resistant group) for both in-hospital and 2-year mortality.
The OR (2-year mortality) remained statistically significant when adjusted for age, sex, National Institutes of
Health Stroke Scale (NIHSS), prior stroke and comorbidities (hypertension, diabetes, hyperlipidaemia,
coronary heart disease, renal failure). Only one death (in the aspirin-sensitive group) occurred in the study
by Kim et al.92 in patients undergoing CABG, and no significant difference could be shown.
TABLE 21 Outcomes (VerifyNow® Aspirin, monotherapy)
Study Death MACEs
Ischaemic/
thrombotic
events Bleeding Length of follow-up
Monotherapy at time of PFT and during follow-up
Chen 2007133 ✓ ✓ Mean 379 (SD 200) days
Chu 2010105 ✓ > 30 days and up to 6 months
Gluckman 201199 ✓ 6 months
Lee 2010171 ✓ 4 weeks
Lordkipanidzé 2011162
(abstract)
✓ 3 years
Ozben 201186 ✓ 2 years
Monotherapy at time of PFT, dual therapy during follow-up
Kim 201192 ✓ ✓ ✓ ✓ Responders: mean 9.8 (SD 10.5)
days; non-responders:
mean 10.1 (SD 10.8) days
SD, standard deviation.
TABLE 22 Outcome measures for reporting death (VerifyNow® Aspirin, monotherapy)
Study
Unadjusted
OR
Adjusted
OR
Unadjusted
HR
Adjusted
HR
Other measures
related to prognosis
Sensitivity/specificity
presented or calculable
Monotherapy at time of PFT and during follow-up
Ozben
201186
✓a ✓ ✓a ✓a
Monotherapy at time of PFT, dual therapy during follow-up
Kim
201192
✓a ✓a ✓a
a Calculated from data given in the publication.
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Major adverse cardiac events
Four studies92,105,133,162 reported this outcome (Table 23).
Four92,105,133,162 out of seven studies reported this outcome, and the different outcome statistics are shown in
Figures 15–17. The studies by Chen et al.133 and Chu et al. (for five out of seven subgroups)105 found a
statistically significant difference between groups, with more events in the resistant group (unadjusted OR).
Two further studies92,162 reported more events in the sensitive group, but there were no statistically
significant differences. No study reported adjusted ORs. The pattern was similar for unadjusted HRs, though
with statistically significant results for five out of seven subgroups (Chu et al.105) and a statistically significant
result, with more events in the resistant group, also presented for the population undergoing CABG in the
study by Chen et al.133 Note that the unadjusted HR is not statistically significant compared with the
unadjusted OR (Chen et al.133 CAD population); given the relatively long follow-up period (mean 379 days),
the HR could be considered the more useful outcome statistic. Adjusted HRs were available for three out of
seven subgroups (Chu et al.105 and Chen et al.133 CAD population); these were all statistically significant,
with more events in the resistant group. Note that the factors adjusted for in the two studies are completely
different (troponin-T only in the study by Chu et al.;105 diabetes, prior MI and haemoglobin levels in the
study by Chen et al.133).
Thus, any statistically significant results relate to a greater number of events in the resistant group;
however, not all outcome statistics (particularly adjusted HR) have been reported for all four studies/
subgroups, so there is some missing information.
TABLE 23 Outcome measures for reporting MACEs (VerifyNow® Aspirin, monotherapy)
Study
Unadjusted
OR
Adjusted
OR
Unadjusted
HR
Adjusted
HR
Other measures
related to prognosis
Sensitivity/specificity
presented or calculable
Monotherapy at time of PFT and during follow-up
Chen 2007133 ✓a ✓ ✓ ✓a
Chu 2010105 ✓a ✓/✓a ✓ ✓a
Lordkipanidzé
2011162
(abstract)
✓
Monotherapy at time of PFT, dual therapy during follow-up
Kim 201192 ✓a ✓a ✓a
a Calculated from data given in the publication.
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Ischaemic/thrombotic events
Three studies92,99,133 reported this outcome (Table 24).
Three92,99,133 out of seven studies also reported additional ischaemic/thrombotic outcomes, and the different
outcome statistics are reported in Figures 18 and 19. There were no statistically significant differences
based on unadjusted ORs (two studies92,99). Two of seven unadjusted HRs were statistically significant (both
based on one study133), with more events in the resistant group.
The study by Gluckman et al.99 also reported mean [standard deviation (SD)] values of aspirin reaction units
(ARUs) for groups with one or more occluded saphenous vein grafts (SVGs) versus the group with no
occluded SVG, and also for patients undergoing CABG. The mean values in the group with occluded SVGs
were slightly higher (indicating greater platelet reactivity), but there were no significant differences and all
means were below a threshold of 550 ARUs. No adjusted statistics were reported for any studies.
Thus, there is no evidence of a greater number of events in one or the other group in the two studies with
CABG populations,92,99 while the only study113 with the CAD population found significant differences for
two outcomes.
TABLE 24 Outcome measures for reporting ischaemic/thrombotic events (VerifyNow® Aspirin, monotherapy)
Study
Unadjusted
OR
Adjusted
OR
Unadjusted
HR
Adjusted
HR
Other measures
related to prognosis
Sensitivity/specificity
presented or calculable
Monotherapy at time of PFT and during follow-up
Chen
2007133
✓
Gluckman
201199
✓ Mean ARU presented
for groups with and
without events
Monotherapy at time of PFT, dual therapy during follow-up
Kim
201192
✓a ✓a ✓a
ARU, aspirin reaction unit.
a Calculated from data given in the publication.
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Bleeding events
Two studies92,171 reported this outcome (Table 25).
Only two92,171 out of seven studies reported bleeding events; these were postoperative in one study92 and
over a 4-week period in ischaemic stroke patients [randomised to aspirin and placebo or aspirin and
cilostazol (Pletal®, Otsuka) in the other study].171 The study by Kim et al.92 also measured postoperative
blood loss and transfused units of blood; there were no significant differences between the aspirin-resistant
and sensitive groups. Too few events occurred to draw any overall conclusions: none in Lee et al.,171 and
two (re-exploration for bleeding) in Kim et al.92 (Figures 20 and 21). No studies using VerifyNow® Aspirin as
a PFT were identified that measured long-term adverse bleeding events.
Summary: VerifyNow® Aspirin
Seven studies86,92,99,105,133,162,171 were identified in this category, most in stable populations, but one in
patients with UA/ACS105 and one92 in patients with severe CAD undergoing CABG.
There was a lack of reporting of quality criteria and no study reported all details considered to be
important to assess risk of bias. No study reported on blinding to patient characteristics (when undertaking
the PFT). Only one study171 gave details on the level of compliance and exclusions on the basis of this.
Four99,105,133,171 of the seven studies gave details of missing data and four86,99,105,133 gave details of blinding
of outcome assessors.
The risk of death in the resistant and sensitive groups was reported in only two studies.86,92 In one of these,92
only one death occurred. The other study found statistically significant results based on unadjusted and
adjusted ORs, and unadjusted HR (more events in the resistant group); this was based on 43 events in
106 patients.
Major adverse cardiac events were reported in four studies.92,105,133,162 The direction of effect was consistent
across all results (more events in the resistant group). Around half of the unadjusted ORs and unadjusted HRs
were statistically significant, but it should be noted that a single study105 contributed to a large proportion of
these results as several subgroup results were presented. Adjusted HRs based on two studies105,133 were also
statistically significant.
Ischaemic/thrombotic events were reported in three studies;92,99,133 most unadjusted outcome measures
were statistically non-significant, though there was a trend towards more events in resistant groups. There
were no adjusted outcome measures.
Two studies92,171 measured (short-term) bleeding events (postoperative or re-exploration for bleeding).
There were only two events in total and no conclusion can be drawn from the data.
TABLE 25 Outcome measures for reporting bleeding events (VerifyNow® Aspirin, monotherapy)
Study
Unadjusted
OR
Adjusted
OR
Unadjusted
HR
Adjusted
HR
Other measures
related to prognosis
Sensitivity/specificity
presented or calculable
Monotherapy at time of PFT and during follow-up
Lee 2010171 ✓a ✓a 0 events, therefore not
calculable
Monotherapy at time of PFT, dual therapy during follow-up
Kim 201192 ✓a ✓a ✓
a Calculated from data given in the publication.
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Despite the heterogeneity and lack of many statistically significant results, the direction of prognostic effect
appears to be largely consistent with more events in aspirin-resistant patients (ORs and HRs usually > 1).
This suggests that VerifyNow® Aspirin is a potential prognostic factor, but this is only a qualitative
judgement on the evidence available; meta-analysis was not possible owing to the heterogeneity, and
therefore a firm quantitative conclusion regarding whether or not VerifyNow® Aspirin is prognostic is not
currently possible.
Summary: VerifyNow® Aspirin
l Seven studies used this commercial PFT.
l A lack of reporting of quality criteria hampered an overall assessment of risk of bias; only one of seven
studies gave details on level of compliance.
l Heterogeneity in outcomes, patient groups and types of reported statistics meant that meta-analysis
was not considered appropriate.
l Adjusted results were rarely presented, and thus the additional prognostic value of the test over other
prognostic factors is difficult to ascertain.
l There was a consistent trend towards a greater number of events in the resistant groups within the
studies; some of the results were statistically significant.
l Some studies contributed more results by reporting on several subgroups and not all studies
contributed to all outcome measures; therefore, there are potentially some missing data and/or a bias
towards certain studies (though results were not pooled).
l No studies were identified that reported on long-term bleeding events.
Thromboxane metabolite measurement
Population and test characteristics
Eleven studies46,76,99,108,110,148,151,162,164,195,202 were identified in this category, three of which were reported in
abstract form only.162,164,202 Populations had CAD (nine studies46,76,99,108,110,162,164,195,202) or CVD disease/stroke
(one study148). One study151 included patients with various conditions including CAD, stroke, PVD
and diabetes.
Most studies did not report for how long patients had had their primary underlying condition. One study117
reported that patients had their primary underlying condition for a mean period of 41.4 months.
In nine studies46,99,108,110,148,151,162,164,202 it appeared that patients were exclusively on monotherapy both at
the time of the PFT and during follow-up. In two studies, patients were on monotherapy at the time of the
PFT, and 32%76 and 54.8%195 of patients respectively went on to additionally receive clopidogrel at some
point during follow-up. It is possible that not all studies have reported where a proportion of patients
commenced additional therapies during follow-up.
Three studies measured thromboxane metabolite levels in serum/plasma46,76,164 and nine studies measured
thromboxane metabolite levels in urine.99,108,110,148,151,162,164,195,202 Data in these groups were analysed separately.
Comedications were reported in five studies108,148,162,164,202 and included ACE inhibitors, angiotensin II
antagonists, calcium blockers, statins, beta-blockers, COX-2 antagonists, heparin, warfarin, diuretics,
insulin, oral hypoglycaemics, antidepressants, anticoagulants, lipid-lowering agents and vitamin E. NSAIDs
were not permitted (or had to be discontinued within a certain time period) in two studies.108,110 One
study99 stated that ‘concurrent nonsteroidal anti-inflammatory drug use did not correlate with the presence
of aspirin non-responsiveness defined by this method at either time point’. In two studies, 10%76 and 24%195
of patients respectively were taking NSAIDs. There were no details on NSAIDs in the remaining studies.
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The number of participants in the studies ranged from 61 to 3261 (see Table 26). Where reported, average
ages of patients ranged from 53 years (mean value) to 69 years (median value), with most average ages
around the early 60s. There were more men than women in the eight studies that reported this46,76,99,108,110,
148,151,195 (the remaining three studies162,164,202 did not report details), with proportions of men ranging from
59% to 90%. The proportion of patients with diabetes ranged from 19% to 48%, and that of smokers
from 16.6% to 71% (where reported, see Table 26). All studies were conducted in hospital settings.
The dose of aspirin ranged between 75mg/day and 325mg/day, with the exception of one study,148
where the dose was high at 650mg/day. This study included patients with a non-cardioembolic,
non-incapacitating cerebral infarction. There were no details on dose in one study.151 Details were variable
across studies regarding the length of time patients had been receiving aspirin therapy, with some noting a
minimum period and some giving no details (see Table 26). Two studies stated aspirin was provided in
enteric or plain form99,110 and no other studies provided this information.
The main study characteristics are listed in Table 26. Note that in some studies baseline characteristics have
been reported only according to groups with/without adverse clinical events, or groups with occluded or
patent SVG during CABG surgery, rather than for the total study population.
Most studies reported no details on the timing of the PFT after aspirin ingestion. One study148 stated that
there were up to 24 hours between aspirin dose and PFT. Table 27 shows details of test characteristics.
Study design and quality
Results of the risk-of-bias assessment can be found in Tables 28–31.
Patient selection was independent of study outcome in 10 of the included studies,46,76,99,108,110,148,162,164,195,202
with the PFT preceding any outcomes (as specified in the study selection criteria). One study151 used a
case–control design, so patient selection was not independent of outcome, but the taking of samples for
the PFT still preceded the outcomes and so this study was included. Five of 11 studies stated that
consecutive patients were enrolled into the study.46,76,108,110,164 Details on posteligibility exclusion of patients
were provided in five studies;46,76,99,148,151 reasons included compliance with aspirin treatment at each
follow-up visit,151 patients in whom the outcome was not assessed99 or no provision of urine sample.148
A predefined threshold was stated in only three studies46,99,202 and this was not consistent across the
studies (cut-offs of 298 pg/mg creatinine,202 400 pg/mg creatinine99 and 5 nmol/1011 platelets46).
The remaining studies used tertiles,108 quartiles,195 median value,110 derived the value by receiver operating
characteristic (ROC) analysis,76 presented mean values for groups with and without events148,151 or gave no
details.162,164 Three studies108,151,195 gave clear details of blinding of laboratory staff to patient characteristics.
Outcome measures of interest were clearly predefined in all studies, and five studies76,99,108,148,151 had details
of blinded assessment of outcomes. Five studies appeared to have no loss to follow-up46,108,148,151,195 and
there were no details in three studies.162,164,202 In the remaining three studies the loss to follow-up was 4%,99
17%110 and 19%.76
Compliance was assessed in six studies.46,99,108,151,164,195 Methods included interview, plasma concentration
of salicylates and pill counts. In one study,46 patients who stated that they were not taking the prescribed
aspirin were included as a separate subgroup in the analysis (resistant and non-compliant). Another study76
did not exclude patients as ‘resistance cannot be distinguished from non-compliance’.
Three studies76,148,151 undertook adjusted analyses, with some overlap between the adjustment factors
where stated.
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TABLE 27 Test characteristics (thromboxane metabolite measurement, monotherapy)
Study Details of kit/manufacturer
Anticoagulant
(concentration)
Agonist
(concentration)
Time since last
aspirin dose
Serum/plasma and urinary
Monotherapy at time of PFT and during follow-up
Miyata 2011,164
(abstract)
Serum TxB2
Urinary 11-dehydro-TxB2
No details Serum TxB2
Urinary 11-
dehydro-TxB2
No details
Serum
Monotherapy at time of PFT and during follow-up
Cotter 200446 TxB2 plasma (enzyme
immunoassay kit obtained
from Amersham,
Buckinghamshire, UK)
No details Collagen (1 µmol) Aspirin
administered
on enrolment
Frelinger 200976 Serum TxB2 No details No details No details
Urinary
Monotherapy at time of PFT and during follow-up
Addad 2010108 Urinary 11-dehydro-TxB2 Enzyme-linked
immunoassay
Enzyme-linked
immunoassay
No details
Bruno 2004148 Urinary 11-dehydro-TxB2 No details No details Up to 24 hours
Eikelboom
2002151
Urinary 11-dehydro-TxB2 Enzyme immunoassay
(Cayman Chemical,
Ann Arbor, MI, USA)
Enzyme immunoassay
(Cayman Chemical,
Ann Arbor, MI, USA)
No details
Eikelboom
2008195
Urinary 11-dehydro-TxB2 No details No details No details
Eskandarian
2011202
Urinary 11-dehydro-TxB2 No details No details No details
Gluckman
201199
Urinary 11-dehydro-TxB2 No details No details No details
Lordkipanidzé
2011162
(abstract)
Urinary 11-dehydro-TxB2 No details No details No details
Thomson
2009110
Urinary 11-dehydro-TxB2 No details No details No details
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TABLE 28 Risk of bias, patient selection (thromboxane metabolite measurement, monotherapy)
Domain 1:
patient selection
Was a consecutive or
random sample of
patients enrolled?
Was patient selection
independent of
patient outcomes?
Were reasons for any posteligibility
exclusions provided?
Serum/plasma and urinary
Miyata 2011164
(abstract)
Consecutive Yes No details
Serum/plasma
Cotter 200446 Consecutive Yes 76/82 potentially eligible patients agreed to
be interviewed; 73/76 who were on aspirin
for at least 1 month were enrolled
Frelinger 200976 Consecutive Yes Stated that less than 3% of eligible patients
declined participation (reason not given)
Urinary
Addad 2010108 Consecutive Yes No details
Bruno 2004148 Unclear: consecutive
patients screened for
participation in the trial
Yes 98 patients initially gave signed consent;
8/98 withdrew consent and 7/98 did not
provide a urine sample
Eikelboom 2002151 Control subjects
randomly selected
No 9541 patients in HOPE study; 9282 provided
urine samples, samples from 5529 (Canadian
centres only) sent to laboratory. Of those,
only those who were taking aspirin before
and at randomisation, and at each follow-up
visit, were eligible for inclusion (number not
stated). 488 cases and controls selected from
the eligible/included
Eikelboom 2008195 Unclear (patients who
complied with a request
to provide a sample)
Yes No details
Eskandarian 2011202
(abstract)
No details Yes No details
Gluckman 201199 No details Yes Patients for whom SVG patency not assessed
or those not on aspirin monotherapy.
Authors stated that the study population
was representative of patients undergoing
isolated CABG surgery based on comparison
with the Society of Thoracic Surgeons
National Database
Lordkipanidzé
2011162 (abstract)
No details Yes No details
Thomson 2012110 Consecutive Yes No details
HOPE, Heart Outcomes Prevention Evaluation.
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TABLE 29 Risk of bias, PFT (thromboxane metabolite measurement, monotherapy)
Domain 2: PFT
If a threshold was used,
was it prespecified?
How was the threshold
derived (e.g. literature cut-off,
based on study data)?
Is the undertaking and
interpretation of the index
test blinded to the patient
characteristics (including
clinical outcomes)?
Serum/plasma and urinary
Miyata 2011164
(abstract)
No details No details No details
Serum/plasma
Cotter 200446 Yes (5 nmol/1011 platelets) Patients classified as
nonresponsive: results in the
range observed in volunteers not
taking aspirin
Patients classified as responsive:
results in ranges that are
observed in takers
Cut-off: lowest TxB2 production
value that was observed in
non-takers
No details
Frelinger 200976 No (ROC analysis) ROC analysis of serum TxB2
levels in current study with
regard to MACE (resistant if
≤ 3.1 ng/ml)
No details
Urinary
Addad 2010108 No (tertiles) Tertiles Yes; stated that all assays were
performed in a blinded manner
Bruno 2004148 No (median values for
patients with and without
events presented)
N/A Possible; no details, but laboratory
off-site
Eikelboom
2002151
No (mean/median values for
patients with and without
events presented)
N/A Assays were performed by
laboratory staff blinded to patient
status (case or control) and also
assayed in random order
Eikelboom
2008195
No (quartiles) Quartiles Yes; ‘Laboratory staff performing
the assays were blinded to
treatment allocation and
to whether the patients had
experienced a primary event’
Eskandarian
2011202
(abstract)
Yes (three groups: resistant
> 298 pg/mg, intermediate
response 134–298 pg/mg,
sensitive < 134 pg/mg)
No details No details
Gluckman
201199
Yes (aspirin responsive if
< 400 pg/mg creatinine; but a
threshold of 450 pg/mg
creatinine used in model)
‘According to established
criteria’ (reference cited221)
No details
Lordkipanidzé
2011162
(abstract)
No details No details No details
Thomson
2012110
No (population median value) Median value of absolute urinary
11-dehydro-TxB2 level of 320pg/ml
used as cut-off in relation to
clinical outcomes
No details
N/A, not applicable; ROC, receiver operating characteristic.
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TABLE 30 Risk of bias, outcomes and study attrition (thromboxane metabolite measurement, monotherapy)
Domains 3 and 4:
outcomes and
study attrition
Were the outcomes
of interest clearly
defined in advance?
Were the outcome results
interpreted without
knowledge of the results
of the PFT?
What was the proportion of
missing data? (State reasons
for loss to follow-up or
differences in those who
completed or were lost)
Serum/plasma and urinary
Miyata 2011164
(abstract)
Yes No details No details
Serum/plasma
Cotter 200446 Yes No details Appears that there was no loss
to follow-up
Frelinger 200976 Yes Yes; all clinical outcome data
obtained by research personnel
blinded to results of PFTs
127/682 lost to follow-up
(for MACE outcome)
Urinary
Addad 2010108 Yes Yes; follow-up clinicians were
blinded to PFT results
Stated that none of the included
patients was lost to follow-up
Bruno 2004148 Yes Yes; assay results not revealed to
investigators until after follow-up
examinations and vascular
event determinations
Appears that there was no loss to
follow-up
Eikelboom 2002151 Yes Yes (outcome occurred before
analysis of sample)
None; retrospective [patients who
had a confirmed event were
defined as cases and controls
were randomly selected from
among those with no events
(sex and age matched)]
Eikelboom 2008195 Yes No details Appears that there was no loss
to follow-up
Eskandarian 2011202
(abstract)
Yes No details No details
Gluckman 201199 Yes Yes; stated that images were
analysed by two blinded
reviewers (98% concordance)
with a third reviewer adjudicating
as necessary
10/229 not included at 6 months
Lordkipanidzé
2011162 (abstract)
Yes No details No details
Thomson 2012110 Yes No details 11/63 lost to follow-up, unclear if
excluded from analysis
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Overview of outcomes
Eleven studies were identified; three of these46,76,164 undertook thromboxane measurement in serum/
plasma, and nine studies99,108,110,148,151,162,164,195,202 measured thromboxane in urine (one study164 in both
categories) (Table 32).
Death
Death was reported in only 376,151,195 of 11 studies (Table 33). Outcome statistics are shown in Figures 22–25.
Unadjusted ORs and HRs were calculable from Frelinger et al.76 (measurement in serum/plasma), all of which
showed a trend towards more events in the resistant arm, though none were statistically significant. The
other two studies (measurement in urine) reported adjusted ORs151 and adjusted HRs.195 Again, all reflected
a greater number of events in the resistant arm; two of the adjusted ORs were statistically significant. Note
that this is based on comparison of different quartiles rather than using a single cut-off. Overall, the trend
was consistent (more events in the resistant arm), but based on few studies.
TABLE 32 Outcomes (thromboxane metabolite measurement, monotherapy)
Study Death MACE
Ischaemic/
thrombotic Bleeding Length of follow-up
Serum/plasma and urinary
Miyata 2011164 (abstract) ✓ 2 years
Serum/plasma
Cotter 200446 ✓ ✓ 12 months
Frelinger 200976 ✓ ✓ Mean 24.8 (SD 0.3) months
Urinary
Addad 2010108 ✓ 1 year
Bruno 2004148 ✓ Mean 2 months (no SD)
Eikelboom 2002151 ✓ ✓ ✓ 5 years
Eikelboom 2008195 ✓ ✓ ✓ ✓ Median 28 months (no SD)
Eskandarian 2011202 (abstract) ✓ 1 year
Gluckman 201199 ✓ 6 months
Lordkipanidzé 2011162 (abstract) ✓ 3 years
Thomson 2012110 ✓ Median 36 (range 1–53) months
TABLE 33 Outcome measures for reporting death (thromboxane metabolite measurement, monotherapy)
Study
Unadjusted
OR
Adjusted
OR
Unadjusted
HR
Adjusted
HR
Other measures
related to prognosis
Sensitivity/specificity
presented or calculable
Serum/plasma
Frelinger
200976
✓a ✓a ✓a
Urinary
Eikelboom
2002151
✓
Eikelboom
2008195
✓
a Calculated from data given in the publication.
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Major adverse cardiac events
Major adverse cardiac events were reported in nine studies (Table 34).46,76,108,110,151,162,164,195,202 Outcome
statistics are shown in Figures 26–29. For two studies,110,164 results could not be presented in forest plots:
one164 stated that ‘no ex vivo measurements for residual platelet functions and COX activities were
associated with cardiovascular events. Residual platelet functions correlated poorly with residual COX
activities, and were inconsistent with assessments made 6 months later.’ The other110 found that a greater
number of MACEs occurred in the upper two quartiles (higher urinary thromboxane levels) than in the
lower two and that this difference was statistically significant (p= 0.04); however, the difference was not
present when normalised levels of urinary thromboxane were considered.
Eight unadjusted ORs were presented, based on four studies, three measuring thromboxane in urine108,162,202
and one in serum/plasma.76 Six of the ORs reflected more events occurring in the resistant arm, but only two
were statistically significant. Four adjusted ORs were presented, based on two studies.76,151 The direction of
effect was consistent and two were statistically significant (more events in the resistant arm).
There were 10 unadjusted HRs based on four studies.76,108,195,202 Although overall results showed that there
were more events in the resistant group, including the three statistically significant results, the direction of
effect is not consistent within two studies contributing three195 and four108 unadjusted HRs each; this
reflects the effect of using different cut-offs (in this case comparison of different tertiles or quartiles).
TABLE 34 Outcome measures for reporting MACEs (thromboxane, monotherapy)
Study
Unadjusted
OR
Adjusted
OR
Unadjusted
HR
Adjusted
HR
Other measures
related to prognosis
Sensitivity/specificity
presented or calculable
Serum/plasma and urinary
Miyata 2011164
(abstract)
Narrative description of
results only
Serum/plasma
Cotter 200446 ✓a
Frelinger
200976
✓a ✓ ✓a ✓ ✓a
Urinary
Addad 2010108 ✓a ✓a ✓a
Eikelboom
2002151
✓
Eikelboom
2008195
✓ ✓
Eskandarian
2011202
(abstract)
✓a ✓a ✓a
Lordkipanidzé
2011162
(abstract)
✓
Thomson
2012110
Raw data not
presented (only a
p-value)
a Calculated from data given in the publication.
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There were 12 adjusted HRs based on two studies,76,195 with 11 being based on only one study,195
reflecting the use of different models (adjustment factors) and the comparison of different quartiles
rather than one cut-off. One study (serum/plasma)76 showed a statistically significant result (more events
in the resistant group), whereas the direction of effect was evenly split in the study generating
11 outcome statistics.
Overall, there is a trend towards more MACEs in the resistant arm, but there is some uncertainty due to
the relatively small number of studies contributing MACE results and the fact that there is some
inconsistency within studies (depending on thresholds used). Only one study76 measuring thromboxane in
serum/plasma was represented in the forest plots. It was therefore not possible to compare results
between the two methods, though the direction of effect (more events in the resistant group) was
consistent with the majority of results.
Ischaemic/thrombotic events
This outcome measure was reported in five studies (Table 35).46,99,148,151,195 Outcome statistics are presented
in Figures 30–33. Data from one study148 could not be represented in the forest plots. There was no
significant difference in thromboxane levels in those with and without a vascular event.
Unadjusted and adjusted ORs (based on three studies46,99,151) showed a consistent direction of effect (more
events in the resistant group), with the exception of two of six results from one study (Eikelboom,151
adjusted ORs). All four unadjusted ORs and three of the eight adjusted ORs were statistically significant.
Two unadjusted HRs (based on one study46) were statistically significant (more events in the resistant
groups), as was one of two adjusted HRs (based on a different study195).
Overall, the direction of effect is consistent (more events in the resistant group), but based on few studies.
Note that one study151 contributes to six of eight adjusted ORs, and that the direction of effect is not
consistent within this study (reflecting different outcomes and thresholds).
TABLE 35 Outcome measures for reporting ischaemic/thrombotic events (thromboxane metabolite measurement,
monotherapy)
Study
Unadjusted
OR
Adjusted
OR
Unadjusted
HR
Adjusted
HR
Other measures
related to prognosis
Sensitivity/specificity
presented or calculable
Serum/plasma
Cotter 200446 ✓a ✓a ✓a
Urinary
Bruno 2004148 Median thromboxane
levels compared in
those with and without
an event
Eikelboom
2002151
✓
Eikelboom
2008195
✓
Gluckman
201199
✓ ✓
a Calculated from data given in the publication.
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Bleeding events
One study reported this outcome (Table 36).195
Only one study195 using a thromboxane test reported bleeding events [Global Utilization of Streptokinase
and tPA for Occulded Coronary Arteries (GUSTO) bleeds]. The study found no significant difference when
looking at a trend for bleeding rates across quartiles.
Summary: thromboxane metabolite measurement
Eleven studies were identified in this category,46,76,99,108,110,148,151,162,164,195,202 all including stable disease
populations, thus making this set of studies more homogenous in terms of population compared with
studies reporting other PFTs. There was still heterogeneity, however, for example relating to specific patient
characteristics and aspirin dose.
There was a lack of reporting of relevant quality criteria, making overall judgements about risk of bias
difficult. No study provided details on all relevant quality criteria. Lack of details related in particular to
whether or not assays were performed in a blinded manner and levels of compliance. In one study,46
patients who stated that they were not taking their prescribed aspirin were included as a separate
subgroup in the analysis (both resistant and non-compliant, as opposed to resistant and compliant).
In the analysis here, these groups have been merged in order to be consistent with the other studies,
where it is not possible to make this distinction. There was a lack of consistency in defining thresholds,
both in methods and in actual values. Only 346,99,202 of 11 studies gave a predefined threshold. One study151
used a retrospective case–control design, which is more prone to bias than prospective designs; however,
as the sampling for the PFT preceded the outcomes, this study was included.
Overall, there was a consistent trend for more deaths reported in the resistant arm, with some statistically
significant results, but this was based on only three studies.76,151,195 There was also a trend for more events
in the resistant groups for MACEs and ischaemic/thrombotic events, with some results showing statistical
significance, but this is based on relatively few studies (no more than four studies contributed results to
any one forest plot).
It is noteworthy that the direction of effect is not consistent within individual studies, reflecting different
thresholds used and different outcomes (for ischaemic/thrombotic events). Some studies contributed
considerably more to forest plots than others, for example where more outcomes were reported or where
results could be presented for different thresholds.
Only one study195 reported bleeding events and this found no significant difference when looking at a
trend for bleeding rates across quartiles.
It was not possible to assess any differences between tests measuring thromboxane in urine or serum/
plasma, as only one study76 measuring thromboxane in serum/plasma was represented in the forest plots.
TABLE 36 Outcome measures for reporting bleeding events (thromboxane metabolite measurement, monotherapy)
Study
Unadjusted
OR
Adjusted
OR
Unadjusted
HR
Adjusted
HR
Other measures
related to prognosis
Sensitivity/specificity
presented or calculable
Urinary
Eikelboom
2008195
Trend across
quartiles reported
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Summary: thromboxane
l Eleven studies were identified, all with stable disease populations.
l Methods for deriving thresholds and thresholds themselves were variable.
l A lack of detail on reporting of quality criteria hampered an overall risk-of-bias assessment.
l Heterogeneity in outcomes, test thresholds and types of reported statistics meant that meta-analysis
was not considered appropriate.
l Adjusted results were rarely presented, and thus the additional prognostic value of the test over other
prognostic factors is difficult to ascertain.
l Despite clinical heterogeneity between studies, there was a general trend for more events to occur in
the ‘aspirin-resistant’ group for all relevant outcomes (death, MACEs, ischaemic/thrombotic events);
however, this was often based on few studies and there was inconsistency in direction of effect within
some studies (based on different thresholds or outcomes).
l Only one study reported bleeding events and this found no significant differences when looking at a
trend for bleeding rates.
l Potential differences between measurements of thromboxane in urine or serum/plasma could not be assessed.
Platelet function analyser-100
Population and test characteristics
Twenty-one studies76,99,108,109,112,115,116,118,123,127,132,135,137,138,144,145,150,162,186,187,189 were identified in this category,
of which two162,189 were reported in abstract form, and one123 in the form of a letter. Populations had CAD
in 10 studies,76,99,108,112,118,127,137,144,145,162 CVD/stroke in two studies,116,186 UA/ACS in six studies109,115,132,135,138,187
and PAD/PVD in one study.150 One large study (n= 600)189 had a mixed population (PVD, ACS and CVD/stroke)
and in one further study123 all patients were undergoing PCI.
In one study, only patients with a first stroke were included.186 In all other studies there were no details on
how long patients had had their primary condition for.
In 19/21 studies, patients were on monotherapy at the time of the PFT and during follow-up. In the two
other studies,115,138 patients were on dual therapy during follow-up, and in one,138 a small proportion (9%)
were also on dual therapy (+ clopidogrel) at the time of the PFT.
Comedications across all studies included beta-blockers, lipid-lowering agents, anticoagulants, thrombolytic
agents, ACE inhibitors, statins, heparin, COX-2 antagonists, warfarin, calcium channel blockers, diuretics,
insulin, oral hypoglycaemics, antidepressants, cholesterol-lowering, antihypertensive and antidiabetic drugs,
nitrate infusion and glycoprotein IIb/IIIa receptor agonists. Some studies restricted the use of some
medications during a certain time period before the PFT.
Non-steroidal anti-inflammatory drugs were clearly not permitted in six studies,108,109,112,116,186,187 and in a
further study137 they were not permitted during 7 days preceding the PFT.
The numbers of participants in the studies ranged from 51 to 700 (see Table 37). Where reported, mean ages
ranged from 59 to 72 years, with more men than women in all studies (range 56–79%). The proportion of
smokers ranged from 15% to 72% and that of diabetics from 7% to 49% (note that some proportions were
presented according to resistant and sensitive groups). All studies were conducted in hospital settings.
The dose of aspirin ranged from 75mg/day to 325mg/day. Two studies123,189 provided no details on dose.
Details were variable across studies regarding the length of time patients had been receiving aspirin
therapy prior to the PFT; where reported, the time varied from a minimum of 3 days up to 2 months.
One study144 stated that no patients were treated with antiplatelets for 10 days before undergoing CABG.
One study reported that aspirin was provided in enteric form.99 There were no details in the other studies.
The main study characteristics are reported in Table 37.
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All studies used the PFA-100®. The cartridge used was mainly collagen/epinephrine (CEPI), with three
studies99,150,189 additionally using collagen/ADP. One study123 used collagen/ADP only. There were no details
in one study.162 Test characteristics are shown in Table 38.
Study design and quality
Results of the risk-of-bias assessment can be found in Tables 39–42.
Patient selection was independent of study outcome in all included studies, with the PFT preceding any
outcomes (as specified in the study selection criteria). Fifteen of 21 studies stated that consecutive patients were
enrolled.76,108,112,115,116,123,127,132,135,137,138,150,186,187,189,193 Two studies76,99 had clear details on posteligibility exclusions.
A predetermined threshold value for defining resistance was given in 18 studies;76,99,109,112,115,116,118,123,127,132,
135,137,138,145,150,186,187,189,193 thresholds varied between 150 and 193 seconds, though one study138 had a much
higher threshold at 300 seconds. One study used tertiles,108 one used a median value and also conducted
ROC analysis123 and one187 stated that high residual platelet reactivity was defined as a normal closure time
value even when the subject was taking aspirin. There were no details on threshold in two studies.144,162
There were a number of methods for deriving the thresholds (as reflected in the different cut-offs
obtained); these included values established in previous studies or by other research groups. Only one
study108 stated that assays were performed in a blinded manner.
Outcome measures of interest were (at least partly) clearly stated in the methodology of 20 out of 21 studies.
Only one study145 did not clearly prespecify these. Ten studies76,99,108,109,116,118,127,135,187,193 had details on blinding
of outcome assessors to the PFT results. In 10 studies108,115,118,123,127,137,144,150,186,187 it was stated or appeared that
there was no loss to follow-up. There were no details in two studies.162,193 The remaining studies reported
varying proportions of loss to follow-up; this was between 8% and 58%. In the study with the largest loss to
follow-up (58%),112 data on clinical outcomes were only available for those patients who had a repeat PFT.
Compliance was measured in 11 studies99,108,112,116,123,127,132,135,137,144,145 using interview, pill counts, self-reports
and, in one study,145 a test for salicylates in urine. Four studies112,123,135,145 reported levels of compliance:
one123 stated that 90% of patients were still taking aspirin at year 2 (though the method of how this was
ascertained was not stated); one135 stated that all patients continued with their treatment (based on
interviews); in one study,112 patients confirmed that they had all taken aspirin over the last 14 days
(based on interview); and in one study145 patients were excluded on the basis of inadequate salicylate levels.
One study76 stated that ‘Two patients had serum TXB2 levels in the range observed for aspirin-free healthy
controls, and their platelet function was therefore consistent with aspirin noncompliance; as “resistance”
cannot be distinguished from noncompliance, these subjects were not excluded from follow-up.’
Nine studies76,99,109,115,118,123,135,138,187 undertook adjusted analyses (based on HRs or ORs). There was some
overlap in adjustment factors between the different studies, but no studies used all of the same ones.
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TABLE 38 Test characteristics (PFA-100®, monotherapy)
Study Details of kit
Anticoagulant
(concentration)
Agonist
(concentration)
Time since last
aspirin dose
Monotherapy at time of PFT and during follow-up
Addad 2010108 PFA-100® 3.2% buffered
trisodium citrate
CEPI No details
Aksu 2009109 PFA-100® 3.8% citrate CEPI No details
Bevilacqua 2009118 PFA-100® 3.8% citrate CEPI No details
Boncoraglio
2009116
PFA-100® 3.8% citrate CEPI No details
Campo 2008123
(letter)
PFA-100® No details Collagen/ADP No details
Christiaens 2008127 PFA-100® No details CEPI Up to 24 hours
Frelinger 200976 PFA-100® 3.8% sodium citrate CEPI No details
Gluckman 201199 PFA-100® 3.8% citrate CEPI
Collagen/ADP
No details
Hobikoglu 2007135 PFA-100® No details CEPI Up to 24 hours
Linnemann 2009112 PFA-100® 0.129M (3.8%)
trisodium citrate
CEPI 1–24 hours
Lordkipanidzé
2011162 (abstract)
PFA-100® No details No details No details
Modica 2009187 PFA-100® No details Epinephrine (30 µl of a
solution containing
0.1mg epinephrine)
Up to 24 hours
Morawski 2005144 PFA-100® No details CEPI Up to 12 hours
Pamukcu 2007137 PFA-100® No details CEPI 1–4 hours
Poulsen 2007132 PFA-100® No details CEPI Up to 24 hours
Sambola 2004145 PFA-100® 0.128M buffered
sodium citrate
CEPI Approximately 3 hours
Silver 2009189,193
(abstract)
PFA-100® No details CEPI
Collagen/ADP
No details
Sobol 2009186 PFA-100® No details CEPI First test: before
aspirin
Second test: up to
24 hours
Ziegler 2002150 PFA-100® No details CEPI
Collagen/ADP
Up to 24 hours
Monotherapy at time of PFT, dual therapy during follow-up
Foussas 2009115 PFA-100® No details CEPI Up to 24 hours
Fuchs 2006138 PFA-100® 129mM buffered
sodium citrate
CEPI No details
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TABLE 39 Risk of bias, patient selection (PFA-100®, monotherapy)
Domain 1:
patient selection
Was a consecutive or
random sample of
patients enrolled?
Was patient selection
independent of
patient outcomes?
Were reasons for any
posteligibility exclusions
provided?
Monotherapy at time of PFT and during follow-up
Addad 2010108 Consecutive Yes No details
Aksu 2009109 No details Yes No details
Bevilacqua 2009118 All patients undergoing
isolated primary CABG
surgery over the course of
1 year
Yes Appears that no eligible patients
were excluded
Boncoraglio 2009116 Consecutive Yes No details
Campo 2008123 Consecutive Yes No details
Christiaens 2008127 Consecutive Yes No details
Frelinger 200976 Consecutive Yes Stated that less than 3% of eligible
patients declined participation
(reason not given)
Gluckman 201199 No details Yes Patients in whom SVG patency not
assessed or those not on aspirin
monotherapy. Authors stated that
the study population was
representative of patients
undergoing isolated CABG surgery
based on comparison with the
Society of Thoracic Surgeons
National Database
Hobikoglu 2007135 Consecutive Yes No details
Linnemann 2009112 Consecutive Yes No details
Lordkipanidzé 2011162
(abstract)
No details Yes No details
Modica 2009187 Consecutive Yes No details
Morawski 2005144 No details for whole
sample, patients randomly
assigned to aspirin
or placebo
Yes No details
Pamukcu 2007137 Consecutive Yes No details
Poulsen 2007132 Consecutive Yes No details
Sambola 2004145 No details Yes No details
Silver 2009189,193
(abstract)
Consecutive Yes No details
Sobol 2009186 Consecutive Yes No details
Ziegler 2002150 Consecutive Yes No details
Monotherapy at time of PFT, dual therapy during follow-up
Foussas 2009115 Consecutive Yes No details
Fuchs 2006138 Consecutive Yes No details
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TABLE 40 Risk of bias, PFT (PFA-100®, monotherapy)
Domain 2: PFT
If a threshold was used,
was it prespecified?
How was the threshold
derived (e.g. literature cut-off,
based on study data)?
Is the undertaking and
interpretation of the index
test blinded to the patient
characteristics (including
clinical outcomes)?
Monotherapy at time of PFT and during follow-up
Addad 2010108 No (tertiles) Tertiles Yes; stated that all assays were
performed in a blinded manner
Aksu 2009109 Yes; stated (wrongly) that
resistant if CEPI CT of
≥ 170 seconds, but appears
that subsequent figures relate
to correct definition
(i.e. resistant if ≤ 170 seconds)
As described in authors’
previous studies
No details
Bevilacqua
2009118
Yes (< 190 seconds) Reference cited222 No details
Boncoraglio
2009116
Yes (< 165 seconds) Manufacturer’s information,
corroborated in authors’
laboratory
No details
Campo 2008123 Yes (for CADP) For CADP: median value as
cut-off between high and low
platelet reactivity; also ROC
analysis for exploratory
evaluation of best cut-off
For CEPI: no details
No details
Christiaens
2008127
Yes (< 187 seconds) Previously established in
authors’ laboratory
No details
Frelinger 200976 Yes (≤ 193 seconds) Cut-off represents the upper limit
of the 90% central interval of
duplicate results measured in an
aspirin-free healthy population
(references given)
No details
Gluckman
201199
Yes (≤ 193 seconds) The upper limit of the normal
range in the authors’ laboratory
for aspirin-naive patients
No details
Hobikoglu
2007135
Yes (< 170 seconds) Mean (+ 2 SD) CT of healthy
volunteers not on aspirin. Aspirin
resistance defined as a normal CT
(below the control group cut-off
value) despite aspirin treatment
No details
Linnemann
2009112
Yes (CT< 192 seconds) Previously determined by the
research group from the 95th
percentile of measurements in a
group of 50 healthy volunteers
No details
Lordkipanidzé
2011162
(abstract)
No details No details No details
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TABLE 40 Risk of bias, PFT (PFA-100®, monotherapy) (continued )
Domain 2: PFT
If a threshold was used,
was it prespecified?
How was the threshold
derived (e.g. literature cut-off,
based on study data)?
Is the undertaking and
interpretation of the index
test blinded to the patient
characteristics (including
clinical outcomes)?
Modica 2009187 Yes No specific value; high residual
platelet reactivity defined as a
normal CT value even when the
subject was taking aspirin
(reference cited77). In-house
reference ranges were
established from analyses in a
control group of 278 volunteers
No details
Morawski
2005144
No details No details (appears authors were
trying to measure a correlation
between the CT and
postoperative bleeding)
No details
Pamukcu
2007137
Yes (CT< 186 seconds) Reference cited223 for normal
reference range (98–185
seconds) for the PFA-100® with
CEPI cartridges
No details
Poulsen 2007132 Yes (CT< 165 seconds for
CEPI; no details for CADP)
Cut-off value based on the
results from a previous study
evaluating the performance of
the PFA-100® in patients
taking aspirin
No details
Sambola
2004145
Yes (CT≤ 137 seconds) Reference cited224 No details
Silver 2009189,193
(abstract)
Yes (CT< 164 seconds for
CEPI; no details for CADP)
No details No details
Sobol 2009186 Yes (CT≤ 150 seconds) No details No details
Ziegler 2002150 Yes (CT< 170 seconds during
at least one follow-up visit)
No details No details
Monotherapy at time of PFT, dual therapy during follow-up
Foussas 2009115 Yes (CT≤ 193 seconds) References cited219,225 No details
Fuchs 2006138 Yes (CT< 300 seconds) For this purpose CEPI CT was
stratified according to values > or
< 300 seconds, as 77% of
the ACS patients reached the
maximal CT value of 300 seconds
after aspirin infusion. Quartiles
also used in analysis
No details
CADP, collagen/ADP; CT, closure time.
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TABLE 41 Risk of bias, outcomes and study attrition (PFA-100®, monotherapy)
Domains 3 and 4:
outcomes and
study attrition
Were the outcomes of
interest clearly defined
in advance?
Were the outcome results
interpreted without
knowledge of the results
of the PFT?
What was the proportion of
missing data? (State reasons
for loss to follow-up or
differences in those who
completed or were lost)
Monotherapy at time of PFT and during follow-up
Addad 2010108 Yes Yes; follow-up clinicians were
blinded to PFT results
Stated that none of the included
patients was lost to follow-up
Aksu 2009109 Yes Yes; people performing
follow-up interviews were
blind to aspirin resistance and
mean platelet volume status of
the patients
20/240 lost to follow-up;
reasons not stated. Analyses
based on 220
Bevilacqua 2009118 Yes Yes; follow-up visits conducted
by cardiologists not involved in
the present study
Stated that follow-up
100% complete
Boncoraglio
2009116
Partly (vascular cognitive
impairment is mentioned in
results, but not as part of
composite outcome defined
in methods)
Yes; personnel responsible for
data collection were not aware
of PFT results
13/142 lost to follow-up
(seven had changed address and
telephone number, four refused
to reply to the questions and
two had stopped taking aspirin
for reasons unconnected with
vascular disease)
Campo 2008123 Yes No details Appears there was loss to
follow-up
Christiaens 2008127 Yes Yes; observers collecting
follow-up data were blinded to
the PFT results
All patients who enrolled
completed the study
Frelinger 200976 Yes Yes; all clinical outcome data
obtained by research personnel
blinded to results of PFTs
127/682 not included in
follow-up (appears test not
done in everyone)
Gluckman 201199 Yes Yes; stated that images were
analysed by two blinded
reviewers (98% concordance)
with a third reviewer
adjudicating as necessary
73/229 not included at
follow-up
Hobikoglu 2007135 Yes Yes; scores were determined
by one of the investigators,
who had no knowledge of the
presence of aspirin resistance
16/140 lost to follow-up and
excluded from analysis
Linnemann 2009112 Yes Unclear; reported events were
only considered if they were
confirmed by medical reports
from GPs or admitting
hospitals
Data on clinical outcome
available only from patients
whose platelet function was
assessed twice (57/98). Of the
41 excluded, 4 patients died and
16 had their antithrombotic
medication changed. Remaining
reasons for dropouts not stated.
Authors state that there was no
difference observed in aspirin
resistance rates between
dropouts and those remaining
in study
Lordkipanidzé
2011162 (abstract)
Yes No details No details
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TABLE 41 Risk of bias, outcomes and study attrition (PFA-100®, monotherapy) (continued )
Domains 3 and 4:
outcomes and
study attrition
Were the outcomes of
interest clearly defined
in advance?
Were the outcome results
interpreted without
knowledge of the results
of the PFT?
What was the proportion of
missing data? (State reasons
for loss to follow-up or
differences in those who
completed or were lost)
Modica 2009187 Yes Yes; states that the test results
were not accessible by the
attending physicians
Stated that no patients were
lost to follow-up
Morawski 2005144 Yes No details Appears to be no loss to
follow-up
Pamukcu 2007137 Yes No details Appears to be no loss to
follow-up
Poulsen 2007132 Yes No details Stated that patients were
excluded from follow-up if they
were no longer taking aspirin,
had suffered an acute MI or
stroke, or had undergone
mechanical revascularisation
because of atherothrombotic
disease within the previous
3 months
111/298 excluded from the
follow-up visit for the following
reasons: death (n=39),
withdrawal of aspirin treatment
(n=27), unwillingness to
participate (n=35), geographical
reasons (n=5), recurrent MI or
stroke within the last 3 months
(n=4). One participant was lost
to follow-up
Even though these patients were
excluded, clinical outcomes
are linked to the full sample
(297/298 patients)
Sambola 2004145 No No details 19/100 patients lost to follow-up
at 6 months. Five cardiovascular
deaths and 14 patients excluded
[9 declared non-compliant with
aspirin treatment based on
interview, 5 treated with other
regimens (3 clopidogrel,
2 warfarin)]
Silver 2009189,193
(abstract)
Yes Yes; treating physicians,
patients and researchers were
blind to the test results
No details
Sobol 2009186 Yes No details No losses to follow-up
Ziegler 2002150 Yes No details Appears that there was no loss
to follow-up
Monotherapy at time of PFT, dual therapy during follow-up
Foussas 2009115 Yes (for one outcome)
No (for two outcomes)
No details Stated that no patients lost
during follow-up
Fuchs 2006138 Yes No details 13% of patients lost to follow-up
(6% in the first year)
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Overview of outcomes
Twenty-one studies were found in this category,76,99,108,109,112,115,116,118,123,127,132,135,137,138,144,145,150,162,186,187,189 with
MACEs being the most frequently reported outcome (Table 43). Bleeding events were reported in one study
only.144
Death
Death rates were reported in 10 studies (Table 44).76,109,115,118,127,132,135,137,145,186 Outcome statistics are
shown in Figures 34–36. Results for three of these could not be presented in forest plots. In the study by
Aksu et al.,109 results were presented according to both resistance status and a cut-off for mean platelet
volume. One group (resistant and mean platelet volume> 8.4 fl) has an increased event rate compared
with the other three groups, but it is unclear how much the resistance is contributing to this. In the study
by Sobol et al.,186 one death occurred in the resistant group, but it was unclear if this was in the group
classified as resistant with PFA-100® or WBA. Frelinger et al.76 does not present deaths separately by
resistant and sensitive groups.
TABLE 43 Outcomes (PFA-100®, monotherapy)
Study Death MACE Ischaemic/thrombotic Bleeding Length of follow-up
Monotherapy at time of PFT and during follow-up
Addad 2010108 ✓ 1 year
Aksu 2009109 ✓ ✓ ✓ Mean 14.86 (SD 5.93) months
Bevilacqua 2009118 ✓ ✓ ✓ Mean 32 (SD 10) months
Boncoraglio 2009116 ✓ Mean 56.6 (range 32–91) months
Campo 2008123 ✓ 2 years
Christiaens 2008127 ✓ ✓ ✓ Median 2.5 years
Frelinger 200976 ✓ ✓ Mean 24.8 (SD 0.3) months
Gluckman 201199 ✓ 6 months
Hobikoglu 2007135 ✓ ✓ ✓ Mean 20 (range 18–24) months
Linnemann 2009112 ✓ ✓ Median 17 (range 10–37) months
Lordkipanidzé
2011162 (abstract)
✓ 3 years
Modica 2009187 ✓ Median 44 (IQR 35–55) months
Morawski 2005144 ✓ 7 days
Pamukcu 2007137 ✓ ✓ Mean 20.6 (SD 6.9) months
Poulsen 2007132 ✓ ✓ ✓ 1 year
Sambola 2004145 ✓ ✓ 6 months
Silver 2009189,193
(abstract)
✓ Unclear; 2268 patient-years of
follow-up between 2002 and 2004
Sobol 2009186 ✓ 10 days
Ziegler 2002150 ✓ 1 year
Monotherapy at time of PFT, dual therapy during follow-up
Foussas 2009115 ✓ ✓ 1 year
Fuchs 2006138 ✓ Mean 859 (range 830–887) days
IQR, interquartile range.
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TABLE 44 Outcome measures for reporting death (PFA-100®, monotherapy)
Study
Unadjusted
OR
Adjusted
OR
Unadjusted
HR
Adjusted
HR
Other measures
related to prognosis
Sensitivity/specificity
presented or calculable
Monotherapy at time of PFT and during follow-up
Aksu
2009109
Results not presented
according to resistant
and sensitive only, but
also depending on
mean platelet volume
Bevilacqua
2009118
✓a ✓a ✓a
Christiaens
2008127
✓a ✓a ✓a
Frelinger
200976
Total number of
deaths reported by
resistant or sensitive
groups unclear
Hobikoglu
2007135
✓
Pamukcu
2007137
✓a ✓a ✓a
Poulsen
2007132
✓a ✓a ✓a
Sambola
2004145
✓a ✓a ✓a
Sobol
2009186
Unclear if event in
resistant group
defined by PFA-100®
or WBA
Monotherapy at time of PFT, dual therapy during follow-up
Foussas
2009115
✓
a Calculated from data given in the publication.
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Six unadjusted ORs are presented based on five studies.118,127,132,137,145 There were more events in the
resistant arm in four of the five studies,118,127,137,145 but no differences were statistically significant. Seven of
eight unadjusted HRs (based on seven studies115,118,127,132,135,137,145) are also not statistically significant. Note
that the very large ORs and HRs118,145 are based on two118 and five145 events respectively in the resistant
group and zero events in the sensitive group. The one statistically significant result (unadjusted HR)
remained statistically significant after adjustment; this was in a UA/ACS population.115
Overall, there was a trend towards more deaths in the resistant groups, but most results were not
statistically significant.
TABLE 45 Outcome measures for reporting MACEs (PFA-100®, monotherapy)
Study
Unadjusted
OR
Adjusted
OR
Unadjusted
HR
Adjusted
HR
Other measures
related to prognosis
Sensitivity/specificity
presented or calculable
Monotherapy at time of PFT and during follow-up
Addad
2010108
✓a ✓a ✓ ✓a
Aksu
2009109
✓a ✓a ✓a
Bevilacqua
2009118
✓
Boncoraglio
2009116
✓a ✓a ✓a
Campo
2008123
✓
Christiaens
2008127
✓a ✓a ✓a
Frelinger
200976
OR reported in graph
only, but not exact
numbers
Hobikoglu
2007135
✓a ✓ ✓ ✓a
Linnemann
2009112
✓a ✓a ✓a
Lordkipanidzé
2011162
(abstract)
✓
Modica
2009187
✓ ✓
Pamukcu
2007137
✓a ✓a ✓a
Poulsen
2007132
✓a ✓a ✓a
Monotherapy at time of PFT, dual therapy during follow-up
Fuchs 2006138 ✓ ✓
a Calculated from data given in the publication.
DOI: 10.3310/hta19370 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 37
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
137
A
dd
ad
20
10
10
8
Tu
ni
si
a/
Fr
an
ce
20
4
CA
D
M
on
o
6.
33
 (1
.2
4 
to
 3
2.
26
)
Y
ea
r
Co
un
tr
y
Pa
ti
en
ts
Pa
ti
en
t
gr
ou
p
Th
er
ap
y
CE
PI
A
go
ni
st
14
3 
s
N
o
Th
re
sh
ol
d
O
R 
di
re
ct
ly
av
ai
la
bl
e?
Fi
rs
t 
te
rt
ile
 v
s.
 s
ec
on
d
an
d 
th
ir
d 
te
rt
ile
 (R
A
V
E)
A
dd
ad
20
10
10
8
Tu
ni
si
a/
Fr
an
ce
20
4
CA
D
M
on
o
1.
69
 (0
.6
6 
to
 4
.3
0)
CE
PI
14
3 
s
N
o
Fi
rs
t 
te
rt
ile
 v
s.
 s
ec
on
d
an
d 
th
ir
d 
te
rt
ile
 (M
A
CE
)
A
dd
ad
20
10
10
8
Tu
ni
si
a/
Fr
an
ce
20
4
CA
D
M
on
o
57
9.
06
 (0
.0
0 
to
 4
.9
5e
+1
2)
CE
PI
29
8 
s
N
o
Fi
rs
t 
an
d 
se
co
nd
 t
er
ti
le
vs
. t
hi
rd
 t
er
ti
le
 (R
A
V
E)
A
dd
ad
20
10
10
8
Tu
ni
si
a/
Fr
an
ce
20
4
CA
D
M
on
o
1.
56
 (0
.5
4 
to
 4
.4
9)
CE
PI
29
8 
s
N
o
Fi
rs
t 
an
d 
se
co
nd
 t
er
ti
le
vs
. t
hi
rd
 t
er
ti
le
 (M
A
CE
)
Ch
ri
st
ia
en
s
20
08
12
7
Fr
an
ce
97
CA
D
M
on
o
1.
37
 (0
.4
1 
to
 4
.5
0)
CE
PI
18
7 
s
N
o
Lo
rd
ki
pa
ni
dz
é
20
11
16
2
Ca
na
da
19
8
CA
D
M
on
o
1.
30
 (0
.5
1 
to
 3
.2
9)
N
ot
 s
ta
te
d
N
o 
de
ta
ils
Y
es
Pa
m
uk
cu
20
07
13
7
Tu
rk
ey
23
4
CA
D
M
on
o
1.
47
 (0
.6
1 
to
 3
.5
7)
CE
PI
18
6 
s
N
o
Bo
nc
or
ag
lio
20
09
11
6
It
al
y
12
9
CV
D
/
st
ro
ke
M
on
o
1.
07
 (0
.3
2 
to
 3
.5
3)
CE
PI
16
5 
s
N
o
Li
nn
em
an
n
20
09
11
2
G
er
m
an
y
57
PA
D
/
PV
D
M
on
o
0.
01
 (0
.0
0 
to
 2
67
9.
07
)
CE
PI
19
2 
s
N
o
A
ks
u
20
09
10
9
Tu
rk
ey
22
0
U
A
/A
CS
M
on
o 
at
 b
as
el
in
e;
fo
llo
w
-u
p 
73
%
m
on
o,
 2
7%
 d
ua
l
3.
17
 (1
.7
1 
to
 5
.9
0)
CE
PI
17
0 
s
N
o
H
ob
ik
og
lu
20
07
13
3
Tu
rk
ey
14
0
U
A
/A
CS
M
on
o
2.
80
 (1
.1
9 
to
 6
.5
7)
CE
PI
17
0 
s
N
o
Po
ul
se
n
20
07
13
2
D
en
m
ar
k
29
7
U
A
/A
CS
M
on
o
1.
06
 (0
.5
2 
to
 2
.1
7)
CE
PI
16
5 
s
D
ea
th
, M
I, 
or
 s
tr
ok
e
N
o
Po
ul
se
n
20
07
13
2
D
en
m
ar
k
29
7
U
A
/A
CS
M
on
o
0.
93
 (0
.5
0 
to
 1
.7
4)
Co
lla
ge
n/
A
D
P
U
nc
le
ar
D
ea
th
, M
I, 
or
 s
tr
ok
e
an
d 
re
va
sc
ul
ar
is
at
io
n
N
o
Po
ul
se
n
20
07
13
2
D
en
m
ar
k
29
7
U
A
/A
CS
M
on
o
0.
93
 (0
.5
0 
to
 1
.7
4)
CE
PI
U
nc
le
ar
D
ea
th
, M
I, 
or
 s
tr
ok
e
an
d 
re
va
sc
ul
ar
is
at
io
n
N
o
Po
ul
se
n
20
07
13
2
D
en
m
ar
k
29
7
U
A
/A
CS
M
on
o
1.
06
 (0
.5
2 
to
 2
.1
7)
Co
lla
ge
n/
A
D
P
U
nc
le
ar
D
ea
th
, M
I, 
or
 s
tr
ok
e
N
o
W
it
hi
n-
st
ud
y
di
ff
er
en
ce
St
ud
y
O
R 
(9
5%
 C
l)
0.
5
U
na
dj
us
te
d 
O
R
1
2
5
10
FI
G
U
R
E
37
PF
A
-1
00
®
,
m
o
n
o
th
er
ap
y:
M
A
C
Es
,u
n
ad
ju
st
ed
O
R
s.
R
A
V
E,
re
cu
rr
en
t
ac
u
te
va
sc
u
la
r
ev
en
t;
s,
se
co
n
d
s.
RESULTS OF PROGNOSTIC UTILITY REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
138
A
dd
ad
20
10
10
8
Tu
ni
si
a/
Fr
an
ce
20
4
CA
D
M
on
o
1.
64
 (0
.6
8 
to
 3
.9
7)
Y
ea
r
Co
un
tr
y
Pa
ti
en
ts
CE
PI
A
go
ni
st
14
3 
s
Th
re
sh
ol
d
Fi
rs
t 
te
rt
ile
 v
s.
 s
ec
on
d
an
d 
th
ir
d 
te
rt
ile
 (M
A
CE
)
W
it
hi
n-
st
ud
y
di
ff
er
en
ce
N
o
A
dd
ad
20
10
10
8
Tu
ni
si
a/
Fr
an
ce
20
4
CA
D
M
on
o
56
1.
68
 (0
.0
0 
to
 4
.7
9e
+1
2)
CE
PI
29
8 
s
Fi
rs
t 
an
d 
se
co
nd
 t
er
ti
le
vs
. t
hi
rd
 t
er
ti
le
 (R
A
V
E)
N
o
A
dd
ad
20
10
10
8
Tu
ni
si
a/
Fr
an
ce
20
4
CA
D
M
on
o
6.
09
 (1
.2
3 
to
 3
0.
20
)
CE
PI
14
3 
s
Fi
rs
t 
te
rt
ile
 v
s.
 s
ec
on
d
an
d 
th
ir
d 
te
rt
ile
 (R
A
V
E)
N
o
A
dd
ad
20
10
10
8
Tu
ni
si
a/
Fr
an
ce
20
4
CA
D
M
on
o
1.
53
 (0
.5
6 
to
 4
.2
1)
CE
PI
29
8 
s
Fi
rs
t 
an
d 
se
co
nd
 t
er
ti
le
vs
. t
hi
rd
 t
er
ti
le
 (M
A
CE
)
N
o
Be
vi
la
cq
ua
20
09
11
8
It
al
y
20
2
CA
D
M
on
o
2.
11
 (1
.3
3 
to
 3
.3
4)
CE
PI
19
0 
s
Y
es
Ch
ri
st
ae
ns
20
08
12
7
Fr
an
ce
97
CA
D
M
on
o
1.
33
 (0
.4
5 
to
 3
.9
8)
CE
PI
18
7 
s
N
o
Pa
m
uk
cu
20
07
13
7
Tu
rk
ey
23
4
CA
D
M
on
o
1.
44
 (0
.6
3 
to
 3
.2
6)
CE
PI
18
6 
s
N
o
Bo
nc
or
ag
lio
20
09
11
6
It
al
y
12
9
CV
D
/
st
ro
ke
M
on
o
1.
07
 (0
.3
5 
to
 3
.3
0)
CE
PI
16
5 
s
N
o
Li
nn
em
an
n
20
09
11
2
G
er
m
an
y
57
PA
D
/
PV
D
M
on
o
0.
01
 (0
.0
0 
to
 2
79
2.
29
)
CE
PI
19
2 
s
N
o
A
ks
u
20
09
10
9
Tu
rk
ey
22
0
U
A
/A
CS
M
on
o 
at
 b
as
el
in
e;
fo
llo
w
-u
p 
73
%
m
on
o,
 2
7%
 d
ua
l
2.
67
 (1
.5
8 
to
 4
.5
1)
CE
PI
17
0 
s
N
o
Fu
ch
s
20
06
13
8
A
us
tr
ia
20
8
U
A
/A
CS
M
on
o
2.
00
 (1
.1
1 
to
 3
.6
2)
CE
PI
30
0 
s
Re
cu
rr
en
ce
 o
f 
A
CS
Y
es
Fu
ch
s
20
06
13
8
A
us
tr
ia
20
8
U
A
/A
CS
M
on
o
3.
30
 (1
.4
4 
to
 7
.5
9)
Co
lla
ge
n/
A
D
P
H
ig
h 
vs
.
lo
w
 q
ua
rt
ile
Re
cu
rr
en
ce
 o
f 
A
CS
Y
es
H
ob
ik
og
lu
20
07
13
5
Tu
rk
ey
14
0
U
A
/A
CS
M
on
o
2.
32
 (1
.1
1 
to
 4
.8
4)
CE
PI
17
0 
s
Y
es
M
od
ic
a
20
09
18
7
Sw
ed
en
33
4
U
A
/A
CS
M
on
o
0.
80
 (0
.5
4 
to
 1
.1
9)
Ep
in
ep
hr
in
e
Q
ua
rt
ile
s
Y
es
Po
ul
se
n
20
07
13
2
D
en
m
ar
k
29
7
U
A
/A
CS
M
on
o
0.
94
 (0
.5
5 
to
 1
.6
2)
Co
lla
ge
n/
A
D
P
N
ot
 c
le
ar
D
ea
th
, M
I, 
st
ro
ke
 o
r
re
va
sc
ul
ar
is
at
io
n
N
o
Po
ul
se
n
20
07
13
2
D
en
m
ar
k
29
7
U
A
/A
CS
M
on
o
1.
06
 (0
.5
5 
to
 2
.0
3)
CE
PI
16
5 
s
D
ea
th
, M
I, 
or
 s
tr
ok
e
N
o
Po
ul
se
n
20
07
13
2
D
en
m
ar
k
29
7
U
A
/A
CS
M
on
o
1.
06
 (0
.5
5 
to
 2
.0
3)
Co
lla
ge
n/
A
D
P
N
ot
 c
le
ar
D
ea
th
, M
I, 
or
 s
tr
ok
e
N
o
Po
ul
se
n
20
07
13
2
D
en
m
ar
k
29
7
U
A
/A
CS
M
on
o
0.
94
 (0
.5
5 
to
 1
.6
2)
CE
PI
16
5 
s
D
ea
th
, M
I, 
st
ro
ke
 o
r
re
va
sc
ul
ar
is
at
io
n
N
o
H
R 
di
re
ct
ly
av
ai
la
bl
e?
Pa
ti
en
t
gr
ou
p
Th
er
ap
y
St
ud
y
H
R 
(9
5%
 C
l)
U
na
dj
us
te
d 
H
R
0.
5
1
2
5
10
FI
G
U
R
E
38
PF
A
-1
00
®
,
m
o
n
o
th
er
ap
y:
M
A
C
Es
,u
n
ad
ju
st
ed
H
R
s.
R
A
V
E,
re
cu
rr
en
t
ac
u
te
va
sc
u
la
r
ev
en
t;
s,
se
co
n
d
s.
DOI: 10.3310/hta19370 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 37
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
139
B
ev
ila
cq
u
a
20
09
11
8
It
al
y
20
2
C
A
D
M
o
n
o
1.
88
 (
1.
15
 t
o
 3
.0
7)
Y
ea
r
C
o
u
n
tr
y
Pa
ti
en
ts
Pa
ti
en
t
g
ro
u
p
Th
er
ap
y
W
it
h
in
-s
tu
d
y
d
if
fe
re
n
ce
19
0 
s
Th
re
sh
o
ld
CE
PI
C
am
p
o
20
08
12
3
It
al
y
16
0
C
A
D
M
o
n
o
4.
50
 (
1.
84
 t
o
 1
1.
02
)
N
o
t 
cl
ea
r
C
o
lla
g
en
/
A
D
P
Fu
ch
s
20
06
13
8
A
u
st
ri
a
20
8
U
A
/A
C
S
M
o
n
o
R
ec
u
rr
en
ce
 o
f 
A
C
S
2.
80
 (
0.
80
 t
o
 9
.8
0)
H
ig
h
es
t 
vs
.
lo
w
es
t 
q
u
ar
ti
le
CE
PI
Fu
ch
s
20
06
13
8
A
u
st
ri
a
20
8
U
A
/A
C
S
M
o
n
o
R
ec
u
rr
en
ce
 o
f 
A
C
S
2.
30
 (
1.
22
 t
o
 4
.3
5)
30
0 
s
CE
PI
H
o
b
ik
o
g
lu
20
07
13
5
Tu
rk
ey
14
0
U
A
/A
C
S
M
o
n
o
3.
03
 (
1.
06
 t
o
 8
.6
4)
17
0 
s
CE
PI
M
o
d
ic
a
20
09
18
7
Sw
ed
en
33
4
U
A
/A
C
S
M
o
n
o
0.
70
 (
0.
47
 t
o
 1
.0
4)
H
ig
h
es
t 
vs
.
lo
w
es
t 
q
u
ar
ti
le
Ep
in
ep
h
ri
n
e
A
g
o
n
is
t
St
u
d
y
H
R
 (
95
%
 C
l)
0.
5 A
d
ju
st
ed
 H
R
1
2
5
10
FI
G
U
R
E
39
PF
A
-1
00
®
,
m
o
n
o
th
er
ap
y:
M
A
C
Es
,a
d
ju
st
ed
H
R
s.
s,
se
co
n
d
s.
RESULTS OF PROGNOSTIC UTILITY REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
140
Major adverse cardiac events
Fourteen studies reported MACEs (Table 45).76,108,109,112,116,118,123,127,132,135,137,138,162,187 Outcome statistics are
shown in Figures 37–39. One76 was not presented in a forest plot as exact numbers were not reported.
The graphical representation indicates an unadjusted OR below 1 (more events in the sensitive group), but
this was not statistically significant.
Fifteen unadjusted ORs are presented, based on nine studies;108,109,112,116,127,132,135,137,162 note that two108,132
of these studies contribute four results each. Three ORs are statistically significant (more events in the
resistant group), based on three studies.108,109,135 Apart from one study132 contributing four results which
are all close to 1, the direction of effect based on the other eight studies108,109,112,116,127,135,137,162 is consistent
(more events in the resistant groups). Note that six results are based on three studies109,132,135 with an
acute population.
Eighteen unadjusted HRs are presented, based on 11 studies.108,109,112,116,118,127,132,135,137,138,187 Two108,132 of these
studies contribute four results each. With the exception of two studies,132,187 the direction of effect is again
consistent (more events in the resistant arm). Six unadjusted HRs (based on five studies108,109,118,135,138) were
statistically significant.
Six adjusted HRs (based on five studies118,123,135,138,187) were available, four of which were statistically
significant (more events in the resistant arm). One study187 clearly shows the opposite direction of effect
(though this is not statistically significant); this may be a result of differences in threshold (highest vs.
lowest quartile was compared rather than using a single cut-off), population differences or differences in
adjustment factors.
Overall, there was a mainly consistent trend, with more MACEs in the resistant arm, and some results
were statistically significant. Not all studies contributed to the results, particularly the adjusted results. In
addition, five of six unadjusted HRs were based on an acute population, which may not be representative
of the general population prescribed aspirin monotherapy.
Ischaemic/thrombotic events
Eleven studies reported additional ischaemic/thrombotic outcomes (Table 46).99,109,112,115,118,127,132,135,145,150,189,193
Results from two studies could not be presented in the forest plots. In the study by Aksu et al.,109 results were
presented according to both resistance status and a cut-off for mean platelet volume. One group (resistant
and mean platelet volume> 8.4 fl) had an increased event rate compared with the other three groups, but it
was unclear how much the resistance was contributing to this. Sambola et al.145 stated that no significant
differences were found between resistant and sensitive groups in rates of infarction, angina or need
for revascularisation.
Outcome statistics are shown in Figures 40–43. Nineteen unadjusted ORs were presented based on
seven studies.99,112,115,118,127,132,150 Two ORs were statistically significant (more events in the resistant group),
but for one of these (from the Gluckman et al. study99) the threshold was unclear. Note that eight ORs are
derived from populations with UA/ACS. The overall direction of effect was not consistent across (or within,
e.g. Poulsen et al.,132 Linnemann et al.112) studies. There were two adjusted ORs (based on one study99),
one of which was statistically significant (more events in the resistant group).
Two of 22 unadjusted HRs were statistically significant (more events in the resistant group); however,
the direction of effect was again not consistent. Eleven of the 21 ORs were based on populations with
UA/ACS. Note also that some studies contributed disproportionately to the results, for example where
they measured more outcomes. There was only one adjusted HR, showing a statistically significant result
(more events in the resistant group).
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TABLE 46 Outcome measures for reporting ischaemic/thrombotic events (PFA-100®, monotherapy)
Study
Unadjusted
OR
Adjusted
OR
Unadjusted
HR
Adjusted
HR
Other measures
related to prognosis
Sensitivity/specificity
presented or calculable
Monotherapy at time of PFT and during follow-up
Aksu
2009109
Results not presented
according to resistant
and sensitive only, but
also depending on
mean platelet volume
Bevilacqua
2009118
✓a ✓ ✓ ✓a
Christiaens
2008127
✓a ✓a ✓a
Gluckman
201199
✓ ✓
Hobikoglu
2007135
✓
Linnemann
2009112
✓a ✓a ✓a
Poulsen
2007132
✓a ✓a ✓a
Sambola
2004145
Narrative description
Silver
2009189,193
(abstract)
✓
Ziegler
2002150
✓a ✓a ✓a
Monotherapy at time of PFT, dual therapy during follow-up
Foussas
2009115
✓a ✓a ✓a
a Calculated from data given in the publication.
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Bleeding events
One study reported bleeding events (Table 47).144
No studies were identified that looked at bleeding outcomes over the long term. One study144 evaluated
postoperative bleeding and found that PFA-100® failed to correlate with postoperative bleeding, but
PFA-100® measurements repeated immediately after CABG were predictive of blood loss.
Summary: platelet function analyser-100
Twenty-one studies were identified in this category.76,99,108,109,112,115,116,118,123,127,132,135,137,138,144,145,150,162,186,187,189
There were more populations with stable disease, but those studies with acute populations contributed
quite substantially to the results (roughly half of the outcome statistics). There was heterogeneity across
studies in terms of specific patient characteristics.
There was a lack of reporting of relevant quality criteria, making overall judgements about risk of bias
difficult. No study provided details on all relevant quality criteria. Lack of detail related in particular to
whether or not assays were performed in a blinded manner, reporting of compliance levels and, to a lesser
extent, whether or not outcome assessors had been blinded to PFT results. In terms of consequences of
non-compliance, it appears that in one study145 patients were excluded on the basis of inadequate salicylate
levels, whereas another study76 did not exclude patients with aspirin non-compliance on the basis that
resistance cannot be distinguished from non-compliance. There were a number of methods for deriving the
thresholds, which was reflected in the different cut-offs employed (between 150 and 193 seconds where
stated, with one study138 having a much higher threshold at 300 seconds). Some studies provided adjusted
results but there was no consistency between studies in terms of factors adjusted for.
Based on 10 studies76,109,115,118,127,132,135,137,145,186 reporting this outcome, there was an overall trend towards
more deaths in the resistant groups, but most results were not statistically significant.
Based on 14 studies,76,108,109,112,116,118,123,127,132,135,137,138,162,187 there was a mainly consistent trend for MACEs,
with more events in the resistant arm, and some results statistically significant. Note that not all studies
contributed to the results, particularly the adjusted results. In addition, five of six unadjusted HRs are based
on an acute population, which may not be representative of the total population.
TABLE 47 Outcome measures for reporting bleeding events (PFA-100®, monotherapy)
Study
Unadjusted
OR
Adjusted
OR
Unadjusted
HR
Adjusted
HR
Other measures
related to prognosis
Sensitivity/specificity
presented or calculable
Monotherapy at time of PFT and during follow-up
Morawski
2005144
Narrative description
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Eleven studies reported additional ischaemic/thrombotic outcomes.99,109,112,115,118,127,132,135,145,150,189,193
Compared with the large number of unadjusted outcome statistics reported, there were very few adjusted
results. The direction of effect was not consistent for these outcomes and there were only a few statistically
significant results (with more events in the resistant group). Given the large number of different outcomes
and heterogeneity of other factors across studies, it was not possible to compare results for different
outcomes (e.g. MI, stroke).
No studies were identified that looked at bleeding outcomes over the long term.
The mainly consistent trend for MACEs and death, with more events in the resistant arm, suggests that
PFA-100® is a potential prognostic factor, but this is only a qualitative judgement on the evidence available;
the trend for ischaemic/thrombotic events was, however, less consistent. Meta-analysis was not possible
owing to the heterogeneity, and therefore a firm quantitative conclusion regarding whether or not PFA-100®
is prognostic is not currently possible.
Summary: platelet function analyser-100
l Twenty-one studies were identified for this test.
l There were more stable than acute populations, though studies with acute populations contributed
substantially to the results.
l Methods for deriving thresholds and thresholds themselves were variable.
l A lack of detail in reporting of quality criteria, for example whether or not assays were performed
in a blinded manner, and in reporting of compliance levels (where measured), hampered an overall
risk-of-bias assessment.
l Adjusted results were rarely presented, and thus the additional prognostic value of the test over other
prognostic factors is difficult to ascertain.
l There was a mainly consistent trend for MACEs, with more events in the resistant arm, and some
statistically significant results; this trend was reflected in studies reporting death, but most results were
not statistically significant for this outcome.
l The direction of effect was not consistent for ischaemic/thrombotic events.
l No studies were identified that looked at bleeding outcomes over the long term.
l Not all studies are represented in the forest plots, particularly for the adjusted outcome measures.
l Heterogeneity in outcomes, patient groups and types of reported statistics meant that meta-analysis was
not considered appropriate; there is insufficient quantitative information and methodological/clinical
homogeneity across studies to enable evidence-based conclusions about the prognostic ability of PFA-100®.
Whole-blood aggregometry
Population and test characteristics
Eight studies99,117,128,153,162,166,186,196 were identified in this category, two of which were reported in abstract
form only.162,166 Populations had CAD (three studies),99,117,162 CVD/stroke (two studies),128,186 PAD/PVD
(one study)153 and UA/ACS where patients were undergoing PPCI (one study).196 There was one study166 in
patients with end-stage renal disease. Two studies included only patients reporting a first event,186,196 one
study consisted of patients who had suffered previous event(s)128 and one study reported patients who had
their primary underlying condition for a mean period of 41.4 months.117 Four studies did not report how long
patients had been on aspirin therapy.99,149,166,186
In seven studies99,117,128,153,162,166,186 it appeared that patients were exclusively on monotherapy both at the
time of the PFT and during follow-up. It is possible that not all studies have reported where a proportion of
patients commenced additional therapies during follow-up. In the remaining study,196 patients were on
monotherapy at the time of the PFT and all were on dual therapy (+ clopidogrel or ticlopidine) during a
portion of the follow-up period.
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Two different methods of WBA were identified across studies and were analysed separately. One study166
used Multiplate® and seven studies used impedance methodology.99,117,128,153,162,186,196 Most tests used
arachidonic acid or collagen as an agonist, with some also using ADP and epinephrine, and citrate as the
anticoagulant (where reported).
Most studies did not report use of other medications. Medications were reported in two studies99,117 and
included statins, beta-blockers, ACE inhibitors, angiotensin receptor blockers, nitrate, lipid-lowering agents,
diuretics, digoxin, spironolactone, warfarin, intravenous inotropic therapy and amiodarone. NSAIDs were
not permitted (or had to be discontinued within a certain time period) in two studies.186,196 One study99
stated that ‘concurrent nonsteroidal anti-inflammatory drug use did not correlate with the presence of
aspirin non-responsiveness defined by this method at either time point’. There were no details on NSAIDs
in the remaining studies.
The number of participants in the studies ranged from 26 to 653 (see Table 48). Where reported, mean
ages of patients ranged from 52 to 66 years, with most means around the early 60s. There were more
men than women in five out of six studies99,117,128,153,186,196 that reported this, with proportions of men
ranging from 52% to 82%. Only one study128 included more women (55%). The proportion of patients
with diabetes ranged from 17% to 44%, and that of smokers from 23% to 69% (where reported)
(see Table 48). Where reported, studies were conducted in hospital settings.
The dose of aspirin ranged from 75mg/day to > 325mg/day. There were no details on dose in one study.166
Details were variable across studies regarding the length of time patients had been receiving aspirin
therapy, with some noting a minimum period and some whether or not patients were chronic users, but
many giving no details (see Table 48). One study99 stated that aspirin was provided in enteric form, another
reported that aspirin was provided in both enteric and plain forms117 and the other studies did not report
this information.
The main study characteristics are listed in Table 48. Note that in some studies baseline characteristics
have been reported only according to resistant/sensitive groups, groups with or without diabetes, or
groups with occluded or patent SVG during CABG surgery, rather than for the total study population.
Four studies99,128,162,166 reported no details on the timing of the PFT after aspirin ingestion. Four
studies117,153,186,196 stated that there were up to 24 hours between aspirin dose and the PFT. Table 49
provides details of test characteristics.
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TABLE 49 Test characteristics (WBA, monotherapy)
Study Details of kit (manufacturer)
Anticoagulant
(concentration)
Agonist
(concentration)
Time since last
aspirin dose
Multiplate® (MEA)
Monotherapy at time of PFT and during follow-up
Orta 2011166
(abstract)
Multiplate® analyser (Dynabyte
Medical, Munich, Germany)
No details No details No details
WBA (impedance)
Monotherapy at time of PFT and during follow-up
Gengo 2008128 WBA (Model 700, Chrono-Log
Corporation, Havertown,
PA, USA)
No details Collagen (1 µg/ml) No details
Gluckman 201199 WBA (Model 560CA,
Chrono-Log Corporation,
Havertown, PA, USA)
3.2% citrate AA (0.5mM)
ADP (5 µM)
ADP (10 µM)
ADP (20 µM)
Epinephrine (50 µM)
Collagen (1 µg/ml)
No details
Lordkipanidzé
2011162 (abstract)
WBA No details AA (1.6mM) No details
Majeed 2009117 WBA (Whole-Blood
Aggregometer®, Chrono-Log
Corporation, Havertown,
PA, USA)
No details Collagen (1 µg/ml)
Collagen (5 µg/ml)
Up to 24 hours
Mueller 1997153 WBA (CHRONO LOG®
four-channel whole-blood
aggregometer, Chrono-Log
Corporation, Havertown,
PA, USA)
No details AA (500 µM)
ADP (5 µM)
ADP (10 µM)
Collagen (2 µg/ml)
Collagen (5 µg/ml)
Baseline test: before
starting antiplatelet
therapy
Follow-up tests: up to
24 hours
Sobol 2009186 WBA (Chrono-Log,
Havertown, PA, USA)
No details AA (0.5mM) Up to 24 hours
Monotherapy at time of PFT, dual during follow-up
Kaminska 2007196 WBA (Chronolog 560,
Chrono-Log Corporation,
Havertown, PA, USA)
No details AA (0.125mM)
Collagen (0.5 µg)
Collagen (1 µg)
Collagen (2 µg)
Up to 24 hours
AA, arachidonic acid; MEA, multiple electrode aggregometry.
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Study design and quality
Results of the risk-of-bias assessment can be found in Tables 50–53.
Patient selection was independent of study outcome in all included studies, with the PFT preceding any
outcomes (as specified in the study selection criteria). Four studies stated that consecutive patients were
enrolled into the study117,128,153,186 and the other studies did not provide details. Only two studies99,153
had clear details on posteligibility exclusion of patients; in one of these studies153 a criterion for exclusion
was lack of compliance.
TABLE 50 Risk of bias, patient selection (WBA, monotherapy)
Domain 1:
patient
selection
Was a consecutive or
random sample of
patients enrolled?
Was patient selection
independent of
patient outcomes?
Were reasons for any posteligibility
exclusions provided?
Multiplate® (MEA)
Monotherapy at time of PFT and during follow-up
Orta 2011166
(abstract)
No details Yes No details
WBA (impedance)
Monotherapy at time of PFT and during follow-up
Gengo
2008128
Consecutive Yes No details
Gluckman
201199
No details Yes Patients in whom SVG patency not
assessed or those not on aspirin
monotherapy. Authors stated that the
study population was representative of
patients undergoing isolated CABG
surgery based on comparison with
the Society of Thoracic Surgeons
National Database
Lordkipanidzé
2011162
(abstract)
No details Yes No details
Majeed
2009117
Consecutive Yes No details
Mueller
1997153
Consecutive Yes 45/145 patients initially enrolled and
then excluded. Reasons for exclusion: if it
could be shown that patients claiming
not to have used medication containing
aspirin, had been using aspirin; lack of
compliance in correct usage of aspirin;
other exclusion criteria. All exclusion
criteria seem to have been applied after
enrolment and consent
Sobol 2009186 Consecutive Yes No details
Monotherapy at time of PFT, dual during follow-up
Kaminska
2007196
No details Yes No details
MEA, multiple electrode aggregometry.
DOI: 10.3310/hta19370 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 37
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
153
TABLE 51 Risk of bias, PFT (WBA, monotherapy)
Domain 2: PFT
If a threshold was used,
was it prespecified?
How was the threshold
derived (e.g. literature
cut-off, based on study data)?
Is the undertaking and
interpretation of the index
test blinded to the patient
characteristics (including
clinical outcomes)?
Multiplate® (MEA)
Monotherapy at time of PFT and during follow-up
Orta 2011166
(abstract)
No details No details No details
WBA (impedance)
Monotherapy at time of PFT and during follow-up
Gengo 2008128 Yes (patients considered to be
non-responsive to aspirin if their
platelet response, measured in
ohms of impedance, to 1 µg/ml
of collagen was > 10Ω, > 50%
of their response to 5 µg/ml of
collagen and/or > 6Ω to
0.5mM AA)
Criteria similar to ones cited
(references given226–230)
No details (but quality control
procedures described)
Gluckman
201199
Yes (aspirin resistant if
AA-induced platelet
aggregation was > 1Ω)
Stated that normal range in
authors’ laboratory for
aspirin-naive subjects was 5–7Ω.
No further details
No details
Lordkipanidzé
2011162
(abstract)
No details No details No details
Majeed 2009117 Yes (aspirin resistance defined as
at least 50% platelet response)
Formula and reference cited231 No details
Mueller 1997153 No threshold Different ‘classes’ of effect of
aspirin on platelet function
depending on change from
baseline derived from data
No details
Sobol 2009186 Yes (but no numerical cut-off) A lack of complete inhibition of
AA-induced whole-blood
aggregation
No details
Monotherapy at time of PFT, dual during follow-up
Kaminska
2007196
Not explicitly stated; assumed
that if there is any aggregation
patients are classed as
aspirin resistant
No details No details
AA, arachidonic acid; MEA, multiple electrode aggregometry.
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TABLE 52 Risk of bias, outcomes and study attrition (WBA, monotherapy)
Domains
3 and 4:
outcomes and
study attrition
Were the outcomes of
interest clearly defined
in advance?
Were the outcome results
interpreted without
knowledge of the results of
the PFT?
What was the proportion of
missing data? (State reasons for
loss to follow-up or differences
in those who completed or
were lost)
Multiplate® (MEA)
Monotherapy at time of PFT and during follow-up
Orta 2011166
(abstract)
Yes No details Appears to be no loss to follow-up
WBA (impedance)
Monotherapy at time of PFT and during follow-up
Gengo 2008128 Yes No details Appears to be no loss to follow-up
Gluckman
201199
Yes Yes. Stated that images were
analysed by two blinded reviewers
(98% concordance) with a third
reviewer adjudicating as necessary
75/229 patients not included at
follow-up
Lordkipanidzé
2011162
(abstract)
Yes No details No details
Majeed 2009117 Yes No details No losses to follow-up
Mueller 1997153 Yes No details 4/100 patients lost to follow-up by
52 weeks (for repeat PFT) but
appears all patients included
for outcomes
Sobol 2009186 Yes No details No losses to follow-up
Monotherapy at time of PFT, dual during follow-up
Kaminska
2007196
No; the paper did not
focus on clinical
outcomes (it was focused
on the results of the PFTs)
Yes The paper states that one person
(out of 27) was lost to follow-up at
6 months as a result of MI; this is
the same person who is recorded as
having the clinical event of MI
MEA, multiple electrode aggregometry.
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A predetermined threshold percentage (for platelet aggregation) was given in four studies.99,117,128,186
Thresholds were > 1Ω99 at least 50% platelet response;117 and > 10Ω in response to 1 μg/ml of collagen,
> 50% of the response to 5 μg/ml of collagen and/or > 6Ω to 0.5mM arachidonic acid.128 In one study the
numerical cut-off was not stated and patients were described as resistant if there was a ‘lack of complete
inhibition of arachidonic acid induced whole blood aggregation’.186 Another study196 stated that patients
were classed as aspirin resistant if there was any aggregation at all. One study stated that quartiles were
used,153 and the remaining two studies162,166 reported no details. None of the studies gave clear details on
blinding of laboratory staff to patient characteristics.
Outcome measures of interest were clearly predefined in all but one study.99,117,128,153,162,166,186 None of the
studies provided clear details regarding blinding to the PFT results of those assessing outcomes.
There appeared to be no loss to follow-up in four studies.117,128,166,186 Loss to follow-up was stated in two
studies153,196 and was approximately 4% in both. There were no clear details in one study.162 The
differences in completeness of follow-up may reflect length of follow-up, study design (outcome only
followed up in those that had repeat PFTs) or quality of reporting.
Compliance was measured in four studies,99,117,128,153 but there were no details on level of compliance. It
was determined by presence of salicylates in urine,128 pill counts,99 patient interview, nurse assessment and
pharmacy records during the period of hospitalisation and through self-report only after discharge,117 and a
positive reaction to arachidonic acid-mediated aggregometry.153 The four remaining studies reported no
details on compliance.162,166,186,196
Six studies did not appear to undertake any adjusted analyses.99,117,153,166,186,196 One study128 attempted to
adjust for a number of factors, including age, sex, presence of various comorbidities, nature of recurrent
event and use of various other drugs. In one study162 it is not clear whether the ORs reported were
adjusted or unadjusted. There may be selective reporting in that only variables that showed significance on
univariate analysis might have been included in multivariate analyses.
Overview of outcomes
There were eight studies99,117,128,153,162,166,186,196 using WBA as a PFT and reporting on death, MACEs and
ischaemic/thrombotic events (Table 54).
Death
Two studies186,196 reported deaths (Table 55). One of these186 could not be presented in a forest plot, as
although it stated that one death occurred in the resistant group, it was unclear whether resistance was
determined by WBA and/or PFA-100®. Outcome statistics are presented in Figures 44 and 45. Unadjusted
ORs and HRs were calculable for the other study.196 These were not statistically significant; the wide CIs
reflect the fact that there were two events in the resistant arm and no events in the sensitive arm.
Though the trend across the two studies is consistent (the only events are in the resistant group), there
were too few studies and events to draw any conclusion regarding risk of death.
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TABLE 55 Outcome measures for reporting death (WBA, monotherapy)
Study
Unadjusted
OR
Adjusted
OR
Unadjusted
HR
Adjusted
HR
Other measures
related to prognosis
Sensitivity/specificity
presented or calculable
WBA (impedance)
Monotherapy at time of PFT and during follow-up
Sobol 2009186 Unclear which test
used to classify
as resistant
Monotherapy at time of PFT, dual during follow-up
Kaminska
2007196
✓a ✓a ✓a
a Calculated from data given in the publication.
TABLE 54 Studies and outcomes (WBA, monotherapy)
Study Death MACEs
Ischaemic/
thrombotic events Bleeding Length of follow-up
Multiplate® (MEA)
Monotherapy at time of PFT and during follow-up
Orta 2011166
(abstract)
✓ Mean 20.7 months
(SD 6.1 months)
WBA (impedance)
Monotherapy at time of PFT and during follow-up
Gengo 2008128 ✓ 29 months
Gluckman 201199 ✓ 6 months
Lordkipanidzé 2011162
(abstract)
✓ 3 years
Majeed 2009117 ✓ Median 315 days
(range 9–833 days)
Mueller 1997153 ✓ 18 months
Sobol 2009186 ✓ 10 days
Monotherapy at time of PFT, dual during follow-up
Kaminska 2007196 ✓ ✓ 12 months
MEA, multiple electrode aggregometry.
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Major adverse cardiac events
Two studies reported MACEs162,166 (Table 56). Outcome statistics are shown in Figures 46 and 47. One
study,162 in a CAD population, reported a non-statistically significant unadjusted OR. The other study166
reported an unadjusted OR and HR, which were both statistically significant. It should be noted that,
although considered to be at cardiovascular risk, this was primarily a renal failure population, which might
not be comparable with the other studies included here. This study also used the Multiplate® system.
Based on these two studies, no conclusions can be drawn regarding the risk of MACEs.
TABLE 56 Outcome measures for reporting MACEs (WBA, monotherapy)
Study
Unadjusted
OR
Adjusted
OR
Unadjusted
HR
Adjusted
HR
Other measures
related to prognosis
Sensitivity/specificity
presented or calculable
Multiplate® (MEA)
Monotherapy at time of PFT and during follow-up
Orta 2011166
(abstract)
✓a ✓ ✓a
WBA (impedance)
Monotherapy at time of PFT and during follow-up
Lordkipanidzé
2011162
(abstract)
✓a
MEA, multiple electrode aggregometry.
a Calculated from data given in the publication.
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Ischaemic/thrombotic events
Five studies99,117,128,153,196 reported ischaemic/thrombotic outcomes (Table 57). Results from two117,153 of
these could not be presented in a forest plot. In one117 it appeared that all eight thromboembolic events
occurred in the resistant arm, but overall numbers of patients in the resistant and sensitive groups were
unclear. In the other study,153 no patients were defined as resistant and therefore all eight events
(reocclusions) occurred in sensitive patients.
Outcome statistics are presented in Figures 48–50. Eleven unadjusted ORs were presented based on three
studies.99,128,196 There was only one event (MI) in one study,196 therefore the four ORs are associated with
very wide CIs. One study99 finds no difference in risk, whereas in one128 the ORs are statistically significant
(more events in the resistant arm).
These ORs remain statistically significant when adjusted for. Unadjusted HRs are also statistically significant
for the same study,128 but not for the other study196 presenting unadjusted HRs.
Given the heterogeneity between studies (population, outcomes) and the lack of consistency in terms of
direction of effect, no firm conclusions can be drawn.
Summary: whole-blood aggregometry
Eight studies were identified,99,117,128,153,162,166,186,196 with mainly stable disease populations (seven of
eight studies). In one study196 with an acute disease population, dual therapy was initiated after the PFT.
Only one166 of the eight studies used the Multiplate® system.
There was a lack of reporting of quality criteria, making overall judgements about risk of bias difficult. Lack
of detail related to blinding in particular (to patient characteristics and results of the PFT) and the level of
compliance. Only two studies99,153 gave details on posteligibility exclusions and only three studies99,117,128
gave details on the threshold used.
Only two studies reported deaths,186,196 with a total of three events across both studies. There are therefore
too few data to draw any firm conclusions on the risk of death. MACEs were also only reported by two
studies.162,166 A statistically significant result (more events in the resistant arm) was shown by one of these,166
TABLE 57 Outcome measures for reporting ischaemic/thrombotic events (WBA, monotherapy)
Study
Unadjusted
OR
Adjusted
OR
Unadjusted
HR
Adjusted
HR
Other measures
related to prognosis
Sensitivity/specificity
presented or calculable
WBA (impedance)
Monotherapy at time of PFT and during follow-up
Gengo
2008128
✓a ✓ ✓a ✓a
Gluckman
201199
✓
Majeed
2009117
Proportions of
patients in resistant
and sensitive groups
were unclear
Mueller
1997153
No patients defined
as resistant
Monotherapy at time of PFT, dual during follow-up
Kaminska
2007196
✓a ✓a ✓a
a Calculated from data given in the publication.
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and again, firm conclusion cannot be drawn, particularly as there were differences in populations between
the studies and differences in test characteristics. More data were available for ischaemic/thrombotic events,
based on five studies.99,117,128,153,196 However, there were differences in populations (e.g. CAD, UA/ACS),
outcome measures (e.g. SVG patency, MI, reocclusion, cerebral ischaemic events) and treatment (e.g. dual
therapy after the PFT), and there appeared to be little consistency across results, though some were
statistically significant (more events in the resistant arm). There were no studies reporting bleeding events.
Given the above data it is difficult to assess the overall prognostic effect, and no conclusions can be drawn
regarding the overall potential usefulness of WBA as a prognostic factor.
Summary: whole-blood aggregometry
l Eight studies were identified, with patients with stable disease in seven of these.
l The PFT thresholds used were not always reported or consistent across studies.
l A lack of detail in reporting of quality criteria, particularly around blinding and details (and implications)
of compliance, hampered an overall risk-of-bias assessment.
l Heterogeneity in outcomes, patient groups and types of reported statistics meant that meta-analysis
was not possible.
l Few adjusted results were presented, and thus it is not possible to ascertain the additional prognostic
value of the test over other prognostic factors.
l Given the limited number of data, no firm conclusions could be drawn regarding risk of death or MACEs.
l Heterogeneity around populations, outcomes and treatment (post PFT), and a lack of a clear consistent
trend across the studies, meant that firm conclusions could also not be drawn for ischaemic/thrombotic
events, though there were some statistically significant results (more events in the resistant arm).
l No studies reported bleeding events.
Thromboelastography
Population and test characteristics
Three studies117,168,174 were identified in this category, two of which were reported in abstract form only.168,174
Populations had CAD (two studies)117,168 and UA/ACS (one study).174 One study117 reported that patients had
their primary underlying condition for a mean period of 41.4 months. The two remaining studies did not report
this information.
In all three studies,117,168,174 it appeared that patients were exclusively on monotherapy both at the time
of the PFT and during follow-up. It is possible that not all studies have reported where a proportion of
patients commenced additional therapies during follow-up.
Only one study117 reported medications used by patients. These included diuretics, ACE inhibitors,
angiotensin II receptor blockers, beta-blockers, digoxin, spironolactone, nitrate, statins, warfarin,
intravenous inotropic therapy and amiodarone. None of the studies reported details on NSAIDs.
The number of participants in the studies ranged from 26 to 250 (see Table 58). Mean ages of patients
were 52,117 60168 and 62 years.174 There were more men than women in two studies,117,168 with proportions
of 73%117 and 68.5%.168 The remaining study174 reported sex data for aspirin-resistant patients only (42 of
the total sample of 250), 74% of whom were male.
The dose of aspirin was reported in all studies and ranged from 15mg/day to 325mg/day. Two studies168,174
gave no details regarding the length of time patients had been receiving aspirin therapy, and one study
reported that patients had been taking aspirin for at least 7 days117 (see Table 58). One study117 reported that
aspirin was provided in both enteric and plain forms, and the other studies did not report this information.
The main study characteristics are listed in Table 58.
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The test performed in all studies was TEG. All studies used arachidonic acid as an agonist and details
regarding anticoagulants were not reported in any studies.
Two studies117,174 stated that there were up to 24 hours between aspirin dose and PFT. The remaining
study168 provided no details on the time between taking aspirin and the PFT. Table 59 provides details of
test characteristics.
Study design and quality
Results of the risk-of-bias assessment can be found in Tables 60–63.
Patient selection was independent of study outcome in all three included studies,117,168,174 with the PFT
preceding any outcomes (as specified in the study selection criteria). All studies stated that consecutive
patients were enrolled into the study and no studies had clear details on posteligibility exclusion
of patients.
A predetermined threshold percentage (for platelet aggregation) was given as > 50% or ≥ 50% for all
three studies.117,168,174 Only one study117 cited a reference232 and provided details on the method of
derivation of this threshold. For the remaining two studies there were no details on threshold derivation.
None of the studies gave clear details on blinding of laboratory staff to patient characteristics.
Outcome measures of interest were clearly predefined in two studies.117,174 In one of these studies it was
unclear if outcomes were separate or composite,174 and the remaining study provided no details. None of
the studies had clear details regarding blinding to the PFT results of those assessing outcomes. There
appeared to be no loss to follow-up in two studies117,168 and the remaining study174 provided no details on
missing data or whether or not there was any loss to follow-up.
Compliance was measured in one study117 by patient interview, nurse assessment and pharmacy records
during the period of hospitalisation, and through self-report only after discharge. No details on the level of
compliance were stated.
All three studies did not appear to undertake any adjusted analyses.
TABLE 59 Test characteristics (TEG, monotherapy)
Study Details of kit (manufacturer)
Anticoagulant
(concentration)
Agonist
(concentration)
Time since last
aspirin dose
Monotherapy at time of PFT and during follow-up
Majeed 2009117 TEG® 5000 (Thromboelastograph®
Hemostasis Analyzer, Haemonetics
Corporation, Braintree, MA)
No details Collagen (1 µg/ml)
Collagen (5 µg/ml)
Up to 24 hours
Sahin 2011168
(abstract)
Modified thromboelastogram No details AA No details
Tan 2010174
(abstract)
TEG® (Haemonetics Corporation,
Braintree, MA)
No details AA Up to 24 hours
AA, arachidonic acid.
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TABLE 61 Risk of bias, PFT (TEG, monotherapy)
Domain 2: PFT
If a threshold was used,
was it prespecified?
How was the threshold
derived (e.g. literature
cut-off, based on study data)?
Is the undertaking and
interpretation of the index
test blinded to the patient
characteristics (including
clinical outcomes)?
Monotherapy at time of PFT and during follow-up
Majeed 2009117 Yes (≥ 50%) Formula and reference cited232 No details
Sahin 2011168 (abstract) Yes (< 50% AA-induced
whole-blood thrombosit
aggregation inhibition
by TEG)
No details No details
Tan 2010174 (abstract) Yes (> 50%) No details No details
AA, arachidonic acid.
TABLE 62 Risk of bias, outcomes and study attrition (TEG, monotherapy)
Domains 3 and 4:
outcomes and
study attrition
Were the outcomes of
interest clearly defined
in advance?
Were the outcome results
interpreted without
knowledge of the results
of the PFT?
What was the proportion of
missing data? (State reasons
for loss to follow-up or
differences in those who
completed or were lost)
Monotherapy at time of PFT and during follow-up
Majeed 2009117 Yes No details No losses to follow-up
Sahin 2011168 (abstract) No details No details No losses to follow-up
Tan 2010174 (abstract) Yes (although unclear if
separate or composite)
No details No details
TABLE 60 Risk of bias, patient selection (TEG, monotherapy)
Domain 1:
patient selection
Was a consecutive or
random sample of
patients enrolled?
Was patient selection
independent of
patient outcomes?
Were reasons for any
posteligibility
exclusions provided?
Monotherapy at time of PFT and during follow-up
Majeed 2009117 Consecutive Yes No details
Sahin 2011168 (abstract) Consecutive Yes No details
Tan 2010174 (abstract) Consecutive Yes No details
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Overview of outcomes
Three studies were identified,117,168,174 reporting on only two of the outcomes of interest (death and
ischaemic/thrombotic events) (Table 64).
Death
Two studies reported on deaths (Table 65).168,174 One study was not presented in the forest plots.174 This
found a death rate of 26% in the resistant group and 11% in the sensitive group (UA/ACS population),
but there were no raw data to confirm these proportions. Outcome statistics are presented in Figures 51
and 52. In the other study, both the adjusted OR and HR were statistically non-significant. The wide CI
reflects the fact that there was only one death in the resistant group and no deaths in the sensitive group.
Overall, there is too little evidence on which to base any conclusions regarding risk of death.
TABLE 64 Outcomes (TEG, monotherapy)
Study Death MACEs Ischaemic/thrombotic events Bleeding Length of follow-up
Monotherapy at time of PFT and during follow-up
Majeed 2009117 ✓ Median 315 days
(range 9–833 days)
Sahin 2011168
(abstract)
✓ ✓ Mean 464 days
(SD 264 days)
Tan 2010174
(abstract)
✓ ✓ 360 days (range 0–523 days);
not stated if mean or median
TABLE 65 Outcome measures for reporting death (TEG, monotherapy)
Study
Unadjusted
OR
Adjusted
OR
Unadjusted
HR
Adjusted
HR
Other measures
related to prognosis
Sensitivity/specificity
presented or calculable
Monotherapy at time of PFT and during follow-up
Sahin 2011168
(abstract)
✓a ✓a ✓a
Tan 2010174
(abstract)
a Calculated from data given in the publication.
DOI: 10.3310/hta19370 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 37
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
173
Sa
h
in
20
11
16
8
Tu
rk
ey
16
8
C
A
D
M
o
n
o
14
7.
46
 (
0.
00
 t
o
 4
,7
41
,3
85
.0
0)
Y
ea
r
C
o
u
n
tr
y
Pa
ti
en
ts
Pa
ti
en
t
g
ro
u
p
Th
er
ap
y
50
%
N
o
Th
re
sh
o
ld
O
R
 d
ir
ec
tl
y
av
ai
la
b
le
?
C
ar
d
io
va
sc
u
la
r 
d
ea
th
 d
u
e 
to
 M
I
W
it
h
in
-s
tu
d
y
d
if
fe
re
n
ce
O
u
tc
o
m
e
st
u
d
y
O
R
 (
95
%
 C
l)
0.
5
U
n
ad
ju
st
ed
 O
R
1
2
5
10
FI
G
U
R
E
51
Th
ro
m
b
o
el
as
to
g
ra
p
h
y,
m
o
n
o
th
er
ap
y:
d
ea
th
,u
n
ad
ju
st
ed
O
R
s.
Sa
h
in
20
11
16
8
Tu
rk
ey
16
8
C
A
D
M
o
n
o
14
4.
70
 (0
.0
0 
to
 4
,6
13
,4
33
.0
0)
Y
ea
r
C
o
u
n
tr
y
Pa
ti
en
ts
Pa
ti
en
t
g
ro
u
p
Th
er
ap
y
A
A
 (
n
o
 d
et
ai
ls
)
A
g
o
n
is
t
50
%
N
o
Th
re
sh
o
ld
H
R
 d
ir
ec
tl
y
av
ai
la
b
le
?
C
ar
d
io
va
sc
u
la
r 
d
ea
th
 d
u
e 
to
 M
I
W
it
h
in
-s
tu
d
y
d
if
fe
re
n
ce
St
u
d
y
H
R
 (
95
%
 C
l)
0.
5
U
n
ad
ju
st
ed
 H
R
1
2
5
10
FI
G
U
R
E
52
Th
ro
m
b
o
el
as
to
g
ra
p
h
y,
m
o
n
o
th
er
ap
y:
d
ea
th
,
u
n
ad
ju
st
ed
H
R
s.
A
A
,a
ra
ch
id
o
n
ic
ac
id
.
RESULTS OF PROGNOSTIC UTILITY REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
174
Ischaemic/thrombotic events
Three studies reported ischaemic/thrombotic events (Table 66).117,168,174 Two of these were not presented in
the forest plots. One174 found a rate of 74% in the resistant group for recurrent MI or thrombosis and
24% in the sensitive group (UA/ACS population), but there were no raw data to confirm these
proportions. In the other study,117 it appeared that all eight thromboembolic events occurred in the
aspirin-resistant group.
Outcome statistics are presented in Figures 53 and 54. Unadjusted ORs and HRs of the third study168 were
all statistically significant for different outcomes.
Thus, it appears that more events occurred consistently in the resistant arm; however, this is based on only
three studies,117,168,174 two of which117,174 did not report all relevant data clearly.
Summary: thromboelastography
Only three studies were identified in this category,117,168,174 two with a stable117,168 and one with an acute174
disease population. Two of the three were in abstract form,168,174 so there is a lack of detail on specific
patient characteristics.
There was a lack of detail in reporting of quality criteria, making overall judgements about risk of bias
difficult. Lack of detail related in particular to blinding and level of compliance. The same threshold was
used across the three studies. No adjusted outcome statistics were reported.
TABLE 66 Outcome measures for reporting ischaemic/thrombotic events (TEG, monotherapy)
Study
Unadjusted
OR
Adjusted
OR
Unadjusted
HR
Adjusted
HR
Other measures
related to prognosis
Sensitivity/specificity
presented or calculable
Monotherapy at time of PFT and during follow-up
Majeed
2009117
Sahin 2011168
(abstract)
✓a ✓a ✓a
Tan 2010174
(abstract)
a Calculated from data given in the publication.
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Two studies reported deaths168,174 and three reported ischaemic/thrombotic events. Only one study for each
outcome could be presented in a forest plot.168 There was too little evidence to draw any conclusions for
risk of death. The direction of effect was consistent for ischaemic/thrombotic events (more events in the
resistant group), but this was based on few studies and there were some reporting issues. There were
differences in study populations and types of outcome measures reported (for ischaemic/thrombotic
events). No adjusted measures were reported and there were no studies reporting MACEs or
bleeding events.
Despite the heterogeneity, the direction of prognostic effect appears to be largely consistent with more
events occurring in aspirin-resistant patients (ORs and HRs usually > 1). This suggests that TEG is a
potential prognostic factor, but this is only a qualitative judgement on the evidence available and is based
on very few studies; meta-analysis was not possible as there was only one study in the forest plots,
and therefore a firm quantitative conclusion regarding whether or not TEG is prognostic is not
currently possible.
Summary: thromboelastography
l Three studies were identified (two with stable, one with an acute disease population).
l The threshold used was consistent (50%).
l A lack of detail in reporting of quality criteria, particularly around blinding and details (and implications)
of compliance, hampered an overall risk-of-bias assessment.
l Heterogeneity in outcomes, patient groups and types of reported statistics, and the fact that only one
study presented data suitable for use in a forest plot, meant that meta-analysis was not possible.
l No adjusted results were presented, and thus it is not possible to ascertain the additional prognostic
value of the test over other prognostic factors.
l No conclusions could be drawn regarding risk of death in resistant and sensitive groups.
l Despite clinical heterogeneity between studies, there was an overall consistent trend for more events to
occur in the ‘aspirin-resistant’ group for ischaemic/thrombotic events; however, this was based on one
study only.
l No studies reported MACEs or bleeding events.
Miscellaneous tests
The population and test characteristics are presented in Tables 67 and 68. There was a large amount of
heterogeneity across the studies in terms of PFTs and populations. No two studies used both the same PFT
and the same treatment after the PFT (i.e. monotherapy or dual therapy; see Table 67), therefore each
study needs to be considered on its own.
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TABLE 68 Test characteristics (other, monotherapy)
Study
Details of kit
(manufacturer)
Anticoagulant
(concentration)
Agonist
(concentration)
Time since last
aspirin dose
Monotherapy at time of PFT and during follow-up
Flow cytometry
Frelinger 200976 Flow cytometry (FACSCalibur™
flow cytometer, BD Biosciences,
Franklin Lakes, NJ, USA)
No details No details No details
Monotherapy at time of PFT, dual during follow-up
Flow cytometry
Kaminska
2007196
Flow cytometry No details AA
Collagen
Up to 24 hours
Surgicutt II
Buchanan
2000152
Surgicutt II bleeding time
device (ITC Commercial Group,
Piscataway, NJ, USA)
No details No details First testing: up to 24 hours
Repeat testing: when each
patient had not taken
aspirin for a minimum of
7 days
Apact II platelet aggregometer
Stejskal 2006198 Apact II platelet aggregometer
(Labitec GmbH, Ahrensburg,
Germany)
No details CPG
3 µM
concentration
Up to 24 hours
Platelet reactivity test
Grotemeyer
1993154
Platelet reactivity test
(newly developed modification –
reference cited233)
No details EDTA 12 hours
Impact-R® (cone and platelet analyser test)
Monotherapy at time of PFT and during follow-up
Schwammenthal
2008125
Impact-R® (cone and platelet
analyser test)
No details AA (1.6mM) At least 6 hours before
blood sampling
Monotherapy at time of PFT, dual during follow-up
Spectre 201193 Impact-R® (cone and platelet
analyser test)
Sodium citrate AA (0.32mM) Up to 24 hours
AA, arachidonic acid; CPG, cationic propyl gallate; EDTA, ethylenediaminetetraacetic acid.
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As it was not possible to compare directly across tests or to usefully summarise results, there has been
no discussion on the quality of studies and no presentation of results. For reference, the main quality
characteristics are presented in Tables 69–72 and extracted results can be found in the webpage linked to
the report (http://medweb4.bham.ac.uk/NIHR_Aspirin_Resistance/).
TABLE 69 Risk of bias, patient selection (other, monotherapy)
Domain 1:
patient selection
Was a consecutive or
random sample of
patients enrolled?
Was patient selection
independent of
patient outcomes?
Were reasons for any
posteligibility exclusions
provided?
Monotherapy at time of PFT and during follow-up
Flow cytometry
Frelinger 200976 Consecutive Yes Stated that less than 3% of
eligible patients declined
participation (reason not given)
Monotherapy at time of PFT, dual during follow-up
Flow cytometry
Kaminska 2007196 No details Yes No details
Surgicutt II
Buchanan 2000152 Consecutive Yes 15% of those recruited withdrew
from the study; 28% of those who
continued were excluded as a result
of non-compliance
Apact II platelet aggregometer
Stejskal 2006198 No details Yes No details
Platelet reactivity test
Grotemeyer 1993154 Consecutive Yes No details
Impact-R® (cone and platelet analyser test)
Monotherapy at time of PFT and during follow-up
Schwammenthal
2008125
Consecutive Yes No details
Monotherapy at time of PFT, dual during follow-up
Spectre 201193 Consecutive Yes No details
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TABLE 70 Risk of bias, PFT (other, monotherapy)
Domain 2: PFT
If a threshold was used, was
it prespecified?
How was the threshold
derived (e.g. literature
cut-off, based on study data)?
Is the undertaking and
interpretation of the index
test blinded to the patient
characteristics (including
clinical outcomes)?
Monotherapy at time of PFT and during follow-up
Flow cytometry
Frelinger 200976 No details (appears to be a
threshold as OR calculated)
No details No details
Monotherapy at time of PFT, dual during follow-up
Flow cytometry
Kaminska
2007196
Not explicitly stated; assumed
that if there is any aggregation
patients are classed as
aspirin resistant
No details No details
Surgicutt II
Buchanan
2000152
Yes; coefficient of variation
between on and off aspirin
bleeding times > 26% is an
aspirin responder
Coefficient of variation between
on and off aspirin bleeding
times ≤ 26% classified as
aspirin resistant
A pilot study with healthy
volunteers was performed to
determine the reproducibility of
the Surgicutt II bleeding time
test as performed by the BRAT
study nurses and technicians,
and to determine the biological
variability of the bleeding times
over 10 weeks
No details
Apact II platelet aggregometer
Stejskal 2006198 Yes; a patient was considered
to be an ‘aspirin responder’
(without aspirin resistance) if
spontaneous aggregation was
below 5%
No details No details
Platelet reactivity test
Grotemeyer
1993154
Yes (platelet reactivity
value > 1.25)
Stated that patients arbitrarily
subdivided (author’s own
reference cited234)
No details
Impact-R® (cone and platelet analyser test)
Monotherapy at time of PFT and during follow-up
Schwammenthal
2008125
Yes; partial response 20–39%
vs. good response < 20%
Literature cited149 Unclear; treating physicians and
the investigators evaluating the
patients were blinded to the
results of the platelet function
studies
Monotherapy at time of PFT, dual during follow-up
Spectre 201193 Yes, but no specific values;
tertiles of percentage surface
coverage of adherent platelets
Tertiles No details
BRAT, Benefits and Risks of ASA [acetylsalicylic acid] on Thrombosis.
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TABLE 71 Risk of bias, outcomes and study attrition (other, monotherapy)
Domains 3 and
4: outcomes
and study
attrition
Were the outcomes of
interest clearly defined
in advance?
Were the outcome results
interpreted without knowledge
of the results of the PFT?
What was the proportion of
missing data? (State reasons for
loss to follow-up or differences
in those who completed or
were lost)
Monotherapy at time of PFT and during follow-up
Flow cytometry
Frelinger 200976 Yes Yes; all clinical outcome data
obtained by research personnel
blinded to results of PFTs
127/682 lost to follow-up
(for MACE outcome)
Monotherapy at time of PFT, dual during follow-up
Flow cytometry
Kaminska
2007196
No – the paper did not
focus on clinical
outcomes; it was focused
on the results of the PFTs
Yes The paper states that one person
(out of 27) was lost to follow-up at
6 months as a result of MI; this is
the same person who is recorded
as having the clinical event of MI
Surgicutt II
Buchanan
2000152
Yes Yes; outcome assessors unaware
of aspirin responder status
227/516 lost to follow-up at
2 years (withdrawal or exclusion
because of non-compliance)
Apact II platelet aggregometer
Stejskal 2006198 Yes (broadly) No details Appeared to be no loss to
follow-up
Platelet reactivity test
Grotemeyer
1993154
Yes No details 6/180 lost to follow-up
Impact-R® (cone and platelet analyser test)
Monotherapy at time of PFT and during follow-up
Schwammenthal
2008125
Yes Yes; treating physicians and the
investigators evaluating the patients
were blinded to the results of the
platelet function studies
Follow-up data were available for
81/105 patients (77%)
Monotherapy at time of PFT, dual during follow-up
Spectre 201193 Yes No details 7/63 lost to follow-up at 6 months
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Population and test characteristics
Seven studies76,93,125,152,154,196,198 were identified in this category.
In two studies76,196 the test performed was flow cytometry. In two other studies93,125 the test performed was
Impact-R® (cone and platelet analyser test). Other tests were bleeding time by Surgicutt II (one study),152
cationic propyl gallate-induced aggregation (one study)198 and the ‘platelet reactivity test’ (one study).154
Populations comprised patients with CVD/stroke (two studies),125,154 CAD (one study)76 and ACS (one study),198
and those undergoing non-urgent CABG152 and PPCI.93 There was one study196 in patients with UA/ACS
undergoing PPCI. One study included only patients with a first and recent MI,196 and no other studies reported
how long patients had had their primary underlying condition for.
In four studies125,152,154,198 it appeared that patients were exclusively on monotherapy both at the time of
the PFT and during follow-up. In one study,125 around 4% of patients were on dual therapy (+ clopidogrel)
at the time of the PFT. Given the small proportion on dual therapy, these studies have been included in the
‘monotherapy’ category.
In a further study,76 patients were on monotherapy at the time of the PFT, and around 32% went on to
additionally receive clopidogrel at some point during follow-up. It is possible that not all studies have
reported where a proportion of patients commenced additional therapies during follow-up.
In two studies93,196 patients were on monotherapy at the time of the PFT and all were on dual therapy
(+ clopidogrel) during follow-up. These studies have been listed separately, as the addition of clopidogrel
therapy in all patients may affect the rate of events, and may also be a reflection of underlying population
differences compared with the other studies.
Comedications across studies, where reported, included statins, COX-2 antagonists, heparin, warfarin,
beta-blockers, ACE inhibitors, calcium channel blockers, diuretics, insulin, oral hypoglycaemics
and antidepressants.
Non-steroidal anti-inflammatory drugs were not permitted (or had to be discontinued within a certain time
period) in two studies.196,198 One study76 stated that 10% of patients were on NSAIDs, and there were no
details on NSAIDs in the remaining studies.
The number of participants in the studies ranged from 27 to 700 (see Table 67). Where reported, mean
ages of patients ranged from 58 to 64 years, with most means around the early 60s. There were more
men than women across all studies, with proportions of men ranging from 52% to 86%. The proportion
of patients with diabetes ranged from 20% to 44%, and that of smokers from 19% to 37%
(where reported; see Table 67). All studies were conducted in hospital settings.
The dose of aspirin ranged between 75mg/day and 500mg/day. Details were variable across studies
regarding the length of time patients had been receiving aspirin therapy, with some noting a minimum
period, and some whether patients were chronic or first time users (see Table 67). No study stated whether
aspirin was provided in enteric or plain form, though one study93 noted that aspirin was in chewable form.
The main study characteristics were listed in Table 67. Note that in some studies baseline characteristics
have been reported only according to resistant/sensitive groups or groups with/without diabetes, rather
than for the total study population.
Studies noted that there were at least 6 hours (one study125) and 12 hours (one study154) between aspirin
dose and PFT. Five other studies93,147,152,196,198 stated that there were up to 24 hours between aspirin dose
and PFT (see Table 68).
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Studies with more than one test
Fourteen studies undertook more than one PFT (Table 73); however, there were very few data that could
be compared given the differences in reported outcomes and outcome statistics. Thus, data from only four
studies99,108,112,162 have been presented in forest plots (Figures 55–58). These included the two studies that
compared most PFTs.99,162 The unadjusted OR was the most frequently reported statistic and thus provided
most information.
Note that data from all studies, on all reported outcomes and reported or calculable outcome statistics, are
presented in the main results sections.
TABLE 73 Studies with more than one test
Study LTA
VerifyNow®
Aspirin PFA-100® TxA2 WBA TEG Other Outcomes reported
Addad108 ✓ ✓ MACEs
Frelinger76 ✓ ✓ ✓ (flow
cytometry)
MACEs, death
Gluckman99 ✓ ✓ ✓ ✓ Ischaemic/thrombotic
events
Kaminska196 ✓ ✓ (flow
cytometry)
Death, ischaemic/
thrombotic events
Linnemann112 ✓ ✓ MACEs, ischaemic/
thrombotic events
Lordkipanidzé162 ✓ ✓ ✓ ✓ ✓ MACEs
Majeed117 ✓ ✓ Ischaemic/thrombotic
events
Miyata164 ✓ ✓ MACEs
Modica187 ✓ (PA-200) ✓ MACEs
Payne147 ✓ ✓ (flow
cytometry)
Death, ischaemic/
thrombotic events
Schwammenthal125 ✓ ✓ (Impact-R®) Ischaemic/thrombotic
events
Sobol186 ✓ ✓ Death
Spectre93 ✓ ✓ (Impact-R®) MACEs
Tan174 (abstract) ✓ ✓ Death, ischaemic/
thrombotic events
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Within-study comparisons
The study by Addad et al.108 used two tests, PFA-100® and thromboxane; there is a lack of consistency
both within and between the different tests in terms of direction of effect and statistical significance. For
example, when comparing the first tertile with the second and third (as a threshold) tertiles, there are more
events in the resistant group with PFA-100®, and more events in the sensitive group with a thromboxane
test. Gluckman et al.99 compared four tests; again there is no consistency across tests in terms of how
many individuals are classified as resistant or sensitive. Patients classified as resistant by a thromboxane PFT
are, for example, more likely to have an event (compared with the sensitive group) than those classified as
resistant by WBA, where there is no difference in event rate between resistant and sensitive. This lack of
consistency in direction of effect is further demonstrated by the studies by Lorkipanidzé et al.162 and
Linnemann et al.112 Clearly, the choice of test and threshold will influence whether an individual is
classified as resistant or sensitive.
Between-study comparisons
Given the inconsistency within studies, the added heterogeneity between studies and the limited number
of data, a comparison across studies of the direction of effect for individual PFTs is not feasible.
Dual therapy
The tests identified for assessing platelet function in patients on dual therapy (aspirin plus a second
antiplatelet agent) are (i) LTA induced by arachidonic acid, (ii) VerifyNow® Aspirin, (iii) measurement of
urinary or serum/plasma 11-dehydro-TxB2 concentrations, (iv) PFA-100®, (v) WBA induced by arachidonic
acid, (vi) TEG and (vii) other miscellaneous tests. Table 3 identified the studies that have used these tests in
a dual-therapy population.
The original intention was to report and analyse these studies in a similar way to the studies in patients
receiving monotherapy with aspirin. However, the finding of limited evidence of the prognostic utility of
platelet function testing related to aspirin monotherapy led to the decision not to undertake such analyses
in dual-therapy studies.
Data on the population and test characteristics, along with quality characteristics of the studies in patients
undergoing platelet function testing while receiving dual therapy, were, however, extracted and are
included in the data extraction database (see Appendix 4). Should the need for these studies to be analysed
exist in the future, this work can build on the data already collected.
Studies in patients with diabetes
No studies in a solely diabetic population were included in this review.
Prognostic models
The methods of this systematic review allowed for the inclusion of available prognostic models in which a
PFT is one of multiple prognostic factors predicting clinical outcomes in a population of interest.
No such models were identified.
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Systematic reviews
Fifteen systematic reviews were identified that met the initial inclusion criteria (Table 74).203–217 On more
detailed scrutiny, two reviews did not link the results of PFTs to clinical outcomes (one review on
pharmacogenetics203 and one on the role of PFTs in guiding clinical practice which did not provide
prospective follow-up of clinical outcomes204). A further review205 was predominantly focused on patients
with renal insufficiency and therefore is not discussed further.
The remaining 12 reviews all included relevant populations and at least some primary studies where the
results of a PFT were linked to clinical outcomes.
One review was in abstract form only;206 the authors were contacted for further details but no response
was obtained.
Most reviews did not restrict inclusion of studies by type of PFT, except two,207,208 both of which focused
on the PFA-100® test only.
Only four reviews specified whether studies with patients receiving monotherapy or dual therapy were
included, three including both monotherapy and dual therapy studies206,209,210 and one stipulating
monotherapy only.207
Few reviews provided details on whether only prospective or also retrospective studies were included (four
studies provided this information208–211), but it appears that many included both, in some cases separating
them in analysis.
All the reviews reported details of at least one database search (as per the inclusion criterion for this
report). However, most presented only limited additional details on methodological aspects. Searches were
limited to PubMed or MEDLINE and citation checking in half the reviews.206,207,210,212–214 Five reviews
supplied no further methodological details beyond the basic search strategy,206,210,212–214 with a further three
reporting limited details on study inclusion or exclusion criteria.207,215,216 Four reviews reported more
comprehensive methodological details208,209,211,217 and these papers were critically appraised using the
Assessment of Multiple Systematic Reviews (AMSTAR) checklist.
The reviews included between 5 and 84 studies (not restricted by PFT), or between 5 and 31 studies where
restriction to monotherapy studies was made clear. The review with the highest number of included
studies, both overall and monotherapy, was Velkovic and Coulthard206 a conference abstract with no listing
of citations. By PFT, the highest number of studies identified by any review was 15 PFA-100® studies.208,216
By comparison, the current review found 57 distinct monotherapy studies overall46,76,86,88,90,92,93,95,99,105,108–110,
112,113,115–118,121,123,125,127,128,132,133,135,137,138,142,144–155,159,162–164,166,168,169,171,174,186,187,189,193,195,196,198,201,202 (and 21
monotherapy studies using the PFA-100® test76,99,108,109,112,115,116,118,123,127,132,135,137,138,144,145,150,162,186,187,189,193),
despite using more stringent inclusion criteria including a restriction to prospective studies only. Including
mono-, dual- and triple-therapy studies, 21 of the studies identified in this review46,127,132,134,135,137–143,145,148–154,198
were also included in the seven previous reviews207–209,211,215–217 which provided any information on exclusion
criteria (see Table 75). Conversely, of the studies included by at least one other review, the current review
excluded 16 at the full-text stage38,235–249 and seven at the title and abstract stage,250–256 as they did not meet
the inclusion criteria. Three studies were included in other reviews which were not identified by the search
strategy; one was subsequently excluded as it was a cross-sectional study,256 while the correct citation was not
identifiable for the other two studies.219,257
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Critical appraisals
Four reviews208,209,211,217 reporting more comprehensive methodological details were critically appraised
using the AMSTAR checklist. Significant information was nevertheless found to be lacking from all four
publications which would enable a complete assessment of the validity of their conclusions.
Krasopoulos et al.’s209 review focused on the relationship between aspirin resistance and clinical outcomes
in patients with cardiovascular disease, and identified 20 studies totalling 2930 patients. The paper
provided no details of a protocol or whether or not the research question and inclusion criteria were
prespecified. As no search strategy was presented, it was difficult to gauge whether or not the strategy
was likely to have included all potentially relevant studies; thus, it was not possible to determine whether
the reduction from the 36,573 articles identified by the initial search to 320, using only the term ‘aspirin
resistance’, was appropriate or had resulted in the omission of relevant studies. It appeared that only a
small proportion of identified articles (57/320) were reviewed independently, but that each of the authors
reviewed and tabulated data from every included paper. Four bibliographic databases were searched, and
citations (from 210 papers) were reviewed. Nevertheless, there was no mention of searching grey/
unpublished literature (including ongoing trials or conference abstracts) or contacting experts. Although a
list of included studies was provided, one was not provided for the excluded studies.
Although the authors presented the characteristics of included studies, there were no details on thresholds
(for determining resistance) or on follow-up time, and limited information on the use of a prospective or
retrospective study design, all of which may have influenced the event rate in the two groups. A further
concern is that though the method of establishing compliance was considered, the authors considered that
aspirin status measured in hospital could be assured independent of non-compliance, and further stated
that it is unlikely that patients would subsequently become non-compliant, which seems an unwarranted
assumption when there might be a long follow-up period. Furthermore, as it appeared that both
prospective and retrospective studies had been included in the review, compliance with treatment in
hospital may not reflect previous compliance with treatment.
The authors assessed included studies using a quality rating, but it was unclear how this was derived and
which specific criteria were considered, and therefore it was not possible to make a judgement on the
robustness of the quality assessment, or whether their assessment was correct that the few studies (3/20)
rated as not having a low risk of bias were insignificant in affecting overall results. A high level of
heterogeneity was evident but a fixed-effects model was used incorrectly. Given the high level of
heterogeneity (potentially due to study design, study quality, underlying disease, follow-up time, type of
PFT, threshold and level of compliance), the exploration of heterogeneity was limited. This, coupled with a
failure to differentiate adjusted and non-adjusted results, reduced confidence in the reported conclusion
that aspirin-resistant patients are at greater risk of long-term cardiovascular morbidity [OR of any
cardiovascular event 3.85, 95% CI 3.08 to 4.80; p< 0.001 overall, or OR 3.53, 95% CI 2.66 to 4.68;
p< 0.001 in monotherapy (14 studies)].
The review by Reny et al.208 considered the clinical predictive value of only one PFT, PFA-100®, in
aspirin-treated cardiovascular patients, and found seven non-prospective and eight prospective studies,
incorporating 1466 and 1227 patients respectively. Again, no details were provided about the existence of
a protocol or whether or not the research question was prespecified, though inclusion criteria were clearly
stated. Three databases were searched, and reference lists of studies and conference abstracts were also
examined. However, only English-language studies were searched for. Study selection and data extraction
were conducted independently by two reviewers, and disagreements were resolved by discussion among
all authors. Lists of included studies and studies excluded at full-text stage, were provided.
The authors’ assessment of study quality was extremely limited. Whether or not assessment was blinded
for biologists and clinicians was considered (though ill-defined), and results were found to be similar in
studies whose reports explicitly mentioned blinding compared with those that did not mention the use of
blinded assessments. However, the issue of blinded assessment appeared to be the only mention of study
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quality considered consistently. The discussion considered some other methodological limitations of the
included studies, for example lack of assessment of patient compliance (on which no data were provided
by individual study), sample size and non-evaluation of von Willebrand factor. However, it was apparent
that none of these assessments of methodological rigour and scientific quality were specified a priori.
Prospective and non-prospective studies were considered separately. However, adjusted and non-adjusted
results were not distinguished. The heterogeneity of the prospective studies was assessed, and found to be
non-significant using a random-effects model. The difference in thresholds used in the studies was
recognised and discussed. Perhaps as a result of the small number of (prospective) studies, subgroup
analysis was restricted to narrative discussion, and then focused on the prevalence of non-responders as
opposed to the relationship with cardiovascular events. A more detailed exploration of heterogeneity was
lacking and would have been desirable in interpreting the review’s findings. Publication bias was
considered with regard to non-prospective studies, but the funnel plot for prospective studies was
not discussed.
The authors concluded that high residual platelet reactivity (i.e. non-responder status) in cardiovascular
patients treated with aspirin was associated with recurrent ischaemic events. In the prospective studies they
included the OR for the recurrence of an ischaemic event in aspirin non-responders relative to aspirin
responders, which was 2.1 (95% CI 1.4 to 3.4, p< 0.001). Although the authors acknowledged the
potential impact of dosage and threshold on this association, other important caveats should be noted in
light of the limited information concerning study quality in the papers incorporated in this review. Finally,
it was unclear if patients in any of the studies were on aspirin alone or on dual or triple therapy.
Snoep et al.217 found 16 studies in their review of the relationship between laboratory aspirin resistance
and the risk of cardiovascular recurrent events. In a comprehensive, as well as a priori, search strategy,
four bibliographic databases were searched, with no language restrictions, and reference lists were
searched and authors contacted. However, although the search terms were listed as available from the
authors, they were not presented, and there was no sample search strategy, so it was difficult to assess the
appropriateness of the search strategy. Although meeting abstracts were included, there were no details
regarding ongoing trials or other sources of unpublished studies. Selection, quality assessment and data
extraction of studies were all independently performed by two reviewers, with disagreements resolved by
consensus and discussion with a third party. A list of included, but not of excluded, studies was provided.
The authors stated that a funnel plot did not suggest the existence of publication bias, but did not present
it in the publication.
The authors stated that the following quality criteria were assessed: control for confounders, measurement
of exposure, completeness of follow-up and blinding, and, for case–control studies, matching and case
definition. There was no formal scoring system. Overall findings on the quality of all included studies were
not presented. Some quality findings were reported in the discussion section, but it was uncertain if this
was extensive enough to capture any potential implications of quality for the results. Furthermore, while it
was stated that studies were excluded because of insufficient quality during study selection, there were no
details on a quality threshold. The only reference to compliance was to note that patient adherence to
treatment was assessed in only three of the studies.
The review found that 15 of the 16 included studies revealed an adverse association between laboratory
aspirin resistance and occurrence of cardiovascular events, with a pooled OR across all cardiovascular
outcomes of 3.8 (95% CI 2.3 to 6.1). A random-effects model was used, which is appropriate as there
was evidence of heterogeneity. There was no discussion of any attempt to discriminate between adjusted
and non-adjusted studies. There was some subgroup analysis by type of outcome. Given the high level of
heterogeneity (potentially owing to study design, study quality, underlying disease, follow-up time, type of
test, threshold and level of compliance), a more detailed exploration of heterogeneity would have been
appropriate. Again, a further concern was that it was unclear if patients in any of the studies were on dual
or triple therapy as opposed to aspirin monotherapy.
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Sofi et al.211 conducted a meta-analysis on the relationship between residual platelet reactivity in coronary
heart disease patients and the occurrence of adverse coronary events, and found 11 prospective studies
comprising 1952 patients. Though the aim of the study was clearly stated, as were the inclusion criteria,
again there was no reference to a protocol or to a priori published research objectives. Data were
independently extracted by two reviewers, and disagreements were resolved by discussion with a third
investigator. However, whether or not two reviewers also independently selected studies for inclusion was
unclear. Four bibliographic databases and citations from relevant original studies and review articles were
searched. No detail on whether or not grey literature was searched was provided. Only included studies,
and not excluded studies, were listed. Publication bias was assessed using a funnel plot of effect size
against standard error. The authors report that the funnel plot was broadly symmetrical, and so consistent
with the conclusion that there was no publication bias; however, the plot was not presented in
the publication.
No assessment of study quality was provided. The authors did consider the heterogeneity of the included
studies in the discussion, and noted that most of the studies did not systematically assess adherence to
aspirin therapy or adjust for confounding factors in the multivariate statistical models (6 out of the 11
included studies reported statistical data not adjusted for potential confounders).
The authors documented a significantly increased relative risk of adverse clinical events for patients with
residual platelet reactivity on aspirin treatment (relative risk 3.11, 95% CI 1.88 to 5.15; p< 0.0001).
A random-effects model was used, appropriately, as there was significant heterogeneity (I2 reported).
Subgroup analyses were performed according to relevant specific variables (duration of follow-up,
aspirin dosage, PFT and patient characteristics), and in each case the risk of clinical recurrences increased.
In addition, the association remained statistically significant even after the exclusion of studies that
reported only crude unadjusted data (relative risk 3.19, 95% CI 1.97 to 5.19; p< 0.00001). Even so,
a major caveat for this review related to the lack of data on study quality, and the fact that it was unclear
if patients in any of the studies were on dual or triple therapy.
All four reviews found a positive association between aspirin non-responder status and likelihood of
adverse cardiovascular outcomes, despite their differences in precise research question, range of included
studies (Table 75) and primary outcome measures. However, although the four critically appraised reviews
were those with the most detailed methodological information from the relevant reviews identified, all had
important deficiencies, variously:
l a lack of a rigorous and transparent approach to quality assessment
l insufficient comprehensiveness and a failure to account for the complexity of the field by not
considering the effect of different PFTs, thresholds, etc.
l not distinguishing between adjusted and non-adjusted statistical data
l uncertainty regarding whether patients were on aspirin monotherapy or if those on dual therapy were
merged in the analysis
l uncertainty over whether included studies were prospective or retrospective in design
l failure to account for the effect of non-compliance.
In this context, caution must be exercised in interpreting the findings from these previous reviews.
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Ongoing studies
The searches of research registers identified 65 potentially relevant records of apparent ongoing studies
(see Chapter 4, Searches for the sources searched and Quantity of research available, earlier in this
chapter, for the identification of these records). Copies of these records were obtained and the review
selection criteria (see Chapter 4, Study selection) were applied, except for the criterion for publication type,
which was ignored because it was irrelevant. Key difficulties with this selection process were the absences
of information in the records given that these were not protocols for studies but only brief outlines of
study aims with limited associated methodological information provided. Furthermore, it was frequently
unclear whether the same record was in more than one register or some of the studies in older records
had actually been completed and published.
Despite these difficulties, it was possible to identify a number of records that met the selection criteria258–262
and also records that potentially relate to fully published articles.263,264
However, for the reasons mentioned, the selection process could not provide definitive sets of included
and excluded records in regard to ongoing studies, and as such no lists are given in this report.
Therefore, this section only serves to indicate that there are a number of ongoing studies which may add
further data in the future.
Relevant studies identified after the search cut-off dates
After the searches were undertaken for this review, further relevant studies continued to be published.265–267
Although the authors of this report were aware of these publications, these have not been included in the
above analysis to prevent the introduction of bias. A robust approach would be to update all the searches;
however, given the magnitude and complexity of this project, this was beyond the resources available.
An alternative approach would be to discuss the sensitivity of the review findings to the more recent
subjectively identified evidence. However, given the heterogeneity of included studies, even within
subgroups, and the absence of the ability to undertake any pooled analyses, this approach was considered
to be of limited benefit.
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Chapter 6 Economic analysis
This section has two aims: (i) to review systematically the published evidence relating to thecost-effectiveness of platelet function testing in patients on aspirin therapy with established
cardiovascular disease, CVD or diabetes; and (ii) to assess the cost-effectiveness of platelet function testing
plus change in treatment for patients with established CAD on aspirin therapy compared with no testing
and no change in treatment, from a NHS and Personal Social Services (PSS) perspective. For this aim, a
speculative economic model was developed.
The methods and findings of the systematic review are presented first followed by those of the speculative
economic model.
Systematic review of cost-effectiveness studies
Methods
The broad methods of this systematic review were similar to those presented in Chapter 4, and thus only
key details are given here.
Search strategy
Searches for economic studies were run on MEDLINE, EMBASE and NHS EED using, where appropriate,
relevant terms for economic studies along with terms for clinical populations and PFTs. Examples of these
strategies can be found in Appendix 2. The yield of articles from these searches was supplemented with
any further economic evaluations and cost studies identified during screening of the search yield in the
prognostic/diagnostic utility review.
Study selection
Two reviewers independently screened titles and abstracts for relevance. All potentially relevant articles
were obtained for scrutiny against the full selection criteria, with any disagreements resolved by discussion.
The criteria were:
l Study design Cost–consequence analysis, cost-effectiveness analysis, cost–benefit analysis, cost–utility
analysis, cost studies.
l Population Patients aged ≥ 18 years on aspirin (as monotherapy or in combination with other
antiplatelet agents), with established cardiovascular disease, CVD or diabetes. Studies with mixed
populations were included as long as data for relevant patients were extractable.
l Intervention Aspirin-specific platelet function assay or global PFT where patients are receiving aspirin as
the only antiplatelet therapy. The list of eligible assays has been outlined previously in Table 2.
l Comparator No assessment of aspirin resistance or current practice.
l Outcome Cost-effectiveness, cost estimates, utilisation estimates, quality-of-life estimates.
Data extraction and quality assessment strategy
Data on the following, where available, were extracted from included studies by one health economics
reviewer and checked by another:
l study characteristics, such as study question, form of economic analysis, population, interventions,
comparators, perspective, time horizon and form of modelling used
l clinical effectiveness and cost parameters, such as effectiveness data, health state valuations (utilities),
resource use data, unit cost data, price year, discounting and key assumptions
l results and sensitivity analyses.
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Studies were quality assessed using tools as part of the data extraction process, namely the Consensus
on Health Economic Criteria list268 for economic evaluations and the checklist by Philips et al.269 for
model-based analyses.
Results
A total of 387 records were identified from the searches and, following the removal of duplicates, there
were 299 unique records. No additional articles were identified from the process of the systematic review
of prognostic/diagnostic utility studies.
None of the records was deemed relevant to this economic review and, as such, no hard copies were
obtained for scrutiny against the inclusion criteria for the review.
A flow diagram presenting the process of selecting studies can be found in Figure 59.
Discussion
No economic evaluations or cost studies were found during the search for literature on the cost and
cost-effectiveness of platelet function testing in patients with established cardiovascular disease or CVD.
This is surprising given the amount of research identified by the systematic review of prognostic/diagnostic
utility (see Chapter 4) and the degree of debate around this topic.
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FIGURE 59 Flow diagram showing study selection for the economic evaluations review.
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Economic modelling
This section provides a detailed description of the speculative economic model developed to estimate the
cost-effectiveness of platelet function testing with the option of a change in treatment, compared with
the current approach of no platelet function testing and no change in treatment. The model considers how
being classified as aspirin resistant based on a test of platelet function and subsequently adding or changing
treatment may lead to a reduced risk of experiencing a MACE, but may also increase the risk of major
bleeding. Owing to the large amount of clinical uncertainty identified by the systematic review of prognostic
and diagnostic utility (see Chapter 5), this economic model evaluates a hypothetical PFT and hypothetical
change of treatment in patients with existing cardiovascular disease or CVD, considers whether or not such
a test would be cost-effective and investigates the main factors affecting cost-effectiveness. An overview of
the key characteristics of the cost-effectiveness analysis is shown in Box 1.
BOX 1 Characteristics of the cost-effectiveness analysis
Intervention Hypothetical aspirin-specific PFT or global PFT where patients are receiving aspirin as the only
antiplatelet therapy at the time of testing, followed by a hypothetical change of treatment if, based on the test,
patients are defined as aspirin resistant. Possible treatment options are (1) increase dose, (2) increase frequency
(split dose), (3) combination therapy, (4) change treatment (alternative monotherapy).
Comparator No assessment of platelet function and no change of treatment (current practice).
Population Cohort of patients with stable CAD who are receiving aspirin as the sole antiplatelet agent
(monotherapy); 66% male and aged 60 years.
Time frame Lifetime time horizon; 1-year time cycle.
Perspective NHS/PSS.
Effects MACEs and major bleeds.
Costs Costs associated with platelet function testing, changing antiplatelet therapy and treating patients who
have experienced a fatal or non-fatal MACE or major bleed.
Outcomes Mortality, quality of life, QALYs.
Assessment of cost-effectiveness Cost per additional QALY gained.
QALY, quality-adjusted life-year.
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Methods
Model description
A speculative economic model developed as a decision tree combined with a Markov model was built in
TreeAge Pro® (TreeAge Software, Inc., Williamstown, MA, USA ) to estimate the cost-effectiveness of
platelet function testing with the option of change in treatment compared with no testing and no change
in treatment (current treatment). The population considered was patients with stable CAD on aspirin
monotherapy. Based on clinical judgement the patient cohort was assumed to be aged 60 years and 66%
male, in keeping with studied populations included in this report. The time horizon of the model was
patient lifetime and the model was therefore run for 41 years. Mortality data were weighted to take into
account the greater proportion of men with the disease. A time cycle of 1 year was chosen, as it was felt
that a shorter and more detailed time period would not be required owing to the speculative nature of the
model and data inputs. The model structure is shown in Figure 60.
In the decision tree, for both treatment options of testing with a change in treatment and no testing and
no change in treatment (current treatment), the cohort was separated at a chance node based on whether
patients were identified as aspirin resistant or aspirin sensitive. The Markov model followed on from each
of these branches. Therefore, patients identified as aspirin resistant followed one model pathway, while
those identified as aspirin sensitive followed a separate model pathway. However, the subsequent model
pathways were the same for all test and treatment options.
The entire cohort began in the state ‘event free (on treatment)’. From this health state, patients moved
along a pathway where they could remain in this health state, die from other causes or experience a fatal
or non-fatal MACE or major bleed. Depending on the events experienced during this initial pathway,
patients moved to the subsequent health states ‘post event’ after a non-fatal MACE, ‘event free (off
treatment)’ after suffering a non-fatal major bleed and having antiplatelet therapy discontinued, or ‘dead’,
or remained in the health state ‘event free (on treatment)’. Once in a ‘post event’ health state, the patient
either remained in this state or died, with the mortality risk higher as a result of having suffered a previous
MACE. The pathway for ‘event free (off treatment)’ was the same as for those who were event free and
on treatment, but with adjustments to event rates taking into account whether or not treatment was
being taken.
The intervention option assumed that all patients received a hypothetical PFT with a one-off cost, and, if
defined as aspirin resistant, had their treatment changed with an associated additional cost. The treatment
change could decrease the risk of a MACE but could also increase the risk of a major bleed. If a major
bleed occurred, all antiplatelet therapy was discontinued and the risk of a future MACE increased to a
higher level. Those who were defined as aspirin sensitive did not have their treatment changed. In the
current treatment option, there was no testing (although the differentiation between aspirin resistant and
aspirin sensitive was maintained) and aspirin monotherapy was continued, unless a major bleed caused a
discontinuation of treatment. In the base case, the model assumed that those defined as aspirin resistant
had an overall average raised risk of MACEs and an overall average benefit from a change in treatment.
The model was designed to estimate costs, from the perspective of the NHS and PSS, and outcomes in
terms of quality-adjusted life-years (QALYs) gained by each arm of the model, with costs and QALYs
accumulated depending on the transitions between health states. The difference between the costs,
incidence of health outcomes and impact on quality of life and mortality between treatment options was
used to estimate the incremental costs and effects of applying a hypothetical PFT and treatment change.
The model also attempted to incorporate uncertainty in model parameters by incorporating probability
distributions for the majority of input parameters. All costs were for a price year of 2011–12, and were
inflated to this price year where appropriate. Costs and QALYs were discounted at a rate of 3.5%
per annum.
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Estimation of model parameters
The parameters and sources used in the model are summarised in Tables 76–78. Given the range of data
required to populate the model, a variety of approaches were used to identify parameter estimates. First,
systematic reviews were undertaken to identify parameter estimates reported in the existing literature.
However, as described in Chapter 5 and in Systematic review of cost-effectiveness studies, the prognostic
and diagnostic utility data available were associated with heterogeneity and uncertainty and no relevant
published economic evaluations were identified. Several parameter estimates were sourced from clinical
papers, for example the risk of major bleeding, and utility values for health states were obtained from
previous modelling studies in cardiovascular disease. However, as a result of the clinical uncertainty in this
area, the majority of the data in this model are based on expert opinion and assumptions. As the model is
speculative, the base-case result aims to present cost-effectiveness for a hypothetical test and treatment
strategy which reduces the risk of MACEs in aspirin-resistant patients. The values used in the sensitivity
analysis aim to test all of the assumptions and present different scenarios to show when a test and change
in treatment may or may not be cost-effective.
TABLE 76 Base-case clinical data and assumptions included in the economic model
Probabilities Value Distribution Source
Testing positive for aspirin resistance 0.225 Beta
α= 2, β= 6.89
Estimate from clinical review (see Tables 4,
15, 26, 37, 48, 58 and 67)
MACE (aspirin sensitive) (1 year) 0.05 Beta
α= 2, β= 38
Assumption from expert opinion
Proportion of MACEs as stroke 0.2 Beta
α= 2, β= 8
Assumption from expert opinion
Fatal MACE 0.09 Beta
α= 2, β= 20.2
Assumption from expert opinion
Major bleed (1 year) 0.001 Beta
α= 2, β= 1998
Antithrombotic Trialists’ Collaboration
(2009)4
Death from a major bleed 0.125 Beta
α= 2, β= 14
Assumption from expert opinion
Relative risks
Relative risk applied to baseline MACE risk
to calculate risk if aspirin resistant (note the
reciprocal was applied to the baseline risk)
0.66 Beta
α= 3.88, β= 2
Assumption from expert opinion
Relative risk of a major bleed with a change
in treatment
1.4 Beta
(reciprocal value
of 0.71 used)
α= 5, β= 2
Assumption using data from Eikelboom
(2012)5
Relative risk of impact of change in
treatment on MACE
0.8 α= 8, β= 2 Assumption from expert opinion
Standardised mortality ratio
Post MACE 2.7 Log normal
σ= 0.036
Bronnum-Hansen (2001)270,271
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Clinical parameters Many of the clinical parameters in the model were not known with any certainty,
therefore values were estimated after discussion with clinical experts in the study team, and wide
probability distributions were applied to these estimates to reflect the extent of uncertainty. The clinical
parameter values can be found in Table 76.
The base-case value for the proportion defined as aspirin resistant varied considerably between tests and
studies. Given this high variation across studies included in the prognostic utility review, an arbitrary value
of 22.5% was used in the base case, in keeping with the range of values identified. This parameter was
tested across a wide range of values in the sensitivity analysis. The annual risk of a MACE in clinically stable
patients who were defined as aspirin sensitive and on aspirin was assumed to be 5%. An overall baseline
risk of MACEs in aspirin-resistant patients was difficult to determine from the prognostic review, therefore
an assumption was made for the base case that this risk would be, on average, higher. A base case value
of 7.5% was chosen (assumption from expert opinion). In order to vary this value in both the deterministic
TABLE 77 Unit costs used in the model
Variable Cost (£) Source
Test for aspirin resistance 50 Assumption (minimum cost)
Antiplatelet therapy (aspirin) (annual) 11 BNF (2013)272
Hypothetical additional treatment if
aspirin resistant (annual)
30 BNF (2013)272
Major bleed 4287 Weighted cost of GI bleed from
NHS reference costs 2011–12273 (75%)
and acute stroke cost (25%)
Acute MI 5487 Robinson (2005)274
Acute stroke 11,020 Youman (2003)275
Long-term MI (annual) 2196 Robinson (2005)274
Long-term stroke (annual) 2721 Youman (2003)275
Fatal MI 2359 Greenhalgh (2011)276
Fatal stroke 9326 Greenhalgh (2011)276
BNF, British National Formulary.
TABLE 78 Utility data used in the model
Event/health state Value Beta distribution Source
Post MI 0.88 α= 285.94, β= 38.99 Cooper (2008)277
Acute MI 0.76
(distribution for decrement of 0.12)
α= 2, β= 14.67 Ward (2007)278
Post stroke 0.63 α= 91.15, β= 53.53 Ward (2007)278
Acute stroke 0.55
(distribution for decrement of 0.08)
α= 2, β= 23 Cooper (2008)277
One-off disutility of a bleed –0.1426 α= 2, β= 12.03 Greenhalgh (2011)276
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and probabilistic sensitivity analysis (PSA), the risk of a MACE in aspirin-sensitive patients was divided by a
relative risk to give the higher risk estimate for aspirin-resistant patients. For the base case a relative risk
of 0.66 was used to obtain a risk of 7.5%. The model was constructed to allow an assumption of no
association between the result of the PFT and the risk of MACEs (and relative risk is equal to 1), with a
hypothesis that either platelet function as measured by the test is not related to the clinical outcome, the
test does not discriminate well or there is little difference in the risks between those defined as aspirin
resistant and those defined as aspirin sensitive. In the PSA, this relative risk was sampled from a distribution
in two stages. A uniform distribution was used to determine a number between 0 and 1. For all values
between 0 and a certain proportion, x, sampling would be from a beta distribution around the relative risk
of 0.66. For values sampled between x and 1, the risk of MACEs in aspirin-resistant and aspirin-sensitive
patients would be the same, and the relative risk would be 1. Therefore the smaller the fixed proportion x,
the more likely there would not be an increased risk of events in patients defined as aspirin resistant.
A hypothetical change in treatment for aspirin-resistant patients was assumed to have some effect in the
base-case model, and a relative risk of 0.8 was used (assumption from expert opinion). As described
previously for the risk of MACEs in aspirin-resistant patients, in the PSA the distribution of the relative risk
for treatment effect was constructed so that a value of no effect could be applied for a fixed proportion,
and an assumption of no effect of a change in treatment could be tested. The annual risk of major
bleeding due to antiplatelet therapy in aspirin-sensitive patients was set at 0.01% (assumption from expert
opinion). To account for a change in antiplatelet therapy, and a possible increase in major bleeds, a relative
risk was applied to increase this risk of bleeding. As the change in treatment was hypothetical, a value of
1.4 was chosen, taking into account evidence on the impact of adding clopidogrel to aspirin or doubling
the dose of an antiplatelet agent.5 If an aspirin-resistant or aspirin-sensitive patient was taken off all
antiplatelet therapy as a result of a major bleed, the patient’s risk of a further bleeding event (in an ‘off
treatment’ health state) was assumed to be zero. Although there will be a very small risk of a major bleed
in reality, this will be lower than the aspirin estimate of 0.01%, and is therefore considered to be
negligible with regards to impact on the model results.
It was estimated that 9% of major bleeds would result in death, from the assumption that 1 in 10 events
would be fatal. Probability of death from a major bleed was assumed to be 12.5%, assuming that 25% of
major bleeds were intracranial haemorrhage (ICH) and that half of these were fatal.
Mortality Sex-specific life tables were used to determine the probability of death for all ages. The risk of
death was adjusted to ensure there was no double counting of cardiovascular disease deaths, using data
from the Office for National Statistics on the proportion of deaths by cardiovascular disease causes.279
The model assumed that there was an increased risk of death once in the postevent health state and this
was applied to the probability of death.
Resource use and costs No published data were available on the cost of any of the PFTs, and as the test
in the model was deemed to be hypothetical, an arbitrary cost of £50 was used, with alternative higher
costs included in the sensitivity analysis. The cost of a change in treatment was also unknown as there are
a number of potential changes in treatment that could be made, which may increase costs greatly or not
at all. In the base-case analysis, the cost of generic clopidogrel (£30 a year, 75mg once daily) in addition
to aspirin was used. This was varied in the sensitivity analysis to consider the approximate cost of adding a
newer branded drug such as prasugrel (£600 a year, assuming a body weight of > 60 kg and a daily dose
of 10mg) or ticagrelor (£702 a year, assuming 90mg twice daily). The cost of aspirin for a year (£11)
applied to all patients in the model except for those who had all antiplatelet treatment discontinued. All
drug costs were obtained from the British National Formulary (BNF).272 The acute and long-term costs of
stroke were obtained from a UK study collecting primary data,275 and acute and long-term costs of MI
were obtained from a previous cardiovascular disease model.274 The source of fatal stroke and MI costs
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was an economic modelling study concerning other antiplatelet therapy for cardiovascular disease.276
The exact split between stroke and MI events is not known, therefore an estimate of 20% stroke and 80% MI
was used, and costs weighted accordingly. The cost of a major bleed assumed that 75% of bleeds were GI
and 25% were ICH. NHS reference costs273 provided the cost of a GI bleed, and the cost of an acute stroke
was assumed for an ICH. No long-term costs were attributed to bleeds, and this underestimated the cost;
however, it was assumed that 50% of those who suffered an ICH died, and the initial risk of a bleed was very
low. The perspective adopted for the model was that of the NHS/PSS, and a price year of 2011–12 was
applied. Unit costs used in the model can be found in Table 77.
Estimation of quality-adjusted life-years Outcomes were measured in QALYs. Age-related general
population utilities from the European Quality of Life-5 Dimensions (EQ-5D) provided the baseline values
for quality of life,280 with quality of life decreasing with increasing age. Utility values were given for all
health states. When a MACE occurred within the model, a utility for an acute event was applied for the
first year, with further, slightly higher utility applied in the postevent health state. The lower utility value for
an acute health state was applied as a decrease in utility which was subtracted from the postevent utility
value. The weighting of stroke to MI events used for MACE costs was also utilised here. Values were
applied multiplicatively; therefore, the value for the state of the clinical event was multiplied by the value
for the age. Where a major bleed occurred, a one-off reduction in utility was applied. The utility values
were obtained from previous studies,276–278 and entered into the model as beta distributions (see Table 78).
Model assumptions
Owing to the speculative nature of this model, a number of assumptions were made regarding the model
structure and input parameters. In the base case it was assumed that, based on a hypothetical test of platelet
function, patients could be defined as aspirin resistant (having insufficient platelet function inhibition) or
aspirin sensitive, and that patients defined as aspirin resistant have a higher average risk of MACEs than
those defined as aspirin sensitive. This higher risk could, on average, be subsequently reduced with a
hypothetical change in treatment. MACEs only included fatal and non-fatal stroke and MI, with the
assumption that MI was the event occurring 80% of the time. Recurrent events were not included in the
model, and once a MACE occurred, the patient moved into a postevent state with a lower quality of life and
ongoing costs. Furthermore, it was assumed that a change in antiplatelet therapy would increase the risk of a
major bleed (assumed to be a GI bleed or ICH). If a major bleed of this type occurred anywhere in the model,
a one-off cost and reduction in quality of life was applied and all antiplatelet therapy ceased, thus increasing
the risk of a MACE in the future. The model did not take into account the possible ongoing costs or
additional reduction in quality of life from the starting state of stable CAD; however, this applied to all
treatment options. The cost of a change in treatment was assumed to be the additional cost of clopidogrel in
the base case, with newer, more expensive drugs included in the sensitivity analysis. Although these drugs
are more appropriate for acute coronary syndromes rather than stable disease, it was felt that these prices
would be a reasonable approximation of a newer drug which may be available for stable patients.
Assessment of cost-effectiveness
The analysis was designed to generate the cost per additional QALY gained of performing a PFT and
modifying treatment based on the test findings. In order to ensure consistency in the model, an additional
arm (test and no change of treatment) was also included in the economic model. However, this is not a
feasible clinical option, because if no change in treatment is intended based on the test result, then there
is no reason to test. As the only difference between this arm and the standard care (no test and no change
of treatment) arm is the cost of the test, it served as a consistency check for the functioning of the model.
Results for this option are not presented in this report.
Where available, data were entered into the model as distributions in order to fully incorporate the
uncertainty around parameter values so that a PSA could be undertaken. The PSA was run with
1000 simulations and cost-effectiveness planes and acceptability curves were produced. Owing to
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the speculative nature of the model and the large amount of uncertainty around many of the model
variables, beta distributions were applied to those parameters where neither a reasonable point estimate
nor an actual distribution was known. The beta distributions were constructed in order to represent the
greatest amount of uncertainty and were presented in Tables 76 and 78. The currently accepted, lower
National Institute for Health and Care Excellence threshold of £20,000 per QALY gained is used to assess
cost-effectiveness.281
Deterministic sensitivity analysis
A sensitivity analysis was performed to determine the impact of changing key parameters on the model
results. Therefore, many of the model parameters were subject to one- and two-way sensitivity analysis,
using hypothetical increases or decreases, to determine the key drivers of the model results. Parameters
varied included the costs of the test and change in treatment, event costs, the probability of testing
positive for aspirin resistance, changes to the risk of MACEs with aspirin resistance, fatality rate and
composition of MACEs (in terms of proportions of stroke and MI) and reduction in risk with a change in
treatment. Parameters associated with major bleeding were also varied. A ‘worst-case scenario’ was also
run, which assumed that those who were aspirin resistant did not have a higher risk of MACEs, a change
in treatment was not effective, the test cost was £1000, the change in treatment cost £702 a year and the
risk of major bleeding increased by a relative risk of 2.8.
Results
This section presents the results of the cost-effectiveness analysis.
The base-case results shown in Table 79 indicate that the intervention of ‘test and change treatment’
is cost-effective, and ‘no test and no change of treatment’ (standard care) is absolutely dominated,
i.e. is more costly and less effective. This analysis assumed that for aspirin-resistant patients, there was an
overall higher average risk of MACEs and an overall average reduction in MACE risk with a change in
treatment. Results from the PSA show that although there is a wide spread of points, the majority are in
the south-east quadrant of the cost-effectiveness plane (Figure 61), indicating dominance of the ‘test and
change treatment’ strategy. The cost-effectiveness acceptability curve (Figure 62) also shows that the
intervention has a high probability of being cost-effective at all willingness-to-pay thresholds.
TABLE 79 Base-case cost-effectiveness analysis
Strategy
Mean
cost (£)
Cost
difference (£)
Mean
QALYs
QALY
difference
ICER (cost
per QALY)
‘No test and no change
of treatment’
13,256 9.6607
‘Test and change treatment’ 12,940 –316 9.7370 0.0763 Dominant
ICER, incremental cost-effectiveness ratio.
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Sensitivity analysis
Tables 80 and 81 present the results of one-way sensitivity analysis of key model parameters, where each
variable was varied with all other parameters fixed at base-case values.
Most of the clinical variables did not change the overall results where the ‘test and change treatment’ was
cost-effective and dominant over standard care (see Table 80). Decreasing the percentage that test positive for
aspirin resistance to only 1% meant that the intervention was no longer dominant, but was still cost-effective at
approximately £10,000 per QALY gained. Neither changing the nature of MACEs in terms of proportions of
strokes and MIs and percentage of fatal MACEs, nor changing the risk and fatality rate from bleeds, had any
impact on the results. Reducing the effectiveness of the treatment change (in terms of preventing MACE) did
change the magnitude of the cost and QALY differences; however, only an ineffective treatment changed the
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FIGURE 62 Cost-effectiveness acceptability curve of ‘test and change treatment’ vs. ‘no test and no change in
treatment’: base-case analysis.
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FIGURE 61 Cost-effectiveness plane of ‘test and change treatment’ vs. ‘no test and no change in treatment’:
base-case analysis.
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TABLE 80 Result of the one-way sensitivity analysis of ‘test and change treatment’ vs. ‘no test and no change in
treatment’ (standard care): clinical parameters
Results
Cost difference
vs. standard
care (£)
QALY
difference vs.
standard care
ICER for ‘test and change
treatment’ (cost per QALY
gained) (£)
Base-case result –316 0.0763 Dominant
Sensitivity analysis
Testing positive for aspirin resistance
0.5 –763 0.1696 Dominant
0.1 –116 0.0346 Dominant
0.01 34 0.0034 9951
MACE risk if aspirin resistant
0.05 (no change) –263 0.0704 Dominant
0.10 (risk doubled) –328 0.0754 Dominant
Fatal MACEs
0.18 (doubled) –278 0.0858 Dominant
0.045 (halved) –335 0.0715 Dominant
Proportion of MACEs as stroke
0.4 (doubled) –348 0.0821 Dominant
0.5 (equal split) –364 0.0850 Dominant
Major bleed on aspirin
0.01 (risk increased tenfold) –267 0.0617 Dominant
Death from a major bleed
0.25 (doubled) –317 0.0754 Dominant
Relative risk of a major bleed with a
change in treatment
2.8 (risk doubled) –305 0.0726 Dominant
1.2 (risk reduced) –317 0.0768 Dominant
Relative risk of a MACE with change
in treatment
0.9 –94 0.0357 Dominant
1 108 –0.0008 Dominated by no test and no
change of treatment
No change in MACE risk if aspirin resistant
and no reduced risk of MACEs with change
in treatment
121 –0.0010 Dominated by no test and no
change of treatment
ICER, incremental cost-effectiveness ratio.
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TABLE 81 Result of the one-way sensitivity analysis of ‘test and change treatment’ vs. ‘no test and no change in
treatment’ (standard care): cost parameters and time horizon
Results
Cost difference
vs. standard care (£)
QALY difference
vs. standard care
ICER for ‘test and change
treatment’ (cost per QALY
gained) (£)
Base-case result –316 0.0763 Dominant
Sensitivity analysis
Cost of test for aspirin resistance
£100 (doubled) –266 0.0763 Dominant
£500 (increased tenfold) 134 0.0763 1760
£1000 (high value) 634 0.0763 8314
Cost of hypothetical additional
treatment
£600 (annual cost of prasugrel) 870 0.0763 11,410
£702 (annual cost of ticagrelor) 1083 0.0763 14,192
All event costs increased by 50%
All events –529 0.0763 Dominant in all cases
Major bleed –314 0.0763
Acute MI –345 0.0763
Acute stroke –330 0.0763
Long-term MI –444 0.0763
Long-term stroke –356 0.0763
Fatal MI –317 0.0763
Fatal stroke –317 0.0763
All event costs decreased by 50%
All events –100 0.0763 Dominant in all cases
Major bleed –318 0.0763
Acute MI –287 0.0763
Acute stroke –301 0.0763
Long-term MI –185 0.0763
Long-term stroke –275 0.0763
Fatal MI –314 0.0763
Fatal stroke –314 0.0763
Time horizon (years)
5 –50 0.0059 Dominant
10 –168 0.0191 Dominant
20 –304 0.0495 Dominant
ICER, incremental cost-effectiveness ratio.
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result in favour of standard treatment. This was more apparent when it was assumed that there was no
baseline increased risk of MACEs and no impact of testing and treating.
Table 81 presents the sensitivity analysis around the cost parameters and time horizon of the model.
Increasing or decreasing all of the event costs, or each one separately by 50%, did not change the overall
result. However, the model was sensitive to the cost of a PFT, although the ‘test and change treatment’
option was still cost-effective even at a value of £1000 per test. The cost of the hypothetical treatment also
had an impact, with the costs of newer, branded antiplatelet therapies giving incremental cost-effectiveness
ratios (ICERs) of over £10,000 per QALY but still below the £20,000-per-QALY threshold. Decreasing the
time horizon of the model to 5, 10 and 20 years did reduce the cost and QALY differences, but ‘test and
change treatment’ was still cost-effective.
Table 82 shows the results of the ‘worst-case scenario’ where, in the ‘test and change treatment’ option,
costs of the PFT and a change in treatment were higher, those who were aspirin resistant did not have
a higher risk of MACEs than those who were aspirin sensitive, a change in treatment was not effective and
the risk of major bleeding was higher. Here, the ‘test and change treatment’ option is dominated by
standard care, and costs £2585 more per patient with a loss of 0.0043 QALYs.
Two-way sensitivity analyses were also undertaken to assess the impact of changing two key variables at
the same time (Table 83). The cost of the PFT and change in treatment were both increased at the same
time, which changed the result from dominance to a positive ICER. Once both test and treatment costs
were in the region of £600–700 each, then the intervention was no longer cost-effective, assuming a
£20,000-per-QALY threshold.
TABLE 83 Two-way sensitivity analysis of ‘test and change treatment’ vs. ‘no test and no change in treatment’
(standard care)
Cost of
test (£)
Cost of change in
treatment (£)
Cost difference vs.
standard care (£)
QALY difference vs.
standard care
ICER for ‘test and change treatment’
(cost per QALY gained) (£)
50 30 –316 0.0763 Dominant
125 125 –43 0.0763 Dominant
250 250 342 0.0763 4276
375 375 727 0.0763 9090
500 500 1112 0.0763 13,904
625 625 1498 0.0763 18,719
750 750 1883 0.0763 23,533
875 875 2268 0.0763 28,346
1000 1000 2653 0.0763 33,160
TABLE 82 ‘Worst-case scenario’ sensitivity analysis
Strategy
Mean
cost (£)
Cost difference
(£)
Mean
QALYs
QALY
difference ICER (cost per QALY)
‘No test and no change
of treatment’
12,445 9.8073
‘Test and change treatment’ 15,030 2585 9.8030 –0.0043 Dominated by no test and
no change of treatment
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Finally, PSA was undertaken where a variable related to the presence of a reduction in MACE risk due to
a change in treatment was altered. In the base case, it was assumed there would be some impact of
treatment. However, the model was constructed so that, in a PSA, the variable for risk reduction could
hold the value 1 (no change) for a given proportion, x, with the assumption that for this proportion x of
patients, the treatment had no impact on MACE risk. The first PSA set this value x to 0.5 and the results
can be seen in Figures 63 and 64. This analysis reduces the probability of ‘test and change treatment’
being cost-effective at the £20,000-per-QALY threshold to 48% – no longer a cost-effective option. A
further PSA was run with 50% of patients getting no benefit from treatment and the cost of a change
in treatment set to £702 a year, and this further reduced the probability of cost-effectiveness to 24%
(Figures 65 and 66). Finally, a PSA was undertaken to consider a scenario where 50% of all patients
defined as aspirin resistant had no increase in MACE risk and 50% of all those defined as aspirin resistant
do not benefit from a change in treatment (Figures 67 and 68). Again, the ‘test and change treatment’
option is not cost-effective, and has a 50% probability of being cost-effective at £20,000 per QALY.
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FIGURE 64 Cost-effectiveness acceptability curve of ‘test and change treatment’ vs. ‘no test and no change in
treatment’: 50% of patients have no change in MACE risk with a change in treatment.
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FIGURE 63 Cost-effectiveness plane of ‘test and change treatment’ vs. ‘no test and no change in treatment’: 50%
of patients have no change in MACE risk with a change in treatment.
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FIGURE 66 Cost-effectiveness acceptability curve of ‘test and change treatment’ vs. ‘no test and no change in
treatment’: 50% of patients have no change in MACE risk with a change in treatment and change in treatment
costs are £702.
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FIGURE 65 Cost-effectiveness plane of ‘test and change treatment’ vs. ’no test and no change in treatment’: 50%
of patients have no change in MACE risk with a change in treatment and change in treatment costs are £702.
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FIGURE 68 Cost-effectiveness acceptability curve of ‘test and change treatment’ vs. ‘no test and no change in
treatment’: 50% of patients do not have elevated MACE risk and 50% have no change in MACE risk with a change
in treatment.
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FIGURE 67 Cost-effectiveness plane of ‘test and change treatment’ vs. ‘no test and no change in treatment’: 50%
of patients do not have elevated MACE risk and 50% have no change in MACE risk with a change in treatment.
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Cost-effectiveness discussion
The results of the cost-effectiveness analysis for the base-case values indicate that if a PFT were available that
was able to accurately identify individual patients who, while receiving aspirin therapy, were at higher risk of
an adverse clinical outcome than other patients, and a subsequent change in treatment reduced the risk of
MACEs in such individuals, this would be a highly cost-effective strategy, as long as the costs of testing and a
change in treatment were not excessively high. This result was robust with regards to most model variables.
However, this result changes when values of important (and currently unknown) variables are varied. Within
the sensitivity analyses, results were sensitive to the proportion defined as ‘aspirin resistant’, and the
availability of an effective treatment alternative for patients on aspirin discovered to be at an elevated risk of
MACEs. Factors that adversely affect the cost-effectiveness of testing and changing therapy include only a
very small proportion of patients being defined as ‘aspirin resistant’, if the cost of testing is high and a
change in treatment is costly and/or not highly effective. This is exemplified by the ‘worst-case scenario’
sensitivity analysis, which demonstrates that if an expensive test cannot identify individuals at a higher risk of
clinical events and a costly change in treatment does not reduce the risk of MACEs but increases the risk of
bleeding, then the ‘test and change treatment’ option results in much higher costs and
a reduction in QALYs, and is therefore not cost-effective.
A key strength of this analysis is that this is the first economic model to consider the cost-effectiveness of
testing for and treating patients defined as ‘aspirin resistant’, and it can illustrate the key variables that
have an impact on the results. Although few good-quality data currently exist to populate the model, a
model structure exists for reanalysis once additional data become available. The main limitation is the
highly speculative nature of the model and the uncertainty around parameter values resulting from the
absence of evidence. This has been addressed where possible by the deterministic sensitivity analysis that
has been undertaken and by applying the greatest amount of uncertainty around many of the model
parameter values. However, as most distributions have been assumed, there should be caution in
interpreting the results of the PSA, as there may be biases in quantifying the uncertainty and the direction
of this bias is unknown.
The model assumes that patients at elevated risk of cardiovascular outcomes can be accurately identified
by a test, i.e. that PFTs are perfectly accurate in discriminating those patients with and without ‘abnormal’
platelet function and that ‘abnormal’ platelet function is associated with a risk of cardiovascular outcomes.
This assumption was, in part, explored in sensitivity analyses. The preferred approach in economic models for
diagnostic testing is to consider test performance in terms of sensitivity and specificity, requiring prevalence
data and a reference standard test, which do not exist for PFTs. In the absence of information, a perfect test
has been assumed, and the probability of being ‘aspirin resistant’ varied in the sensitivity analysis.
The model structure may also be viewed as somewhat simplistic, with no recurrence of clinical events and
no increase in the risk of events over time. However, if the model had included both features, a reasonable
‘test and change treatment’ strategy is likely to appear even more cost-effective. This model is for stable
CAD patients only, and an additional model was not constructed for ACS patients on dual therapy. As this
patient group is likely to have an even higher risk of MACEs, the results are likely to have shown similar
levels of cost-effectiveness.
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Summary
l Currently, there is no existing economic evidence on the cost or cost-effectiveness of platelet function
testing for ‘aspirin resistance’, which is surprising considering the amount of research identified by the
systematic review of prognostic/diagnostic utility and the degree of debate around this topic.
l This is the first model to attempt to estimate the cost-effectiveness of a ‘test and change treatment’
strategy for ‘aspirin resistance’.
l The model is highly speculative owing to the heterogeneity and uncertainty around the prognostic/
diagnostic utility of PFTs available to populate the model and contains a number of assumptions.
l If a PFT can accurately identify patients at higher risk of adverse clinical outcomes while receiving
aspirin therapy as the sole antiplatelet agent, and patients have an effective treatment change, then
a ‘test and change treatment’ option is very likely to be cost-effective. Conversely, if a PFT cannot
identify these patients, and a treatment change is not effective in reducing MACE risk, then a ‘test and
change treatment’ strategy is not cost-effective.
l The parameters with the greatest impact on model results are the proportion of patients who are
correctly identified as having a high risk of adverse clinical outcomes, the effectiveness of a change in
treatment if ‘aspirin resistant’, the cost of a test and the cost of a change in treatment.
l The model requires more robust data on the association between a designation of ‘aspirin resistance’
and the risk of adverse clinical outcomes, PFTs that can accurately define patients as ‘aspirin resistant’
and appropriate alternative therapy options for those at higher risk of adverse clinical outcomes.
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Chapter 7 Discussion
Summary of results: prognostic utility review
Monotherapy
For assessment of the prognostic utility of PFTs in patients receiving aspirin as a monotherapy (at the time
of testing), a majority of patients in all studies included were considered to have stable disease. There
was considerable heterogeneity in other population characteristics (e.g. smoking, diabetes), as well as
differences relating to treatment (e.g. aspirin dose), tests and testing procedures used, threshold for
classifying patients as ‘aspirin resistant’, range and definition of clinical outcomes recorded and length of
patient follow-up. There was a lack of detail in reporting of quality criteria and no study reported all the
items considered to be important. Lack of detail related in particular to blinding (of those undertaking PFTs
to patient characteristics, or blinding of outcome assessors), loss-to-follow-up information and level of
compliance with aspirin treatment. There was no consistent reporting of outcome statistics (e.g. OR and
HR, adjusted and unadjusted). Given the above, pooling of data for each type of test was deemed to be
inappropriate. As such, the summary results below are based on non-statistical assessment of trends
across studies.
The data show variability in prognostic effect sizes across the studies. In most assessments of association
between a PFT designation of ‘aspirin resistance’ and clinical events, there are more studies with effect
estimates above 1 (i.e. the risk of adverse clinical outcome in a group of patients designated ‘aspirin
resistant’ is greater than that in a group designated ‘aspirin sensitive’), but this was not uniform.
Many of the included studies contain very small numbers of patients and outcome events. This can lead
to extreme prognostic effect estimates that arise merely by chance; however, the uncertainty about the
estimates will be reflected by extremely wide CIs. Studies with extremely wide CIs covering values well
above and below the null effect (e.g. intervals spanning ORs or HRs from close to zero to over 20) are
essentially providing very little, if any, useful information. Therefore, caution should be applied when
focusing on the estimates from such studies, and rather the focus should be on the wide CIs that reflect
the large uncertainty.
Overall, there is a possible trend suggestive of more clinical events occurring in those groups of patients
designated ‘aspirin resistant’, with some results in some studies showing statistical significance;
this is the case across the majority of tests (LTA, VerifyNow® Aspirin, PFA-100®, thromboxane metabolite
measurement), to a lesser extent for TEG, and with data for WBA not allowing many conclusions to
be drawn. This trend is also fairly consistent across some outcomes (i.e. death, MACEs and ischaemic
thrombotic events) irrespective of test, though the direction of effect is not always consistent for different
thresholds applied to the data from the same study. There are very limited data on bleeding events and
thus no inference could be drawn.
The results suggest that PFTs (specifically LTA, VerifyNow® Aspirin, PFA-100®, thromboxane metabolite
measurement and TEG) may have some prognostic value as they are fairly consistently associated with
elevated risk of cardiovascular events (MACEs or death). However, as meta-analysis was not possible, no
firm quantitative conclusions can be drawn as to their prognostic value. Given that the effect sizes for an
association with clinical events are relatively small and highly uncertain, a determination of the diagnostic
utility of PFTs (for an individual, determining if they are at higher risk of a clinical event) was not possible in
this report.
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Dual-therapy studies
The tests identified for assessing platelet function in patients on dual therapy (aspirin plus a second
antiplatelet agent at the time of the PFT) are (i) LTA, (ii) VerifyNow® Aspirin, (iii) measurement of urinary
or serum/plasma 11-dehydro-TxB2 concentrations, (iv) PFA-100®, (v) WBA, (vi) TEG and (vii) other
miscellaneous tests (see Chapter 5, Dual therapy). The original intention was to report and analyse these
studies in a similar way to the studies in patients receiving monotherapy with aspirin. As a result of the
complex nature of the searches and study selection process, and also issues around reporting, studies on
dual-therapy patients were included and data extraction undertaken in parallel with that for monotherapy
studies. As it remains unclear whether ‘aspirin resistance’ is a distinct biological entity, with specific
underlying mechanisms, or signals a more general platelet hyperactivity state in which aspirin is simply
insufficient to inhibit platelet responses on its own,14,44,74 the interplay between aspirin and a second
antiplatelet agent in terms of platelet inhibition is an area of intense research. While clinical trials have
demonstrated that the addition of a second antiplatelet agent results in more pronounced platelet
inhibition, and consequently reduced risk of MACEs and increased risk of bleeding,5,22 it remains unknown
whether or not poor platelet response to one agent is linked to poor response to the other. For example, a
number of studies have shown that ‘aspirin-resistant’ patients had normal responses to clopidogrel;195,282,283
conversely, a number of studies have reported concomitant resistance to both aspirin and clopidogrel.98,142,284
Given the high variability and the limited evidence of prognostic utility found in patient cohorts taking aspirin
alone, it was decided not to analyse the results in populations exposed to dual antiplatelet therapy, as this
introduced an extra unpredictable variable. The data on ‘aspirin resistance’ (but not ‘clopidogrel resistance’)
have, however, been extracted from the included studies, and are available for analysis (see Appendix 4).
Strengths and limitations of available evidence and the
prognostic utility review
Considerations on the volume of evidence identified
Within the limited parameters of the review, it became clear that there was an underestimate of the
number of studies available based on the initial scoping exercise. It had been assumed that any new
studies identified would have been subsequent to the previous systematic reviews; however,
i. Not all the studies had been published since the previous systematic reviews, and thus the previous
systematic reviews were not sufficiently comprehensive (see Chapter 5, Systematic reviews).
ii. As a more thorough approach to identifying the evidence was undertaken, this revealed a surprisingly
large number of studies which scoping could not easily predict. This is exemplified by the large number
of hard-copy articles which were retrieved in order to make selection judgements. This was often driven
by the fact that the nature of the studies did not easily convey that relevant information for this report
was available.
iii. It became clear that the nature of the studies, in terms of both the populations and the interventions,
had also altered. Thus, more patients with acute rather than stable disease were included, particularly
patients with ACS, acute stroke and patients undergoing PCIs.
The nature of the included populations also drove a change in the nature of the interventions, with many
of the later studies including populations treated with aspirin plus at least one other antiplatelet agent.
A stepwise approach to analysis of the included studies was planned and this aided management of the
large number of included studies.
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Considerations on the reporting of available evidence
The availability of a larger-than-expected volume of evidence has already been discussed above, as has the
unrepresentativeness of most existing systematic reviews. A further salient point is the amount of
unreported evidence relevant to this report. One-third of the articles meeting the inclusion criteria for the
prognostic/diagnostic review did not report the association between PFT results and subsequent clinical
outcomes, despite both being measured in the study being reported. Although reporting of this
association might not have been within the aims of these studies and was thus, understandably, not
reported as a priority, it suggests that a large number of data were not accessible to this review. It was
beyond the scope of this project to ascertain the availability of these data for analysis. Lack of reporting
may also relate to results not being reported for all thresholds for a designation of ‘aspirin resistance’, and/
or time points for outcome measurement, changes in antiplatelet treatment during the course of a study
and items relevant to quality assessment (see Monotherapy).
Considerations on the analysis
Tests are measured on a continuous scale for each patient. However, the studies identified by our review
focused predominantly on comparing test-positive (‘aspirin-resistant’) and test-negative (‘aspirin-sensitive’)
groups, with ‘resistant’ and ‘sensitive’ groups defined by dichotomising the continuous test by a chosen
threshold value. This was not surprising, and indeed the data extraction and meta-analysis strategy was
planned to synthesise results for each threshold reported where possible. However, the chosen threshold
value was often highly variable from study to study, and this was a major reason why meta-analysis was
not deemed sensible. Some studies presented results for three or four categories (e.g. based on tertiles or
quartiles). It is now recognised that it is better to analyse continuous variables on a continuous scale.
Dichotomisation285/categorisation reduces power to detect genuine prognostic factors, and misses the
opportunity to examine non-linear trends and the underlying prognostic association across the entire range
of the factor’s values. For meta-analysis, availability of individual patient data (IPD) would help synthesise
linear and non-linear trends across multiple studies of the same factor.286,287 Though the collection, cleaning
and synthesis of IPD can be time-consuming and expensive,288 it eases many problems with meta-analysis
and avoids the complexity of extracting and dealing with multiple, variable and often selectively reported
thresholds from published reports. However, an IPD analysis in the context of the current report would have
required the consistent within- and between-study collection of all possible patient, test and outcome effect
modifiers and a substantial proportion of study authors to make these data available. This was beyond the
scope of this report and would likely be hampered by a number of factors, as outlined in the research
recommendations (see Recommendations for future research).
Thus, pooling could only be considered for dichotomous data for each test. An array of data extraction
and validated analysis methods allowed us to directly and indirectly obtain effect sizes and CIs from the
included studies (see Chapter 4, Prognostic ability: unadjusted and adjusted odds ratios and hazard ratios).
This led to substantially more information being available than would otherwise have been the case.
Sometimes only rounded percentages of events were reported in each group (rather than exact numbers)
and so only approximate numbers were obtainable.
However, as a result of poor or incomplete reporting, many studies did not allow suitable results to be
extracted or calculated. In addition, even when the same types of effect sizes could be obtained from
multiple studies of the same test, there was a vast amount of clinical and methodological heterogeneity
across studies in important factors, as outlined above (see Monotherapy).
It was therefore decided that pooled results would be difficult to interpret meaningfully. The extracted
results were therefore summarised on forest plots (but without pooled results). These plots provide the effect
estimate and its CI for each study, alongside key clinical and methodological information such as the patient
group, outcome, sample size, threshold level and agonist. The absence of the ability to pool studies meant
that examinations of publication bias (e.g. funnel plots) were also not possible, which was unfortunate as
publication bias is a known issue in prognosis research.289–292
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Consideration on the usefulness of prognostic factors
Prognostic factors are defined as measurable characteristics associated with the risk of a subsequent
outcome in people with a given disease or health condition. A recent series on prognosis research293–296
discusses how a single prognostic factor rarely predicts individual outcome risk accurately, and usually does
not suitably discriminate between high-risk and low-risk individuals, as in this report. This is why prognostic
models are developed, as they utilise multiple prognostic factors in combination to improve individual risk
prediction accuracy and to better discriminate the underlying risk across individuals. No prognostic models
were identified that aimed to utilise multiple tests with multiple prognostic factors for the purpose of
predicting individual outcome risk in patients on aspirin monotherapy for prevention of cardiovascular events.
It should be noted that prognostic factors do have a broad array of potential uses in both clinical practice
and health research.293–296 For instance, they help to define disease at diagnosis; they aid the design and
analysis of trials; they are confounders to consider in observational studies and unbalanced trials; and they
are the building blocks of risk prediction models. The designation of ‘aspirin resistance’ based on a PFT is a
potential prognostic factor, but it should ideally be considered in conjunction with any other factors
identified as prognostic of future adverse clinical outcomes. Thus, even if there was certainty around the
prognostic utility of PTFs, there is a need to ascertain if any other factors have prognostic utility and, if so,
ideally a prognostic model should be developed and validated to aid treatment management.
Summary of the economic evaluation
Currently, there is no existing economic evidence on the cost or cost-effectiveness of platelet function
testing for ‘aspirin resistance’, which might seem surprising considering the amount of research identified
by the systematic review of prognostic/diagnostic utility, the positive findings of many existing systematic
reviews of prognostic utility of PFTs in this area and the degree of debate around this topic. This report
presents the first model to attempt to estimate the cost-effectiveness of a ‘test and change treatment’
strategy using platelet function testing to define an at-risk population. The model is highly speculative
owing to the large degree of heterogeneity and uncertainty around the prognostic utility of PFTs, and it
contains numerous assumptions. This has been addressed, where possible, by the deterministic sensitivity
analysis and also by taking into account the uncertainty around many of the model parameter values.
In addition, further analyses have been presented to show scenarios where platelet function testing for
‘aspirin resistance’ and a change in treatment would not be cost-effective. The model structure may also
be viewed as somewhat simplistic, with no recurrence of clinical events and no increase in the risk of
events over time, but as the model is speculative, with few data to populate it, there would be little value
in making the model unnecessarily complex at this stage.
Assuming that a PFT can accurately identify patients at higher risk of adverse clinical outcomes while
receiving aspirin therapy as the sole antiplatelet agent, and patients changed to an effective treatment,
then a ‘test and change treatment’ option is very likely to be cost-effective. Conversely, if a PFT cannot
identify these patients, and a treatment change is not effective in reducing adverse clinical outcome
(MACE) risk, then a ‘test and change treatment’ strategy is not cost-effective. The parameters with the
greatest impact on model results are the proportion of patients who are correctly identified as having high
risk of clinical outcome, the effectiveness of a change in treatment if designated ‘aspirin resistant’, the
cost of a test and the cost of a change in treatment. The accuracy of testing, the additional risk of an
adverse outcome associated with a designation of ‘aspirin resistance’ and the effectiveness of a change in
therapy are the most uncertain parameters. The model requires more robust data on all of these aspects.
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Recommendations for future research
The heterogeneity and methodological problems identified in this review are similar to other attempted
meta-analyses of prognostic factor studies. Attempting to conduct and draw inferences from systematic
reviews of prognostic factor studies is difficult.293 Primary prognostic factor studies are often poorly
designed, inappropriately analysed and poorly/selectively reported.289–292,297–304 This leads to confusion about
whether or not factors are genuinely prognostic, with the play of chance and selective reporting typically
leading to overoptimism in the prognostic effect sizes seen in the literature.
Primary studies evaluating the prognostic ability of tests should focus on standardising how the tests are
measured and conducting large, protocol-driven studies with statistical analysis plans that aim to examine
prognostic and predictive ability. Guidelines for those planning and undertaking a prognostic factor study
have been suggested and should be used, to ensure higher standards of study quality, design and analysis
than are currently observed.305,306 This is important in the current context as many studies included in the
prognostic utility review had other primary aims (e.g. effectiveness of an intervention).
A prospective rather than retrospective design is preferable as it enables clear inclusion criteria, more
complete baseline and follow-up data, and greater standardisation of diagnostic and therapeutic
procedures, as well as ensuring that the primary factors and outcomes can be specified in advance,
reducing the potential for data dredging and thus type I errors and selective reporting. This is especially
important in larger studies aiming to replicate earlier exploratory prognostic factor findings, and these
should incorporate a suitable sample size calculation to ensure adequate power to detect an important
prognostic effect, if one exists. Statistical analysis methods can be improved by analysing continuous
factors on their continuous scale, thereby avoiding the use of arbitrary threshold levels to categorise them;
by considering non-linear relationships; and by including multivariable analyses that assess a factor’s
prognostic value over existing prognostic factors.293
Future research should ideally concentrate on developing and validating prognostic models that utilise
multiple prognostic factors in combination. For an individual with a given state of health (start point), a
prognostic model converts the combination of predictor values to an estimate of the risk of experiencing a
specific end point within a specific time period. Ideally, this produces an estimate of the absolute risk
(absolute probability) of experiencing the end point. This is the information that clinicians require to make
decisions, rather than reliance on the result of a single PFT. One option is to use IPD from high-quality,
prospective, primary studies that use very similar clinical populations and measure similar tests, patient
characteristics (prognostic factors) and outcomes.295 Having IPD from multiple studies offers a natural
opportunity to increase sample size and essentially develop a prognostic model within a meta-analysis
framework.307 Variation in model accuracy across studies, and its causes, can be explored. Additionally,
such collaborative efforts encourage consensus towards a single, well-developed and validated prognostic
model, rather than a number of competing and non-validated models for the same clinical problem,
championed by each group separately.
However, in the current context, an IPD meta-analysis would be hampered by substantial heterogeneity
across studies, even if only a single PFT at a time was considered in a well-defined population. In particular,
heterogeneity relates to test thresholds used, variability in test methods, timing of test and length of
follow-up, and range and definition of clinical events. A large number of variables would likely need to be
considered (e.g. smoking status, age, sex, prior events, disease severity, diabetes, mean platelet volume,
etc.), even allowing for the fact that not all will be found to have a significant effect. Given that a minimum of
10 events per variable is considered necessary in a prognostic model, the frequently low event rates in studies
limit the number of variables that can be assessed. An IPD analysis may also be biased, depending on which
study authors make their data available and the different methodological quality of the studies.
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Given the above, using IPD from existing studies could render a useful prognostic model improbable to
build. Therefore, one or more new prospective cohort studies may be a more feasible option. A primary
study could incorporate the following elements, the majority of which have not been appropriately
considered in existing studies:
l several tests performed in the same individuals (at present there are very few studies looking at more
than one or two tests)
l standardisation of laboratory methods
l tests performed in duplicate to assess variability
l repeat tests to assess variability over time
l sufficiently large sample size to allow for sufficient events in both resistant and sensitive groups
l sufficiently long follow-up for relevant clinical outcomes to occur
l use of standardised criteria for individual outcomes, and also individual reporting of all outcomes
contributing to composite outcome measures
l rigorous assessment of adherence
l robust methodological quality
l analyses could be undertaken for different test thresholds.
The above should be applied to one or more well-described cardiovascular/cerebrovascular population(s)
and should also consider current treatment guidelines with regard to antiplatelet therapy for the
given population.
The aim of a primary study would be to (i) identify what tests (variables) have a prognostic association with
future outcomes, both on their own (unadjusted) and independent of other prognostic factors (adjusted);
and (ii) develop a prognostic model that utilises the identified prognostic tests and variables in combination, in
order to predict absolute risk of adverse outcomes for future individuals.
Before initiating such a study, a group of clinical and methodological leaders in the field should meet and
agree criteria such as the tests to be measured, the relevant clinical populations and timing of test
measurement, how the tests are measured, and what outcomes are relevant and how these are measured.
If more than one new cohort study is to be undertaken on a similar population, ideally this should be done
in collaboration, ensuring similar protocols, methodology and factors/tests to be recorded, with agreement
to pool IPD once each individual study is completed. This would ensure reduced heterogeneity across
studies and the opportunity to then simultaneously develop and validate a model.
Once these issues have been addressed it may be possible to undertake a ‘test–treat trial’ using a
prognostic model to tailor antiplatelet therapy to individuals.
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Chapter 8 Conclusions
The current report has failed to demonstrate a convincing association between ‘aspirin resistance’, asdefined by a PFT, and clinical outcome, on any test and in any outcome, despite the existence of a
vast number of studies which have sought to clarify this association. The issues surrounding potential
inaccessibility of relevant data and the heterogeneity across all of the study parameters have been discussed.
The implications of a designation of ‘aspirin resistance’ based on a PFT remain uncertain and, thus, so does
the question of how best to define ‘aspirin resistance’. Until a definitive study has been undertaken to answer
this question, which must include some measure of adherence to therapy, platelet function testing has no
demonstrable clinical utility.
Although evidence indicates that some tests may have some prognostic value, methodological and clinical
heterogeneity of studies and different approaches to analyses create confusion and inconsistency in
prognostic results, and prevented a quantitative summary of their prognostic effect. Large, protocol-driven
and adequately powered primary studies are needed, using standardised and agreed methods of
measurements to evaluate the prognostic ability of each test in the same population(s). For PFTs to inform
individual risk prediction, and thus be useful for clinical decision-making, it is likely that they need to be
considered in combination and alongside other prognostic factors, within a prognostic model.
DOI: 10.3310/hta19370 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 37
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
235

Acknowledgements
The authors thank the following:
Simon Stevens for his invaluable administrative support, excellent organisational skills and heroic efforts to
source articles.
Jo Hine for additional administrative support.
Steve Watson, Paul Harrison and Gregory Y H Lip for clinical and platelet function testing guidance.
Pelham Barton for economic modelling guidance.
All the people who kindly gave their time to help translate articles.
Contribution of authors
Janine Dretzke wrote and edited sections of the report and undertook study selection, data extraction
and quality assessment for the prognostic review.
Richard D Riley devised, led and executed the statistical analysis, extracted statistical data for the
prognostic review and wrote sections of the report.
Marie Lordkipanidzé provided detailed knowledge of the PFTs, their utilisation and interpretation of their
results, undertook study selection for the prognostic review and wrote the background section of the report.
Susan Jowett led the economic section of the report, contributed to all parts of the economic review and
development of the economic model and associated analysis, and wrote sections of the report.
Jennifer O’ Donnell undertook study selection, data extraction and quality assessment for the prognostic
review, and contributed to several sections of the report.
Joie Ensor contributed to the plan for statistical analysis and interpretation of the data, extracted statistical
data for the prognostic review, managed the flow of statistical evidence and contributed to several sections
of the report.
Eoin Moloney contributed to all parts of the economic review and development of the economic model
and associated analysis, and wrote sections of the report.
Malcolm Price contributed to the plan for statistical analysis and interpretation of the data and extracted
statistical data for the prognostic review.
Smriti Raichand contributed to the development of the protocol and undertook study selection.
James Hodgkinson undertook data extraction and an appraisal of existing systematic reviews.
Susan Bayliss contributed to deriving the search strategies and ran the searches in electronic databases.
DOI: 10.3310/hta19370 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 37
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
237
David Fitzmaurice contributed to all parts of the project, undertook study selection, provided clinical
insight, wrote sections of the report and takes responsibility for overall content.
David Moore led the review section of the report, contributed to all parts of the project, undertook study
selection, compiled the report, and wrote and edited sections of the report.
Publications
Dretzke J, Riley R, Lordkipanidzé M, Jowett S, O’Donnell J, Ensor J, et al. Protocol for a systematic review of
the diagnostic and prognostic utility of tests currently available for the detection of aspirin resistance in
patients with established cardiovascular or cerebrovascular disease. Syst Rev 2013;2:16.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
238
References
1. Scarborough P, Bhatnagar P, Wickramasinghe K, Smolina K, Mitchell C, Rayner M. Coronary
Heart Disease Statistics 2010. 2010 edn. London: British Heart Foundation; 2010.
2. Jack DB. One hundred years of aspirin. Lancet 1997;350:437–9. http://dx.doi.org/10.1016/
S0140-6736(97)07087-6
3. Health and Social Care Information Centre, Prescribing and Primary Care Services. Prescriptions
Dispensed in the Community: England, Statistics for 2001 to 2011. Leeds: Health and Social Care
Information Centre; 2011.
4. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and
secondary prevention of vascular disease: collaborative meta-analysis of individual participant data
from randomised trials. Lancet 2009;373:1849–60. http://dx.doi.org/10.1016/S0140-6736(09)
60503-1
5. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: Antithrombotic
Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines. Chest 2012;141(Suppl. 2):e89–119.
6. Bell AD, Roussin A, Cartier R, Chan WS, Douketis JD, Gupta A, et al. The use of antiplatelet
therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary.
Can J Cardiol 2011;27:208–21. http://dx.doi.org/10.1016/j.cjca.2010.12.033
7. American Diabetes Association. Standards of medical care in diabetes – 2013. Diabetes Care
2013;36(Suppl. 1):11–66. http://dx.doi.org/10.2337/dc13-S011
8. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for
primary prevention of cardiovascular events in people with diabetes: a position statement of the
American Diabetes Association, a scientific statement of the American Heart Association, and an
expert consensus document of the American College of Cardiology Foundation. Diabetes Care
2010;33:1395–402. http://dx.doi.org/10.2337/dc10-0555
9. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug
Discov 2010;9:154–69. http://dx.doi.org/10.1038/nrd2957
10. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and
stroke statistics – 2010 update: a report from the American Heart Association. Circulation
2010;121:e46–215. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192667
11. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the
primary prevention of stroke: a guideline for healthcare professionals from the American Heart
Association/American Stroke Association. Stroke 2011;42:517–84. http://dx.doi.org/10.1161/
STR.0b013e3181fcb238
12. Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E, et al. A
population-based study of peripheral arterial disease prevalence with special focus on critical
limb ischemia and sex differences. J Vasc Surg 2007;45:1185–91. http://dx.doi.org/10.1016/
j.jvs.2007.02.004
13. Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clement D, Collet JP, et al. ESC Guidelines
on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic
disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries:
the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European
Society of Cardiology (ESC). Eur Heart J 2011;32:2851–906. http://dx.doi.org/10.1093/
eurheartj/ehr211
DOI: 10.3310/hta19370 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 37
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
239
14. Lordkipanidzé M. Advances in monitoring of aspirin therapy. Platelets 2012;23:526–36. http://dx.
doi.org/10.3109/09537104.2012.711865
15. Awtry EH, Loscalzo J. Aspirin. Circulation 2000;101:1206–18. http://dx.doi.org/10.1161/01.CIR.
101.10.1206
16. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.
Nat New Biol 1971;231:232–5. http://dx.doi.org/10.1038/newbio231232a0
17. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation
of a particulate fraction protein. J Clin Invest 1975;56:624–32. http://dx.doi.org/10.1172/
JCI108132
18. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane
production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366–72. http://dx.doi.
org/10.1172/JCI110576
19. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin – what’s the risk? Aliment
Pharmacol Ther 2006;24:897–908. http://dx.doi.org/10.1111/j.1365-2036.2006.03077.x
20. Bertrand OF, Larose E, Rodes-Cabau J, Gleeton O, Taillon I, Roy L, et al. Incidence, predictors, and
clinical impact of bleeding after transradial coronary stenting and maximal antiplatelet therapy.
Am Heart J 2009;157:164–9. http://dx.doi.org/10.1016/j.ahj.2008.09.010
21. Suh JW, Mehran R, Claessen BE, Xu K, Baber U, Dangas G, et al. Impact of in-hospital major
bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute
myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and
Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol 2011;58:1750–6. http://dx.doi.org/
10.1016/j.jacc.2011.07.021
22. Patrono C, Andreotti F, Arnesen H, Badimon L, Baigent C, Collet JP, et al. Antiplatelet agents for
the treatment and prevention of atherothrombosis. Eur Heart J 2011;32:2922–32. http://dx.doi.
org/10.1093/eurheartj/ehr373
23. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the
management of acute coronary syndromes in patients presenting without persistent ST-segment
elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients
presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).
Eur Heart J 2011;32:2999–3054. http://dx.doi.org/10.1093/eurheartj/ehr236
24. Smith SC, Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF
Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other
Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association
and American College of Cardiology Foundation. Circulation 2011;124:2458–73. http://dx.doi.
org/10.1161/CIR.0b013e318235eb4d
25. Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE, Jr, Ettinger SM, et al. 2011 ACCF/
AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/
Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American
College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
Circulation 2011;123:2022–60. http://dx.doi.org/10.1161/CIR.0b013e31820f2f3e
26. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial
revascularization. Eur Heart J 2010;31:2501–55. http://dx.doi.org/10.1093/eurheartj/ehq277
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
240
27. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI
Guideline for Percutaneous Coronary Intervention: a report of the American College of
Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the
Society for Cardiovascular Angiography and Interventions. Circulation 2011;124:e574–651.
http://dx.doi.org/10.1161/CIR.0b013e31823ba622
28. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, et al.
Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost
2005;3:1309–11. http://dx.doi.org/10.1111/j.1538-7836.2005.01351.x
29. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler
Thromb Vasc Biol 2004;24:1980–7. http://dx.doi.org/10.1161/01.ATV.0000145980.39477.a9
30. European Agency for the Evaluation of Medicinal Products. Position Paper on the Regulatory
Requirements for the Authorization of Low-Dose Modified Release ASA Formulations in the
Secondary Prevention of Cardiovascular Events. London: European Medicines Agency; 2002.
31. Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction
and pharmacology. Pharmacol Ther 2008;118:18–35. http://dx.doi.org/10.1016/j.pharmthera.
2008.01.001
32. Grove EL, Storey RF, Wurtz M. Platelet function testing in atherothrombotic disease. Curr Pharm
Des 2012;18:5379–91. http://dx.doi.org/10.2174/138161212803251862
33. FitzGerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for
other agonists. Am J Cardiol 1991;68:11B–15B. http://dx.doi.org/10.1016/0002-9149(91)90379-Y
34. Crescente M, Di Castelnuovo A, Iacoviello L, De Gaetano G, Cerletti C. PFA-100 closure time to
predict cardiovascular events in aspirin-treated cardiovascular patients: a meta-analysis of
19 studies comprising 3,003 patients. Thromb Haemost 2008;99:1129–31. http://dx.doi.org/
10.1160/TH08-03-0130
35. Chan MV, Armstrong PC, Papalia F, Kirkby NS, Warner TD. Optical multichannel (optimul) platelet
aggregometry in 96-well plates as an additional method of platelet reactivity testing. Platelets
2011;22:485–94. http://dx.doi.org/10.3109/09537104.2011.592958
36. Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, et al. Platelet
cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function
assays: implications for aspirin ‘resistance’. J Am Coll Cardiol 2009;53:667–77. http://dx.doi.org/
10.1016/j.jacc.2008.10.047
37. Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison
of six major platelet function tests to determine the prevalence of aspirin resistance in patients
with stable coronary artery disease. Eur Heart J 2007;28:1702–8. http://dx.doi.org/10.1093/
eurheartj/ehm226
38. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by
thrombelastograph platelet mapping and validation by conventional aggregometry using
arachidonic acid stimulation. J Am Coll Cardiol 2005;46:1705–9. http://dx.doi.org/10.1016/
j.jacc.2005.05.090
39. Gurbel PA, Bliden KP, Dichiara J, Newcomer J, Weng W, Neerchal NK, et al. Evaluation of
dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect
(ASPECT) study. Circulation 2007;115:3156–64. http://dx.doi.org/10.1161/CIRCULATIONAHA.
106.675587
DOI: 10.3310/hta19370 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 37
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
241
40. Faraday N, Yanek LR, Mathias R, Herrera-Galeano JE, Vaidya D, Moy TF, et al. Heritability of
platelet responsiveness to aspirin in activation pathways directly and indirectly related to
cyclooxygenase-1. Circulation 2007;115:2490–6. http://dx.doi.org/10.1161/CIRCULATIONAHA.
106.667584
41. Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM. Screening for aspirin
responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet
function tests with optical aggregometry. Stroke 2005;36:1001–5. http://dx.doi.org/10.1161/
01.STR.0000162719.11058.bd
42. Frelinger AL III, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, et al. Residual arachidonic
acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1-
and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation
2006;113:2888–96. http://dx.doi.org/10.1161/CIRCULATIONAHA.105.596627
43. Rocca B, Petrucci G. Variability in the responsiveness to low-dose aspirin: pharmacological and
disease-related mechanisms. Thrombosis 2012;2012:376721. http://dx.doi.org/10.1155/
2012/376721
44. Lordkipanidzé M, Pharand C, Palisaitis DA, Diodati JG. Aspirin resistance: truth or dare. Pharmacol
Ther 2006;112:733–43. http://dx.doi.org/10.1016/j.pharmthera.2006.05.011
45. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. Compliance as a
critical consideration in patients who appear to be resistant to aspirin after healing of myocardial
infarction. Am J Cardiol 2005;95:973–5. http://dx.doi.org/10.1016/j.amjcard.2004.12.038
46. Cotter G, Shemesh E, Zehavi M, Dinur I, Rudnick A, Milo O, et al. Lack of aspirin effect: aspirin
resistance or resistance to taking aspirin? Am Heart J 2004;147:293–300. http://dx.doi.org/
10.1016/j.ahj.2003.07.011
47. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al. Use of secondary prevention
drugs for cardiovascular disease in the community in high-income, middle-income, and low-income
countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378:1231–43.
http://dx.doi.org/10.1016/S0140-6736(11)61215-4
48. Peace A, McCall M, Tedesco T, Kenny D, Conroy RM, Foley D, et al. The role of weight and
enteric coating on aspirin response in cardiovascular patients. J Thromb Haemost 2010;8:2323–5.
http://dx.doi.org/10.1111/j.1538-7836.2010.03997.x
49. Katona E, Kovacs E, Bereczky Z, Balogh L, Homorodi N, Haramura G, et al. Development of
reference methods for evaluating the effect of aspirin and for comparison with routinely used
methods; the lack of aspirin resistance in healthy volunteers. J Thromb Haemost 2011;9:15–19.
50. Schwartz KA, Schwartz DE, Barber K, Reeves M, De Franco AC. Non-compliance is the
predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Transl Med
2008;6:46. http://dx.doi.org/10.1186/1479-5876-6-46
51. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al.
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809–17.
http://dx.doi.org/10.1056/NEJMoa003199
52. Capone ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, Renda G, et al. Pharmacodynamic
interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol
2005;45:1295–1301. http://dx.doi.org/10.1016/j.jacc.2005.01.045
53. Wilner KD, Rushing M, Walden C, Adler R, Eskra J, Noveck R, et al. Celecoxib does not affect
the antiplatelet activity of aspirin in healthy volunteers. J Clin Pharmacol 2002;42:1027–30.
http://dx.doi.org/10.1177/009127002401102858
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
242
54. Van Ryn J, Kink-Eiband M, Kuritsch I, Feifel U, Hanft G, Wallenstein G, et al. Meloxicam does not
affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol
2004;44:777–84. http://dx.doi.org/10.1177/0091270004266623
55. Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, et al. Platelet response to low-dose
enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol
2005;46:1258–63. http://dx.doi.org/10.1016/j.jacc.2005.06.058
56. Angiolillo DJ. Antiplatelet therapy in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes
2007;14:124–31. http://dx.doi.org/10.1097/MED.0b013e32807f2ad9
57. Dichiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA, et al. The effect of aspirin
dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced
platelet effect (ASPECT) study. Diabetes 2007;56:3014–19. http://dx.doi.org/10.2337/db07-0707
58. Watala C, Boncler M, Gresner P. Blood platelet abnormalities and pharmacological modulation of
platelet reactivity in patients with diabetes mellitus. Pharmacol Rep 2005;57(Suppl.):42–58.
59. Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B, et al. Reduced sensitivity of
platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin) – its relation to metabolic
control. Thromb Res 2004;113:101–13. http://dx.doi.org/10.1016/j.thromres.2003.12.016
60. Pulcinelli FM, Biasucci LM, Riondino S, Giubilato S, Leo A, Di Renzo L, et al. COX-1 sensitivity and
thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin
treatment. Eur Heart J 2009;30:1279–86. http://dx.doi.org/10.1093/eurheartj/ehp097
61. Watala C, Pluta J, Golanski J, Rozalski M, Czyz M, Trojanowski Z, et al. Increased protein
glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation
and reduced sensitivity of blood platelets to aspirin. J Mol Med (Berl) 2005;83:148–58.
http://dx.doi.org/10.1007/s00109-004-0600-x
62. Kobzar G, Mardla V, Samel N. Short-term exposure of platelets to glucose impairs inhibition of
platelet aggregation by cyclooxygenase inhibitors. Platelets 2011;22:338–44. http://dx.doi.org/
10.3109/09537104.2010.535931
63. Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pagliaccia F, et al. Aspirin-insensitive
thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of
the drug target. Blood 2012;119:3595–603. http://dx.doi.org/10.1182/blood-2011-06-359224
64. Dillinger JG, Sideris G, Henry P, Bal dit Sollier C, Ronez E, Drouet L. Twice daily aspirin to improve
biological aspirin efficacy in patients with essential thrombocythemia. Thromb Res 2012;129:91–4.
http://dx.doi.org/10.1016/j.thromres.2011.09.017
65. Dragani A, Pascale S, Recchiuti A, Mattoscio D, Lattanzio S, Petrucci G, et al. The contribution of
cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential
thrombocythemia: implications for antiplatelet therapy. Blood 2010;115:1054–61. http://dx.doi.
org/10.1182/blood-2009-08-236679
66. Henry P, Vermillet A, Boval B, Guyetand C, Petroni T, Dillinger JG, et al. 24-hour time-dependent
aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2011;105:336–44.
http://dx.doi.org/10.1160/TH10-02-0082
67. Lordkipanidzé M, Pharand C, Schampaert E, Palisaitis DA, Diodati JG. Heterogeneity in platelet
cyclooxygenase inhibition by aspirin in coronary artery disease. Int J Cardiol 2011;150:39–44.
http://dx.doi.org/10.1016/j.ijcard.2010.02.025
68. Perneby C, Wallen NH, Rooney C, Fitzgerald D, Hjemdahl P. Dose- and time-dependent
antiplatelet effects of aspirin. Thromb Haemost 2006;95:652–8.
DOI: 10.3310/hta19370 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 37
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
243
69. Di Minno G. Aspirin resistance and platelet turnover: a 25-year old issue. Nutr Metab Cardiovasc
Dis 2011;21:542–5. http://dx.doi.org/10.1016/j.numecd.2011.04.002
70. Grove EL, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD. Effect of platelet turnover on whole
blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost
2011;9:185–91. http://dx.doi.org/10.1111/j.1538-7836.2010.04115.x
71. Capodanno D, Patel A, Dharmashankar K, Ferreiro JL, Ueno M, Kodali M, et al. Pharmacodynamic
effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery
disease. Circ Cardiovasc Interv 2011;4:180–7. http://dx.doi.org/10.1161/CIRCINTERVENTIONS.
110.960187
72. Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, et al. The recovery of platelet
cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in
patients with and without diabetes. J Thromb Haemost 2012;10:1220–30. http://dx.doi.org/
10.1111/j.1538-7836.2012.04723.x
73. Spectre G, Arnetz L, Ostenson CG, Brismar K, Li N, Hjemdahl P. Twice daily dosing of aspirin
improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or
macrovascular complications. Thromb Haemost 2011;106:491–9. http://dx.doi.org/10.1160/
TH11-04-0216
74. Wurtz M, Grove EL. Interindividual variability in the efficacy of oral antiplatelet drugs: definitions,
mechanisms and clinical importance. Curr Pharm Des 2012;18:5344–61. http://dx.doi.org/
10.2174/138161212803251925
75. Grove EL, Hvas AM, Johnsen HL, Hedegaard SS, Pedersen SB, Mortensen J, et al. A comparison of
platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy
individuals and patients with coronary artery disease. Thromb Haemost 2010;103:1245–53.
http://dx.doi.org/10.1160/TH09-08-0527
76. Frelinger AL III, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, et al. Association of
cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical
outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation
2009;120:2586–96. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.900589
77. Cattaneo M. Laboratory detection of ‘aspirin resistance’: what test should we use (if any)?
Eur Heart J 2007;28:1673–5. http://dx.doi.org/10.1093/eurheartj/ehm232
78. Raichand S, Moore D, Riley R, Lordkipanidzé M, Dretzke J, O’Donnell J, et al. Protocol for a
systematic review of the diagnostic and prognostic utility of tests currently available for the
detection of aspirin resistance in patients with established cardiovascular or cerebrovascular
disease. Syst Rev 2013;2:16. http://dx.doi.org/10.1186/2046-4053-2-16
79. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2:
a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med
2011;155:529–36. http://dx.doi.org/10.7326/0003-4819-155-8-201110180-00009
80. Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic
reviews. Ann Intern Med 2006;144:427–37. http://dx.doi.org/10.7326/0003-4819-144-6-
200603210-00010
81. Altman DG. Prognostic models: a methodological framework and review of models for breast
cancer. Cancer Invest 2009;27:235–43. http://dx.doi.org/10.1080/07357900802572110
82. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the
published literature for survival endpoints. Stat Med 1998;17:2815–34. http://dx.doi.org/10.1002/
(SICI)1097-0258(19981230)17:24%3C2815::AID-SIM110%3E3.0.CO;2-8
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
244
83. Perneger TV. Estimating the relative hazard by the ratio of logarithms of event-free proportions.
Contemp Clin Trials 2008;29:762–6. http://dx.doi.org/10.1016/j.cct.2008.06.002
84. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity
corrections in meta-analysis of sparse data. Stat Med 2004;23:1351–75. http://dx.doi.org/
10.1002/sim.1761
85. Kip KE, Hollabaugh K, Marroquin OC, Williams DO. The problem with composite end points in
cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary
intervention. J Am Coll Cardiol 2008;51:701–7. http://dx.doi.org/10.1016/j.jacc.2007.10.034
86. Ozben S, Ozben B, Tanrikulu AM, Ozer F, Ozben T. Aspirin resistance in patients with acute
ischemic stroke. J Neurol 2011;258:1979–86. http://dx.doi.org/10.1007/s00415-011-6052-7
87. Lee SP, Park KW, Shin DH, Lee HY, Kang HJ, Koo BK, et al. Efficacy of predicting thrombotic
events with combination of dual point-of-care testing (POCT) after drug-eluting stent implantation
for coronary heart disease: results from the CILON-T randomized trial POCT substudy.
J Atheroscler Thromb 2011;18:914–23. http://dx.doi.org/10.5551/jat.9290
88. Feher A, Pusch G, Harang G, Gasztonyi B, Papp E, Werling D, et al. Aspirin resistance in
cerebrovascular patients. Int J Cardiol 2011;152:111–12. http://dx.doi.org/10.1016/j.ijcard.2011.
07.028
89. Chiu FC, Wang TD, Lee JK, Shih FY, Lin JW, Huang CH, et al. Residual platelet reactivity after aspirin
and clopidogrel treatment predicts 2-year major cardiovascular events in patients undergoing
percutaneous coronary intervention. Eur J Intern Med 2011;22:471–7. http://dx.doi.org/10.1016/
j.ejim.2011.02.021
90. van der Loo B, Braun J, Koppensteiner R. On-treatment function testing of platelets and long-term
outcome of patients with peripheral arterial disease undergoing transluminal angioplasty. Eur J Vasc
Endovasc Surg 2011;42:809–16. http://dx.doi.org/10.1016/j.ejvs.2011.08.014
91. Amoah V, Smallwood A, Worrall AP, Lovatt T, Armesilla AL, Nevill AM, et al. Poor aspirin
response in diabetic patients presenting with acute coronary syndromes: results using a near
patient test. Thromb Res 2011;128:196–9. http://dx.doi.org/10.1016/j.thromres.2011.04.003
92. Kim HJ, Lee JM, Seo JH, Kim JH, Hong DM, Bahk JH, et al. Preoperative aspirin resistance does
not increase myocardial injury during off-pump coronary artery bypass surgery. J Korean Med Sci
2011;26:1041–6. http://dx.doi.org/10.3346/jkms.2011.26.8.1041
93. Spectre G, Mosseri M, Abdelrahman NM, Briskin E, Bulut A, Loncar S, et al. Clinical and
prognostic implications of the initial response to aspirin in patients with acute coronary syndrome.
Am J Cardiol 2011;108:1112–18. http://dx.doi.org/10.1016/j.amjcard.2011.06.013
94. Grdinic A, Vojvodic D, Djukanovic N, Colic M, Grdinic AG, Ignjatovic V, et al. PCI and clopidogrel:
antiplatelet responsiveness and patient characteristics. Acta Cardiol 2011;66:333–40.
95. Abumiya T, Houkin K. Association of recurrent cerebral infarction with adenosine diphosphate- and
collagen-induced platelet aggregation in patients treated with ticlopidine and/or aspirin. J Stroke
Cerebrovasc Dis 2011;20:319–23. http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2010.01.013
96. Angiolillo DJ, Bernardo E, Zanoni M, Vivas D, Capranzano P, Malerba G, et al. Impact of insulin
receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with
type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2011;58:30–9.
http://dx.doi.org/10.1016/j.jacc.2011.02.040
97. Kuliczkowski W, Greif M, Gasior M, Kaczmarski J, Pres D, Polonski L. Effects of platelet and
inflammatory system activation on outcomes in diabetic patients with ST segment elevation
myocardial infarction treated with primary percutaneous coronary intervention. Kardiol Pol
2011;69:531–7.
DOI: 10.3310/hta19370 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 37
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
245
98. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Harmsze AM, Hackeng CM, et al. High
on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk
of adverse events following percutaneous coronary intervention. Heart 2011;97:983–90.
http://dx.doi.org/10.1136/hrt.2010.220491
99. Gluckman TJ, McLean RC, Schulman SP, Kickler TS, Shapiro EP, Conte JV, et al. Effects of aspirin
responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass
graft surgery. J Am Coll Cardiol 2011;57:1069–77. http://dx.doi.org/10.1016/j.jacc.2010.08.650
100. Ko YG, Suh JW, Kim BH, Lee CJ, Kim JS, Choi D, et al. Comparison of 2 point-of-care platelet
function tests, VerifyNow Assay and Multiple Electrode Platelet Aggregometry, for predicting early
clinical outcomes in patients undergoing percutaneous coronary intervention. Am Heart J
2011;161:383–90. http://dx.doi.org/10.1016/j.ahj.2010.10.036
101. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, ten Berg JM, Hackeng CM. High on-aspirin
platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive
platelet function tests is associated with the occurrence of atherothrombotic events. J Thromb
Haemost 2010;8:2140–8. http://dx.doi.org/10.1111/j.1538-7836.2010.04017.x
102. Smit JJ, van Werkum JW, ten Berg J, Slingerland R, Ottervanger JP, Heestermans T, et al.
Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction
leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy.
Heart 2010;96:1815–20. http://dx.doi.org/10.1136/hrt.2010.201889
103. Campo G, Fileti L, de Cesare N, Meliga E, Furgieri A, Russo F, et al. Long-term clinical outcome
based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary
intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin
and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol 2010;56:1447–55.
http://dx.doi.org/10.1016/j.jacc.2010.03.103
104. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, et al. High on-treatment platelet
reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and
non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting.
Thromb Haemost 2010;104:279–86. http://dx.doi.org/10.1160/TH10-01-0007
105. Chu JW, Wong CK, Chambers J, Wout JV, Herbison P, Tang EW. Aspirin resistance determined
from a bed-side test in patients suspected to have acute coronary syndrome portends a worse
6 months outcome. QJM 2010;103:405–12. http://dx.doi.org/10.1093/qjmed/hcq038
106. Eshtehardi P, Windecker S, Cook S, Billinger M, Togni M, Garachemani A, et al. Dual low
response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent
thrombosis after coronary stent implantation. Am Heart J 2010;159:891–8. http://dx.doi.org/
10.1016/j.ahj.2010.02.025
107. Campo G, Valgimigli M, Frangione A, Luccarelli S, Cangiano E, Cavazza C, et al. Evaluation of
platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel
responsiveness: the 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to
aspirin and/or resistance to clopidogrel). J Am Coll Cardiol 2010;55:255–6. http://dx.doi.org/
10.1016/j.jacc.2009.08.052
108. Addad F, Chakroun T, Abderazek F, Ben-Farhat M, Hamdi S, Dridi Z, et al. Response variability to
aspirin and one-year prediction of vascular events in patients with stable coronary artery disease.
J Thromb Thrombolysis 2010;29:108–13. http://dx.doi.org/10.1007/s11239-009-0335-1
109. Aksu H, Ozer O, Unal H, Hobikoglu G, Norgaz T, Buturak A, et al. Significance of mean platelet
volume on prognosis of patients with and without aspirin resistance in settings of non-ST-segment
elevated acute coronary syndromes. Blood Coagul Fibrinolysis 2009;20:686–93. http://dx.doi.org/
10.1097/MBC.0b013e32833161ac
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
246
110. Thomson VS, John B, George P, Joseph G, Jose J. Aspirin resistance in Indian patients with coronary
artery disease and cardiovascular events. J Postgrad Med 2009;55:252–6. http://dx.doi.org/10.4103/
0022-3859.58927
111. Cuisset T, Cayla G, Frere C, Quilici J, Poyet R, Gaborit B, et al. Predictive value of post-treatment
platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary
syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? Eurointervention
2009;5:325–9. http://dx.doi.org/10.4244/51
112. Linnemann B, Prochnow S, Mani H, Schwonberg J, Lindhoff-Last E. Variability of non-response
to aspirin in patients with peripheral arterial occlusive disease during long-term follow-up.
Ann Hematol 2009;88:979–88. http://dx.doi.org/10.1007/s00277-009-0708-8
113. Kempfert J, Anger K, Rastan A, Krabbes S, Lehmann S, Garbade J, et al. Postoperative
development of aspirin resistance following coronary artery bypass. Eur J Clin Invest
2009;39:769–74. http://dx.doi.org/10.1111/j.1365-2362.2009.02175.x
114. Ivandic BT, Sausemuth M, Ibrahim H, Giannitsis E, Gawaz M, Katus HA. Dual antiplatelet drug
resistance is a risk factor for cardiovascular events after percutaneous coronary intervention.
Clin Chem 2009;55:1171–6. http://dx.doi.org/10.1373/clinchem.2008.115089
115. Foussas SG, Zairis MN, Tsirimpis VG, Makrygiannis SS, Patsourakos NG, Adamopoulou EN, et al.
The impact of aspirin resistance on the long-term cardiovascular mortality in patients with non-ST
segment elevation acute coronary syndromes. Clin Cardiol 2009;32:142–7. http://dx.doi.org/
10.1002/clc.20293
116. Boncoraglio GB, Bodini A, Brambilla C, Corsini E, Carriero MR, Parati EA. Aspirin resistance
determined with PFA-100 does not predict new thrombotic events in patients with stable
ischemic cerebrovascular disease. Clin Neurol Neurosurg 2009;111:270–3. http://dx.doi.org/
10.1016/j.clineuro.2008.11.001
117. Majeed F, Kop WJ, Poston RS, Kallam S, Mehra MR. Prospective, observational study of
antiplatelet and coagulation biomarkers as predictors of thromboembolic events after
implantation of ventricular assist devices. Nat Clin Pract Cardiovasc Med 2009;6:147–57.
http://dx.doi.org/10.1038/ncpcardio1441
118. Bevilacqua S, Alkodami AA, Volpi E, Cerillo AG, Berti S, Glauber M, et al. Risk stratification after
coronary artery bypass surgery by a point-of-care test of platelet function. Ann Thorac Surg
2009;87:496–502. http://dx.doi.org/10.1016/j.athoracsur.2008.05.038
119. Saw J, Densem C, Walsh S, Jokhi P, Starovoytov A, Fox R, et al. The effects of aspirin and
clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief
Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial
substudy. JACC Cardiovasc Interv 2008;1:654–9. http://dx.doi.org/10.1016/j.jcin.2008.08.017
120. Gori AM, Marcucci R, Paniccia R, Giusti B, Fedi S, Antonucci E, et al. Thrombotic events in high
risk patients are predicted by evaluating different pathways of platelet function. Thromb Haemost
2008;100:1136–45.
121. Cha JK, Jeon HW, Kang MJ. ADP-induced platelet aggregation in acute ischemic stroke patients on
aspirin therapy. Eur J Neurol 2008;15:1304–8. http://dx.doi.org/10.1111/j.1468-1331.2008.02306.x
122. Gurbel PA, Antonino MJ, Bliden KP, Dichiara J, Suarez TA, Singla A, et al. Platelet reactivity to
adenosine diphosphate and long-term ischemic event occurrence following percutaneous
coronary intervention: a potential antiplatelet therapeutic target. Platelets 2008;19:595–604.
http://dx.doi.org/10.1080/09537100802351065
DOI: 10.3310/hta19370 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 37
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
247
123. Campo G, Valgimigli M, Frangione A, Tebaldi M, Ferrari R. Prognostic value of serial platelet
reactivity measurements on long-term clinical outcome in patients with ST-elevation myocardial
infarction undergoing primary PCI. J Thromb Haemost 2008;6:1824–6. http://dx.doi.org/10.1111/
j.1538-7836.2008.03112.x
124. Gori AM, Marcucci R, Migliorini A, Valenti R, Moschi G, Paniccia R, et al. Incidence and clinical
impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents.
J Am Coll Cardiol 2008;52:734–9. http://dx.doi.org/10.1016/j.jacc.2008.05.032
125. Schwammenthal Y, Tsabari R, Shenkman B, Schwartz R, Matetzky S, Lubetsky A, et al. Aspirin
responsiveness in acute brain ischaemia: association with stroke severity and clinical outcome.
Cerebrovasc Dis 2008;25:355–61. http://dx.doi.org/10.1159/000118382
126. Aradi D, Konyi A, Palinkas L, Berki T, Pinter T, Tahin T, et al. Thienopyridine therapy influences
late outcome after coronary stent implantation. Angiology 2008;59:172–8. http://dx.doi.org/
10.1177/0003319707304572
127. Christiaens L, Ragot S, Mergy J, Allal J, Macchi L. Major clinical vascular events and aspirin-
resistance status as determined by the PFA-100 method among patients with stable coronary
artery disease: a prospective study. Blood Coagul Fibrinolysis 2008;19:235–9. http://dx.doi.org/
10.1097/MBC.0b013e3282f9ade8
128. Gengo FM, Rainka M, Robson M, Gengo MF, Forrest A, Hourihane M, et al. Prevalence of platelet
nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients
with recurrent ischemic events. J Clin Pharmacol 2008;48:335–43. http://dx.doi.org/10.1177/
0091270007313324
129. Jacopo G, Elisabetta V, Silverio S, Massimiliano M, Sergio B, Grazia AM, et al. Identification of
platelet hyper-reactivity measured with a portable device immediately after percutaneous coronary
intervention predicts in stent thrombosis. Thromb Res 2007;121:407–12. http://dx.doi.org/
10.1016/j.thromres.2007.04.009
130. Blindt R, Stellbrink K, de Taeye A, Muller R, Kiefer P, Yagmur E, et al. The significance of
vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost
2007;98:1329–34.
131. Foussas SG, Zairis MN, Patsourakos NG, Makrygiannis SS, Adamopoulou EN, Handanis SM, et al.
The impact of oral antiplatelet responsiveness on the long-term prognosis after coronary stenting.
Am Heart J 2007;154:676–81. http://dx.doi.org/10.1016/j.ahj.2007.06.013
132. Poulsen TS, Kristensen SR, Korsholm L, Haghfelt T, Jorgensen B, Licht PB, et al. Variation and
importance of aspirin resistance in patients with known cardiovascular disease. Thromb Res
2007;120:477–84. http://dx.doi.org/10.1016/j.thromres.2006.10.022
133. Chen WH, Cheng X, Lee PY, Ng W, Kwok JY, Tse HF, et al. Aspirin resistance and adverse clinical
events in patients with coronary artery disease. Am J Med 2007;120:631–5. http://dx.doi.org/
10.1016/j.amjmed.2006.10.021
134. Buch AN, Singh S, Roy P, Javaid A, Smith KA, George CE, et al. Measuring aspirin resistance,
clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing
percutaneous coronary intervention. Am J Cardiol 2007;99:1518–22. http://dx.doi.org/10.1016/
j.amjcard.2007.01.023
135. Hobikoglu GF, Norgaz T, Aksu H, Ozer O, Erturk M, Destegul E, et al. The effect of acetylsalicylic
acid resistance on prognosis of patients who have developed acute coronary syndrome during
acetylsalicylic acid therapy. Can J Cardiol 2007;23:201–6. http://dx.doi.org/10.1016/S0828-282X
(07)70744-4
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
248
136. Bliden KP, Dichiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with
high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous
coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol
2007;49:657–66. http://dx.doi.org/10.1016/j.jacc.2006.10.050
137. Pamukcu B, Oflaz H, Onur I, Oncul A, Ozcan M, Umman B, et al. Clinical relevance of aspirin
resistance in patients with stable coronary artery disease: a prospective follow-up study
(PROSPECTAR). Blood Coagul Fibrinolysis 2007;18:187–92. http://dx.doi.org/10.1097/
MBC.0b013e328040c115
138. Fuchs I, Frossard M, Spiel A, Riedmuller E, Laggner AN, Jilma B. Platelet function in patients with
acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost 2006;4:2547–52.
http://dx.doi.org/10.1111/j.1538-7836.2006.02239.x
139. Marcucci R, Paniccia R, Antonucci E, Gori AM, Fedi S, Giglioli C, et al. Usefulness of aspirin
resistance after percutaneous coronary intervention for acute myocardial infarction in predicting
one-year major adverse coronary events. Am J Cardiol 2006;98:1156–9. http://dx.doi.org/
10.1016/j.amjcard.2006.05.041
140. Pamukcu B, Oflaz H, Oncul A, Umman B, Mercanoglu F, Ozcan M, et al. The role of aspirin
resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel
therapy in the prevention of major cardiovascular events. J Thromb Thrombolysis 2006;22:103–10.
http://dx.doi.org/10.1007/s11239-006-8952-4
141. Gianetti J, Parri MS, Sbrana S, Paoli F, Maffei S, Paradossi U, et al. Platelet activation predicts
recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study.
Thromb Res 2006;118:487–93. http://dx.doi.org/10.1016/j.thromres.2005.10.011
142. Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, Mimuro J, et al. Aspirin resistance
detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other
signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost
2006;4:1271–8. http://dx.doi.org/10.1111/j.1538-7836.2006.01958.x
143. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, et al. High post-treatment platelet
reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent
cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost
2006;4:542–9. http://dx.doi.org/10.1111/j.1538-7836.2005.01751.x
144. Morawski W, Sanak M, Cisowski M, Szczeklik M, Szczeklik W, Dropinski J, et al. Prediction of the
excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: role of
aspirin and platelet glycoprotein IIIa polymorphism. J Thorac Cardiovasc Surg 2005;130:791–6.
http://dx.doi.org/10.1016/j.jtcvs.2005.02.041
145. Sambola A, Heras M, Escolar G, Lozano M, Pino M, Martorell T, et al. The PFA-100 detects
sub-optimal antiplatelet responses in patients on aspirin. Platelets 2004;15:439–46. http://dx.doi.
org/10.1080/69537100412351272550
146. Stejskal D, Proskova J, Lacnak B, Horalik D, Hamplova A, Oral I, et al. [Use of assessment of
aggregation of thrombocytes induced by cationic propyl gallate to estimate recurrence of
cardiovascular complications.] Vnitr Lek 2004;50:591–9.
147. Payne DA, Jones CI, Hayes PD, Thompson MM, London NJ, Bell PR, et al. Beneficial effects of
clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid
endarterectomy. Circulation 2004;109:1476–81. http://dx.doi.org/10.1161/01.CIR.0000121739.
05643.E6
148. Bruno A, McConnell JP, Cohen SN, Tietjen GE, Wallis RA, Gorelick PB, et al. Serial urinary
11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral
infarction. Stroke 2004;35:727–30. http://dx.doi.org/10.1161/01.STR.0000117097.76953.A6
DOI: 10.3310/hta19370 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 37
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
249
149. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of
the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll
Cardiol 2003;41:961–5. [Erratum published in J Am Coll Cardiol 2006;48:1918.] http://dx.doi.org/
10.1016/S0735-1097(02)03014-0
150. Ziegler S, Maca T, Alt E, Speiser W, Schneider B, Minar E. Monitoring of antiplatelet therapy with
the PFA-100 in peripheral angioplasty patients. Platelets 2002;13:493–7. http://dx.doi.org/
10.1080/0953710021000057866
151. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane
biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at
high risk for cardiovascular events. Circulation 2002;105:1650–5. http://dx.doi.org/10.1161/
01.CIR.0000013777.21160.07
152. Buchanan MR, Schwartz L, Bourassa M, Brister SJ, Peniston CM; BRAT Investigators. Results of the
BRAT study – a pilot study investigating the possible significance of ASA nonresponsiveness on
the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass
surgery. Can J Cardiol 2000;16:1385–90.
153. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, et al. Variable platelet response to
low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial
angioplasty. Thromb Haemost 1997;78:1003–7.
154. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and
aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993;71:397–403.
http://dx.doi.org/10.1016/0049-3848(93)90164-J
155. Sørensen PS, Agerskov AL, Gormsen J, Pedersen H, Marquardsen J, Petersson H, et al. Prognostic
value of in vitro measurements of platelet aggregability and fibrinolytic activity in patients with
reversible cerebral ischemic attacks. Eur Neurol 1983;22:437–41. http://dx.doi.org/10.1159/
000115599
156. Tang FK, Lin LJ, Hua N, Lu H, Qi Z, Tang XZ. Earlier application of loading doses of aspirin and
clopidogrel decreases rate of recurrent cardiovascular ischemic events for patients undergoing
percutaneous coronary intervention. Chin Med J 2012;125:631–8.
157. Breet NJ, Sluman MA, van Berkel MAJPJ, van Werkum JW, Bouman HJ, Harmsze AM, et al. Effect
of gender difference on platelet reactivity. Neth Heart J 2011;19:451–7. http://dx.doi.org/
10.1007/s12471-011-0189-y
158. Milicic D, Lovric D, Skoric B, Narancic-Skoric K, Gornik I, Sertic J. Platelet response to standard
aspirin and clopidogrel treatment correlates with long-term outcome in patients with acute
ST-elevation myocardial infarction. Int J Cardiol 2011;153:227–9. http://dx.doi.org/10.1016/
j.ijcard.2011.09.055
159. De Boni A, De Riva V, Galloni E, Perini F. Residual platelet activity and clinical failure of
antithrombotic prophylaxis in acute cerebral ischaemic stroke. Riv Ital Med Labor 2011;7:163–9.
http://dx.doi.org/10.1007/s13631-011-0024-8
160. Marcucci R, Gori AM, Paniccia R, Giusti B, Cordisco A, Balzi D, et al. High-on treatment platelet
reactivity by different stimuli is a determinant of 1 year mortality in acute coronary syndrome
patients: Data from AMI-florence 2 study. J Thromb Haemost 2011;9:546–7.
161. Marcucci R, Gori AM, Paniccia R, Giusti B, Cordisco A, Balzi D, et al. High-on clopidogrel platelet
reactivity is a determinant of 1-year mortality in acute coronary syndrome patients: Data from
AMI-florence 2 study. J Thromb Haemost 2011;9:546.
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
250
162. Lordkipanidzé M, Diodati JG, Schampaert E, Palisaitis DA, Pharand C. Lack of clinical predictiveness
of six major platelet function tests used to assess aspirin response in patients with stable coronary
artery disease. J Thromb Haemost 2011;9:343.
163. Spectre G, Mosseri M, Abdelrahman NM, Briskin E, Bulut A, Loncar S, et al. Dynamic response to
aspirin in patients with acute coronary syndrome, clinical and prognostic implications. J Thromb
Haemost 2011;9:338. http://dx.doi.org/10.1016/j.amjcard.2011.06.013
164. Miyata S, Kada A, Nagatsuka K. Clinical impact of aspirin ‘resistance’ on the secondary prevention
of atherothrombosis. J Thromb Haemost 2011;9:257.
165. Kaymaz C, Tokgoz HC, Tanboga IH, Poci N, Aktemur T, Kirca N, et al. Can we translate the high
and low on-treatment platelet reactivity to early, mid and long term risks for ischemic and
bleeding events following the stent placement. Eur Heart J 2011;32:755.
166. Orta KK, Kocas C, Yildiz A, Abaci O, Okcun B, Coskun U, et al. Long-term follow-up of the
patients with Aspirin resistant end stage kidney disease. Eur Heart J 2011;32:322–3.
167. Kaymaz C, Tanboga IH, Tokgoz HC, Can MM, Poci N, Aktemur T, et al. Comparison of
multiplate, VerifyNow and PFA-100 in the assessment of on-treatment platelet reactivity in
patients treated with aspirin and clopidogrel following coronary stenting. Eur Heart J 2011;32:246.
168. Sahin DY, Koc M, Cayli M, Sen O, Kalkan GY, Kanadasi M, et al. Frequency of aspirin resistance
in patients with chronic ischemic heart disease in Cukurova region and the relationship between
aspirin resistance and adverse clinical events. Int J Cardiol 2011;147:S157. http://dx.doi.org/
10.1016/S0167-5273(11)70427-2
169. Zanow J, Eckart A, Ludewig S, Losche W. Frequency and clinical significance of the ‘non-response’
to acetylsalicylic acid in patients with peripheral occlusive artery disease. Vasomed 2010;22:277.
170. Ryu D-S, Hong C-K, Sim Y-S, Kim C-H, Jung J-Y, Joo J-Y. Anti-platelet drug resistance in the
prediction of thromboembolic complications after neurointervention. J Korean Neurosurg Soc
2010;48:319–24. http://dx.doi.org/10.3340/jkns.2010.48.4.319
171. Lee J-H, Cha J-K, Lee SJ, Ha S-W, Kwon SU. Addition of cilostazol reduces biological aspirin
resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial.
Eur J Neurol 2010;17:434–42. http://dx.doi.org/10.1111/j.1468-1331.2009.02837.x
172. Angiolillo D, Bernardo E, Zanoni M, Capranzano P, Malerba G, Trabetti E, et al. Impact of IRS-1
genotypes on platelet reactivity and cardiovascular outcomes in type 2 diabetes mellitus patients
with coronary artery disease. J Am Coll Cardiol 2010;55(Suppl. 1):A207. http://dx.doi.org/
10.1016/j.jacc.2011.02.040
173. Bouman HJ, van Werkum JW, Smit JJ, Breet NJ, Postma S, Heestermans T, et al. Predictive value
of various platelet function tests on ST-segment resolution and clinical outcome in stemi patients
randomized to either dual or triple antiplatelet therapy: the onTIME2 platelet function substudy.
J Am Coll Cardiol 2010;55(Suppl. 1):A207. http://dx.doi.org/10.1016/S0735-1097(10)61949-3
174. Tan C, Lin J, Chen W, Lin R, Chen S. Elevated serum ubiquitin and ubiquitin conjugates:
A potential biomarker for aspirin resistance in acute myocardial infarction patients. Arterioscler
Thromb Vasc Biol 2010;30:e219–20.
175. Toth G, Pride GL, Novakovic R, Matevosyan K, Sarode R, Welch BG. Thromboembolic
complications and response to antiplatelet therapy in patients undergoing endovascular stenting
for aneurysm treatment. Stroke 2010;41:e265–6.
176. Bobesc E, Rado M, Datc G, Dobrean D, Dok BF. The effects of endothelial dysfunction, platelets
hyperactivity, oxidative stress biomarkers on ejection fraction, wall motion score index and
prognosis in patients with acute coronary syndromes. Eur J Echocardiogr 2010;11:ii122–3.
DOI: 10.3310/hta19370 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 37
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
251
177. Bobescu E, Radoi M, Datcu G, Dobreanu D, Doka B. Correlation between endothelial dysfunction,
platelets hyperactivity, oxidative stress biomarkers and cumulative effects on prognosis in patients
with acute coronary syndromes. Eur Heart J Suppl 2010;12:F19.
178. Ripley AW, Narang J, Fifi J, Bennett HL. Aspirin and clopidogrel resistance in patients requiring
endovascular neurological intervention. J Neurosurg Anesthesiol 2010;22:437.
179. Kuliczkowski W, Kaczmarski J, Greif M, Polonski L, Gasior M, Serebruany V, et al. Thrombin
induced aggregation and 6-months outcome in patients with diabetes and STEMI treated with
primary PCI. Eur Heart J 2010;31:972.
180. Bobescu E, Radoi M, Datcu G, Dobreanu D, Donea M, Doka B, et al. Evaluation of platelets
hyperactivity, hypercoagulability status and oxidative stress biomarkers and outcomes in patients
with acute coronary syndromes. Eur Heart J 2010;31:971–2.
181. Fateh-Moghadam S, Mueller E, Ziemer S, Dietz R, Gawaz M, Bocksch W. Responsiveness to
higher maintenance dose of dual antiplatelet therapy and its impact on stent thrombosis.
Eur Heart J 2010;31:971.
182. Ko YG, Suh JW, Kim JS, Choi DH, Hong MK, Jang YS, et al. Prognostic significance of dual
hyporesponsiveness to aspirin and clopidogrel measured by verifynow assay in the patients
undergoing percutaneous coronary intervention. Eur Heart J 2010;31:970–1.
183. Tokgoz HC, Tanboga IH, Can MM, Bezgin T, Akgun T, Turkyilmaz E, et al. Does platelet response
to clopidogrel and/or aspirin as assessed by multiplate analyser predict short and long-term
outcome following coronary stenting? Eur Heart J 2010;31:967.
184. Colic M, Calija B, Babic T, Sarenac D, Ljubic M, Spasojevic B, et al. Exaggerated platelet hypo
reactivity increases bleeding risk as measured by multiplate impedance aggregometry test after
coronary stenting. Eur Heart J 2010;31(Suppl. 1):204.
185. Catakoglu AB, Aytekin S, Celebi H, Sener M, Kurtoglu H, Demiroglu C, et al. The influence of
aspirin resistance on non-fatal coronary events following percutaneous coronary interventions.
Arch Med Sci 2009;5:531–8.
186. Sobol AB, Mochecka A, Selmaj K, Loba J. Is there a relationship between aspirin responsiveness
and clinical aspects of ischemic stroke? Adv Clin Exp Med 2009;18:473–9.
187. Modica A, Karlsson F, Mooe T. The impact of platelet function or C-reactive protein, on
cardiovascular events after an acute myocardial infarction. Thromb J 2009;7:12. http://dx.doi.org/
10.1186/1477-9560-7-12
188. Angiolillo D, Bernardo E, Capranzano P, Sabate M, Jimenez-Quevedo P, Ferreiro JL, et al.
Prognostic implications of high platelet reactivity as defined by multiple agonists in diabetes
mellitus patients on dual antiplatelet therapy. J Am Coll Cardiol 2009;53:A68.
189. Harrison P, Silver L, Segal H, Syed A, Mehta Z, Rothwell P. Long term prognostic value of aspirin
non-responsiveness and platelet reactivity after acute vascular events: a population-base cohort
study. J Thromb Haemost 2009;7(Suppl. 2):104.
190. Range G, Richard P, Chassaing S, Belle L, Thuaire C, Cazaux P, et al. Impact of low response to
aspirin and/or clopidogrel in 1001 patients undergoing coronary stenting: 1-month results of the
VERIFRENCHY registry. Eur Heart J 2009;30:858. http://dx.doi.org/10.1016/j.acvd.2014.03.004
191. Milicic D, Lovric D, Skoric B, Samardzic J, Gornik I, Narancic SK, et al. Effects of lower platelet
aspirin and clopidogrel response on long-term outcomes in patients with acute STEMI. Eur Heart J
2009;30(Suppl. 1):193. http://dx.doi.org/10.1016/j.ijcard.2011.09.055
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
252
192. Vaduganathan M, Guthikonda S, Nure B, Siqueiros-Garcia A, Mangalpally KR, Paranilam J, et al.
Point-of-care measurement of aspirin responsiveness predicts long-term clinical outcomes in patients
undergoing elective percutaneous coronary intervention. Am J Cardiol 2009;104(Suppl. 1):174D.
http://dx.doi.org/10.1016/j.amjcard.2009.08.501
193. Silver LE, Harrison P, Segal H, Syed A, Mehta Z, Rothwell PM. Long-term prognostic value of
aspirin non-responsiveness and platelet reactivity after acute vascular events: a population-based
prospective cohort study. Cerebrovasc Dis 2009;27(Suppl. 6):28.
194. Kim S, Lee DH, Lim HK, Kwon SU, Choi CG, Suh DC. Change of platelet reactivity to antiplatelet
therapy after stenting procedure for cerebral artery stenosis: Verifynow antiplatelet assay before
and after stenting. Neuroradiology 2009;51:S43.
195. Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G, et al. Incomplete inhibition
of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk.
Circulation 2008;118:1705–12. http://dx.doi.org/10.1161/CIRCULATIONAHA.108.768283
196. Kaminska M, Osada J, Dabrowska M, Kloczko J, Kramkowski K, Musial WJ. The assessment of
antiplatelet activity of aspirin among survivors of myocardial infarction treated with PCI in
six months observation – preliminary results. Pol Prz Kardiol 2007;9:335–41.
197. Gurbel PA, Bliden KP, Navickas I, Cohen E, Tantry US. Post-coronary intervention recurrent
ischemia in the presence of adequate platelet inhibition by dual antiplatelet therapy: What are
we overlooking? J Thromb Haemost 2007;5:2300–1. http://dx.doi.org/10.1111/j.1538-7836.
2007.02749.x
198. Stejskal D, Vaclavik J, Lacnak B, Proskova J. Aspirin resistance measured by cationic propyl gallate
platelet aggregometry and recurrent cardiovascular events during 4 years of follow-up. Eur J
Intern Med 2006;17:349–54. http://dx.doi.org/10.1016/j.ejim.2006.01.006
199. Sambu N, Radhakrishnan A, Dent H, Calver AL, Corbett S, Gray H, et al. Personalised antiplatelet
therapy in stent thrombosis: observations from the Clopidogrel Resistance in Stent Thrombosis
(CREST) registry. Heart 2012;98:706–11. http://dx.doi.org/10.1136/heartjnl-2011-301164
200. Lee DH, Kim HS, Kim SM, Kwon SU, Suh DC. Change of platelet reactivity to antiplatelet therapy
after stenting procedure for cerebral artery stenosis: VerifyNow antiplatelet assay before and after
stenting. Neurointervention 2012;7:23–6. http://dx.doi.org/10.5469/neuroint.2012.7.1.23
201. Feng XR, Liu ML, Liu F, Tian QP, Fan Y, Liu QZ. [Aspirin response and related factors in aged
patients.] Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih 2011;39:925–8.
202. Eskandarian R, Darabian M. Impact of aspirin resistance on one year’s prognosis in chronic stable
angina in Semnan – Iran. Atheroscler Suppl 2011;12:170. http://dx.doi.org/10.1016/S1567-5688
(11)70811-X
203. Verschuren JJ, Trompet S, Wessels JA, Guchelaar HJ, de Maat MP, Simoons ML, et al. A systematic
review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? Eur Heart J
2012;33:165–75. http://dx.doi.org/10.1093/eurheartj/ehr239
204. Dickinson KJ, Troxler M, Homer-Vanniasinkam S. The surgical application of point-of-care haemostasis
and platelet function testing. Br J Surg 2008;95:1317–30. http://dx.doi.org/10.1002/bjs.6359
205. El-Menyar A, Hussein H, Al Suwaidi J. Coronary stent thrombosis in patients with chronic renal
insufficiency. Angiology 2010;61:297–303. http://dx.doi.org/10.1177/0003319709344574
206. Velkovic J, Coulthard A. The drugs don’t work: low response to antiplatelet agents in patients
undergoing endovascular procedures. J Med Imaging Radiat Oncol 2009;53:A275.
DOI: 10.3310/hta19370 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 37
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
253
207. Crescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, De Gaetano G. Response
variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review.
Thromb Haemost 2008;99:14–26. http://dx.doi.org/10.1160/TH07-08-0530
208. Reny JL, de Moerloose P, Dauzat M, Fontana P. Use of the PFA-100 closure time to predict
cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis.
J Thromb Haemost 2008;6:444–50. http://dx.doi.org/10.1111/j.1538-7836.2008.02897.x
209. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin ‘resistance’ and risk of cardiovascular
morbidity: systematic review and meta-analysis. BMJ 2008;336:195–8. http://dx.doi.org/10.1136/
bmj.39430.529549.BE
210. Ferguson AD, Dokainish H, Lakkis N. Aspirin and clopidogrel response variability: review of the
published literature. Tex Heart Inst J 2008;35:313–20.
211. Sofi F, Marcucci R, Gori AM, Abbate R, Gensini GF. Residual platelet reactivity on aspirin therapy and
recurrent cardiovascular events – a meta-analysis. Int J Cardiol 2008;128:166–71. http://dx.doi.org/
10.1016/j.ijcard.2007.12.010
212. Musallam KM, Charafeddine K, Bitar A, Khoury M, Assaad S, Beresian J, et al. Resistance to
aspirin and clopidogrel therapy. Int J Lab Hematol 2011;33:1–18. http://dx.doi.org/10.1111/
j.1751-553X.2010.01268.x
213. Wong S, Appleberg M, Ward CM, Lewis DR. Aspirin resistance in cardiovascular disease: a review.
Eur J Vasc Endovasc Surg 2004;27:456–65. http://dx.doi.org/10.1016/j.ejvs.2003.12.025
214. Howard PA. Aspirin resistance. Ann Pharmacother 2002;36:1620–4. http://dx.doi.org/10.1345/
aph.1C013
215. Canivano PL, Garcia YC. [Resistance to aspirin: prevalence, mechanisms of action and association
with thromboembolic events. A narrative review.] Farm Hosp 2010;34:32–43. http://dx.doi.org/
10.1016/j.farma.2009.08.002
216. Pusch G, Feher G, Kotai K, Tibold A, Gasztonyi B, Feher A, et al. Aspirin resistance: focus on
clinical endpoints. J Cardiovasc Pharmacol 2008;52:475–84. http://dx.doi.org/10.1097/
FJC.0b013e31818eee5f
217. Snoep JD, Hovens MM, Eikenboom JC, Van Der Bom JG, Huisman MV. Association of laboratory-
defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review
and meta-analysis. Arch Intern Med 2007;167:1593–9. http://dx.doi.org/10.1001/archinte.167.
15.1593
218. Mansour K, Taher AT, Musallam KM, Alam S. Aspirin resistance. Adv Hematol 2009;2009:937352.
http://dx.doi.org/10.1155/2009/937352
219. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and
prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol
2001;88:230–5. http://dx.doi.org/10.1016/S0002-9149(01)01631-9
220. Andersen LA, Gormsen J. Platelet aggregation and fibrinolytic activity in transient cerebral ischemia.
Acta Neurol Scand 1976;55:76–82. http://dx.doi.org/10.1111/j.1600-0404.1977.tb05628.x
221. Fritsma GA, Ens GE, Alvord MA, Carroll AA, Jensen R. Monitoring the antiplatelet action of
aspirin. JAAPA 2001;14:57–8, 61–2.
222. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet
dysfunction. J Lab Clin Med 2001;138:152–63. http://dx.doi.org/10.1067/mlc.2001.117406
223. Favaloro EJ. Clinical application of the PFA-100. Curr Opin Hematol 2002;9:407–15.
http://dx.doi.org/10.1097/00062752-200209000-00004
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
254
224. Escolar G, Cases A, Vinas M, Pino M, Calls J, Cirera I, et al. Evaluation of acquired platelet
dysfunctions in uremic and cirrhotic patients using the platelet function analyser (PFA 100TM):
Influence of hematocrit elevation. Haematologica 1999;84:614–19.
225. Borna C, Lazarowski E, van Heusden C, Ohlin H, Erlinge D. Resistance to aspirin is increased by
ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J
2005;3:10. http://dx.doi.org/10.1186/1477-9560-3-10
226. Sathiropas P. Detection of small inhibitory effects on acetylsalicylic acid (ASA) by platelet
impedance aggregometry in whole blood. Thromb Res 1988;51:55–62. http://dx.doi.org/10.1016/
0049-3848(88)90282-4
227. Friend M, Vucenik I, Miller M. Platelet responsiveness to aspirin in patients with hyperlipidemia.
BMJ 2003;326:82–3. http://dx.doi.org/10.1136/bmj.326.7380.82
228. Korpanty A, Ravindra S, Yassin J, Frenkel EP. Sensitivity of whole blood aggregation, platelet rich
plasma, and platelet function analyzer in detection aspirin effect on platelet function. J Am Soc
Hematol 2002;100:11.
229. Korpanty A, Frenkel EP, Sarode R. An approach to the assessment of platelet function: comparison
of optical platelet rich and impedance whole blood aggregation methods. Thromb Hemost
2005;11:25–35. http://dx.doi.org/10.1177/107602960501100103
230. Ivandic B, Giannitis E, Schlick P, Staritz P, Katus H, Hohlfeld T. Determination of aspirin
responsiveness by use of whole blood platelet aggregometry. Clin Chem 2007;53:614–19.
http://dx.doi.org/10.1373/clinchem.2006.081059
231. Poston RS, White C, Gu J, Brown J, Gammie J, Pierson RN, et al. Aprotinin shows both hemostatic
and antithrombotic effects during off-pump coronary artery bypass grafting. Ann Thorac Surg
2006;81:104–10. http://dx.doi.org/10.1016/j.athoracsur.2005.05.085
232. Haude M, Hafner G, Jablonka A, Rupprecht HJ, Prellwitz W, Meyer J, et al. Guidance of
anticoagulation after intracoronary implantation of Palmaz-Schatz stents by monitoring
prothrombin and prothrombin fragment 1+ 2. Am Heart J 1995;130:228–38. http://dx.doi.org/
10.1016/0002-8703(95)90433-6
233. Grotemeyer KH. The platelet-reactivity-test – a useful ‘by-product’ of the blood-sampling
procedure? Thromb Res 1991;61:423–31. http://dx.doi.org/10.1016/0049-3848(91)90656-H
234. Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a
subpopulation of treated patients. Thromb Res 1991;63:587–93. http://dx.doi.org/10.1016/
0049-3848(91)90085-B
235. Zhang Y, Liang J, Zhou YJ, Yuan H, Zhang YZ, Dong L. [Study on the relationship between aspirin
resistance and incidence of myonecrosis after non-emergent percutaneous coronary intervention.]
Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih 2005;33:695–9.
236. Yilmaz MB, Balbay Y, Caldir V, Ayaz S, Guray Y, Guray U, et al. Late saphenous vein graft
occlusion in patients with coronary bypass: possible role of aspirin resistance. Thromb Res
2005;115:25–9. http://dx.doi.org/10.1016/j.thromres.2004.07.004
237. Valles J, Santos MT, Fuset MP, Moscardo A, Ruano M, Perez F, et al. Partial inhibition of platelet
thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment
elevation myocardial infarction. Am J Cardiol 2007;99:19–25. http://dx.doi.org/10.1016/
j.amjcard.2006.07.058
238. Malek LA, Spiewak M, Filipiak KJ, Grabowski M, Szpotanska M, Rosiak M, et al. Persistent platelet
activation is related to very early cardiovascular events in patients with acute coronary syndromes.
Kardiol Pol 2007;65:40–5.
DOI: 10.3310/hta19370 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 37
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
255
239. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, et al. Aspirin and clopidogrel drug
response in patients undergoing percutaneous coronary intervention: the role of dual drug
resistance. J Am Coll Cardiol 2006;47:27–33. http://dx.doi.org/10.1016/j.jacc.2005.08.058
240. Hobikoglu GF, Norgaz T, Aksu H, Ozer O, Erturk M, Nurkalem Z, et al. High frequency of aspirin
resistance in patients with acute coronary syndrome. Tohoku J Exp Med 2005;207:59–64.
http://dx.doi.org/10.1620/tjem.207.59
241. Faraday N, Braunstein JB, Heldman AW, Bolton ED, Chiles KA, Gerstenblith G, et al. Prospective
evaluation of the relationship between platelet–leukocyte conjugate formation and recurrent
myocardial ischemia in patients with acute coronary syndromes. Platelets 2004;15:9–14.
http://dx.doi.org/10.1080/09537100310001644006
242. Chen W-H, Lee P-Y, Ng W, Tse H-F, Lau C-P. Aspirin resistance is associated with a high incidence
of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel
pretreatment. J Am Coll Cardiol 2004;43:1122–6. http://dx.doi.org/10.1016/j.jacc.2003.12.034
243. Chen W-H, Lee P-Y, Ng W, Kwok JYY, Cheng X, Lee SWL, et al. Relation of aspirin resistance to
coronary flow reserve in patients undergoing elective percutaneous coronary Intervention.
Am J Cardiol 2005;96:760–3. http://dx.doi.org/10.1016/j.amjcard.2005.04.056
244. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100
in patients with coronary artery disease. Thromb Res 2002;108:37–42. http://dx.doi.org/10.1016/
S0049-3848(02)00405-X
245. Atiemo AD, Ng’Alla LS, Vaidya D, Williams MS. Abnormal PFA-100 closure time is associated with
increased platelet aggregation in patients presenting with chest pain. J Thromb Thrombolysis
2008;25:173–8. http://dx.doi.org/10.1007/s11239-007-0045-5
246. Berrouschot J, Schwetlick B, von Twickel G, Fischer C, Uhlemann H, Siegemund T, et al. Aspirin
resistance in secondary stroke prevention. Acta Neurol Scand 2006;113:31–5. http://dx.doi.org/
10.1111/j.1600-0404.2005.00419.x
247. Poston RS, Gu J, Brown JM, Gammie JS, White C, Nie L, et al. Endothelial injury and acquired
aspirin resistance as promoters of regional thrombin formation and early vein graft failure after
coronary artery bypass grafting. J Thorac Cardiovasc Surg 2006;131:122–30. http://dx.doi.org/
10.1016/j.jtcvs.2005.08.058
248. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in
patients with recurrent cerebral ischemic attacks. J Neurol 2003;250:63–6. http://dx.doi.org/
10.1007/s00415-003-0954-y
249. McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Lawrie AS, Purdy G, et al. Assessment of the
antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic
stroke and TIA. Platelets 2005;16:269–80. http://dx.doi.org/10.1080/09537100400020567
250. Poulsen TS, Jørgensen B, Korsholm L, Licht PB, Haghfelt T, Mickley H. Prevalence of aspirin
resistance in patients with an evolving acute myocardial infarction. Thromb Res 2007;119:555–62.
http://dx.doi.org/10.1016/j.thromres.2006.04.005
251. Pamukcu B, Oflaz H, Nisanci Y. The role of platelet glycoprotein IIIa polymorphism in the high
prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis. Am Heart J
2005;149:675–80. http://dx.doi.org/10.1016/j.ahj.2004.10.007
252. Linden MD, Furman MI, Frelinger AL III, Fox ML, Barnard MR, Li Y, et al. Indices of platelet
activation and the stability of coronary artery disease. J Thromb Haemost 2007;5:761–5.
http://dx.doi.org/10.1111/j.1538-7836.2007.02462.x
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
256
253. Gulmez O, Yildirir A, Kaynar G, Konas D, Aydinalp A, Ertan C, et al. Effects of persistent platelet
reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective
percutaneous coronary interventions. J Thromb Thrombolysis 2007;25:239–46. http://dx.doi.org/
10.1007/s11239-007-0067-z
254. Cornelissen J, Kirtland S, Lim E, Goddard M, Bellm S, Sheridan K, et al. Biological efficacy of low
against medium dose aspirin regimen after coronary surgery: analysis of platelet function.
Thromb Haemost 2006;95:476–82.
255. Cheng X, Chen WH, Lee PY, Ng W, Kwok YY, Lau CP. Prevalence, profile, predictors, and natural
history of aspirin resistance measured by the Ultegra Rapid Platelet Function Assay-ASA in
patients with coronary heart disease. Circulation 2005;111:E339.
256. Geisler T, Kapp M, Gohring-Frischholz K, Daub K, Dosch C, Bigalke B, et al. Residual platelet
activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute
coronary syndromes compared with stable coronary artery disease. Heart 2008;94:743–7.
http://dx.doi.org/10.1136/hrt.2006.100891
257. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response
variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation
2003;107:2908–13. http://dx.doi.org/10.1161/01.CIR.0000072771.11429.83
258. ClinicalTrials.gov. Aspirin Resistance and Prognosis of Patients With Critical Limb Ischaemia.
URL: http://ClinicalTrials.gov/show/NCT01104441 (accessed 2 April 2012).
259. ClinicalTrials.gov. Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following
Coronary Artery Bypass Grafting. URL: http://ClinicalTrials.gov/show/NCT01159639
(accessed 2 April 2012).
260. ClinicalTrials.gov. Aspirin Responsiveness and Outcome in Coronary Artery Bypass Graft (CABG)
Surgery. URL: http://ClinicalTrials.gov/show/NCT01174862 (accessed 2 April 2012).
261. ClinicalTrials.gov. Resistance to Aspirin and/or Clopidogrel Among Patients With PAD.
URL: http://ClinicalTrials.gov/show/NCT00262561 (accessed 2 April 2012).
262. ClinicalTrials.gov. The Study on Profile and Genetic Factors of Aspirin Resistance (ProGEAR Study).
URL: http://clinicaltrials.gov/ct2/show/study/NCT00250380 (accessed 2 April 2012).
263. ClinicalTrials.gov. Evaluation and Comparison of Several Point-of-Care Platelet Function Tests in
Predicting Clinical Outcomes in Clopidogrel Pre-Treated Patients Undergoing Elective PCI.
URL: http://ClinicalTrials.gov/show/NCT00352014 (accessed 2 April 2012).
264. ClinicalTrials.gov. Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery
Bypass Grafting: The PAPA CABG Study. URL: https://clinicaltrials.gov/show/NCT00330772
(accessed 2 April 2012).
265. Reny JL, Berdague P, Poncet A, Barazer I, Nolli S, Fabbro-Peray P, et al. Antiplatelet drug response
status does not predict recurrent ischemic events in stable cardiovascular patients: results of the ADRIE
study. Circulation 2012;125:3201–10. http://dx.doi.org/10.1161/CIRCULATIONAHA.111.085464
266. Collet J-P, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, et al. Bedside monitoring to adjust
antiplatelet therapy for coronary stenting. New Engl J Med 2012;367:2100–9. http://dx.doi.org/
10.1056/NEJMoa1209979
267. Yamane K, Taniguchi R, Watanabe S, Kawato M, Shirakawa R, Higashi T, et al. Impact of platelet
reactivity on long-term clinical outcomes and bleeding events in Japanese patients receiving
antiplatelet therapy with aspirin. J Atheroscler Thromb 2012;19:1142–53. http://dx.doi.org/
10.5551/jat.14100
DOI: 10.3310/hta19370 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 37
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
257
268. Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of
methodological quality of economic evaluations: Consensus on Health Economic Criteria.
Int J Technol Assess Health Care 2005;21:240–5.
269. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic
modelling in health technology assessment: a review and consolidation of quality assessment.
Pharmacoeconomics 2006;24:355–71. http://dx.doi.org/10.2165/00019053-200624040-00006
270. Bronnum-Hansen H, Davidsen M, Thorvaldsen P. Long-term survival and causes of death after
stroke. Stroke 2001;32:2131–6. http://dx.doi.org/10.1161/hs0901.094253
271. Bronnum-Hansen H, Jorgensen T, Davidsen M, Madsen M, Osler M, Gerdes LU, et al. Survival
and cause of death after myocardial infarction: the Danish MONICA study. J Clin Epidemiol
2001;54:1244–50. http://dx.doi.org/10.1016/S0895-4356(01)00405-X
272. Joint Formulary Committee. British National Formulary. 65 edn. London: BMJ Group and
Pharmaceutical Press; 2013.
273. Department of Health. NHS Reference Costs: Financial Year 2011 to 2012. London: Department
of Health; 2012.
274. Robinson M, Palmer S, Sculpher MJ, Philips Z, Ginnelly L, Bowens A, et al. Cost-effectiveness of
alternative strategies for the initial medical management of non-ST elevation acute coronary
syndrome: systematic review and decision analytic modelling. Health Technol Assess 2005;9(27).
http://dx.doi.org/10.3310/hta9270
275. Youman P, Wilson K, Harraf F, Kalra L. The economic burden of stroke in the United Kingdom.
Pharmacoeconomics 2003;21(Suppl. 1):43–50. http://dx.doi.org/10.2165/00019053-
200321001-00005
276. Greenhalgh J, Bagust A, Boland A, Martin SC, Oyee J, Blundell M, et al. Clopidogrel and
modified-release dipyridamole for the prevention of occlusive vascular events (review of
Technology Appraisal No. 90): a systematic review and economic analysis. Health Technol Assess
2011;15(31). http://dx.doi.org/10.3310/hta15310
277. Cooper A, Nherera L, Calvert N, O’Flynn N, Turnbull N, Robson J, et al. Clinical Guidelines and
Evidence Review for Lipid Modification: Cardiovascular Risk Assessment and the Primary and
Secondary Prevention of Cardiovascular Disease. London: National Collaborating Centre for
Primary Care and Royal College of General Practitioners; 2008.
278. Ward S, Lloyd JM, Pandor A, Holmes M, Ara R, Ryan A, et al. A systematic review and economic
evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11(14).
http://dx.doi.org/10.3310/hta11140
279. Office for National Statistics. Statistical Bulletin: Deaths Registered in England and Wales, 2012.
Newport: Office for National Statistics; 2012.
280. Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D. Centre for Health Economics
discussion paper 172. York: Centre for Health Economics, University of York; 1999.
281. National Institute for Health and Care Excellence (NICE). The Guidelines Manual. London:
NICE; 2012.
282. Lordkipanidzé M, Diodati JG, Schampaert E, Palisaitis DA, Pharand C. Prevalence of
unresponsiveness to aspirin and/or clopidogrel in patients with stable coronary heart disease.
Am J Cardiol 2009;104:1189–93. http://dx.doi.org/10.1016/j.amjcard.2009.06.025
283. Fontana P, Nolli S, Reber G, de Moerloose P. Biological effects of aspirin and clopidogrel in a
randomized cross-over study in 96 healthy volunteers. J Thromb Haemost 2006;4:813–19.
http://dx.doi.org/10.1111/j.1538-7836.2006.01867.x
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
258
284. Cuisset T, Frere C, Quilici J, Morange PE, Camoin L, Bali L, et al. Relationship between aspirin
and clopidogrel responses in acute coronary syndrome and clinical predictors of non response.
Thromb Res 2009;123:597–603. http://dx.doi.org/10.1016/j.thromres.2008.04.003
285. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression:
a bad idea. Stat Med 2006;25:127–41. http://dx.doi.org/10.1002/sim.2331
286. Riley RD, Lambert PC, Abo G. Meta-analysis of individual participant data: rationale, conduct, and
reporting. BMJ 2010;340:410–14. http://dx.doi.org/10.1136/bmj.c221
287. Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C. Traditional reviews,
meta-analyses and pooled analyses in epidemiology. Int J Epidemiol 1999;28:1–9. http://dx.doi.org/
10.1093/ije/28.1.1
288. Altman DG, Trivella M, Pezzella F, Harris AL, Pastorino U. Systematic review of multiple studies of
prognosis: the feasibility of obtaining individual patient data. In Auget J-L, Balakrishnan N,
Mesbah M, Molenberghs G, editors. Advances in Statistical Methods for the Health Sciences.
Boston, MA: Birkhauser; 2006. pp. 3–18.
289. Kyzas PA, Loizou KT, Ioannidis JPA. Selective reporting biases in cancer prognostic factor studies.
J Natl Cancer Inst 2005;97:1043–55. http://dx.doi.org/10.1093/jnci/dji184
290. Hemingway H, Riley RD, Altman DG. Ten steps towards improving prognosis research. BMJ
2009;339:b4184. http://dx.doi.org/10.1136/bmj.b4184
291. Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D, et al. Reporting of prognostic
markers: current problems and development of guidelines for evidence-based practice in the
future. Br J Cancer 2003;88:1191–8. http://dx.doi.org/10.1038/sj.bjc.6600886
292. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using ‘optimal’ cutpoints in the
evaluation of prognostic factors. J Natl Cancer Inst 1994;86:829–35. http://dx.doi.org/10.1093/
jnci/86.11.829
293. Riley RD, Hayden JA, Steyerberg EW, Moons KG, Abrams K, Kyzas PA, et al. Prognosis research
strategy (PROGRESS) 2: prognostic factor research. PLOS Med 2013;10:e1001380. http://dx.doi.org/
10.1371/journal.pmed.1001380
294. Hemingway H, Croft P, Perel P, Hayden JA, Abrams K, Timmis A, et al. Prognosis research strategy
(PROGRESS) 1: a framework for researching clinical outcomes. BMJ 2013;346:e5595.
http://dx.doi.org/10.1136/bmj.e5595
295. Steyerberg EW, Moons KG, van der Windt DA, Hayden JA, Perel P, Schroter S, et al. Prognosis
research strategy (PROGRESS) 3: prognostic model research. PLOS Med 2013;10:e1001381.
http://dx.doi.org/10.1371/journal.pmed.1001381
296. Hingorani AD, Windt DA, Riley RD, Abrams K, Moons KG, Steyerberg EW, et al. Prognosis research
strategy (PROGRESS) 4: stratified medicine research. BMJ 2013;346:e5793. http://dx.doi.org/
10.1136/bmj.e5793
297. Rifai N, Altman DG, Bossuyt PM. Reporting bias in diagnostic and prognostic studies: time for
action. Clin Chem 2008;54:1101–3. http://dx.doi.org/10.1373/clinchem.2008.108993
298. Simon R, Sobin LH. Evaluating prognostic factor studies. In TNM Online. John Wiley & Sons; 2003.
URL: http://onlinelibrary.wiley.com/doi/10.1002/0471463736.tnmp04/abstract;
jsessionid=360A7A5DF057D84D94606C0A801173E1.f02t03 (accessed 24 March 2015).
299. Riley RD, Burchill SA, Abrams KR, Heney D, Lambert PC, Jones DR, et al. A systematic review
and evaluation of the use of tumour markers in paediatric oncology: Ewing’s sarcoma and
neuroblastoma. Health Technol Assess 2003;7(5). http://dx.doi.org/10.3310/hta7050
DOI: 10.3310/hta19370 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 37
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
259
300. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Almost all articles on cancer prognostic markers report
statistically significant results. Eur J Cancer 2007;43:2559–79. http://dx.doi.org/10.1016/
j.ejca.2007.08.030
301. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ 2001;323:224–8.
http://dx.doi.org/10.1136/bmj.323.7306.224
302. Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, et al. P53 as a prognostic
marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005;6:678–86.
http://dx.doi.org/10.1016/S1470-2045(05)70315-6
303. Hemingway H, Philipson P, Chen R, Fitzpatrick NK, Damant J, Shipley M. Evaluating the quality of
research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of
C-reactive protein in stable coronary artery disease. PLOS Med 2010;7:e1000286. http://dx.doi.
org/10.1371/journal.pmed.1000286
304. Sauerbrei W. Prognostic factors. Confusion caused by bad quality design, analysis and reporting
of many studies. Adv Otorhinolaryngol 2005;62:184–200.
305. Altman DG, Lyman GH. Methodological challenges in the evaluation of prognostic factors in
breast cancer. Breast Cancer Res Treat 1998;52:289–303. http://dx.doi.org/10.1023/
A:1006193704132
306. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer
1994;69:979–85. http://dx.doi.org/10.1038/bjc.1994.192
307. Debray TP, Moons KG, Ahmed I, Koffijberg H, Riley RD. A framework for developing,
implementing, and evaluating clinical prediction models in an individual participant data
meta-analysis. Stat Med 2013;32:3158–80. http://dx.doi.org/10.1002/sim.5732
308. Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH. Bivariate analysis
of sensitivity and specificity produces informative summary measures in diagnostic reviews.
J Clin Epidemiol 2005;58:982–90. http://dx.doi.org/10.1016/j.jclinepi.2005.02.022
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
260
Appendix 1 Search strategies: prognostic/
diagnostic utility review
Database: MEDLINE (Ovid) (1946 to April week 3, 2012)
1. ((ASA or aspirin or acetylsalicylic or anti platelet or antiplatelet or anti-platelet) adj2 (respons$ or
non-respons$ or respond$ or non-respond$ or resistance or resist$)).mp
2. (platelet adj (response or respond$ or reactivity)).mp.
3. 1 or 2
4. exp Aspirin/
5. exp Drug Resistance/
6. 4 and 5
7. 3 or 6
8. (platelet function adj (analys$ or analyz$)).mp.
9. (platelet function adj (assay$ or test$)).mp.
10. Platelet Function Tests/
11. PFA-100.mp.
12. PlateletWorks.mp.
13. Platelet Mapping.mp.
14. Impact Cone.mp.
15. platelet analyser$.mp.
16. platelet analyzer$.mp.
17. multiplate.mp.
18. aggregometry.mp.
19. LTA.mp.
20. AA-induced LTA.mp.
21. lumiaggregometry.mp.
22. WBA.mp.
23. ULTEGRA assay.mp.
24. Impact-R.mp.
25. TRAP-6.mp.
26. TEG.mp.
27. s-TEG.mp.
28. thromboelastometry.mp.
29. ROTEM.mp.
30. VerifyNow.mp.
31. Verify-Now.mp.
32. VN-RPFA.mp.
33. VASP.mp.
34. VASP-P.mp.
35. platelet reactivity index.mp.
36. vasodilator-stimulated phosphoprotein phosphorylation assay$.mp.
37. T-Guide.tw.
38. T Guide.ti,ab.
39. xylum clot signature analyser.mp.
40. xylum clot signature analyzer.mp.
41. ASA test$.mp.
42. ASA assay$.mp.
43. AA-induced LTA.mp.
44. exp Platelet Count/ or platelet counting.mp.
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45. thrombelastography.mp. or Thrombelastography/
46. thrombotic status analyser$.mp.
47. thrombotic status analyzer$.mp.
48. or/8-47
49. exp Cardiovascular Diseases)
50. exp Cerebrovascular Disorders/
51. exp Diabetes Mellitus/
52. or/49-51
53. 48 and 52
54. (predict$ or prognos$).mp.
55. 48 and 54
56. 7 or 53
57. 7 or 55
58. 56 or 57
59. exp animals/ not humans/
60. 58 not 59
Database: MEDLINE (Ovid) In-Process & Other Non-Indexed
Citations (25 April 2012)
1. ((ASA or aspirin or acetylsalicylic or anti platelet or antiplatelet or anti-platelet) adj2 (respons$ or
non-respons$ or respond$ or non-respond$ or resistance or resist$)).mp.
2. (platelet adj (response or respond$ or reactivity)).mp.
3. 1 or 2
4. (platelet function adj (analys$ or analyz$)).mp.
5. (platelet function adj (assay$ or test$)).mp.
6. PFA-100.mp.
7. PlateletWorks.mp.
8. Platelet Mapping.mp.
9. Impact Cone.mp.
10. platelet analyser$.mp.
11. platelet analyzer$.mp.
12. multiplate.mp.
13. aggregometry.mp.
14. LTA.mp.
15. AA-induced LTA.mp.
16. lumiaggregometry.mp.
17. WBA.mp.
18. ULTEGRA assay.mp.
19. Impact-R.mp.
20. TRAP-6.mp.
21. TEG.mp.
22. s-TEG.mp.
23. thromboelastometry.mp.
24. ROTEM.mp.
25. VerifyNow.mp.
26. Verify-Now.mp.
27. VN-RPFA.mp.
28. VASP.mp.
29. VASP-P.mp.
30. platelet reactivity index.mp.
31. vasodilator-stimulated phosphoprotein phosphorylation assay$.mp.
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32. T-Guide.tw.
33. T Guide.ti,ab.
34. xylum clot signature analyser.mp.
35. xylum clot signature analyzer.mp.
36. ASA test$.mp.
37. ASA assay$.mp.
38. AA-induced LTA.mp.
39. exp Platelet Count/ or platelet counting.mp.
40. thrombelastography.mp. or Thrombelastography/
41. thrombotic status analyser$.mp.
42. thrombotic status analyzer$.mp.
43. or/4-42
44. (cardiovascular or cerebrovascular or diabetes).mp.
45. 43 and 44
46. (predict$ or prognos$).mp.
47. 43 and 46
48. 3 or 45
49. 3 or 47
50. 48 or 49
Database: EMBASE (Ovid) (1980 to week 16, 2012)
1. ((ASA or aspirin or acetylsalicylic or anti platelet or antiplatelet or anti-platelet) adj2 (respons$ or
non-respons$ or respond$ or non-respond$ or resistance or resist$)).mp
2. (platelet adj (response or respond$ or reactivity)).mp.
3. 1 or 2
4. exp acetylsalicylic acid/
5. exp drug resistance/
6. 4 and 5
7. 3 or 6
8. (platelet function adj (analys$ or analyz$)).mp.
9. (platelet function adj (assay$ or test$)).mp.
10. PFA-100.mp.
11. PlateletWorks.mp.
12. Platelet Mapping.mp.
13. Impact Cone.mp.
14. platelet analyser$.mp.
15. platelet analyzer$.mp.
16. multiplate.mp.
17. aggregometry.mp.
18. LTA.mp.
19. AA-induced LTA.mp.
20. lumiaggregometry.mp.
21. WBA.mp.
22. ULTEGRA assay.mp.
23. Impact-R.mp.
24. TRAP-6.mp.
25. TEG.mp.
26. s-TEG.mp.
27. thromboelastometry.mp.
28. ROTEM.mp.
29. VerifyNow.mp.
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30. Verify-Now.mp.
31. VN-RPFA.mp.
32. VASP.mp.
33. VASP-P.mp.
34. platelet reactivity index.mp.
35. vasodilator-stimulated phosphoprotein phosphorylation assay$.mp.
36. T Guide.mp.
37. T-Guide.mp.
38. xylum clot signature analy$.mp.
39. ASA tests$.mp.
40. ASA assay$.mp.
41. AA-induced LTA.mp.
42. platelet counting.mp.
43. thrombelastography.mp. or exp thromboelastography/
44. thrombotic status analy$.mp.
45. or/8-44
46. exp cardiovascular disease/
47. exp cerebrovascular disease/
48. exp diabetes mellitus/
49. or/46-48
50. 45 and 49
51. (predict$ or prognos$).mp.
52. 45 and 51
53. 7 or 50
54. 7 or 52
55. 53 or 54
56. exp animal/ not human/
57. 55 not 56
Database: The Cochrane Library (Wiley) (Cochrane Central
Register of Controlled Trials 2012, issue 4 of 12)
#1 (ASA or aspirin or acetylsalicylic or anti next platelet or antiplatelet) near/2 (respon* or non next
respon* or resist*)
#2 (platelet) near/1 (response or respond* or reactivity)
#3 (#1 OR #2)
#4 MeSH descriptor Aspirin explode all trees
#5 MeSH descriptor Drug Resistance explode all trees
#6 (#4 AND #5)
#7 (#3 OR #6)
#8 (platelet function) near/1 (analys* or analyz*)
#9 (platelet function) near/1 (assay* or test*)
#10 PFA-100
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#11 PlateletWorks
#12 Platelet next Mapping
#13 Cone
#14 platelet next analy*
#15 multiplate
#16 aggregometry
#17 LTA
#18 lumiaggregometry
#19 WBA
#20 ULTEGRA
#21 Impact-R
#22 TRAP-6
#23 TEG
#24 thromboelastometry
#25 ROTEM
#26 VerifyNow
#27 Verify-Now
#28 VN-RPFA
#29 VASP
#30 VASP-P
#31 platelet next reactivity next index
#32 vasodilator next stimulated next phosphoprotein
#33 T next Guide
#34 xylum next clot
#35 (ASA) next (test* or assay*)
#36 AA next induced
#37 platelet next counting
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#38 thromboelastography
#39 thrombotic next status next analy*
#40 (#8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR
#20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31
OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39)
#41 MeSH descriptor Cardiovascular Diseases explode all trees
#42 MeSH descriptor Cerebrovascular Disorders explode all trees
#43 MeSH descriptor Diabetes Mellitus explode all trees
#44 (#41 OR #42 OR #43)
#45 (#40 AND #44)
#46 predict* or prognos*
#47 (#40 AND #46)
#48 (#7 OR #45)
#49 (#7 OR #47)
#50 (#48 OR #49)
Conference proceedings searches
Database: Science Citation Index (Web of Knowledge) (searched 1 May 2012)
Title= (aspirin resistance)
Refined by: Web of Science Categories=( PERIPHERAL VASCULAR DISEASE OR CARDIAC
CARDIOVASCULAR SYSTEMS ) AND Document Type=( MEETING ABSTRACT )
Timespan=All Years. Databases=SCI-EXPANDED.
Lemmatization=On
Title=(platelet function test*)
Refined by: Web of Science Categories=( PERIPHERAL VASCULAR DISEASE OR CARDIAC
CARDIOVASCULAR SYSTEMS ) AND Document Type=( MEETING ABSTRACT )
Timespan=All Years. Databases=SCI-EXPANDED.
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Database: Conference Proceedings Citation Index (Web of Knowledge)
(searched 1 May 2012)
Title=(aspirin resistance)
Refined by: Web of Science Categories=( CARDIAC CARDIOVASCULAR SYSTEMS OR PERIPHERAL
VASCULAR DISEASE ) AND Document Type=( MEETING ABSTRACT OR PROCEEDINGS PAPER )
Timespan=All Years. Databases=CPCI-S.
Title=(platelet function test*)
Refined by: Web of Science Categories=( CARDIAC CARDIOVASCULAR SYSTEMS OR PERIPHERAL
VASCULAR DISEASE ) AND Document Type=( MEETING ABSTRACT OR PROCEEDINGS PAPER )
Timespan=All Years. Databases=CPCI-S.
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Appendix 2 Search strategies for economic
studies
Database: MEDLINE (Ovid) (1946 to April week 4, 2012)
1. ((ASA or aspirin or acetylsalicylic or anti platelet or antiplatelet or anti-platelet) adj2 (respons$ or
non-respons$ or respond$ or non-respond$ or resistance or resist$)).mp.
2. (platelet adj (response or respond$ or reactivity)).mp.
3. 1 or 2
4. exp Aspirin/
5. exp Drug Resistance/
6. 4 and 5
7. 3 or 6
8. (platelet function adj (analys$ or analyz$)).mp.
9. (platelet function adj (assay$ or test$)).mp.
10. Platelet Function Tests/
11. PFA-100.mp.
12. PlateletWorks.mp.
13. Platelet Mapping.mp.
14. Impact Cone.mp.
15. platelet analyser$.mp.
16. platelet analyzer$.mp.
17. multiplate.mp.
18. aggregometry.mp.
19. LTA.mp.
20. AA-induced LTA.mp.
21. lumiaggregometry.mp.
22. WBA.mp.
23. ULTEGRA assay.mp.
24. Impact-R.mp.
25. TRAP-6.mp.
26. TEG.mp.
27. s-TEG.mp.
28. thromboelastometry.mp.
29. ROTEM.mp.
30. VerifyNow.mp.
31. Verify-Now.mp.
32. VN-RPFA.mp.
33. VASP.mp.
34. VASP-P.mp.
35. platelet reactivity index.mp.
36. vasodilator-stimulated phosphoprotein phosphorylation assay$.mp.
37. T-Guide.tw.
38. T Guide.ti,ab.
39. xylum clot signature analyser.mp.
40. xylum clot signature analyzer.mp.
41. ASA test$.mp.
42. ASA assay$.mp.
43. AA-induced LTA.mp.
44. exp Platelet Count/ or platelet counting.mp.
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45. thrombelastography.mp. or Thrombelastography/
46. thrombotic status analyser$.mp.
47. thrombotic status analyzer$.mp.
48. or/8-47
49. exp Cardiovascular Diseases/
50. exp Cerebrovascular Disorders/
51. exp Diabetes Mellitus/
52. or/49-51
53. 48 and 52
54. (predict$ or prognos$).mp.
55. 48 and 54
56. 7 or 53
57. 7 or 55
58. 56 or 57
59. economics/
60. exp “costs and cost analysis”/
61. cost of illness/
62. exp health care costs/
63. economic value of life/
64. exp economics medical/
65. exp economics hospital/
66. economics pharmaceutical/
67. exp "fees and charges"/
68. (econom$ or cost or costs or costly or costing or price or pricing or pharmacoeconomic$).tw.
69. (expenditure$ not energy).tw.
70. (value adj1 money).tw.
71. budget$.tw.
72. decision support techniques/
73. markov.mp.
74. exp models economic/
75. decision analysis.mp.
76. cost benefit analysis/
77. or/59-76
78. 58 and 77
Database: EMBASE (Ovid) (1980 to week 17, 2012)
1. ((ASA or aspirin or acetylsalicylic or anti platelet or antiplatelet or anti-platelet) adj2 (respons$ or
non-respons$ or respond$ or non-respond$ or resistance or resist$)).mp.
2. (platelet adj (response or respond$ or reactivity)).mp.
3. 1 or 2
4. exp acetylsalicylic acid/
5. exp drug resistance/
6. 4 and 5
7. 3 or 6
8. (platelet function adj (analys$ or analyz$)).mp.
9. (platelet function adj (assay$ or test$)).mp.
10. PFA-100.mp.
11. PlateletWorks.mp.
12. Platelet Mapping.mp.
13. Impact Cone.mp.
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14. platelet analyser$.mp.
15. platelet analyzer$.mp.
16. multiplate.mp.
17. aggregometry.mp.
18. LTA.mp.
19. AA-induced LTA.mp.
20. lumiaggregometry.mp.
21. WBA.mp.
22. ULTEGRA assay.mp.
23. Impact-R.mp.
24. TRAP-6.mp.
25. TEG.mp.
26. s-TEG.mp.
27. thromboelastometry.mp.
28. ROTEM.mp.
29. VerifyNow.mp.
30. Verify-Now.mp.
31. VN-RPFA.mp.
32. VASP.mp.
33. VASP-P.mp.
34. platelet reactivity index.mp.
35. vasodilator-stimulated phosphoprotein phosphorylation assay$.mp.
36. T Guide.mp.
37. T Guide.mp.
38. xylum clot signature analy$.mp.
39. ASA tests$.mp.
40. ASA assay$.mp.
41. AA-induced LTA.mp.
42. platelet counting.mp.
43. thrombelastography.mp. or exp thromboelastography/
44. thrombotic status analy$.mp.
45. or/8-44
46. exp cardiovascular disease/
47. exp cerebrovascular disease/
48. exp diabetes mellitus/
49. or/46-48
50. 45 and 49
51. (predict$ or prognos$).mp
52. 45 and 51
53. 7 or 50
54. 7 or 52
55. 53 or 54
56. cost benefit analysis/
57. cost effectiveness analysis/
58. cost minimization analysis/
59. cost utility analysis/
60. economic evaluation/
61. (cost or costs or costed or costly or costing).tw.
62. (economic$ or pharmacoeconomic$ or price$ or pricing).tw.
63. (technology adj assessment$).tw.
64. decision support.mp.
65. markov.mp.
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66. exp statistical model/
67. decision analysis.mp.
68. exp “cost benefit analysis”/
69. or/56-68
70. 55 and 69
Database: The Cochrane Library (Wiley) (NHS Economic
Evaluation Database) (2012, issue 2 of 4)
(Search date 4 May 2012.)
#1 (ASA or aspirin or acetylsalicylic or anti next platelet or antiplatelet) near/2 (respon* or non next
respon* or resist*)
#2 (platelet) near/1 (response or respond* or reactivity)
#3 (#1 OR #2)
#4 MeSH descriptor Aspirin explode all trees
#5 MeSH descriptor Drug Resistance explode all trees
#6 (#4 AND #5)
#7 (#3 OR #6)
#8 (platelet function) near/1 (analys* or analyz*)
#9 (platelet function) near/1 (assay* or test*)
#10 PFA-100
#11 PlateletWorks
#12 Platelet next Mapping
#13 Cone
#14 platelet next analy*
#15 multiplate
#16 aggregometry
#17 LTA
#18 lumiaggregometry
#19 WBA
#20 ULTEGRA
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#21 Impact-R
#22 TRAP-6
#23 TEG
#24 thromboelastometry
#25 ROTEM
#26 VerifyNow
#27 Verify-Now
#28 VN-RPFA
#29 VASP
#30 VASP-P
#31 platelet next reactivity next index
#32 vasodilator next stimulated next phosphoprotein
#33 T next Guide
#34 xylum next clot
#35 (ASA) next (test* or assay*)
#36 AA next induced
#37 platelet next counting
#38 thromboelastography
#39 thrombotic next status next analy*
#40 (#8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR
#20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR
#32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39)
#41 MeSH descriptor Cardiovascular Diseases explode all trees
#42 MeSH descriptor Cerebrovascular Disorders explode all trees
#43 MeSH descriptor Diabetes Mellitus explode all trees
#44 (#41 OR #42 OR #43)
#45 (#40 AND #44)
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#46 predict* or prognos*
#47 (#40 AND #46)
#48 (#7 OR #45)
#49 (#7 OR #47)
#50 (#48 OR #49)
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
274
Appendix 3 Sensitivities and specificities
As outlined in Chapter 4, Diagnostic/predictive accuracy, there are limitations with regard to assessmentof the diagnostic utility of PFTs in the context of prediction of future adverse clinical outcomes in
aspirin-treated patients.
Sensitivities and specificities were rarely reported by studies included in this report. Where data were
available to calculate these metrics, they were extracted. In both cases the reference standard for
calculations was the occurrence, or not, of a named clinical outcome. The presence of these data is
mentioned where relevant in the main results section of this report (see Chapter 5). As studies frequently
reported more than one clinical outcome, there was the possibility of using multiple reference standards.
In such cases, sensitivities and specificities are presented for each outcome. It should be noted that the
occurrence of a clinical outcome is not necessarily indicative of a poor response to aspirin therapy, as the
outcome might also occur by chance or as a result of other factors, such as poor adherence to therapy.
This appendix reports a speculative analysis of diagnostic utility for each group of PFTs in patients receiving
aspirin as a monotherapy at the time of platelet function testing for each clinical outcome. Brief methods
are outlined below prior to presentation of the results.
Methods
The diagnostic/predictive accuracy of each test relates to the absolute scale and summarises its ability to
accurately classify which patients go on to experience clinically important outcomes. For test results classed
as ‘positive’ or ‘negative’ (or ‘high’ or ‘low’) and linked to a binary outcome at a particular time, the data
required to complete a 2 × 2 table were sought (Table 84).
When available, the 2 × 2 table allowed estimation of the sensitivity [a/(a+ c)] and specificity [b/(b+ d)] of
the test, with CIs, and (for cohort studies) the prevalence of the outcome (a+ c)/(b+ d). Sensitivity is
defined as the probability of correctly classifying those patients who ultimately experience an event as test
positive, and specificity as the probability of correctly classifying those who do not go on to experience an
event as test negative. If studies provided a 2 × 2 table with one or both groups having a zero cell, then a
continuity correction of 0.5 was added to all cells in order to work out the variance and CI for sensitivity
and specificity.308 CIs were derived on the logit scale, and then transformed back to the original sensitivity
and specificity scale.
Though most studies reported dichotomised test results (e.g. ‘positive’ vs. ‘negative’), sometimes results
were presented by three or more groups of test results (e.g. ‘high’, ‘normal’, ‘low’). In this situation, to
allow greater consistency across studies, the groupings were collapsed where possible to form a dichotomy
again, and allow for the generation of tables that compared two groups (e.g. a table for ‘high’ vs. ‘normal’
or ‘low’, and one for ‘high’ or ‘normal’ vs. ‘low’).
TABLE 84 2 × 2 table to be extracted from each study for each binary outcome of interest
Test result Number of patients with an event Number of patients with no events
Test positive (aspirin resistant) TP (a) FP (b)
Test negative (aspirin sensitive) FN (c) TN (d)
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
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Owing to the clinical and methodological heterogeneity between studies, pooling of data was determined
to be inappropriate even in subgroups of studies employing the same PFT. However, data are presented in
this report in forest plots (without the summary estimate), along with some relevant study characteristics
highlighting heterogeneity.
Results
In all sections below, given the uncertainty around the prognostic utility findings presented in the main
body of this report, the sensitivities and specificities do not meaningfully contribute to the report.
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Appendix 4 Supplementary data
Owing to the extensive nature of the data extracted from the included studies for this project, it wasdeemed unfeasible to adequately present all the data in this report (even as appendices). The results
section of the report contains, where necessary, details of the studies, including the populations studied,
test characteristics and quality-related features, and data for key outcomes are presented in illustrative
forest plots. However, this only applies for studies on patients being treated with aspirin as a single
antiplatelet agent (monotherapy), and even so some data are omitted, including the numerical information
that was used to produce the forest plots. Furthermore, data from studies in patients treated with dual
(and triple) therapy, with aspirin as one of the agents, is completely omitted.
In the interest of transparency, the authors wish for all extracted and analytical data to be available to
readers of this report. The data has been made available through a web portal which can be accessed via
the following URL: http://medweb4.bham.ac.uk/NIHR_Aspirin_Resistance/
The data files available include Microsoft Excel spreadsheets of extracted data and statistical analysis, and
specific data files used in Stata (StataCorp LP, College Station, TX, USA) to produce the forest plots
presented in this report.
Below is an outline of the web portal indicating the files available for online viewing.
Project title: The prognostic utility of tests of platelet function for the detection of ‘aspirin
resistance‘ in patients with established cardiovascular or cerebrovascular disease: a systematic
review and economic evaluation
Project ref.: 10/36/02
Please find below links to the various data files relating to the project.
Data extraction tables
Data tables in Excel for all included studies where patients were receiving aspirin monotherapy at the time
of platelet function testing. These data relate to studies reported in Chapter 5 (section Monotherapy) of
the HTA report.
Monotherapy-Included studies
Data tables in Excel for all included studies where patients were receiving aspirin dual therapy at the time
of platelet function testing. These data relate to studies relevant to Chapter 5, Dual therapy in the
HTA report.
Dual therapy-Included studies
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Stata data files
Light transmission aggregometry for monotherapy studies
The following links relate to the Stata data files used in the analysis of studies using light transmission
aggregometry (LTA) to measure platelet function in patients receiving aspirin monotherapy at the time of
platelet function testing.
LTA-monotherapy-all outcomes-unadjusted hazard ratios
LTA-monotherapy-all outcomes-adjusted hazard ratios
LTA-monotherapy-all outcomes-unadjusted odds ratios
LTA-monotherapy-all outcomes-adjusted odds ratios
LTA-monotherapy-all outcomes-sensitivity and specificity
VerifyNow for monotherapy studies
The following links relate to the Stata data files used in the analysis of studies using VerifyNow to measure
platelet function in patients receiving aspirin monotherapy at the time of platelet function testing.
VerifyNow-monotherapy-all outcomes-unadjusted hazard ratios
VerifyNow-monotherapy-all outcomes-adjusted hazard ratios
VerifyNow-monotherapy-all outcomes-unadjusted odds ratios
VerifyNow-monotherapy-all outcomes-adjusted odds ratios
VerifyNow-monotherapy-all outcomes-sensitivity and specificity
Thromboxane measurement for monotherapy studies
The following links relate to the Stata data files used in the analysis of studies using thromboxane to
measure platelet function in patients receiving aspirin monotherapy at the time of platelet function testing.
Thromboxane-monotherapy-all outcomes-unadjusted hazard ratios
Thromboxane-monotherapy-all outcomes-adjusted hazard ratios
Thromboxane-monotherapy-all outcomes-unadjusted odds ratios
Thromboxane-monotherapy-all outcomes-adjusted odds ratios
Thromboxane-monotherapy-all outcomes-sensitivity and specificity
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PFA-100 for monotherapy studies
The following links relate to the Stata data files used in the analysis of studies using PFA-100 to measure
platelet function in patients receiving aspirin monotherapy at the time of platelet function testing.
PFA-100-monotherapy-all outcomes-unadjusted hazard ratios
PFA-100-monotherapy-all outcomes-adjusted hazard ratios
PFA-100-monotherapy-all outcomes-unadjusted odds ratios
PFA-100-monotherapy-all outcomes-adjusted odds ratios
PFA-100-monotherapy-all outcomes-sensitivity and specificity
Whole blood aggregometry for monotherapy studies
The following links relate to the Stata data files used in the analysis of studies using whole blood
aggregometry to measure platelet function in patients receiving aspirin monotherapy at the time of platelet
function testing.
Whole Blood Aggregometry-all outcomes-unadjusted hazard ratios
Whole Blood Aggregometry-all outcomes-adjusted hazard ratios
Whole Blood Aggregometry-all outcomes-unadjusted odds ratios
Whole Blood Aggregometry-all outcomes-adjusted odds ratios
Whole Blood Aggregometry-all outcomes-sensitivity and specificity
Thromboelastography for monotherapy studies
The following links relate to the Stata data files used in the analysis of studies using TEG to measure
platelet function in patients receiving aspirin monotherapy at the time of platelet function testing.
TEG-all outcomes-unadjusted hazard ratios
TEG-all outcomes-adjusted hazard ratios
TEG-all outcomes-unadjusted odds ratios
TEG-all outcomes-adjusted odds ratios
TEG-all outcomes-sensitivity and specificity
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Appendix 5 List of unobtainable articles for
prognostic/diagnostic utility systematic review
Barbano G, De Matteis F. [The thromboelastogram in the post-infarct period.] Atti Soc Ital Cardiol1962;22:Comunicazioni 90–1.
Bogutskii BV, Ezhova VA, Shibanova ZN. [Thrombelastographic studies in patients with incipient cerebral
atherosclerosis undergoing complex treatment.] Vopr Kurortol Fizioter Lech Fiz Kult 1971;36:504–7.
Bujold E, Tapp S, Giguere Y. Aspirin resistance and adverse pregnancy outcomes. Neuroendocrinol Lett
2011;32:369–70.
Fauknerova M, Osmancik P, Spacek M, Kejst L, Kalvach P. Aggregometry in secondary prevention of
stroke. Aspirin resistance. Ceska Slov Neurol Neurochir 2011;74:527–32.
Fronescu E, Vilcu A. [Thromboelastographic investigations in atherosclerosis.] Med Interna (Bucur)
1962;14:1199–206.
Goelian P. Resistances to antiplatelet agents. Rev Francoph Orthopt 2010;3:12–16.
Gritsiuk AI. [Diagnosis of the pre-thrombotic state in cardiovascular diseases.] Vrach Delo 1971;3:8–14.
Haas T. Point of care diagnostic: thromboelastometry (ROTEM®). Wien Klin Wochenschr
2010;122(Suppl. 5):19–20.
Kwon SU. Overcome Biochemical Aspirin Resistance Through Cilostazol Combination (ARCC). Stroke Trials
Registry, Internet Stroke Center; 2007. URL: www strokecenter org/trials
Laguta PS, Katkova OV, Dobrovol’skii AB, Titaeva EV, Deev AD, Panchenko EP. Aspirin resistance in
patients with stable ischemic heart disease. Kardiologiia 2010;50:4–11.
Liu L, Yang F, Li M, Hou H-J, Liu Y-H, Chen G-H, et al. Evaluation of the efficacy of anti-platelet
aggregation drugs in patients using thromboelastograph after percutaneous transluminal angioplasty and
stenting. Chin J Cerebrovasc Dis 2012;9:67–71.
Manus J-M. Aspirin resistance: How to detect it. Actual Pharm 2005;440:7.
Nidhinandana S, Changchit S. Prevalence of aspirin resistance in stroke patients in Phramongkutklao
Hospital. J Med Assoc Thai 2010;93(Suppl. 6):51–4.
Okeahialiam BN, Ikeme AC. Suspected incidence of aspirin resistance. West Afr J Med 2010;29:129.
Petricevic M, Biocina B, Konosic S, Gasparovic H, Siric F, Burcar I. Early post coronary artery bypass grafting
platelet hyperactivity, assessed by whole blood impedance aggregometry, indicates dual antiplatelet
therapy. Heart Surg Forum 2011;14:S115.
Pregowski J, Przyluski J, Karcz M, Norwa-Otto B, Kruk M, Kalinczuk L, et al. Relation of subacute stent
thrombosis and resistance to acetylsalicylic acid and clopidogrel in patients with acute coronary syndrome.
Insights from the ANIN Myocardial Infarction Registry. Postepy Kardiol Interwencyjnej 2010;6:154–60.
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Sinzinger H, Kritz H, Berent R, Schmid P, Steinbrenner D. Increased inflammatory activity rather than
platelet function predicts events during acetylsalicylic acid (ASA) therapy for secondary prevention – a
10 years follow-up. Proceedings of the 20th International Congress on Thrombosis, Athens, 25–28 June 2008.
pp. 87–91.
Tereshchenko OI. [Thrombelastogram in patients with coronary arteriosclerosis and auricular fibrillation.]
Vrach Delo 1974;0:78–9.
Tulecki L, Gburek T. Aspirin resistance after cardiosurgical operations – Current review. Pol Prz Chir
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Appendix 6 Excluded articles for prognostic/
diagnostic utility systematic review
TABLE 85 List of excluded articles with reason
Article
Reason for
exclusion
Abderrazek F, Chakroun T, Addad F, Dridi Z, Gerotziafas G, Gamra H, et al. The GPIIIa PlA polymorphism
and the platelet hyperactivity in Tunisian patients with stable coronary artery disease treated with aspirin.
Thromb Res 2010;125:e265–8
D
Abuzahra M, Pillai M, Caldera A, Hartley WB, Gonzalez R, Bobek J, et al. Comparison of higher
clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after
percutaneous coronary intervention using drug-eluting stents. Am J Cardiol 2008;102:401–3
C
Ahmed N, Meek J, Davies GJ. Plasma salicylate level and aspirin resistance in survivors of myocardial
infarction. J Thromb Thrombolysis 2010;29:416–20
D
Ahn SG, Lee SH, Sung JK, Kim JY, Yoon J. Intra-individual variability of residual platelet reactivity assessed
by the VerifyNow-P2Y12 assay in patients with clopidogrel resistance after percutaneous coronary
intervention. Platelets 2011;22:305–7
C
Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia 2008;51:385–90 A
Aleil B, Jacquemin L, De PF, Zaehringer M, Collet JP, Montalescot G, et al. Clopidogrel 150mg/day to
overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results
from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc
Interv 2008;1:631–8
C
Aleil B, Meyer N, Cazenave JP, Mossard JM, Gachet C. High stability of blood samples for flow cytometric
analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary
artery disease. Thromb Haemost 2005;94:886–7
C, D
Alessi M-C, Cuisset T, Quilici J, Cohen W, Fourcade L, Grosdidier C, et al. Benefit of tailored therapy with
high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel non responders
undergoing coronary stenting for ACS. J Thromb Haemost 2011;9:48
D
Alessi M-C, Cuisset T, Quilici J, Grosdidier C, Fourcade L, Gaborit B, et al. High post-treatment platelet
reactivity and impaired clinical prognosis but adequate response to thienopyridine in elderly patients with
unstable coronary disease. J Thromb Haemost 2011;9:791
B, C
Alexander W, Price MJ, Mega JL. Platelet reactivity: The GRAVITAS trial. P T 2011;36:47 B, C
Alexopoulos D, Plakomyti T-E, Xanthopoulou I. Variability and treatment of high on-prasugrel platelet
reactivity in patients with initial high on-clopidogrel platelet reactivity. Int J Cardiol 2012;154:333–4
A
Alfonso F, Angiolillo DJ. Platelet function assessment to predict outcomes after coronary interventions:
hype or hope? J Am Coll Cardiol 2006;48:1751–4
A
Almsherqi ZA, McLachlan CS, Sharef SM. More on: enhanced antiplatelet effect of clopidogrel in patients
whose platelets are least inhibited by aspirin: a randomized cross-over trial. J Thromb Haemost
2006;4:1638–9
A
Althoff TF, Fischer M, Knebel F, Langer E, Ziemer S, Baumann G. Elevated residual platelet reactivity to
adenosine diphosphate and arachidonic acid in patients after myocardial infarction compared to patients
after elective coronary stenting. Eur Heart J 2009;30:330
D
Altman R, Luciardi HL, Muntaner J, Herrera RN. The antithrombotic profile of aspirin. Aspirin resistance, or
simply failure? Thromb J 2004;2:1–8
A
Ambrus JL, Ambrus CM, Akhter S. Aspirin ‘allergy’ and resistance. J Am Coll Cardiol 2004;44:939–40 A
Anand SS. Vascular viewpoint. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial
infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Eikelboom JW,
Hirsh J, Weitz J, Johnston M, Yi Q, Yusuf S. Circulation 2002;105:1650–5
A
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TABLE 85 List of excluded articles with reason (continued )
Article
Reason for
exclusion
Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in
patients with coronary artery disease. Thromb Res 2002;108:37–42
D
Andreassi MG, Adlerstein D, Coceani M, Shehi E, Vecoli C, Sampietro T, et al. High-risk single-nucleotide
polymorphisms (SNPs) and genetic score on recurrent cardiovascular events following ischaemic heart
disease. Eur Heart J 2011;32:947
B, C
Angiolillo DJ, Alfonso F. Platelet function testing and cardiovascular outcomes: steps forward in identifying
the best predictive measure. Thromb Haemost 2007;98:707–9
A
Angiolillo DJ, Bernardo E, Sabate M, Jimenez-Quevedo P, Costa MA, Palazuelos J, et al. Impact of platelet
reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
J Am Coll Cardiol 2007;50:1541–7
C
Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ, et al. Bridging antiplatelet
therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA
2012;307:265–74
C
Angiolillo DJ. Applying platelet function testing in clinical practice: What are the unmet needs? JAMA
2011;306:1260–1
A
Angiolillo DJ. Tackling the diabetic platelet: is high clopidogrel dosing the answer? J Thromb Haemost
2006;4:2563–5
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Ankolekar S, Fox S, May J, Bath P. Assessing the efficacy of antiplatelet agents using remote testing of
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systematic review: articles in which outcome data are
not presented in relation to platelet function
test results
Below is a list of 62 articles that met the inclusion criteria for review and contained PFT results andclinical outcome data but failed to report the outcome data in relation to the test result. These articles
provided no relevant information on prognostic utility of the PFT but indicate that there may be unreported
relevant data.
Abumiya T, Houkin K, Morita S, Fukuhara S. Prospective study of platelet aggregation in antiplatelet
therapy. Stroke 2009;40:e248.
Al-Atassi T, Lapierre H, Boodhwani M, Lam K, Forgie M, Rubens F, et al. Cerebral microembolization after
bioprosthetic aortic valve replacement: an open-label study of daily warfarin+ aspirin versus aspirin alone.
Circulation 2011;124(Suppl.1):A14512.
Althoff TF, Fischer M, Langer E, Ziemer S, Baumann G. Sustained enhancement of residual platelet
reactivity after coronary stenting in patients with myocardial infarction compared to elective patients.
Thromb Res 2010;125:e190–6.
Altman R, Rivas AJ, Gonzalez CD. Bleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel:
Rescue of the template bleeding time in a single-center prospective study. Thromb J 2012;10:3.
Ashbrook M, Schwartz J, Heroux A, Walenga J, Jeske W, Escalante V, et al. Left ventricular assist device
induced coagulation and platelet activation and effect of the current anticoagulant therapy regimen.
J Am Coll Cardiol 2012;59(Suppl. 1):E880.
Atiemo AD, Ng’Alla LS, Vaidya D, Williams MS. Abnormal PFA-100 closure time is associated with
increased platelet aggregation in patients presenting with chest pain. J Thromb Thrombolysis
2008;25:173–8.
Beigel R, Hod H, Fefer P, Asher E, Novikov I, Shenkman B, et al. Relation of aspirin failure to clinical
outcome and to platelet response to aspirin in patients with acute myocardial infarction. Am J Cardiol
2011;107:339–42.
Beigel RS, Hod H, Shenkman B, Fefer P, Savion N, Varon D, et al. Aspirin failure is associated with worse
clinical outcome but not with an inadequate platelet response to aspirin in patients with acute myocardial
infarction. J Am Coll Cardiol 2010;55(Suppl. 1):A108.
Berent R, Auer J, Franklin B, Schmid P, von Duvillard SP. Platelet response to aspirin 50 and 100mg in
patients with coronary heart disease over a five-year period. Am J Cardiol 2011;108:644–50.
Berrouschot J, Schwetlick B, von Twickel G, Fischer C, Uhlemann H, Siegemund T, et al. Aspirin resistance
in secondary stroke prevention. Acta Neurol Scand 2006;113:31–5.
Blanchard O, Ehrensperger E, Minuk J, Solymoss S. Antiplatelet resistance in patients with recent cerebral
ischemic events. Stroke 2011;42:e346.
DOI: 10.3310/hta19370 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 37
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
361
Bobescu E, Radoi M, Dobreanu D, Rogozea L, Doka B, Catanescu G. Drugs with effects in reduction of
oxidative stress, platelets hyperactivity, hypercoagulability status and incidence of sudden death in ACS.
Fundam Clin Pharmacol 2011;25:I.
Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Hackeng CM, ten Berg JM. Dual antiplatelet therapy
resistance to aspirin and clopidogrel identifies patients at the highest risk of recurrent atherothrombotic
events after percutaneous coronary intervention. Circulation 2010;122:A16601.
Catella-Lawson F, Kapoor S, Moretti D, De Marco S, Vigilante GJ, Cucchiara AJ, et al. Oral glycoprotein
IIb/IIIa antagonism in patients with coronary artery disease. Am J Cardiol 2001;88:236–42.
Christie DJ, Kottke-Marchant K, Gorman RT. Hypersensitivity of platelets to adenosine diphosphate in
patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy.
Platelets 2008;19:104–10.
Claeys MJ, Van der Planken MG, Michiels JJ, Vertessen F, Dilling D, Bosmans JM, et al. Comparison
of antiplatelet effect of loading dose of clopidogrel versus abciximab during coronary intervention.
Blood Coagul Fibrinolysis 2002;13:283–8.
Collet J-P, Pena A, Hulot JS, Silvain J, Barthelemy O, Beygui F, et al. Can we override clopidogrel
resistance? Eur Heart J 2009;30:199.
Cuisset T, Frere C, Quilici J, Bali L, Poyet R, Morange PE, et al. Predictive value of post treatment platelet
reactivity for occurrence of post-discharge bleeding after non ST elevation acute coronary syndrome.
Arch Cardiovasc Dis Suppl 2010;2:1.
Djukanovic N, Todorovic Z, Obradovic S, Zamaklar-Trifunovic D, Njegomirovic S, Milic NM, et al. Abrupt
cessation of one-year clopidogrel treatment is not associated with thrombotic events. J Pharmacol
Sci 2011;117:12–18.
El-Atat F, Sarkar K, Kodali V, Karajgikar R, Jakkulla M, Mares A, et al. A randomized pilot trial for
aggressive therapeutic approaches in aspirin-resistant patients undergoing percutaneous coronary
intervention. J Invasive Cardiol 2011;23:9–13.
Etz C, Welp H, Rothenburger M, Tjan TD, Wenzelburger F, Schmidt C, et al. Analysis of platelet function
during left ventricular support with the Incor and Excor system. Heart Surg Forum 2004;7:E423–7.
Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, et al. Dabigatran with
or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation
(PETRO study). Am J Cardiol 2007;100:1419–26.
Fateh-Moghadam S, Htun P, Tomandl B, Sander D, Stellos K, Geisler T, et al. Hyperresponsiveness of
platelets in ischemic stroke. Thromb Haemost 2007;97:974–8.
Fifi JT, Hartenstein L, Ortiz RA, Niimi Y, Berenstein A. Antiplatelet drug resistance predicts thrombotic
complications in patients undergoing cerebrovascular stenting. Stroke 2010;41:e282–3.
Fowler JA, Depta J, Novak E, Katzan I, Bakdash S, Kottke-Marchant K, et al. Clinical outcomes using a
platelet-function guided approach for prevention of ischemic events in patients with stroke or TIA.
J Am Coll Cardiol 2012;59(Suppl. 1):E1401.
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
362
Gao P, Xiong H, Zheng Z, Li L, Gao R, Hu SS. Evaluation of antiplatelet effects of a modified protocol by
platelet aggregation in patients undergoing ‘one-stop’ hybrid coronary revascularization. Platelets
2010;21:183–90.
Gardner CD, Zehnder JL, Rigby AJ, Nicholus JR, Farquhar JW. Effect of Ginkgo biloba (EGb 761) and aspirin
on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease:
a randomized clinical trial. Blood Coagul Fibrinolysis 2007;18:787–93.
Geisler T, Mueller K, Aichele S, Bigalke B, Stellos K, Htun P, et al. Impact of inflammatory state and
metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic
relevance of residual platelet aggregability in diabetics undergoing coronary interventions. Clin Res Cardiol
2010;99:743–52. [Erratum published in Clin Res Cardiol 2010;99:769.]
Grotemeyer KH, Evers S, Fischer M, Husstedt IW. Piracetam versus acetylsalicylic acid in secondary stroke
prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study. J Neurol Sci
2000;181:65–72.
Guo Z, Hasbach J, Koschinsky T. Effect of acetylsalicylic acid on renal function of type 1 diabetic patients
with microalbuminuria. Diabetes Stoffwechsel 1998;7:41–7.
Gurbel PA, Bliden KP, Navickas IA, Mahla E, Dichiara J, Suarez TA, et al. Adenosine diphosphate-induced
platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic
events. Am Heart J 2010;160:346–54.
Gurbel PA, Bliden KP, Saucedo JF, Suarez TA, Dichiara J, Antonino MJ, et al. Bivalirudin and clopidogrel
with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic
indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with
Eptifibatide to Arrest the Reactivity of Platelets) study. J Am Coll Cardiol 2009;53:648–57.
Izumi T, Miyachi S, Haraguchi K, Matsubara N, Naito T, Wakabayashi T. Ischemic complications on carotid
artery stenting in the non-responder of antiplatelet agents. Intervent Neuroradiol 2011;17:199–200.
Kaymaz C, Tanboga IH, Can MM, Tokgoz HC, Sonmez K, Saglam M, et al. Gene mutations or
polymorphisms in association with platelet response to aspirin and/or clopidogrel and long-term clinical
outcome following coronary stenting. Eur Heart J 2011;32:244.
Kaymaz C, Tanboga IH, Tokgoz HC, Poci N, Kirca N, Aktemur T, et al. The time-dependent loss in platelet
response to aspirin and clopidogrel: Implications for patient compliance to antiplatelets. Eur Heart J
2011;32:756.
Kidson-Gerber G, Weaver J, Gemmell R, Prasan AM, Chong BH. Serum thromboxane B2 compared to five
other platelet function tests for the evaluation of aspirin effect in stable cardiovascular disease. Heart Lung
Circ 2010;19:234–42.
Kim BJ, Lee S-W, Park S-W, Kang D-W, Kim JS, Kwon SU. Insufficient platelet inhibition is related to silent
embolic cerebral infarctions after coronary angiography. Stroke 2012;43:727–32.
Kim BK, Oh SJ, Yoon SJ, Jeon DW, Ko YG, Yang JY. A randomized study assessing the effects of
pretreatment with cilostazol on periprocedural myonecrosis after percutaneous coronary intervention.
Yonsei Med J 2011;52:717–26.
DOI: 10.3310/hta19370 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 37
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
363
Kwak YL, Kim JC, Choi YS, Yoo KJ, Song Y, Shim JK. Clopidogrel responsiveness regardless of the
discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary
artery bypass graft surgery. J Am Coll Cardiol 2010;56:1994–2002.
Lee J-Y, Park D-W, Kim Y-G, Park G-M, Hwang KW, Kwon CH, et al. Clinical implication of the aspirin
resistance after drug-eluting stent implantation. Circulation 2011;124(Suppl. 1):A15074.
Lee K, Lee S-H, Lee J-W, Youn Y-J, Kim S-Y, Kim J-Y, et al. The significance of clopidogrel
low-responsiveness assessed by a point-of-care assay in acute coronary syndrome patients undergoing
coronary stenting. J Am Coll Cardiol 2009;53:A335–6.
Lee K, Lee S-H, Youn Y-J, Kim S-Y, Lee J-W, Kim J-Y, et al. Significance of slow-response to clopidogrel
assessed by a point-of-care assay in acute coronary syndrome patients undergoing coronary stenting.
Am J Cardiol 2009;103:2B.
Lordkipanidzé M, Diodati JG, Palisaitis DA, Schampaert E, Turgeon J, Pharand C. Genetic determinants of
response to aspirin: appraisal of 4 candidate genes. Thromb Res 2011;128:47–53.
Marcucci R, Gori AM, Paniccia R, Giusti B, Balzi D, Cordisco A, et al. High-on treatment platelet reactivity
by different stimuli is a determinant of mortality in acute coronary syndrome patients: data from
ami-florence 2 study. Eur Heart J 2010;31:157.
Marcucci R, Paniccia R, Consoli A, Maggini N, Miranda M, Antonucci E, et al. Monitoring of platelet
function in patients with cerebral artery aneurysms undergoing endovascular treatment with stents:
a review of 56 cases. J Thromb Haemost 2011;9:547.
Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is
associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial
infarction. Circulation 2004;109:3171–5.
Migliorini A, Valenti R, Marcucci R, Parodi G, Giuliani G, Buonamici P, et al. High residual platelet reactivity
after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left
main coronary disease. Circulation 2009;120:2214–21.
Mrdovic I, Savic L, Perunicic J, Lasica R, Asanin M, Vasiljevic Z, et al. Antiplatelet therapy adjustment
improved composite 30-day clinical outcome after primary percutaneous coronary intervention.
Eur Heart J 2009;30:908.
Muller K, Aichele S, Herkommer M, Bigalke B, Stellos K, Htun P, et al. Impact of inflammatory markers on
platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic
coronary artery disease. Atherosclerosis 2010;213:256–62.
Poston RS, White C, Gu J, Brown J, Gammie J, Pierson RN, et al. Aprotinin shows both hemostatic and
antithrombotic effects during off-pump coronary artery bypass grafting. Ann Thorac Surg 2006;81:104–10.
Ren YH, Zhao M, Chen YD, Chen L, Liu HB, Wang Y, et al. Omeprazole affects clopidogrel efficacy but not
ischemic events in patients with acute coronary syndrome undergoing elective percutaneous coronary
intervention. Chin Med J 2011;124:856–61.
Rodriguez RA, Lapierre H, Boodhwani M, Lam K, Forgie M, Rubens F, et al. Effects of warfarin and aspirin
versus aspirin alone on cerebral microembolization and platelet function after bioprosthetic aortic valve
replacement. Can J Cardiol 2010;26:104D.
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
364
Serebruany VL, Malinin AI, Jerome SD, Lowry DR, Morgan AW, Sane DC, et al. Effects of clopidogrel and
aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients
with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Am Heart J
2003;146:713–20.
Serebruany VL, Malinin AI, Ziai W, Pokov AN, Bhatt DL, Alberts MJ, et al. Effects of clopidogrel and aspirin
in combination versus aspirin alone on platelet activation and major receptor expression in patients after
recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. Stroke
2005;36:2289–92.
Shuldiner AR, O’Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome
P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA
2009;302:849–57.
Sobol AB, Mochecka A, Czupryniak L, Loba J. Aspirin in the treatment of ischemic stroke in type 2 diabetic
patients – preliminary report. Diabetol Pol 2004;11:32–8.
Spiewak M, Malek LA, Kostrzewa G, Kisiel B, Serafin A, Filipiak KJ, et al. Influence of C3435T multidrug
resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute
coronary syndromes. Kardiol Pol 2009;67:827–34.
Suh J-W, Kim S-Y, Park J-S, Kim Y-S, Kang H-J, Koo B-K, et al. Comparison of triple antiplatelet therapy
including triflusal and conventional dual therapy in patients who underwent drug-eluting stent
implantation. Int Heart J 2009;50:701–9.
Talarico GP, Brancati M, Burzotta F, Porto I, Trani C, De Vita M, et al. Glycoprotein IIB/IIIA inhibitor to
reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics:
the ‘OPTIMIZE-IT’ pilot randomized study. J Cardiovasc Med 2009;10:245–51.
Tidjane MA, Voisin S, Lhermusier T, Bongard V, Sie P, Carrie D. More on: adenosine diphosphate-inducible
platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with
clopidogrel. J Thromb Haemost 2011;9:614–16.
Wang Z, Gao F, Men J, Ren J, Modi P, Wei M. Aspirin resistance in off-pump coronary artery bypass
grafting. Eur J Cardiothorac Surg 2012;41:108–12.
Yamamoto K, Hokimoto S, Chitose T, Morita K, Ono T, Kaikita K, et al. Impact of CYP2C19 polymorphism
on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy.
J Cardiol 2011;57:194–201.
DOI: 10.3310/hta19370 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 37
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
365


Part of the NIHR Journals Library 
www.journalslibrary.nihr.ac.uk
Published by the NIHR Journals Library
This report presents independent research funded by the 
National Institute for Health Research (NIHR). The views 
expressed are those of the author(s) and not necessarily 
those of the NHS, the NIHR or the Department of Health
EME
HS&DR
HTA
PGfAR
PHR
